UNITED STATES
SECURITIES AND EXCHANGE COMMISSIONb
WASHINGTON, D.C. 20549
FORM 20-F
(Mark One)
EXCHANGE ACT OF 1934
OR
ACT OF 1934
For the fiscal year ended December 31 , 2023
OR
EXCHANGE ACT OF 1934
OR
EXCHANGE ACT OF 1934
Date of event requiring this shell company report
Commission file number: 001-41842
(Exact name of Registrant as specified in its charter and translation of Registrant’s name into English)
(Jurisdiction of incorporation or organization)
(Address of principal executive offices)
Chief Executive Officer
Tel: +33 (0) 1 53 83 09 63
info@abivax.com
(Name, Telephone, Email and/or Facsimile number and Address of Company Contact Person)
Securities registered or to be registered pursuant to Section 12(b) of the Act.
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
American Depositary Shares, each representing one ordinary share, nominal value €0.01 per share | ||
* |
*Not for trading, but only in connection with the registration of the American Depositary Shares.
Securities registered or to be registered pursuant to Section 12(g) of the Act. None
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act. None
1
Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close
of the period covered by the annual report.
Ordinary shares: 62,928,818 shares outstanding as of December 31, 2023, including 11,339 treasury shares
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities
Act. ☐ Yes ☒ No
If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports
pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. ☐ Yes ☒ No
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of
the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐
No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be
submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for
such shorter period that the registrant was required to submit such files). ☒ Yes ☐ No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer,
or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging
growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐ | Non-accelerated filer ☐ | Emerging growth company |
If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act. ☐
† The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting
Standards Board to its Accounting Standards Codification after April 5, 2012.
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of
the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15
U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial
statements of the registrant included in the filing reflect the correction of an error to previously issued financial
statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of
incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery
period pursuant to §240.10D-1(b). ☐
Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements
included in this filing:
U.S. GAAP ☐
If “Other” has been checked in response to the previous question, indicate by check mark which financial statement
item the registrant has elected to follow. ☐ Item 17 ☐ Item 18
If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act). ☐ Yes ☒ No
2
TABLE OF CONTENTS
Page | |
INTRODUCTION ........................................................................................................................................ | |
PART I ......................................................................................................................................................... | |
Item 1.Identity of Directors, Senior Management and Advisers ................................................ | |
Item 2.Offer Statistics and Expected Timetable ......................................................................... | |
Item 3.Key Information .............................................................................................................. | |
Item 4.Information on the Company. .......................................................................................... | |
Item 4A. Unresolved Staff Comments. ........................................................................................... | |
Item 5.Operating and Financial Review and Prospects .............................................................. | |
Item 6.Directors, Senior Management and Employees .............................................................. | |
Item 7.Major Shareholders and Related Party Transactions ....................................................... | |
Item 8.Financial Information ...................................................................................................... | |
Item 9.The Offer and Listing ...................................................................................................... | |
Item 10.Additional Information. ................................................................................................... | |
Item 11.Quantitative and Qualitative Disclosures About Market Risk ........................................ | |
Item 12.Description of Securities Other than Equity Securities ................................................... | |
PART II ........................................................................................................................................................ | |
Item 13.Defaults, Dividend Arrearages and Delinquencies .......................................................... | |
Item 15.Controls and Procedures .................................................................................................. | |
Item 16.[Reserved] ........................................................................................................................ | |
Item 16A.Audit Committee Financial Expert .................................................................................. | |
Item 16B.Code of Ethics ................................................................................................................. | |
Item 16C.Principal Accountant Fees and Services .......................................................................... | |
Item 16D.Exemptions from the Listing Standards for Audit Committees ...................................... | |
Item 16E.Purchases of Equity Securities by the Issuer and Affiliated Purchasers ......................... | |
Item 16F.Change in Registrant’s Certifying Accountant ................................................................ | |
Item 16G.Corporate Governance ..................................................................................................... | |
Item 16H.Mine Safety Disclosure ................................................................................................... | |
Item 16I.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections ............................ | |
Item 16J.Insider Trading Policies ................................................................................................... | |
Item 16K.Cybersecurity ................................................................................................................... | |
PART III ....................................................................................................................................................... | |
Item 17.Financial Statements ........................................................................................................ | |
Item 18.Financial Statements ........................................................................................................ | |
SIGNATURES ............................................................................................................................................. |
INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS......................................................... | F-1 |
3
INTRODUCTION
Unless otherwise indicated or the context otherwise requires, “Abivax,” “the company,” “our company,” “we,” “us”
and “our” refer to Abivax SA and its consolidated subsidiary, taken as a whole.
“Abivax” and the Abivax logo and other trademarks or service marks of Abivax SA appearing in this Annual Report
on Form 20-F are the property of Abivax SA. Solely for convenience, the trademarks, service marks and trade
names referred to in this annual report are listed without the ® and ™ symbols, but such references should not be
construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their
right thereto. All other trademarks, trade names and service marks appearing in this annual report are the property of
their respective owners. We do not intend to use or display other companies’ trademarks and trade names to imply
any relationship with, or endorsement or sponsorship of us by, any other companies.
This Annual Report on Form 20-F includes our audited financial statements as of and for the years ended December
31, 2023, 2022 and 2021 prepared in accordance with International Financial Reporting Standards (“IFRS”), as
issued by the International Accounting Standards Board (“IASB”). None of our financial statements were prepared
in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). Our financial statements are
presented in euros and, unless otherwise stated, all monetary amounts are in euros. All references in this annual
report to “$”, “U.S. dollars” and “dollars” mean U.S. dollars, and all references to “€”, “EUR” and “euros” mean
European Monetary Union euros, unless otherwise noted. Throughout this annual report, references to ADSs mean
ADSs or ordinary shares represented by such ADSs, as the case may be.
4
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Annual Report on Form 20-F, or annual report, contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended ("Exchange Act"), that are based on our management’s beliefs and assumptions and on information
currently available to our management. All statements other than present and historical facts and conditions
contained in this annual report, including statements regarding our future results of operations and financial
positions, business strategy, plans and our objectives for future operations, are forward-looking statements. When
used in this annual report, the words “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is
designed to,” “may,” “might,” “plan,” “will,” “would,” “potential,” “predict,” “objective,” “should,” or the negative
of these and similar expressions identify forward-looking statements. Forward-looking statements include, but are
not limited to, statements about:
•the prospects of attaining, maintaining and expanding marketing authorization for our drug candidates;
•the potential attributes and clinical advantages of our drug candidates;
•the initiation, timing, progress and results of our preclinical and clinical trials (and those conducted by third
parties) and other research and development programs;
•the timing of the availability of data from our clinical trials;
•the timing of and our ability to advance drug candidates through clinical development;
•the timing or likelihood of regulatory meetings and filings;
•the timing of and our ability to obtain and maintain regulatory approvals for any of our drug candidates;
•our ability to identify and develop new drug candidates from our preclinical studies;
•our ability to develop sales and marketing capabilities and transition into a commercial-stage company;
•the effects of increased competition as well as innovations by new and existing competitors in our industry;
•our ability to enter into strategic relationships or partnerships;
•our ability to obtain, maintain, protect and enforce our intellectual property rights and propriety technologies
and to operate our business without infringing the intellectual property rights and proprietary technology of
third parties;
•our expectations regarding our cash requirements;
•our estimates regarding expenses, future revenues, capital requirements and the need for additional
financing;
•the impact of government laws and regulations;
•our competitive position;
•unfavorable conditions in our industry, the global economy or global supply chain, including financial and
credit market fluctuations, international trade relations, political turmoil, natural catastrophes, warfare (such
as the Russia-Ukraine war and the Israel-Hamas war), and terrorist attacks; and
•other risks and uncertainties, including those listed in this annual report under the caption “Risk Factors.”
You should refer to the section of this annual report titled “Item 3.D-Risk Factors” for a discussion of important
factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking
statements. As a result of these factors, we cannot assure you that the forward-looking statements in this annual
report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the
inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should
not regard these statements as a representation or warranty by us or any other person that we will achieve our
objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any
forward-looking statements, whether as a result of new information, future events or otherwise, except as required
by law.
You should read this annual report and the documents that we reference in this annual report and have filed as
exhibits to this annual report completely and with the understanding that our actual future results may be materially
different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.
This annual report contains market data and industry forecasts that were obtained from industry publications. These
data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such
estimates. We have not independently verified any third-party information. While we believe the market position,
market opportunity and market size information included in this annual report is generally reliable, such information
is inherently imprecise.
5
Summary Risk Factors
•We are a clinical-stage company with a limited operating history and no approved products and no
historical product revenues, which makes it difficult to assess our future prospects and financial results.
•We have incurred considerable losses historically, which we anticipate will continue and may increase in
the future.
•We will require substantial additional funding, which may not be available on acceptable terms or at all,
and failure to obtain this necessary capital may force us to delay, limit or terminate our product
development efforts or other operations.
•We have significant debt commitments, which require us to meet certain operating covenants, and if we fail
to comply with those covenants the bondholders would be able to accelerate our repayment obligations.
Additionally, the conversion of some or all of our bonds into ordinary shares would dilute the ownership
interests of existing shareholders.
•Our principal tangible and intangible assets serve as collateral under the terms of debt agreements for the
Kreos / Claret Financing. If we default on these debt obligations, the Secured Lenders could foreclose on
those assets, and we would be unable to continue our business and operations.
•Drug candidates under development must undergo costly, rigorous and highly regulated preclinical studies
and clinical trials, whose time of completion, number and outcomes are uncertain.
•We are heavily dependent on the success of our drug candidates, in particular obefazimod, and we cannot
be certain that obefazimod or any of our other current or future drug candidates will receive regulatory
approval, and, without regulatory approval, we will not be able to market our drug candidates.
•Clinical failure can occur at any stage of clinical development. The results of earlier clinical trials as well as
data from any interim analysis of ongoing trials are not necessarily predictive of future results and any drug
candidate we advance through clinical trials may not have favorable results in later clinical trials.
•Our future may depend on our most advanced clinical development program, obefazimod, since our other
drug candidates are in a less advanced stage of development.
•We expect to expand our organization, and as a result, we may encounter difficulties in managing our
growth, which could disrupt our operations.
•We rely on a small number of third-party suppliers, and in certain cases a single-source supplier, and we
may be in a position of dependence with respect to our subcontractors.
•Our future success depends on our ability to retain our key executives and to attract, retain and motivate
qualified personnel.
•There are material weaknesses in our internal controls over financial reporting and if we are unable to
maintain effective internal controls over financial reporting, the accuracy and timeliness of our financial
reporting may be adversely affected, which could adversely affect our business, investor confidence and the
market price of our securities.
•Our ability to exclusively commercialize our drug candidates may decrease if we are unable to protect our
intellectual property rights or if these rights are insufficient for our purposes.
6
PART I
Item 1.Identity of Directors, Senior Management and Advisers
Not applicable.
7
Item 2.Offer Statistics and Expected Timetable
Not applicable.
8
Item 3.Key Information
A.[Reserved]
Not applicable.
B.Capitalization and Indebtedness
Not applicable.
C.Reasons for the Offer and Use of Proceeds
Not applicable.
D.Risk Factors
Our business faces significant risks. You should carefully consider all of the information set forth in this
annual report and in our other filings with the United States Securities and Exchange Commission, or the SEC,
including the following risk factors which we face and which are faced by our industry. Our business, financial
condition or results of operations could be materially adversely affected by any of these risks. This report also
contains forward-looking statements that involve risks and uncertainties. Our results could materially differ from
those anticipated in these forward-looking statements, as a result of certain factors including the risks described
below and elsewhere in this annual report and our other SEC filings. See “Special Note Regarding Forward-
Looking Statements” above.
Risks Related to our Financial Position and Need for Additional Capital
We are a clinical-stage company with a limited operating history and no approved products and no historical
product revenues, which makes it difficult to assess our future prospects and financial results.
We are a clinical-stage biopharmaceutical company with a limited operating history upon which you can
evaluate our business and prospects. We were incorporated as a société anonyme (limited liability company) on
December 4, 2013 and, to date, we have focused primarily on organizing and staffing our company, business
planning, raising capital, identifying, acquiring and in-licensing our drug candidates, establishing our intellectual
property portfolio, conducting research, preclinical studies and clinical trials, establishing arrangements with third
parties for the manufacture of our drug candidates and related raw materials and providing general and
administrative support for these operations. Investment in product development in the healthcare industry, including
of biopharmaceutical products, is highly speculative because it entails substantial upfront capital expenditures and
significant risk that any potential drug candidate will fail to demonstrate adequate effect or an acceptable safety
profile, gain regulatory approval or become commercially viable. As a result, our ability to reduce our losses and
reach consistent profitability from product sales is unproven, and we may never sustain profitability. We have no
products approved for commercial sale and have not generated any revenue from product sales to date.
Our ability to generate revenue from product sales and achieve and maintain profitability depends on our
ability, alone or with any future collaborators, to successfully complete the development of, and obtain the
regulatory approvals necessary to commercialize, our lead drug candidate, obefazimod. Our prospects, including our
ability to finance our operations and generate revenue from product sales, therefore will depend substantially on the
development and commercialization of obefazimod, as other programs in our preclinical portfolio are still in earlier
stages of development. Since our inception in 2013, the majority of our operating income has been derived from our
reliance on research collaborations unrelated to obefazimod, and we do not anticipate generating revenue from
product sales for the next several years, if ever. Our ability to generate revenue from product sales depends heavily
on our or any future collaborators’ success in:
•timely and successful completion of clinical development of obefazimod, our lead drug candidate;
•obtaining and maintaining regulatory and marketing approval for obefazimod and any future drug
candidates for which we successfully complete clinical trials;
•launching and commercializing any drug candidates for which we obtain regulatory and marketing
approval by establishing a sales force, marketing and distribution infrastructure or, alternatively,
collaborating with a commercialization partner;
9
•obtaining coverage and adequate reimbursement from government and third-party payors for our
current or any future drug candidates, if approved, both in the United States and internationally, and
reaching acceptable agreements with foreign government and third-party payors on pricing terms;
•developing, validating and maintaining a commercially viable, sustainable, scalable, reproducible and
transferable manufacturing process for obefazimod or any future drug candidates that are compliant
with current good manufacturing practices;
•establishing and maintaining supply and manufacturing relationships with third parties that can provide
an adequate amount and quality of drugs and services to support our planned clinical development, as
well as the market demand for obefazimod and any future drug candidates, if approved;
•obtaining market acceptance, if and when approved, of obefazimod or any future drug candidates as a
viable treatment option by physicians, patients, third-party payors and others in the medical
community;
•effectively addressing any competing technological and market developments;
•implementing additional internal systems and infrastructure, as needed;
•negotiating favorable terms in any collaboration, licensing or other arrangements into which we may
enter, and performing our obligations pursuant to such arrangements;
•maintaining, protecting and expanding our portfolio of intellectual property rights, including patents,
trade secrets and know-how;
•avoiding and defending against third-party interference or infringement claims; and
•attracting, hiring and retaining qualified personnel.
We have incurred considerable losses historically, which we anticipate will continue and may increase in the
future.
Since our inception, we have incurred net losses. For the years ended December 31, 2023, 2022 and 2021, we
reported net losses of €147.7 million, €60.7 million and €42.5 million, respectively. As of December 31, 2023, we
carried forward accumulated tax losses of €459.8 million.
We have devoted most of our financial resources to research and development, including our clinical and
preclinical development activities. Even if we obtain regulatory approval to market a drug candidate, our future
revenues will depend upon the size of any markets in which our drug candidates have received approval and our
ability to achieve sufficient market acceptance, reimbursement from third-party payors and adequate market share
for our drug candidates in those markets. There can be no assurance that we will ever earn any revenues or revenues
sufficient to offset past, current and future losses or achieve profitability, which would impair our ability to sustain
our operations. Moreover, even if we achieve profitability, such profitability may not be sustainable. Any inability to
generate sustained profits could have a material adverse effect on our business, prospects, financial condition, cash
flows and results of operations.
We expect to continue to incur significant expenses and operating losses for the foreseeable future. We do not
anticipate achieving profitability in the future unless we obtain the regulatory approvals necessary to commercialize
obefazimod and any additional drug candidates that we may pursue in the future. We anticipate that our expenses
will increase substantially if, and as, we:
•timely and successfully complete clinical development of obefazimod, our clinical-stage drug
candidate;
•seek and maintain regulatory and marketing approvals for obefazimod and any future drug candidates
for which we successfully complete clinical trials;
•continue the preclinical and clinical development of our drug candidates;
•expand the scope of our current clinical trials for our drug candidates;
•begin new clinical trials for our drug candidates;
•develop, scale and validate our commercial manufacturing capabilities for our drug candidates;
•establish a sales, marketing and distribution infrastructure to commercialize any drugs for which we
may obtain marketing approval for which we have not entered into a collaboration with a third-party;
•seek to discover, identify and validate additional drug candidates;
10
•acquire or in-license other drug candidates and technologies;
•make milestone, royalty or other payments under in-license or collaboration agreements;
•obtain, maintain, protect, enforce and expand our intellectual property portfolio;
•attract new and retain existing skilled personnel; and
•create additional infrastructure to support our operations as a U.S. public company.
In addition, following the issuance of royalty certificates in September 2022 and other royalties that may
become payable under our royalty agreements, the payment of royalties in the event of commercialization of
obefazimod will result in a decrease in cash flows generated by sales of the product, which could have an
unfavorable impact on our financial position, particularly at the beginning of the commercialization phase.
The net losses we incur may fluctuate significantly from quarter-to-quarter and year-to-year, such that a
period-to-period comparison of our results of operations may not be a good indication of our future performance. In
any particular period or periods, our operating results could be below the expectations of securities analysts or
investors, which could cause the price of the ordinary shares (which may be in the form of ADSs) to decline. An
increase in operational losses would have a material adverse effect on our business, financial position, income,
growth and outlook.
We will require substantial additional funding, which may not be available on acceptable terms or at all, and
failure to obtain this necessary capital may force us to delay, limit or terminate our product development efforts
or other operations.
Our operations have consumed substantial amounts of cash since inception. We are currently advancing
obefazimod through clinical development and conducting preclinical studies with respect to other programs.
Developing drug candidates is expensive, lengthy and risky, and we expect our research and development expenses
to increase substantially in connection with our ongoing activities, particularly as we seek to advance obefazimod
toward commercialization. If our clinical trials are successful and we obtain regulatory approval for drug candidates
that we develop, we will incur commercialization expenses before these drug candidates are marketed and sold.
Based on (a) our existing cash and cash equivalents of €251.9 million and other short-term investments of €9.0
million as of December 31, 2023, (b) drawdown of the second tranche of the Kreos / Claret Financing, amounting to
€25.0 million in gross proceeds received on March 28, 2024, and (c) the expected reimbursement of the CIR from
2023 in the second half of 2024 amounting to €4.5 million, we expect to be able to fund our forecasted cash flow
requirements into the fourth quarter of 2025. Under these assumptions and based on our current clinical plan, we
would have sufficient funds to finance our operations through the announcement of our top-line data from the Phase
3 ABTECT-1 and ABTECT-2 induction trials for UC.
This takes into account our assumption that R&D expenditure will be substantially increased in 2024 driven
by the progression of the Phase 3 clinical trials of obefazimod in UC and the initiation of the Phase 2b trial for CD in
2024. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available
capital resources sooner than we expect. For instance, there is no guarantee that we would be able to meet our
conditions to be able to draw down on the remaining tranches of the Kreos / Claret Financing and the Heights
Financing. We anticipate that we will require additional capital as we seek regulatory approval of our drug
candidates. We intend to assess and plan for any such funding requirements and aim to regularly update the market
on our financing need projections.
Until we can generate sufficient product or royalty revenue to finance our cash requirements, which we may
never do, we may seek additional financing in the form of public or private equity or debt financings, government or
other third-party funding, marketing and distribution arrangements and collaborations, strategic alliances and
licensing arrangements or a combination of these sources.
The amount and timing of our funding needs will depend on factors that are largely outside of our control,
such as:
•higher costs and slower-than-expected progress on our research and development programs and
clinical trials;
•costs related to preparing, filing, enforcing and maintaining our patents and other intellectual property
rights;
11
•the scope of the research required and time needed to sign licensing agreements with industrial
partners;
•the expenses needed to respond to technological and market developments;
•higher costs and longer-than-expected lead times obtaining regulatory authorizations, including time
for preparing application dossiers for the relevant authorities; and
•new opportunities for developing new products or acquiring technologies, products or companies.
Any additional fundraising efforts may divert our management from their day-to-day activities, which may
adversely affect our ability to develop and, if approved, commercialize our drug candidates. In addition, we cannot
guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Under
French law, our share capital may be increased only with shareholders’ approval at an extraordinary general
shareholders’ meeting on the basis of a report from the board of directors. In addition, the French Commercial Code
imposes certain limitations on our ability to price certain offerings of our share capital without preferential
subscription rights (droit préférentiel de souscription), which limitation may prevent us from successfully
completing any such offering. To the extent that we raise additional capital, the terms of any financing may
adversely affect the holdings or the rights of our shareholders and the issuance of additional securities, whether
equity or debt, by us, or the possibility of such issuance, may cause the market price of our ordinary shares (which
may be in the form of ADSs) to decline. The sale of additional equity or convertible securities will dilute our
shareholders ownership interest. The incurrence of indebtedness would result in increased fixed payment obligations
and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional
debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions
that could adversely impact our ability to conduct our business. To the extent that we raise additional funds through
arrangements with research and development partners or otherwise, we may be required to relinquish some of our
technologies, drug candidates or revenue streams, license our technologies or drug candidates on unfavorable terms,
or otherwise agree to terms unfavorable for us. If we are unable to obtain adequate financing, we may be required to
delay, reduce or eliminate the number or scope of our projects and drug candidates (including our preclinical studies
and clinical trial programs). In order to obtain financing, we may be required to relinquish rights to some of our
technologies or drug candidates or otherwise agree to terms unfavorable to us. If we are unable to obtain funding on
a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or
development programs or the commercialization of any drug candidate or be unable to expand our operations or
otherwise capitalize on our business opportunities, as desired, which could impair our prospects.
Our financial statements contain a footnote describing management’s assumption regarding our ability to
continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all.
For the years ended December 31, 2023 and 2022, we reported net losses of €147.7 million and €60.7 million,
respectively. As of December 31, 2023, we carried forward accumulated tax losses of €459.8 million. Recurring
losses may cast significant doubt or raise substantial doubt about our ability to continue as a going concern.
There cannot be any assurance that we will be successful in obtaining necessary financing in the future to
continue as a going concern or achieve profitability. We expect that we will need to raise additional capital in order
to complete the necessary trials to achieve commercial viability of some or all of our drug candidates. If funds are
not available, we may be required to delay, reduce the scope of, or eliminate research or development plans or
commercialization efforts with respect to our products. The sale of additional equity may dilute existing
shareholders and newly issued shares may contain senior rights and preferences compared to currently outstanding
ordinary shares. Issued debt securities may contain covenants and limit our ability to pay dividends or make other
distributions to our shareholders. If we are unable to obtain such additional financing, future operations (such as our
clinical development programs) would need to be scaled back or discontinued. These factors may raise substantial
doubt about our ability to continue as a going concern.
There are material weaknesses in our internal controls over financial reporting and if we are unable to maintain
effective internal controls over financial reporting, the accuracy and timeliness of our financial reporting may be
adversely affected, which could adversely affect our business, investor confidence and the market price of our
securities.
Internal control over financial reporting is a process designed to provide reasonable assurance regarding the
reliability of financial reporting for external purposes in accordance with international financial reporting standards.
Internal control over financial reporting includes maintaining records that in reasonable detail accurately and fairly
reflect our transactions; providing reasonable assurance that transactions are recorded as necessary for preparation of
our financial statements; providing reasonable assurance that receipts and expenditures of our assets are made in
accordance with management authorization; and providing reasonable assurance that unauthorized acquisition, use
12
or disposition of our assets that could have a material effect on the financial statements would be prevented or
detected on a timely basis. Because of its inherent limitations, internal control over financial reporting is not
intended to provide absolute assurance that a misstatement of our financial statements would be prevented or
detected.
We must maintain effective internal controls over financial reporting in order to accurately and timely report
our results of operations and financial condition. In addition, as a public company listed in the United States, the
Sarbanes-Oxley Act will require, among other things, that we assess the effectiveness of our internal controls over
financial reporting at the end of each fiscal year, starting with the end of the first full fiscal year after the completion
of our initial public offering of our ADSs in the United States. However, our independent registered public
accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting for
so long as we are an “emerging growth company,” which may be up to five fiscal years following our initial public
offering of our ADSs in the United States. An independent assessment of the effectiveness of our internal controls
could detect problems that our management’s assessment might not.
Our management has not completed an assessment of the effectiveness of our internal controls over financial
reporting, and our independent registered public accounting firm has not conducted an audit of our internal controls
over financial reporting. In conjunction with preparing our financial statements as of and for the years ended
December 31, 2023 and 2022, material weaknesses in our internal controls over financial reporting were identified.
The material weaknesses related to a lack of risk assessment as well as formal, documented and implemented
processes, controls and review procedures, specifically due to a lack of a sufficient number of professionals with an
appropriate level of internal control knowledge, training and experience. These material weaknesses did not result in
a material misstatement to our financial statements included herein, however these material weaknesses could result
in material inaccuracies in our financial statements and impair our ability to comply with applicable financial
reporting requirements and related regulatory filings on a timely basis.
We have developed a remediation plan to address these material weaknesses and strengthen our controls in
these areas. In this regard, we have started to reorganize our finance and accounting function by hiring additional
experienced employees to provide more review and oversight over our financial processes. While we are working to
remediate the material weaknesses as quickly and efficiently as possible, we cannot at this time provide the expected
timeline in connection with implementing our remediation. As of December 31, 2023, we had not yet completed
remediation of these material weaknesses. These remediation measures may be time-consuming and costly and
might place significant demands on our financial and operational resources. There is no assurance that the actions
we may take in the future will be sufficient to remediate the control deficiencies that led to these material
weaknesses in our internal control over financial reporting or that they will prevent or avoid potential future material
weaknesses.
The rules governing the standards that will have to be met for our management to assess our internal controls
over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act are complex and require significant
documentation, testing and possible remediation. These stringent standards require that our audit committee be
advised and regularly updated on management’s review of internal controls over financial reporting. We have begun
the process of designing, implementing, and testing the internal controls over financial reporting required to comply
with this obligation. This process is time-consuming, costly, and complicated. Our management may not be able to
effectively and timely implement controls and procedures that adequately respond to the increased regulatory
compliance and reporting requirements that will be applicable to us as a public company listed in the United States.
If we fail to staff our accounting and finance function adequately or maintain internal controls over financial
reporting adequate to meet the demands that will be placed upon us as a public company listed in the United States,
our business and reputation may be harmed and the price of our ordinary shares and ADSs may decline. In addition,
undetected material weaknesses in our internal controls over financial reporting could lead to restatements of
financial statements and require us to incur the expense of remediation. Any of these developments could result in
investor perceptions of us being adversely affected, which could cause a decline in the market price of our securities.
Our management is responsible for establishing and maintaining adequate internal control over financial
reporting. Our growth will place significant additional pressure on our system of internal control over financial
reporting. Any failure to maintain an effective system of internal control over financial reporting could limit our
ability to report our financial results accurately and timely or to detect and prevent fraud.
Significant impairment of our goodwill could materially impact our financial position and results of our
operations.
We carry a goodwill balance, which is allocated to obefazimod and ABX196 cash generating units, on our
balance sheet as a result of past business acquisitions, including with respect to obefazimod and ABX196. We are
required to review our goodwill for impairment on an annual basis or more frequently if events or changes in
circumstances indicate evidence of impairment. We did not record any goodwill impairment loss for the year ended
December 31, 2023. For the year ended December 31, 2022, we recorded a goodwill impairment loss of €13.6
million. The goodwill impairment loss was related to an impairment test conducted with respect to the ABX196
13
cash-generating unit as a result of significant external changes in the hepatocellular carcinoma treatment landscape,
which are expected to require a new, lengthy, heavy and risky internal development process (use of a combination of
compounds). As such, due to the lack of progress made in the negotiation of a development partnership, we made
the decision to freeze the development program for ABX196 in the treatment of hepatocellular cancer, which led to
full impairment of ABX196 goodwill. In July 2023, we have decided to completely stop our ABX196 program,
which will be reflected in our next financial statements. After full impairment of the goodwill allocated to ABX196,
we continue to carry a goodwill balance allocated to obefazimod amounting to €18.4 million in the aggregate as of
December 31, 2023. We have not currently identified reasons to impair the goodwill allocated to obefazimod.
However, there can be no assurance that, based on the results of our annual goodwill impairment tests, we will not
be required to identify further goodwill impairment losses, which could have a material adverse effect on our results
of operations.
We have significant debt commitments, which require us to meet certain operating covenants, and if we fail to
comply with those covenants the bondholders would be able to accelerate our repayment obligations.
Additionally, the conversion of some or all of our bonds into ordinary shares would dilute the ownership interests
of existing shareholders.
On August 20, 2023, we entered into a framework subscription agreement (the "Framework Subscription
Agreement") with entities affiliated with Kreos Capital ("Kreos") and entities affiliated with Claret European
Growth Capital ("Claret"), as the Secured Lenders (the "Kreos / Claret Financing"). Under this Framework
Subscription Agreement, we may draw up to €75 million in structured debt financing, in three tranches of €25
million in aggregate principal amount each. The first and second tranches were drawn on August 22, 2023 and
March 28, 2024, respectively. The Kreos / Claret Financing provides for certain restrictive covenants (subject to
customary exceptions), which include, among other things, restrictions on the incurrence of indebtedness, cross-
default, the distribution of dividends and the grant of security interests. As security for the Kreos / Claret Financing,
the Secured Lenders benefit from the grant of first-ranking collateral on our principal tangible and intangible assets,
including pledges over our business (fonds de commerce) as a going concern and intellectual property rights in our
lead drug candidate, as well as pledges over our bank accounts and receivables. Such securities apply to all tranches
of the Kreos / Claret Financing.
In addition, on August 20, 2023, we entered into a subscription agreement with entities affiliated with Heights
Capital Management ("Heights", and such agreement, the "Heights Subscription Agreement"). Under the Heights
Subscription Agreement, we may draw up to €75 million in amortizing senior convertible notes, in two tranches of
€35 million and €40 million, respectively, as further described below. The first tranche in aggregate principal
amount of €35 million was drawn on August 24, 2023. The terms and conditions of the Heights Convertible Notes
include a negative pledge providing that any security granted in favor of other borrowed debt or debt instruments
should also be granted in favor of the Heights Convertible Notes on an equal basis (with the exception of the
securities issued pursuant to the Kreos / Claret Financing).
In June 2020, we obtained a non-dilutive financing in the form of a State-guaranteed loan of €5.0 million. The
loan was structured with an initial maturity of 12 months at 0.25% and a five-year extension option. In March 2021,
we exercised the five-year extension option with a one-year deferral of principal repayment, with the following
conditions: (i) a revised interest rate of 0.58% per annum, excluding insurance and State-guaranteed premium; and
(ii) a State-guaranteed premium of €0.1 million to be paid by installments over the contract period starting in June
2021.
The loan includes certain customary covenants and prepayment provisions. The negative covenants include an
undertaking not to dispose of all or part of our assets for more than 50% of the gross value of our fixed assets.
There is also no guarantee that we will have sufficient cash to pay the bonds issued to the Secured Lenders or
Heights at maturity, which could have a negative impact on our business as security interests have been granted on
our principal tangible and intangible assets: in particular, on our goodwill, intellectual property rights relating to our
lead drug candidates, as well as a pledge of our bank accounts and claims. There is also no guarantee that we will
have sufficient cash to make the scheduled payments on the Kreos / Claret Financing, the Heights Financing or the
State-guaranteed loan, which could have a material adverse effect on our business, financial position and results of
operations. Any failure to make scheduled payments or trigger for early repayment of the loan could have a material
adverse effect on our business, financial position, income, growth and outlook. If we breach our obligations under
any of these agreements, it could result in default and trigger an early repayment of the bonds. There is no guarantee
that we would have the necessary resources to fund an advance repayment of the bonds.
14
Our principal tangible and intangible assets serve as collateral under the terms of debt agreements for the Kreos /
Claret Financing. If we default on these debt obligations, the Secured Lenders could foreclose on those assets,
and we would be unable to continue our business and operations.
In August 2023, we entered into the Kreos / Claret Financing. In connection with the financing, we have
granted the Secured Lenders with first-ranking collateral on our principal tangible and intangible assets, including
pledges over our business (fonds de commerce) as a going concern and intellectual property rights in our lead drug
candidate, as well as pledges over our bank accounts and receivables until our debt obligations thereunder are repaid
in full. There can be no assurance that we will not breach the covenants or other terms of, or that an event of default
will not occur under, the debt agreements for the Kreos / Claret Financing. If a breach or event of default occurs,
there can be no assurance that we will be able to cure the breach within the time permitted. In the event of any
failure to pay our obligations when due, any breach or default of our covenants or other obligations, or any other
event that causes an acceleration of payment at a time when we do not have sufficient resources to meet these
obligations, the Secured Lenders could foreclose on the collateral. If the Secured Lenders were to be successful, we
would lose our intellectual property rights in our lead drug candidate and be unable to commercialize our lead drug
candidate and conduct our business. Any of these consequences would have a material adverse effect on our
business, financial condition and share price.
We rely on grants and subsidies, which may not continue to be available and we may be forced to repay
conditional advances prematurely if we fail to comply with our contractual obligations under certain innovation
grant agreements.
We have received various grants and conditional advances from Bpifrance under various development
programs, in a total amount of €20.1 million as of December 31, 2023. In the event that we do not comply with the
contractual conditions stipulated in the aid agreements we have entered into, we may have to repay the sums
advanced early. Such premature repayment could deprive us of the necessary financial resources for our research
and development projects and we cannot guarantee that we will find necessary additional financial resources, the
timeline for or the possibility of replacing these financial resources with others. We cannot guarantee that we will
have the necessary resources to cope with an early repayment. A material repayment would result in a material
adverse effect on our business, operations, financial position, income, growth, and outlook.
In addition, the amount and date of payment of current and future grants and subsidies depend on many factors
that are not in our control, including possible non-distribution decisions or the freezing of funds, as well as the
achievement of key milestones previously agreed on with Bpifrance. Delays or failure in obtaining or replacing
these grants and subsidies in the future could have a material adverse effect on our business, financial position,
income, growth and outlook.
Current equity agreements and convertible debt instruments may dilute our equity resulting in dilution to our
shareholders.
Since our incorporation, we have issued and granted founder’s share warrants (BCE) and share warrants
(BSA) and granted free shares (AGA) to persons linked to us and financing entities. We have also issued convertible
bonds. See "Item 5.B—Liquidity and Capital Resources.”
The theoretical exercise of all the founder’s share warrants (BCE) and share warrant (BSA) instruments giving
access to our capital issued and outstanding as of December 31, 2023, excluding securities held by financing entities,
would allow for the subscription of 638,643 potential new ordinary shares, resulting in a hypothetical dilution equal
to 1.01% based on our existing share capital as of December 31, 2023.
Our general meeting of June 5, 2023 delegated authority to the board of directors (the “Board”) to carry out
one or more capital increases and/or issues of securities giving access to our capital subject to the following
limitations:
•a total maximum nominal amount of the capital increases set at €500,000 (or the equivalent value of
that amount in the event of an issue in another currency) with a total maximum nominal amount of the
debt securities that may be issued set at €150,000,000 (or the equivalent value of that amount in the
event of an issue in another currency); and
•the shares that may be issued or allotted in the context of equity incentive plans (share warrants (BSA),
share options and/or free shares (AGA)) may not exceed 10% of the share capital on a fully diluted
basis recorded as of June 5, 2023.
15
Using such delegation, we issued in August 2023 the following securities in connection with the Kreos / Claret
Financing and the Heights Financing:
•25,000,000 convertible bonds with warrants attached with an individual nominal value of €1.00 issued
to KC and Claret, which allow for the subscription of up to 1,178,084 new ordinary shares at a
conversion price of €21.22 per ordinary share;
•214,198 share warrants (BSA) issued to KC and Claret, which allow for the subscription of up to
214,198 new ordinary shares at an exercise price of €18.67 per ordinary share; and
•350 convertible notes due 2027 with an individual nominal value of €100,000 issued to Heights, which
allow for the subscription of up to 1,472,606 new shares at a conversion price of €23.77 per ordinary
share. In case we opt to repay the principal and accrued interest of such notes entirely in shares, we
may issue up to 2,830,201 new ordinary shares in connection with such repayment.
Our failure to maintain certain tax benefits applicable to French biopharmaceutical companies may adversely
affect our operations and finances.
As a French biopharmaceutical company, we have benefited from certain tax advantages, including, for
example, the Research and Development Tax Credit (crédit impôt recherche) (“CIR”), which is a French tax credit
aimed at stimulating research and development. CIR can be offset against French corporate income tax due and the
portion in excess, if any, may be refunded. CIR is calculated based on our claimed amount of eligible research and
development expenditures in France and represents €4.5 million for 2023. The French tax authorities, with the
assistance of the Higher Education and Research Ministry, may audit each research and development program in
respect of which a CIR benefit has been claimed and assess whether such program qualifies in its view for the CIR
benefit. The French tax authorities may challenge our eligibility for, or our calculation of, certain tax reductions or
deductions in respect of our research and development activities and, should the French tax authorities be successful,
our credits may be reduced, which would have a negative impact on our results of operations and future cash flows.
Furthermore, the French Parliament may decide to eliminate, or to reduce the scope or the rate of, the CIR benefit,
either of which it could decide to do at any time. If we fail to receive future CIR amounts, our business, prospects,
financial condition, cash flows or results of operations could be adversely affected.
We may be unable to carry forward existing tax losses.
As of December 31, 2023, we carried forward accumulated tax losses of €459.8 million. In 2014, we acquired
the companies Splicos, Wittycell and Zophis by means of a universal transfer of assets and liabilities. The tax losses
carried forward of the three companies combined (Splicos, Wittycell and Zophis) amounted to €26.0 million on the
date of the mergers and transfer of remaining assets. The transfer to us of these losses was subject to a post-merger
approval by the French tax authorities, which approved the transfer of a total amount of €22.5 million. As a result of
the transfer of these tax losses to us, our tax losses carried forward amounted to €308.8 million as at the end of 2022.
To the extent we have continued conducting the business that led to these losses for a minimum period of three
years, without making significant changes during this period, the transfer of such tax losses should be definitive. In
France, the maximum amount of carried forward tax losses that can be written off against the tax profits of a given
financial year is limited to €1 million plus 50% of the amount of taxable profits for the financial year exceeding
€1 million. The outstanding tax losses remain valid and can be carried forward to be written off against tax profits of
subsequent financial years subject to the same limit, for an unlimited period of time (subject to any “significant
change of activity” at our level). It cannot be ruled out that regulatory or legislative changes in corporate taxation
may suppress or limit all or part of the ability to use carried forward tax losses, or limit how long they can be used,
to offset future profits. Changes in corporate taxation regarding the use of carried forward tax losses to offset future
tax profits could have a material adverse effect on our financial position and results of operations.
Risks Related to Product Development, Regulatory Approval and Commercialization
Drug candidates under development must undergo costly, rigorous and highly regulated preclinical studies and
clinical trials, whose time of completion, number and outcomes are uncertain.
The development of a drug candidate is a long and expensive process with an uncertain outcome, progressing
in several phases, where the objective is to demonstrate the therapeutic benefit provided by the drug candidate for
one or more indications. Any failure during the various preclinical and clinical phases for a given indication could
delay development, production and commercialization of the therapeutic product concerned or even lead to
discontinuing its development. Identifying potential drug candidates and conducting preclinical testing and clinical
trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate
the data or required results required to obtain regulatory approval and achieve commercialization.
16
During clinical trials, we may encounter difficulties determining and recruiting patients with the appropriate
profile. This profile could also vary depending on the different phases of these clinical trials. Patients might then not
be recruited according to a timetable compatible with our financial resources which may result in a harm to our
operation results.
At each phase of clinical development, we must ask for authorization from the relevant authorities of various
countries, according to our development plan, to conduct clinical trials and then present the results of the clinical
trials to these authorities. The authorities may refuse to provide the authorizations necessary for clinical trials or
have additional requirements (for example, relating to study protocols, patient characteristics, treatment durations,
post-treatment follow-up, certain differences in interpreting results between local regulatory agencies), and in some
cases may require additional studies. Any refusal or decision by health authorities to require additional trials or
examinations would be likely to result in the discontinuation or delay of the development of the products concerned.
An absence of or delay in therapeutic response could also result in the delay or even discontinuation of the
development of our drug candidates.
We cannot guarantee that the development of our drug candidates will ultimately be successful, especially
within time frames compatible with our financial resources or market needs. Any failure or delay in the development
of these products would have a material adverse effect on our business, income, financial position and outlook.
We are developing drug candidates for inflammatory diseases. To our knowledge, currently, there are no
similar immunological treatments with a mechanism of action based on enhanced expression of a single microRNA
miR-124, with marketing authorization granted by competent regulatory authorities. As a result, the outlook is
uncertain for the development and profitability of obefazimod in the area of inflammatory diseases, its efficacy and
acceptance by patients, doctors and paying agencies. Animal testing does not necessarily predict the results that will
be obtained in humans. Positive results for obefazimod during Phase 1, Phase 2b or Phase 3 clinical trials or those
for all the products in the portfolio during their research or preclinical phases might not be confirmed by subsequent
phases. Such outcomes could have a material adverse impact on our business, income, financial position and growth.
We are heavily dependent on the success of our drug candidates, in particular obefazimod, and we cannot be
certain that obefazimod or any of our other current or future drug candidates will receive regulatory approval,
and, without regulatory approval, we will not be able to market our drug candidates.
We currently have no drug candidates approved for marketing, and we cannot guarantee that we will ever have
marketable drug candidates. Our ability to generate revenue related to sales, if any, will in the near future depend
entirely on the successful development and regulatory approval of obefazimod. In Europe and the United States, as
well as in many other countries, access to the drug market is strictly controlled and marketing must be authorized by
a regulatory authority. Most of the time, this registration application is filed with a national or federal health
authority. However, in the European Union, the marketing authorization application (“MAA”) must be submitted at
the EU-level to the European Medicines Agency (“EMA”) for categories of the most innovative medicinal products,
in order to obtain a centralized marketing authorization valid for all the European Union territory.
The research, testing, manufacturing, safety, efficacy, labeling, approval, sale, marketing and distribution of
our drug candidates are, and will remain, subject to comprehensive and extensive regulation controlled by the EMA
and European Union Member States national authorities in the European Union, the Food and Drug Administration
(“FDA”) in the United States, the Pharmaceuticals and Medical Devices Agency (“PMDA”) in Japan and other
regulatory authorities in other countries, with regulations differing from country to country. Subject to limited
exceptions, we are not permitted to market our drug candidates in the European Union, the United States or Japan
until we receive approval of an MAA from the European Commission following EMA’s opinion or (a) European
Union Member State(s) authority(ies) or a new drug application (“NDA”) from the FDA or the PMDA, respectively.
Regulators of each jurisdiction have their own procedures for approval of drug candidates. We have not submitted
any MAA for any of our drug candidates yet. Failure to obtain regulatory approval for our drug candidates in any
jurisdiction will prevent us from commercializing and marketing our drug candidates in such jurisdictions, and
marketing authorizations may be granted for narrow indications which may significantly reduce the scope of market
of our drug candidates.
Obtaining and maintaining marketing authorization, by country or by geographical area in the case of the
European Union, presupposes compliance with the mandatory standards imposed by the concerned regulatory
authorities and submission to the authorities of a great deal of information about the drug candidate regarding its
toxicity, dosage, quality, efficacy and safety all over its life cycle. The authorization process is long and expensive,
and the result of this process remains highly uncertain. We are therefore careful to continuously comply with good
practices in order not to jeopardize our chances of ultimately obtaining, directly or via our business partners,
marketing authorization for the products we are developing. Furthermore, obtaining marketing authorization for a
17
product in a given country or geographical area does not automatically ensure or immediately lead to obtaining
marketing authorization in other countries for the same product.
In order to obtain marketing authorization for one of our drug candidates, we have to perform preclinical
animal studies and complete human clinical trials in order to demonstrate the safety and efficacy of the product.
MAAs, NDAs and similar authorizations must include extensive preclinical and clinical data and supporting
information to establish the drug candidate’s safety and efficacy for each desired indication. In the event patients are
exposed to unforeseen and serious risks, we or the regulatory authorities may choose to suspend or terminate these
clinical trials.
NDAs, MAAs and similar authorizations must also include significant information regarding the chemistry,
manufacturing and controls for the drug. Obtaining approval of a MAA or a NDA and similar authorizations, and
collecting all required information, proof and data for this process, is a lengthy, expensive and uncertain process,
and we may not be successful in obtaining approval. This is further enhanced by the fact that each regulator has its
own requirements and procedures for the scientific evaluation or approval of drug candidates. The EMA, European
Union Member States national authorities, FDA and PMDA review processes can therefore take years to complete
and approval is never guaranteed.
In addition, delays in approvals or rejections of marketing applications in the European Union, the United
States or other countries may be based upon many factors, including regulatory requests for additional analyses,
reports, data, preclinical studies and clinical trials, regulatory questions regarding different interpretations of data
and results, changes in regulatory policy during the period of drug development and the emergence of new
information regarding our drug candidates or other drug candidates. Even if a drug is approved, the FDA, the EMA
or the PMDA, as the case may be, may limit the indications for which the drug may be marketed, require extensive
warnings on the drug labeling or require expensive and time-consuming post-marketing clinical trials or reporting as
conditions of approval.
Even if we receive regulatory approval for any drug candidate, we will be subject to ongoing regulatory
obligations and continued regulatory review, which may result in significant additional expense
Even if we receive approval of any of our drug candidates, such regulatory approval may be withdrawn, or
such approvals may be contingent on ongoing obligations and continued regulatory review, which may result in
significant additional expense. As a general matter, any regulatory approvals that we may receive for our drug
candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage,
advertising, promotion, import, export and recordkeeping for our drug candidates will be subject to extensive and
ongoing regulatory requirements. These requirements include submissions of safety, efficacy and other post-
marketing information and reports, registration, as well as ongoing compliance with current Good Manufacturing
Practice (“GMP”) and Good Clinical Practice requirements (“GCPs”) for any clinical trials that we may be required
to conduct post-marketing. In addition, manufacturers of drug products and their facilities are subject to continual
review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with
GMP regulations and standards.
Additionally, our drug candidates, even if approved, may be subject to restrictions or prohibition on
advertising, include limitations related to prescriptions by specialists, use restrictions for specified age groups,
warnings, precautions or contraindications, and may include burdensome post-approval study or risk management
requirements. For example, the FDA may require a risk evaluation and mitigation strategy (“REMS”) as a condition
of approval of our drugs candidates, which could include requirements for a medication guide, physician training
and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient
registries and other risk minimization tools.
Obtaining and maintaining a Good Manufacturing Practice (“GMP”) certificate will be required in order to
produce the immunotherapies that we are developing (for clinical trial purposes and during the commercialization
phase). We cannot guarantee that we will obtain or be able to maintain this certificate, nor that certain additional
constraints related to this certificate will not be imposed on us in the future. Any failure to follow and document
adherence to such GMP regulations or other regulatory requirements may lead to significant delays in the
availability of products for commercial sale or clinical trials, may result in the termination of or a hold on a clinical
trial, or may delay or prevent filing or approval of marketing applications for our products. Failure to comply with
applicable regulations could also result in the FDA or other applicable regulatory authorities taking various actions,
including:
•levying fines and other civil penalties;
•imposing consent decrees or injunctions;
18
•requiring us to suspend or put on hold one or more of our clinical trials;
•suspending or withdrawing regulatory approvals;
•delaying or refusing to approve pending applications or supplements to approved applications;
•requiring us or our third-party manufacturers to suspend manufacturing activities or product sales,
imports or exports;
•requiring us to communicate with physicians and other customers about concerns related to actual or
potential safety, efficacy and other issues involving our products;
•mandating product recalls or withdrawals or seizing products;
•imposing operating restrictions; and
•seeking criminal prosecutions.
Failure to obtain or maintain authorization for our drug candidates in one or more jurisdictions, particularly in
respect of our lead drug candidate, obefazimod, would have a material adverse effect on our business, outlook,
financial position, results and development.
Our drug candidates may cause undesirable side effects or have other properties that could delay or prevent their
regulatory approval, or, if approval is received, require our drug candidates to be withdrawn from the market,
require them to include safety warnings or otherwise limit their sales.
Undesirable side effects caused by our drug candidates could cause us or regulatory authorities to interrupt,
delay or halt clinical trials, or even discontinuation and could result in a more restrictive label or the delay or denial
of regulatory approval by the European Commission, FDA, PDMA or other comparable authorities in other
jurisdictions. If severe side effects were to occur, or if one of our drug candidates is shown to have other unexpected
characteristics, we may need to either restrict the use of such product to a smaller population or abandon
development of such drug candidates.
If one or more of our drug candidates received marketing approval, and we or others later identify undesirable
side effects caused by such drugs or negative interactions with other products or treatments (including, for example,
as a result of interactions with other products once on the market), a number of potentially significant negative
consequences could result, including:
•regulatory authorities may withdraw or reduce the scope of approvals of such product;
•regulatory authorities may require additional warnings on the product’s label;
•we may be required to create a medication guide outlining the risks of such side effects for distribution
to patients;
•we could be sued and held liable for harm caused to patients;
•physicians, healthcare payors, patients or the medical community in general may not recommend/use
our products;
•sales of the product may decrease significantly; and
•our reputation may suffer.
Any of these events could prevent us from achieving or maintaining market acceptance of the particular drug
candidate, if approved, and could have a material adverse effect on our business, prospects, financial condition, cash
flows or results of operations.
Clinical failure can occur at any stage of clinical development. The results of earlier clinical trials as well as data
from any interim analysis of ongoing trials are not necessarily predictive of future results and any drug candidate
we advance through clinical trials may not have favorable results in later clinical trials.
Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain.
Clinical failure can occur at any stage of our clinical development. Success in preclinical studies and early clinical
trials, as well as data from any interim analysis of ongoing trials do not ensure that subsequent clinical trials will
generate the same or similar results. A number of companies in the pharmaceuticals industry, including those with
greater resources and experience than us, have suffered significant setbacks in the last development phase (Phase 3)
clinical trials, even after seeing promising results in earlier clinical trials, and we could face similar setbacks. In
some instances, there can be significant variation in safety or efficacy results between different clinical trials of the
19
same drug candidate due to numerous factors, including changes in trial procedures set forth in protocols,
differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other
clinical trial protocols and the rate of dropout among clinical trial participants. Any such delays or failures could
negatively impact our business, financial condition, results of operation and prospects. The positive results generated
in preclinical and clinical trials for obefazimod does not ensure that current or future trials will continue to
demonstrate similar safety and/or efficacy results.
Drug candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite
having progressed through preclinical studies and earlier clinical trials. In addition to the safety and efficacy traits of
any drug candidate, clinical trial failures may result from a multitude of factors including flaws in trial design, dose
selection, placebo effect and patient enrollment criteria. Based upon negative or inconclusive results, we or our
collaborators may decide, or regulators may require us, to conduct additional clinical trials or preclinical studies.
Further, data obtained from trials and studies are susceptible to varying interpretation, and regulators may not
interpret our data as favorably as we do, which may delay, limit or prevent regulatory approval.
We cannot guarantee the commercial success or the pricing and reimbursement of the drug candidates that we
develop.
If we or one or more of our commercial partners succeeds in obtaining marketing authorization, allowing us or
them to market the therapeutic products developed by us, it may nevertheless take time to gain the support of the
medical community, health care providers and third-party payors.
The level of market acceptance for each of our products will depend on several factors, notably on the
following:
•prescribers’ perception of the product’s therapeutic benefit;
•healthcare policies established in each of the countries in which we are considering marketing our
products;
•possible occurrence of adverse reactions once marketing authorization has been obtained;
•ease of use of the product, especially relating to its mode of administration;
•cost of treatment;
•reimbursement policies of governments and other third parties;
•effectiveness of sales and marketing efforts;
•effective implementation of a scientific publication strategy;
•willingness of the target patient population to try new therapies and of physicians to prescribe these
therapies;
•prevalence and severity of any side effects;
•development of one or more competing products for the same indication; and
•restrictions on the use of the product together with medications.
Although the products we are developing are intended to provide a therapeutic response to a need that is
presently unmet, poor market penetration resulting from one or more of the factors described above would have a
negative impact on their commercialization and on our ability to generate profits, which could have a material
adverse effect on our business, outlook, financial position, income and growth.
The level of market acceptance and sale of our drug candidates, if approved, will heavily depend on the
availability of coverage and adequate reimbursement from third-party payors. The conditions for setting the sales
price and reimbursement rate for drugs are beyond the control of pharmaceutical companies. They are decided by
competent public committees and bodies and by social security or private insurance companies and are dependent on
a number of factors. Pricing and reimbursement schemes vary widely from country to country. In the European
Union, pricing and reimbursement are determined individually by European Union Member States. Some countries
may approve a specific price for a product while others may instead allow companies to fix their own prices for
products but monitor and control company profits. Within the US, as a principle, drug companies set their own list
prices, which may then be discounted through negotiations with payors. However, as a result of the Inflation
Reduction Act of 2022 (“IRA”), the Secretary of Health and Human Services is now authorized to negotiate prices
20
with pharmaceutical companies for certain drugs covered under Medicare Part D program (i.e., prescription drugs
for Americans aged 65 or older and Americans receiving social security disability).
Generally, the downward pressure on health care costs has become intense. As a result, increasingly high
barriers are being erected to the entry of new products. Delays in the price negotiation procedure may result in a
significant delay in marketing, our product may not obtain an appropriate level of reimbursement, or the accepted
price level and reimbursement rate of the treatments we market may be changed. We are also unable to guarantee
that we will succeed in maintaining, over time, the price level of our products or the accepted reimbursement rate.
Our future may depend on our most advanced clinical development program, obefazimod, since our other drug
candidates are in a less advanced stage of development.
Obefazimod is our most advanced drug candidate. Obefazimod has required, and may continue to require,
significant investments of our time and financial resources, as well as the special attention of highly qualified staff.
Consequently, if we were unable to obtain conclusive results in ongoing maintenance trials, Phase 3 of obefazimod
in UC or Phase 2 of obefazimod in CD, it could have a material adverse effect on our business, outlook, financial
position, results and development.
We may experience setbacks that could delay or prevent regulatory approval of our drug candidates or our
ability to commercialize any products, including:
•negative or inconclusive results from our preclinical studies or clinical trials or the clinical trials of
others for drug candidates similar to ours, leading to a decision or requirement to conduct additional
preclinical testing or clinical trials or abandon a program;
•product-related side effects experienced by subjects in our clinical trials or by individuals using drugs
or therapeutics comparable to our drug candidates;
•delays in submitting investigational new drug applications in the United States or comparable foreign
applications or delays or failure in obtaining the necessary approvals from regulators or institutional
review boards (“IRBs”) or ethics committees to commence a clinical trial, or a suspension or
termination of a clinical trial once commenced;
•if the FDA or comparable foreign authorities do not accept the earlier preclinical and clinical trial
work, then we may need to conduct additional preclinical studies or clinical trials beyond that which
we currently have planned and significant preclinical study or clinical trial delays also could shorten
any periods during which we may have the exclusive right to commercialize our drug candidates or
allow our competitors to bring products to market before we do and impair our ability to successfully
commercialize our drug candidates and may harm our business;
•conditions imposed by the FDA or comparable foreign authorities regarding the scope or design of our
clinical trials;
•delays in contracting with clinical sites or enrolling subjects in clinical trials, including due to any
health pandemic and/or other macroeconomic factors;
•delays or interruptions in the supply of materials necessary for the conduct of our clinical trials;
•regulators or IRBs or ethics committees may not authorize us or our investigators to commence a
clinical trial or conduct a clinical trial at a prospective trial site;
•the FDA or other comparable regulatory authorities may disagree with our clinical trial design,
including with respect to dosing levels administered in our planned clinical trials, which may delay or
prevent us from initiating our clinical trials with our originally intended trial design;
•delays in reaching, or failure to reach, agreement on acceptable terms with prospective trial sites,
investigators and prospective contract research organizations (“CROs”) which can be subject to
extensive negotiation and may vary significantly among different CROs and trial sites;
•the number of subjects required for clinical trials of any drug candidates may be larger than we
anticipate or subjects may drop out of these clinical trials or fail to return for post-treatment follow-up
at a higher rate than we anticipate;
•our CROs for preclinical studies or clinical trials may fail to comply with regulatory requirements or
meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical
trial protocol or take actions that could cause clinical sites or clinical investigators to drop out of the
trial, which may require that we add new clinical trial sites or investigators;
21
•greater than anticipated clinical trial costs, including as a result of delays or interruptions that could
increase the overall costs to finish our clinical trials as our fixed costs are not substantially reduced
during delays;
•we may elect to, or regulators, IRBs or Data Safety Monitoring Boards (“DSMBs”) may require that
we or our investigators, suspend or terminate clinical research or trials for various reasons, including
noncompliance with regulatory requirements or a finding that the participants are being exposed to
unacceptable health risks;
•we may not have the financial resources available to begin and complete the planned trials, or the cost
of clinical trials of any drug candidates may be greater than we anticipate;
•the supply or quality of our drug candidates or other materials necessary to conduct clinical trials of
our drug candidates may be insufficient or inadequate to initiate or complete a given clinical trial;
•the FDA or other comparable foreign regulatory authorities may require us to submit additional data
such as long term toxicology studies, or impose other requirements before permitting us to initiate a
clinical trial, including because the FDA has not reviewed our preclinical or clinical data, to date,
having been developed outside the United States;
•inability to compete with other therapies;
•poor efficacy of our drug candidates during clinical trials;
•unfavorable FDA or other regulatory agency inspection and review of clinical trial sites or
manufacturing facilities;
•unfavorable product labeling associated with any product approvals and any requirements for a Risk
Evaluation and Mitigation Strategy (“REMS”) that may be required by the FDA or comparable
requirements in other jurisdictions to ensure the benefits of an individual product outweigh its risks;
•unfavorable acceptance of our clinical trial data by the patient or medical communities or third-party
payors;
•delays and changes in regulatory requirements, policy and guidelines, including the imposition of
additional regulatory oversight around clinical testing generally or with respect to our technology in
particular; or
•varying interpretations of data by the FDA and similar foreign regulatory agencies.
We do not have complete control over many of these factors, including certain aspects of clinical development
and the regulatory submission process, potential threats to our intellectual property rights and our manufacturing,
marketing, distribution and sales efforts or that of any future collaborator.
We may find it difficult to enroll patients in our clinical trials. If we encounter difficulties enrolling patients in
our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.
Patient enrollment is a significant factor in the timing of clinical trials, and the timing of our clinical trials will
depend, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of
required follow-up periods. We may not be able to initiate or continue clinical trials for our drug candidates if we are
unable to locate and enroll a sufficient number of eligible patients to participate in these trials to such trial’s
conclusion as required by applicable regulatory authorities. The eligibility criteria of our clinical trials, once
established, may further limit the pool of available trial participants.
Patient enrollment in clinical trials may be affected by other factors, including:
•size and nature of the targeted patient population;
•severity of the disease or condition under investigation;
•availability and efficacy of approved therapies for the disease or condition under investigation;
•patient eligibility criteria for the trial in question as defined in the protocol;
•perceived risks and benefits of the drug candidate under study;
•clinicians’ and patients’ perceptions as to the potential advantages of the drug candidate being studied
in relation to other available therapies, including any products that may be approved for, or any drug
candidates under investigation for, the indications we are investigating;
22
•efforts to facilitate timely enrollment in clinical trials;
•patient referral practices of physicians;
•the ability to monitor patients adequately during and after treatment;
•proximity and availability of clinical trial sites for prospective patients;
•continued enrollment of prospective patients by clinical trial sites; and
•the risk that patients enrolled in clinical trials will drop out of such trials before completion.
Additionally, other pharmaceutical companies targeting these same diseases are recruiting clinical trial
patients from these patient populations, which may make it more difficult to fully enroll any clinical trials. We also
rely on, and will continue to rely on, CROs and clinical trial sites to ensure proper and timely conduct of our clinical
trials and preclinical studies. Though we have entered into agreements governing their services, we will have limited
influence over their actual performance. Our inability to enroll a sufficient number of patients for our clinical trials
would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment
delays in our clinical trials may result in increased development costs for our drug candidates and jeopardize our
ability to obtain regulatory approval for the sale of our drug candidates. Furthermore, even if we are able to enroll a
sufficient number of patients for our clinical trials, we may have difficulty maintaining enrollment of such patients
in our clinical trials.
We are developing certain of our drug candidates in combination with other therapies, and safety or supply issues
with combination use products may delay or prevent development and approval of our therapeutic candidates.
We are developing certain of our drug candidates in combination with one or more approved or investigational
therapies. Even if any drug candidate we develop were to receive marketing approval or be commercialized for use
in combination with other existing therapies, we would continue to be subject to the risks that the FDA, European
Commission, PDMA or similar foreign regulatory authorities could revoke approval of the therapy used in
combination with our product or that safety, efficacy, manufacturing or supply issues could arise with any of those
existing therapies. If the therapies we use in combination with our drug candidates are replaced as the standard of
care for the indications we choose for any of our drug candidates, the EMA, FDA, PDMA or similar foreign
regulatory authorities outside may require us to conduct additional clinical trials. The occurrence of any of these
risks could result in our own products, if approved, being removed from the market or being less successful
commercially.
We also may evaluate our drug candidates in combination with one or more therapies that have not yet been
approved for marketing by the FDA, European Commission, PDMA or similar foreign regulatory authorities. We
will not be able to market and sell any drug candidate we develop in combination with an unapproved therapy if that
unapproved therapy does not ultimately obtain marketing approval. In addition, unapproved therapies face the same
risks described with respect to our drug candidates currently in development, including the potential for serious
adverse effects, delay in their clinical trials and lack of FDA, European Commission, or PDMA, or similar foreign
regulatory authorities or PDMA approval.
If the FDA, European Commission or similar foreign regulatory authorities do not approve these other
therapies or revoke their approval of, or if safety, efficacy, manufacturing or supply issues arise with, the therapies
we choose to evaluate in combination with our drug candidates, we may be unable to obtain approval of or market
any such drug candidate.
We may conduct clinical trials for our drug candidates outside of the U.S., and the FDA may not accept data
from such trials, in which case our development plans may be delayed, which could materially harm our
business.
We have in the past conducted clinical trials or a portion of our clinical trials for our drug candidates outside
the U.S. The acceptance of study data from clinical trials conducted outside the U.S. or another jurisdiction by the
FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all.
In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the
U.S., for example, the FDA will generally not approve the application on the basis of foreign data alone unless (i)
the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical
investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid
without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the
FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, even where
the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as
support for an application for marketing approval unless the study is well-designed and well-conducted in
23
accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite
inspection if deemed necessary. Many foreign regulatory authorities have similar requirements for clinical data
gathered outside of their respective jurisdictions. In addition, such foreign trials would be subject to the applicable
local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any
comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the relevant
jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it may result in
the need for additional trials, which could be costly and time-consuming, and which may result in current or future
drug candidates that we may develop not receiving approval for commercialization in the applicable jurisdiction.
Interim, “top-line” and preliminary data from our clinical trials and preclinical studies that we announce or
publish from time to time may change as more patient data become available and are subject to audit and
verification procedures that could result in material changes in the final data.
From time to time, we may publicly disclose interim, top-line or preliminary data from our clinical trials and
preclinical studies, which is based on a preliminary analysis of then-available data, and the results and related
findings and conclusions are subject to change following a more comprehensive review of the data related to the
particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses
of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the
interim, top-line or preliminary results that we report may differ from future results of the same studies or trials, or
different conclusions or considerations may qualify such results, once additional data have been received and fully
evaluated. Top-line and preliminary data also remain subject to audit and verification procedures that may result in
the final data being materially different from the top-line or preliminary data we previously published. As a result,
top-line and preliminary data should be viewed with caution until the final data are available.
Interim data from clinical trials that we may complete are further subject to the risk that one or more of the
clinical outcomes may materially change as patient enrollment continues and more patient data become available.
Adverse differences between interim, top-line or preliminary data and final data could significantly harm our
business prospects. Further, disclosure of such data by us or by our competitors could result in volatility in the price
of our securities.
Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates,
calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could
impact the value of the particular program, the approvability or commercialization of the particular drug candidate or
product and our company in general. In addition, the information we choose to publicly disclose regarding a
particular study or clinical trial is based on what is typically extensive information, and you or others may not agree
with what we determine is material or otherwise appropriate information to include in our disclosure, and any
information we determine not to disclose may ultimately be deemed significant with respect to future decisions,
conclusions, views, activities or otherwise regarding a particular drug candidate or our business. If the interim, top-
line or preliminary data that we report differ from actual results, or if others, including regulatory authorities,
disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our drug candidates
may be harmed, which could harm our business, operating results, prospects or financial condition.
Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns
could hinder their ability to hire, retain or deploy key leadership and other personnel, prevent new or modified
products from being developed, reviewed, approved or commercialized in a timely manner or at all, which could
negatively impact our business.
The ability of the FDA and foreign regulatory authorities to review and approve new products can be affected
by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes,
the FDA’s or foreign regulatory authorities’ ability to hire and retain key personnel and accept the payment of user
fees, and other events that may otherwise affect the FDA’s or foreign regulatory authorities’ ability to perform
routine functions. Average review times at the FDA and foreign regulatory authorities have fluctuated in recent
years as a result. In addition, government funding of other government agencies that fund research and development
activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and
other agencies, such as the EMA following its relocation to Amsterdam and resulting staff changes, may also slow
the time necessary for new drugs or modifications to approved drugs and to be reviewed and/or approved by
necessary government agencies, which would adversely affect our business. For example, over the last several years,
the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to
furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, or if a
public health crisis prevents the FDA or other regulatory authorities from conducting their regular inspections,
reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory
authorities to timely review and process our regulatory submissions, which could have a material adverse effect on
our business.
24
The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of
off-label uses.
The FDA strictly regulates marketing, labeling, advertising and promotion of prescription drugs. These
regulations include standards and restrictions for direct-to-consumer advertising, industry-sponsored scientific and
educational activities, promotional activities involving the internet and off-label promotion. Any regulatory approval
that the FDA grants is limited to those specific diseases and indications for which a product is deemed to be safe and
effective by FDA. While physicians in the United States may choose, and are generally permitted, to prescribe drugs
for uses that are not described in the product’s labeling and for uses that differ from those tested in clinical trials and
approved by the regulatory authorities, our ability to promote any products will be narrowly limited to those
indications that are specifically approved by the FDA.
If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S.
federal government has levied large civil and criminal fines against companies for alleged improper promotion of
off-label use and has enjoined several companies from engaging in off-label promotion. The FDA has also requested
that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is
changed or curtailed. If we cannot successfully manage the promotion of any drug candidates, if approved, we could
become subject to significant liability, which would materially adversely affect our business and financial condition.
We may not be able to find industrial partners to pursue the clinical and commercial development of obefazimod.
We aim to enter into licensing and distribution partnerships with pharmaceutical companies in order to fund
the completion of the clinical development and marketing preparation of our lead drug candidate, obefazimod.
Consequently, we should find partners with sufficient capacity to perform Phase 1, 2 and/or 3 clinical trials on a
national or international scale and mass-produce, distribute and market immunotherapies and anti-inflammatory
treatments such as obefazimod. If we were to enter into such partnerships, the commercialization of our products
would depend, in part, on the clinical, industrial, marketing and commercial development efforts of our business
partners and the ability of these partners to produce and sell obefazimod. Any failure on the part of our partners
could have a material adverse effect on our growth and outlook.
It is also possible that we may not be able to enter into partnerships under economically reasonable conditions
or at all. This could have a material adverse effect on our business, outlook, financial position, results and
development.
We may not be able to conduct, or contract others to conduct, animal testing in the future, which could harm our
research and development activities.
Certain laws and regulations relating to drug development require us to test our drug candidates on animals
before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and
adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal
testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through
protests and other means. To the extent the activities of these groups are successful, our research and development
activities may be interrupted or delayed.
Risks Related to our Operations and Strategic Development
We expect to expand our organization, and as a result, we may encounter difficulties in managing our growth,
which could disrupt our operations.
In order to manage our anticipated development and expansion, including the potential commercialization of
our drug candidates in Europe and the United States, we must continue to implement and improve our managerial,
operational and financial systems, expand our facilities and continue to recruit and train additional qualified
personnel. Due to our limited financial resources and the limited experience of our management team in managing a
company with such expected growth, we may not be able to effectively manage the expansion of our operations or
recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and
may divert the attention of our management and business development resources away from day-to-day activities
and devote a substantial amount of time to managing internal or external growth. Our inability to manage growth or
unexpected difficulties encountered during expansion could have a material adverse effect on our business, income,
financial position, growth and outlook.
25
Our international operations subject us to various risks, and our failure to manage these risks could adversely
affect our results of operations.
We face significant operational risks as a result of doing business internationally, such as:
•fluctuations in foreign currency exchange rates;
•differing payor reimbursement regimes, governmental payors or patient self-pay systems and price
controls;
•potential changes to the accounting standards, which may influence our financial situation and results;
•becoming subject to the different, complex and changing laws, regulations and court systems of
multiple jurisdictions and compliance with a wide variety of foreign laws, treaties and regulations;
•reduced protection of, or significant difficulties in enforcing, intellectual property rights in certain
countries;
•difficulties in attracting and retaining qualified personnel;
•restrictions imposed by local labor practices and laws on our business and operations, including
unilateral cancellation or modification of contracts;
•rapid changes in global government, economic and political policies and conditions, political or civil
unrest or instability, terrorism or epidemics and other similar outbreaks or events, and potential failure
in confidence of our suppliers or customers due to such changes or events; and
•tariffs, trade protection measures, import or export licensing requirements, trade embargoes and other
trade barriers.
The market opportunities for our drug candidates may be limited to patients who are ineligible for or have failed
prior treatments and may be small or different from our estimates.
The current IBD treatment approach is influenced by multiple factors, including disease severity, previous
response to treatment, side effects and co-morbidities. The current standard of care for treatment of patients with
mild IBD involves the use of conventional anti-inflammatory therapies. Conventional anti-inflammatory therapies
include: aminosalicylates (e.g., 5-ASA), immunosuppressants or immunomodulators (e.g., 6-mercaptopurine (“6-
MP”), methotrexate (“MTX”)) and corticosteroids that are usually prescribed for short-term treatment to manage
flare-ups. Despite these conventional therapies, patients suffering from mild IBD may evolve towards moderate and
severe forms of IBD requiring the use of advanced therapies. However, available therapies often only have moderate
efficacy that changes or may wane over time, as patients have the potential to stop responding or do not respond at
all to these treatments and thus require new therapeutic management options.
While we hope to position obefazimod as a potential first-line advanced therapy, there is no guarantee that
even if approved, it would be approved for first-line advanced therapy. This could limit our potential market
opportunity. In addition, we may have to conduct additional clinical trials prior to gaining approval for first-line
advanced therapy.
The estimates of market opportunity and forecasts of market growth included in this Annual Report on Form 20-
F may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our
business may not grow at similar rates, or at all.
Market opportunity estimates and growth forecasts included in this Annual Report on Form 20-F are subject to
significant uncertainty and are based on assumptions and estimates which may not prove to be accurate. The
estimates and forecasts included in this Annual Report on Form 20-F relating to size and expected growth of our
target market may prove to be inaccurate. Even if the markets in which we compete meet the size estimates and
growth forecasts included in this Annual Report on Form 20-F, our business may not grow at similar rates, or at all.
Our growth is subject to many factors, including our success in implementing our business strategy, which is subject
to many risks and uncertainties.
Sales of our drug candidates could be adversely impacted by the reluctance of physicians, healthcare payors,
patients or the medical community in general to adopt them and by the availability of competing drugs.
Even if we obtain regulatory approval for one or more of our drug candidates, physicians, healthcare payors,
patients or the medical community in general may be reluctant to try a new drug due to the high degree of risk
associated with the application of new drugs in the field of human medicine, especially if the new drug differs from
the currently prevailing medication for a given complaint. We will need to expend significant sums of money to
26
market our products to increase the public’s awareness within numerous limits set by the regulations concerning the
promotion of drugs. If our products do not achieve an adequate level of acceptance, we may not generate enough
revenues to become profitable or the profitability may occur much later.
Competing drug candidates in the chronic inflammatory disease field are being manufactured and marketed by
other companies, including, but not limited to, AbbVie, Eli Lilly, Johnson & Johnson, Pfizer and Takeda. To
compete with other drugs, particularly any that sell at lower prices, our drug candidates will have to provide
medically significant advantages or be more cost-effective. Even if we can overcome physician reluctance and
compete with products that are currently on the market, our competitors may succeed in developing new, safer, more
accurate or more cost-effective treatments or therapeutic indications that could render our drug candidates obsolete
or non-competitive.
Global economic conditions could materially adversely impact demand for our drug candidates.
Our operations and performance depend significantly on economic conditions. Global financial conditions
continue to be subject to volatility arising from international geopolitical developments, such as the war in Ukraine
and global economic phenomena, as well as general financial market turbulence, natural phenomena and any public
health crisis. Uncertainty about global economic conditions could result in:
•third-party suppliers being unable to produce components for our drug candidates in the same quantity
or on the same timeline or being unable to deliver such parts and components as quickly as before or
subject to price fluctuations, which could have a material adverse effect on our production or the cost
of such production; and
•once our drug candidates are available for sale, customers postponing purchases of our drug candidates
in response to tighter credit, unemployment, negative financial news and/or declines in income or asset
values and other macroeconomic factors, which could have a material adverse effect on demand for
our drug candidates,
either of which could, accordingly, have a material adverse effect on our business, results of operations or
financial condition.
Access to public financing and credit can be negatively affected by the effect of these events on European,
U.S. and global credit markets. The health of the global financing and credit markets may affect our ability to obtain
equity or debt financing in the future and the terms at which financing or credit is available to us. These instances of
volatility and market turmoil could adversely affect our operations and the trading price of our ordinary shares.
Changes to trade policy, tariffs, and import/export regulations may have a material adverse effect on our
business, financial condition, and results of operations.
Changes in laws and policies governing foreign trade could adversely affect our business. As a result of recent
and future policy changes, there may be greater restrictions and economic disincentives on international trade. Such
changes have the potential to adversely impact the global and local economies, our industry and global demand for
our drug candidates and, as a result, could have a material adverse effect on our business, financial condition and
results of operations.
Fluctuations in currency exchange rates may significantly impact our results of operations.
Our business is located, and our operations are conducted, in Europe. As a result, we are exposed to an
exchange rate risk between the U.S. dollar and the Euro. The exchange rates between these currencies in recent years
have fluctuated significantly and may continue to do so in the future. An appreciation of the Euro against the
U.S. dollar could increase the relative cost of our drug candidates outside of Europe, which could have a negative
effect on sales. Conversely, to the extent that we are required to pay for goods or services in U.S. dollars, the
depreciation of the Euro against the U.S. dollar would increase the cost of such goods and services.
We do not hedge our currency exposure and, therefore, we incur currency transaction risk whenever we enter
into either a purchase or sale transaction using a currency other than the Euro. Given the volatility of exchange rates,
we might not be able to effectively manage our currency transaction risks, and volatility in currency exchange rates
might have a material adverse effect on our business, financial condition or results of operations.
27
We rely on a small number of third-party suppliers and manufacturers, and in certain cases a single-source
supplier, and we may be in a position of dependence with respect to these third parties.
We do not own or operate manufacturing facilities and have no current plans to develop our own clinical or
commercial-scale manufacturing capabilities. We currently rely, and expect to continue to rely, on a small number of
third-party suppliers, and in certain cases a single-source supplier, for the supply of various raw materials and
chemical products and clinical batches needed for our preclinical studies and clinical trials. In the case of certain
manufactured and clinical supplies, we rely on single-source suppliers. The supply of specific raw materials and
products required for conducting clinical trials and manufacturing our products cannot be guaranteed.
We are dependent on third parties for the supply of various materials, including chemical or biological
products that are necessary to produce drug candidates for our clinical trials and, ultimately, commercial supply for
any of our drug candidates that may receive approval.
The facilities used by our third-party manufacturers must be approved for the manufacture of our drug
candidates by the FDA, the EMA and any comparable foreign regulatory authorities in other jurisdictions, pursuant
to inspections that will be conducted after we submit an NDA to the FDA, MAA to the EMA, or submit a
comparable marketing application to a comparable regulatory authority. We do not control the manufacturing
process of, and are completely dependent on, third-party manufacturers for compliance with GMP requirements for
manufacture of our drug candidates. If these third-party manufacturers cannot successfully manufacture material that
conforms to our specifications and the strict regulatory requirements of any applicable regulatory authority, they will
not be able to secure and/or maintain regulatory approval for the use of their manufacturing facilities.
In addition, we have no control over the ability of third-party manufacturers to maintain adequate quality
control, quality assurance and qualified personnel. If any regulatory authority does not approve these facilities for
the manufacture our drug candidates, or if such authorities withdraw any such approval in the future, we may be
required to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain
regulatory approval for or market our drug candidates, if approved. Our failure, or the failure of our third-party
manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including
clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls,
operating restrictions and criminal prosecutions, any of which could significantly and adversely affect our financial
position.
Our or a third party’s failure to execute on our manufacturing requirements on commercially reasonable terms
and in compliance with GMP or other regulatory requirements could adversely affect our business in a number of
ways, including:
•an inability to initiate or complete clinical trials of our drug candidates in a timely manner;
•delay in submitting regulatory applications, or receiving regulatory approvals, for our drug candidates;
•subjecting third-party manufacturing facilities to additional inspections by regulatory authorities;
•requirements to cease development or to recall batches of our drug candidates; and
•in the event of approval to market and commercialize any drug candidate, an inability to meet
commercial demands.
In addition, we do not have any long-term commitments or supply agreements with any third-party
manufacturers. We may be unable to establish any long-term supply agreements with third-party manufacturers or to
do so on acceptable terms, which increases the risk of failing to timely obtain sufficient quantities of our drug
candidates or such quantities at an acceptable cost. Any performance failure on the part of our existing or future
manufacturers or suppliers could delay clinical development or marketing approval, and any related remedial
measures may be costly or time consuming to implement. We do not currently have second source for all required
raw materials used in the manufacture of our drug candidates. If our existing or future third-party manufacturers
cannot perform as agreed, we may be required to replace such manufacturers and we may be unable to replace them
on a timely basis or at all, which would have a material adverse impact on our financial position.
We rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not
successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory
approval for or commercialize our drug candidates and our business could be substantially harmed.
We are dependent on third parties to conduct our clinical trials and preclinical studies. Specifically, we rely
on, and will continue to rely on, medical institutions, clinical investigators, CROs and consultants to conduct
preclinical studies and clinical trials, in each case in accordance with trial protocols and regulatory requirements.
These CROs, investigators and other third parties play a significant role in the conduct and timing of these trials and
28
subsequent collection and analysis of data. Though we expect to carefully manage our relationships with such
CROs, investigators and other third parties, there can be no assurance that we will not encounter challenges or
delays in the future, or that these delays or challenges will not have a material adverse impact on our business,
financial condition and prospects. Further, while we have and will have agreements governing the activities of our
third-party contractors, we have limited influence over their actual performance. Nevertheless, we are responsible
for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol and legal,
regulatory and scientific standards and requirements, and our reliance on our CROs and other third parties does not
relieve us of our regulatory responsibilities.
In addition, we and our CROs are required to comply with stringent standards governing the conduct of
preclinical studies and clinical trials, including Good Laboratory Practice (“GLP”) and GCP requirements, which are
regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities, for our drug
candidates in clinical development. Regulatory authorities enforce GCPs through periodic inspections of trial
sponsors, principal investigators and trial sites. If we or any of our CROs or trial sites fail to comply with applicable
GLP, GCP or other requirements, the data generated in our clinical trials may be deemed unreliable, and the FDA or
comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our
marketing applications, if ever. Furthermore, our clinical trials must be conducted with materials manufactured in
accordance with GMP regulations. Failure to comply with these regulations may require us to repeat clinical trials,
which would delay the regulatory approval process.
There is no guarantee that any of our CROs, investigators or other third parties will devote adequate time and
resources to such trials or studies or perform as contractually required. If any of these third parties fails to meet
expected deadlines, adhere to our clinical protocols or meet regulatory requirements, or otherwise perform in a
substandard manner, our clinical trials may be extended, delayed or terminated. In addition, many of the third parties
with whom we contract may also have relationships with other commercial entities, including our competitors, for
whom they may also be conducting clinical trials or other activities that could harm our competitive position. In
addition, principal investigators for our clinical trials may be asked to serve as scientific advisors or consultants to us
from time to time and may receive cash or equity compensation in connection with such services. If these
relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes
that the financial relationship may have affected the interpretation of the study, the integrity of the data generated at
the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which
could result in the delay or rejection by the FDA of any NDA we submit. Any such delay or rejection could prevent
us from commercializing our drug candidates.
In addition, our CROs have the right to terminate their agreements with us in the event of an uncured material
breach and under other specified circumstances. If any of our relationships with these third parties terminate, we
may not be able to enter into arrangements with alternative third parties on commercially reasonable terms or at all.
Switching or adding additional CROs, investigators and other third parties involves additional cost and requires our
management’s time and focus. In addition, there is a natural transition period when a new CRO commences work.
As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines.
Though we work to carefully manage our relationships with our CROs, investigators and other third parties, there
can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges
will not have a material adverse impact on our business, financial condition and prospects.
If any of our relationships with these third parties terminate, we may not be able to enter into arrangements
with alternative third parties on commercially reasonable terms or at all. Switching or adding additional CROs,
investigators and other third parties involves additional cost and requires our management’s time and focus. In
addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can
materially impact our ability to meet our desired clinical development timelines. Though we work to carefully
manage our relationships with our CROs, investigators and other third parties, there can be no assurance that we will
not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse
impact on our business, financial condition and prospects.
Our future success depends on our ability to retain our key executives and to attract, retain and motivate
qualified personnel.
We are highly dependent on our management, scientific and medical personnel whose services are critical to
our success. Our success depends greatly on the involvement and expertise of our senior executives and qualified
scientific staff. While Dr. Philippe Pouletty, MD, our founder and Chairman of our Board since our inception in
2013, resigned from his Chairman position in August 2022, he continues to support our development as a member of
29
our Board as the representative for Truffle Capital. We do not maintain key person insurance. The temporary or
permanent unavailability of our management and scientific staff, as well as Dr. Pouletty, could lead to:
•loss of know-how and weakening of certain activities, especially in the case of transfer to the
competition; and
•deficiencies in terms of technical skills that could slow down activity and ultimately impair our ability
to reach our objectives.
Recruiting and retaining additional qualified management and scientific, clinical, manufacturing and sales and
marketing personnel will also be critical to our success, particularly as we expand in order to acquire additional
skills, such as manufacturing, quality assurance and regulatory and medical affairs. The loss of the services of our
senior management team or other key employees could impede the achievement of our research, development and
commercialization objectives and seriously harm our ability to successfully implement our business strategy.
Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of
time because of the limited number of individuals in our industry with the breadth of skills and experience required
to successfully develop, gain regulatory approval of and commercialize drug candidates. Competition to hire from
this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable
terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel.
We also experience intense competition for the hiring of scientific and clinical personnel from other
companies, universities and research institutions. We may not be able to attract or retain qualified management and
scientific personnel in the future due to intense competition for a limited number of qualified personnel. Many of
those that compete with us for qualified personnel have greater financial and other resources, different risk profiles
and a longer history in the industry than we do. Our competitors may also provide more diverse opportunities and
better chances for career advancement. An inability to attract and retain high quality personnel will have a material
adverse effect on our business, prospects, financial condition, cash flow or results of operations.
In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in
formulating our research and development and commercialization strategy. Our consultants and advisors may be
employed by employers other than us and may have commitments under consulting or advisory contracts with other
entities that may limit their availability to us. If we are unable to continue to attract and retain high quality
personnel, the marketing and production of our drugs could be delayed or prevented, which could, in turn, have a
material adverse effect on our business, prospects, financial condition, cash flows or results of operations.
Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other
improper activities, including noncompliance with regulatory standards and requirements and insider trading.
We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants
and commercial partners. Misconduct by these parties could include intentional failures, reckless and/or negligent
conduct or unauthorized activity that violates (i) the laws and regulations of the European Economic Area (“EEA”)
countries, the European Commission, FDA and other regulatory authorities, including those laws requiring the
reporting of true, complete and accurate information to such authorities, (ii) manufacturing standards, (iii) federal
and state data privacy, security, fraud and abuse and other healthcare laws and regulations in Europe, the United
States and elsewhere and (iv) laws that require the true, complete and accurate reporting of financial information or
data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive
laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices.
These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales
commission, customer incentive programs and other business arrangements. Such misconduct also could involve the
improper use of individually identifiable information, including, without limitation, information obtained in the
course of clinical trials, creating fraudulent data in our preclinical studies or clinical trials or illegal misappropriation
of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always
possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect
and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting
us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or
regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other
misconduct, even if none occurred. If any such actions are instituted against us and we are not successful in
defending ourselves or asserting our rights, those actions could result in significant civil, criminal and administrative
penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government-funded
healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become
subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these
laws, contractual damages, reputational harm and the curtailment or restructuring of our operations, any of which
could have a negative impact on our business, financial condition, results of operations and prospects.
30
We have limited infrastructure in market access, sales, marketing and distribution.
We lack infrastructure and resources in the fields of sales, marketing and distribution. We need to develop our
own marketing and sales capacity, either alone or with partners once marketing authorizations have been obtained.
As part of setting up our sales and marketing infrastructure, we will need to incur additional expenses, mobilize
management resources, implement new skills and take the time necessary to set up the appropriate organization and
structure to support the products in accordance with current legislation and, more generally, optimize
commercialization efforts. We compete with many companies that currently have extensive, experienced and well-
funded market access, marketing and sales operations to recruit, hire, train and retain marketing and sales personnel,
and will have to compete with those companies to recruit, hire, train and retain any of our own market access,
marketing and sales personnel. If we are unable to expand our sales and marketing team, we may be unable to
compete successfully against these more established companies. Alternatively, if we choose to collaborate, either
globally or on a territory-by-territory basis, with third parties that have direct sales forces and established
distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force
and distribution systems, we will be required to negotiate and enter into arrangements with such third parties relating
to the proposed collaboration. If we are unable to enter into such arrangements when needed, on acceptable terms, or
at all, we may not be able to successfully commercialize any of our drug candidates that receive regulatory approval
or any such commercialization may experience delays or limitations. Factors that may inhibit our efforts to build a
sales, marketing and distribution organization:
•our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;
•the inability of sales personnel to obtain access to physicians, educate physicians about patients for
whom our drug candidates may be appropriate treatment options and attain adequate numbers of
physicians to prescribe any drugs;
•the inability of reimbursement professionals to negotiate arrangements for formulary access,
reimbursement and other acceptance by payors;
•restricted or closed distribution channels that make it difficult to distribute our products to segments of
the patient population;
•the lack of complementary medicines to be offered by sales personnel, which may put us at a
competitive disadvantage relative to companies with more extensive product lines; and
•unforeseen costs and expenses associated with creating an independent sales and marketing
organization.
There are numerous competitors in the market for therapeutic treatments of inflammatory diseases.
The biotechnology and pharmaceutical industries are highly competitive and subject to significant and rapid
technological change as researchers learn more about diseases and develop new technologies and treatments. Many
pharmaceutical companies, biotech companies, institutions, universities and other research organizations are actively
engaged in the research, discovery, development and commercialization of therapeutic responses for the treatment of
the diseases targeted by us. Significant competitive factors in our industry include: (i) product efficacy and safety;
(ii) quality and breadth of an organization’s technology; (iii) skill of an organization’s employees and its ability to
recruit and retain key employees; (iv) timing and scope of regulatory approvals; (v) government reimbursement rates
for, and the average selling price of, pharmaceutical products; (vi) the availability of raw materials and qualified
manufacturing capacity; (vii) manufacturing costs; (viii) intellectual property and patent rights and their protection;
and (ix) sales and marketing capabilities. Given the intense competition in our industry, we cannot assure you that
any of the products that we successfully develop will be clinically superior or scientifically preferable to products
developed or introduced by our competitors. In addition, significant delays in the development of our drug
candidates could allow our competitors to succeed in obtaining European Commission, FDA, PMDA or other
regulatory approvals for their drug candidates more rapidly than us, which could place us at a significant competitive
disadvantage or deny us marketing exclusivity rights.
Our competitors in the chronic inflammatory disease field are primarily large pharmaceuticals companies
including, but not limited to AbbVie, Eli Lilly, Johnson & Johnson, Pfizer and Takeda. Several lines of research are
being developed to improve the treatment of IBD. Many companies are working to develop new, more effective and
better tolerated treatments with more practical formulations, especially small molecules administered orally, better
accepted than monoclonal antibodies that require administration by injection. See “Item 4.B—Competition.”
Further, our competitors may be more effective at using their technologies to develop commercial products.
Many of the organizations competing with us have significantly greater financial resources and expertise in research
and development, manufacturing, preclinical studies, conducting clinical trials, obtaining regulatory approvals and
marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more
31
resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may
also prove to be significant competitors, particularly through partnership arrangements with large and established
companies. These companies also compete with us in recruiting and retaining qualified scientific and management
personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring
technologies complementary to, or necessary for, our programs.
The development potential in the markets in which we operate is such that the arrival of new competition is
probable. New market entrants, increased competition in specific areas, or in general, would have a material adverse
effect on our business, income, financial position and outlook for growth.
We depend on, and will continue to depend on, collaboration and strategic alliances with third partners. To the
extent we are able to enter into collaborative arrangements or strategic alliances, we will be exposed to risks
related to those collaborations and alliances.
An important element of our strategy for developing, manufacturing and commercializing our drug candidates
is entering into partnerships and strategic alliances with other pharmaceutical companies or other industry
participants. The collaboration agreements that we have established, and any collaboration arrangements that we
may enter into in the future, may not be successful, which would have a negative impact on our business, results of
operations, financial condition and growth prospects.
Any partnerships or alliance we have or may have in the future may be terminated for reasons beyond our
control or we may not be able to negotiate future alliances on acceptable terms, if at all. These arrangements may
result in us receiving less revenue than if we sold our products directly, may place the development, sales and
marketing of our products outside of our control, may require us to relinquish important rights or may otherwise be
on unfavorable terms. Collaborative arrangements or strategic alliances will also subject us to a number of risks,
including the risk that:
•we may not be able to control the amount and timing of resources that our strategic partner/
collaborators may devote to the drug candidates;
•strategic partner/collaborators may experience financial difficulties;
•the failure to successfully collaborate with third parties may delay, prevent or otherwise impair the
development or commercialization of our drug candidates or revenue expectations;
•products being developed by partners/collaborators may never reach commercial stage resulting in
reduced or even no milestone or royalty payments;
•business combinations or significant changes in a collaborator’s business strategy may also adversely
affect a collaborator’s willingness or ability to complete their obligations under any arrangement;
•a collaborator could independently move forward with a competing product developed either
independently or in collaboration with others, including our competitors; and
•collaborative arrangements are often terminated or allowed to expire, which would delay the
development and may increase the cost of developing drug candidates.
Our partnerships and licensing agreements relating to the technologies belonging to us may not be successful.
The various drug candidates developed by us arise from proprietary or licensed technologies with leading
academic partners, including Scripps Research Institute, University of Chicago, Brigham Young University, the
Montpellier Institute of Molecular Genetics at the Centre National de la Recherche Scientifique (“CNRS”) and the
Institut Curie. If the clinical trials conducted by us were to reveal safety and/or therapeutic efficacy problems or if
the use of one of the platforms were to violate an intellectual property right held by a third party, this could threaten
the use and operation of some of our technology platforms and require additional research and development efforts
and additional time and expense to address these difficulties, with success not being guaranteed. The development of
a portion of our product portfolio would be affected, which would have a material adverse effect on our business,
outlook, growth, financial position and income.
The reimbursement of drugs and treatments is beyond our control.
After achieving regulatory authorization and once marketing authorization is granted, the process of setting
the sales price of drugs and their reimbursement rates begins. The conditions for setting the sales price and
reimbursement rate for drugs are beyond the control of pharmaceutical companies. They are decided by competent
public committees and bodies and by social security or private insurance companies. In this context, we or our
32
partners could be asked to perform additional studies on our products. These studies could generate additional costs
for us or our partners and lead to delays in marketing the drug, which could have an impact on our financial position.
There is significant uncertainty related to the reimbursement of newly-approved drugs. The level of
reimbursement will impact market acceptance and sale of our drug candidates. Reimbursement by a third-party is
dependent on a number of factors, including, without limitation, the third-party payor’s determination that use of a
product is:
•a covered benefit under its health plan;
•safe, effective and medically necessary;
•appropriate for the specific patient;
•cost-effective; and
•neither experimental nor investigational.
The possibility that we could receive royalties from our industrial partner or partners on the sale of some of
our products and our ability to make sufficient profits on the marketing of our treatments or those for which we have
entered into distribution contracts will depend on these reimbursement conditions. If delays in the price negotiation
procedure result in a significant delay in marketing, if our product does not obtain an appropriate level of
reimbursement, or if the accepted price level and reimbursement rate of the treatments we market are changed, our
profitability will be reduced.
We are also unable to guarantee that we will succeed in maintaining, over time, the price level of our products
or those for which licenses have been granted, or the accepted reimbursement rate. Under these conditions, there
could be a material adverse effect on our business, financial position and results of operations.
The pricing, insurance coverage and reimbursement status of newly-approved products is uncertain. Failure to
obtain or maintain adequate coverage and reimbursement for our drug candidates, if approved, could limit our
ability to market those products and decrease our ability to generate product revenue.
Successful sales of our drug candidates, if approved, depend on the availability of coverage and adequate
reimbursement from third-party payors including governmental healthcare programs, such as Medicare and
Medicaid in the United States, managed care organizations and commercial payors, among others. Significant
uncertainty exists as to the coverage and reimbursement status of any drug candidates for which we obtain
regulatory approval.
In the United States, no uniform policy for coverage and reimbursement exists, and coverage and
reimbursement for drug products can differ significantly from payor to payor. Therefore, one payor’s determination
to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug
product. Third-party payors often follow Medicare coverage policy and payment limitations in setting their own
reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. As
a result, the coverage determination process is often a time-consuming and costly process that will require us to
provide scientific and clinical support for the use of our products to each payor separately, with no assurance that
coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Moreover,
coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and
reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable
coverage policies and reimbursement rates may be implemented in the future.
Reimbursement may impact the demand for, and/or the price of, any product for which we obtain marketing
approval. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement
payment rates may not be adequate or may require co-payments that patients find unacceptably high. Patients who
are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on
third-party payors to reimburse all or part of the costs associated with their prescription drugs. Patients are unlikely
to use our products unless coverage is provided, and reimbursement is adequate to cover all or a significant portion
of the cost of our products. Therefore, coverage and adequate reimbursement is critical to new product acceptance.
Additionally, we or our collaborators may develop companion diagnostic tests for use with our drug
candidates. We or our collaborators will be required to obtain coverage and reimbursement for these tests separate
and apart from the coverage and reimbursement we seek for our drug candidates, once approved. Similar challenges
to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to
companion diagnostics. Our inability to promptly obtain coverage and adequate reimbursement from both third-
party payors for the drug candidates and companion diagnostic tests that we or our collaborators develop and for
33
which we obtain regulatory approval could have a material and adverse effect on our business, financial condition,
results of operations and prospects.
In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide
that products may be marketed only after a reimbursement price has been agreed. Some countries may require the
completion of additional studies that compare the cost-effectiveness of a particular drug candidate to currently
available therapies. EU member states may approve a specific price for a product or it may instead adopt a system of
direct or indirect controls on the profitability of the company placing the product on the market. Other member
states allow companies to fix their own prices for products, but monitor and control company profits. The downward
pressure on health care costs has become intense. As a result, increasingly high barriers are being erected to the
entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert
competitive pressure that may reduce pricing within a country. Any country that has price controls or reimbursement
limitations may not allow favorable reimbursement and pricing arrangements, and prices are usually revised
periodically, such that any given price may decrease upon various occurrences.
Additionally, the containment of healthcare costs has become a priority of federal and state governments, and
the prices of drugs have been a focus of this effort. The U.S. government, state legislatures and foreign governments
have shown significant interest in implementing cost-containment programs, including price controls, restrictions on
reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-
containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures,
could further limit our net revenue and results.
Price controls may be imposed in markets in which we operate, which may negatively affect our future
profitability.
In some countries, particularly EU member states, Japan, Australia and Canada, the pricing of prescription
drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can
take considerable time after receipt of marketing approval for a product. In addition, there can be considerable
pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost
containment measures. Political, economic and regulatory developments may further complicate pricing
negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used
by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member
states, can further reduce prices. In some countries, we or our collaborators may be required to conduct a clinical
trial or other studies that compare the cost-effectiveness of our drug candidates to other available therapies in order
to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or
authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and
other countries. If reimbursement of our drug candidates is unavailable or limited in scope or amount, or if pricing is
set at unsatisfactory levels, there could be a material adverse effect on our business, financial condition or results of
operations.
If our information technology systems or those of the third parties upon which we rely, or our data are or were
compromised, we could experience adverse consequences resulting from such compromise, including but not
limited to: regulatory investigations or actions; litigation; fines and penalties; disruptions of our business
operations; reputational harm; loss of revenue and profits; and other adverse consequences.
In the ordinary course of our business, we and the third parties upon which we rely process personal data
(including data we collect about trial participants in connection with clinical trials) and other sensitive information,
including proprietary and confidential business data, trade secrets, intellectual property, sensitive third-party data,
business plans, transactions, and financial information (collectively, sensitive data). We and the third parties upon
which we rely face a variety of evolving threats to information technology systems and data.
Cyber-attacks, malicious internet-based activity, online and offline fraud and other similar activities threaten
the confidentiality, integrity and availability of our sensitive data and information technology systems, and those of
the third parties upon which we rely. Such threats are prevalent and continue to rise, are increasingly difficult to
detect, and come from a variety of sources, including traditional computer “hackers,” threat actors, “hacktivists,”
organized criminal threat actors, personnel (such as through error, theft or misuse), sophisticated nation states and
nation-state-supported actors. For geopolitical reasons and in conjunction with military conflicts and defense
activities, some actors have in the past and are expected to in the future engage in nefarious acts. During times of
war and other major conflicts, we and the third parties upon which we rely may be vulnerable to a heightened risk of
these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply
chain and ability to produce, sell and distribute our services.
34
We and the third parties upon which we rely are subject to and have experienced a variety of evolving threats,
including but not limited to social-engineering attacks (including through deep fakes, which may be increasingly
more difficult to identify as a fake, and phishing attacks), malicious code (such as viruses and worms), malware
(including as a result of advanced persistent threat intrusions), denial-of-service attacks, credential stuffing attacks,
credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs,
server malfunctions, software or hardware failures, loss of data or other information technology assets, adware,
telecommunications failures, earthquakes, fires, floods, other natural disasters, attacks enhanced or facilitated by AI,
and other similar threats. In particular, severe ransomware attacks are becoming increasingly prevalent and can lead
to significant interruptions in our operations, ability to provide our services, loss of sensitive data and income,
reputational harm, and diversion of funds. Extortion payments may alleviate the negative impact of a ransomware
attack, but we may be unwilling or unable to make such payments due to, for example, applicable laws or
regulations prohibiting such payments.
Remote work has become more common and has increased risks to our information technology systems and
data, as more of our personnel utilize network connections, computers, and devices outside our premises or network,
including working at home, while in transit and in public locations. Additionally, future or past business transactions
(such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our
systems could be negatively affected by vulnerabilities present in acquired or integrated entities’ systems and
technologies. Furthermore, we may discover security issues that were not found during due diligence of such
acquired or integrated entities, and it may be difficult to integrate companies into our information technology
environment and security program.
In addition, our reliance on third-party service providers could introduce new cybersecurity risks and
vulnerabilities, including supply-chain attacks, and other threats to our business operations. We may rely on third-
party service providers and technologies to operate critical business systems to process sensitive data in a variety of
contexts, including, without limitation, cloud-based infrastructure, cybersecurity monitoring, data hosting, personnel
email, and other functions. We may also rely on third-party service providers to provide other products, services,
parts, or otherwise to operate our business. Our ability to monitor these third parties’ information security practices
is limited, and these third parties may not have adequate information security measures in place. If our third-party
service providers experience a security incident or other interruption, we could experience adverse consequences.
While we may be entitled to damages if our third-party service providers fail to satisfy their privacy or security-
related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such
award. In addition, supply-chain attacks have increased in frequency and severity, and we cannot guarantee that
third parties’ infrastructure in our supply chain or our third-party partners’ supply chains have not been
compromised.
While we have implemented security measures designed to protect against security incidents, there can be no
assurance that these measures will be effective. We take steps designed to detect, mitigate, and remediate
vulnerabilities in our information systems (such as our hardware and/or software, including that of third parties upon
whom we rely). We may not, however, detect and remediate all such vulnerabilities including on a timely and
effective basis. Further, we may experience delays in developing and deploying remedial measures and patches
designed to address identified vulnerabilities. These vulnerabilities could be exploited and result in a security
incident.
Any of the previously identified or similar threats have caused and could cause a security incident or other
interruption that could result in unauthorized, unlawful, or accidental acquisition, modification, destruction, loss,
alteration, encryption, disclosure of, or access to or other compromise of our sensitive data or our information
technology systems, or those of the third parties upon whom we rely. A security incident or other interruption could
disrupt our ability (and that of third parties upon whom we rely) to provide our services.
We may expend significant resources or modify our business activities (including our clinical trial activities)
to try to protect against security incidents. Additionally, certain data privacy and security obligations may require us
to implement and maintain specific security measures or industry-standard or reasonable security measures to
protect our information technology systems and sensitive data.
Applicable data privacy and security obligations may require us to notify relevant stakeholders, including
affected individuals, regulators, investors and others, of security incidents. Such disclosures are costly, and the
disclosure or the failure to comply with such requirements could lead to adverse consequences.
If we (or a third party upon whom we rely) experience a security incident or are perceived to have experienced
a security incident, we may experience adverse consequences. These consequences may include: government
enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting
requirements and/or oversight; restrictions on processing sensitive data (including personal data); litigation
35
(including class claims); indemnification obligations; negative publicity; reputational harm; monetary fund
diversions; interruptions in our operations (including availability of data); financial loss; and other similar harms.
Security incidents and attendant consequences may cause customers to stop using our services, deter new customers
from using our services, and negatively impact our ability to grow and operate our business.
Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that
limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our
data privacy and security obligations. We cannot be sure that our insurance coverage will be adequate or sufficient
to protect us from or to mitigate liabilities arising out of our privacy and security practices, that such coverage will
continue to be available on commercially reasonable terms or at all, or that such coverage will pay future claims.
Additionally, sensitive information of the Company could be leaked, disclosed, or revealed as a result of or in
connection with our personnel’s or vendors’ use of generative AI technologies.
As an example of our being subject to the variety of cybersecurity threats discussed above, in 2023, we
learned that two sites at which we conduct clinical trials experienced cybersecurity incidents. In response to each
incident, we conducted an investigation that largely relied upon the sites’ investigations. We determined that neither
of these incidents were material. These incidents, however, exemplify the types of threats we face including due to
our reliance on service providers.
An outbreak of communicable diseases around the world may cause disruption to our business.
Any public health crisis due to the outbreak of communicable diseases may cause any of the following:
•delays or difficulties in recruiting patients for our clinical trials;
•delays or difficulties in launching clinical trial sites, including difficulties in recruiting investigators
and clinical site staff; and
•diversion of health care resources from the conduct of clinical trials, of hospital staff supporting the
conduct of clinical trials.
In addition to the risks listed above, and as part of our clinical trials in countries in pandemic zones, we may
also experience the following adverse effects:
•potential delays in the conduct of our research and preclinical studies, preventing research and
preclinical studies from being conducted as planned;
•delays in obtaining authorizations from the administrative and regulatory authorities required to launch
the planned preclinical studies and clinical trials;
•delays in the receipt of supplies and equipment necessary for the completion of our research activities
and our preclinical studies and clinical trials;
•interruption or delays affecting the activity of contractors who provide research services to us;
•refusal of the competent regulatory authorities to accept data from clinical trials conducted in the
geographical areas affected by the pandemic;
•the interruption of global maritime trade could affect the transportation of research materials for
preclinical studies and clinical trials, such as experimental drugs and comparator drugs used in our
clinical trials; and
•delays in the necessary interactions with local authorities, ethics committees or other important and
third-party co-contracting bodies due to limitations in human resources or forced leave of state
employees.
If one or more of the above risks were to materialize, the planned and ongoing clinical trials and, therefore, the
publication of the data and results of these studies and all subsequent steps leading to the commercialization of drug
candidates being studied, could be significantly delayed. Such a situation could have a material adverse effect on our
business, income, financial position and growth.
The extent to which the outbreak of communicable diseases around the world may impact our activity and
clinical trials will depend on future developments, which cannot be predicted with certainty, such as the emergence
of diseases that may be resistant to the vaccines or treatments currently available, access to vaccines and treatments
for the various populations worldwide, the final geographical spread of the disease, its duration, travel restrictions
and social distancing measures in the European Union, the United States and other countries, business closures or
36
disruptions, and the effectiveness of measures taken in those countries to contain and treat the disease. There can be
no assurance that the outbreak of communicable diseases around the world will not result in an adverse effect on
financial markets, our share price and our ability to obtain finance.
The war between Ukraine and Russia may affect our business, industry and the markets in which we operate.
In February 2022, Russia invaded Ukraine. The conflict has already had major implications for the global
economy and the rate of inflation, particularly in relation to the supply of energy, raw materials and food products. It
has also caused intense volatility on the financial markets, something that is still ongoing at the reporting date and
has pushed down stock market prices around the world.
Given these developments, we have decided not to include Russia and Belarus in our global Phase 3 program
for obefazimod in UC. However, the global scale of this conflict cannot be predicted at this stage. We, therefore,
cannot rule out an adverse impact of this conflict on our business, including in terms of access to raw materials,
logistics, the performance of clinical trials and in relation to any future financing we may seek.
The Phase 2b maintenance trial of obefazimod in moderately to severely active UC is our only clinical trial
currently in progress in Ukraine. We have, however, terminated a few trial sites since the Russia/Ukraine war began.
The 12-month assessment was carried out in all the Ukrainian patients before the war broke out and these patients
are therefore included in the one-year maintenance results that were reported on April 6, 2022. Ukrainian patients
who completed the two-year Phase 2b maintenance trial have been transitioned to the long-term safety and efficacy
trial that is still on-going. None of these sites are located in the Crimea Region of Ukraine, the so-called Donetsk
People’s Republic, or the so-called Luhansk People’s Republic. We are also evaluating the possibility to include a
few Ukrainian sites in the western part of Ukraine in the ABTECT Phase 3 clinical trials.
Risks Related to Intellectual Property
Our ability to exclusively commercialize our drug candidates may decrease if we are unable to protect our
intellectual property rights or if these rights are insufficient for our purposes.
Our commercial success depends in part on our ability and the ability of our partners to obtain, maintain and
ensure, against third parties, the protection of our patents, trademarks and related applications and other intellectual
property rights or similar rights (such as trade secrets, business secrets and know-how) or those we are authorized to
use in the course of our business in Europe, the United States, Asia and other key countries. We dedicate substantial
financial and human resources to this and intend to continue our policy of protection through new patent
applications as soon as we deem it appropriate.
Our technology is currently protected by patents and patent applications that we have filed or for which we
have an exclusive license. However, we or our partners might not be able to maintain the protection of our
intellectual property rights and we could, thereby, lose our technological and competitive advantage in whole or in
part.
Firstly, our intellectual property rights and those of our partners offer protection for a period that may vary
from one territory to another. The term of individual patents depends upon the legal term of the patents in the
countries in which they are obtained. In most countries in which we have obtained or are seeking patent protection
for our drug candidates, the patent term is 20 years from the earliest filing date of a non-provisional patent
application. In the United States, the term of a patent may be lengthened by a patent term adjustment, which
provides for term extension in the case of administrative delays at the United States Patent and Trademark Office
(“USPTO”) in granting a patent, or may be shortened if a patent is terminally disclaimed over another patent with an
earlier expiration date. Furthermore, in the United States, the term of a patent covering an FDA approved drug may
be eligible for a patent term extension under the Hatch-Waxman Amendments as compensation for the loss of patent
term during the FDA regulatory review process. The period of extension may be up to five years beyond the
expiration of the patent but cannot extend the term of a patent beyond a total of 14 years from the date of product
approval. Only one patent covering a single FDA-approved product among those eligible for an extension may be
extended. In the future, if any of our drug candidates receives FDA approval, we expect to apply for a patent term
extension, if available, to extend the term of the patent covering such approved drug product. In France and the rest
of Europe generally, the term of a patent is 20 years from the date the patent application is filed, with the
understanding that this period may be extended up to another five years if a supplementary protection certificate is
filed and an additional six months if a pediatric investigation plan is applied. We expect to seek patent term
extensions in any jurisdictions where they are available, however, there is no guarantee that the applicable
authorities, including the FDA, will agree with our assessment of whether such an extension should be granted, and
even if granted, the length of such an extension.
37
Secondly, we and our partners could encounter difficulties in the filing or examination of some of our patent,
trademark or other intellectual property rights applications currently being examined/registered. During the patent
application process, we may receive Office Actions from the USPTO or from comparable agencies in foreign
jurisdictions rejecting the claims of the patent application. Although we would be given an opportunity to respond to
those objections, we may be unable to overcome such rejections. At the time a patent application is filed, there may
be other patents that could constitute opposable prior art that may have not yet been published. Despite prior art
searches and monitoring, we cannot be certain that we are the first to conceive of an invention and file a patent
application relating thereto; in particular, it should be noted that in most countries, the publication of patent
applications takes place 18 months after the earliest priority date of patent filing, or in some cases not at all, and that
discoveries are sometimes only the subject of publication or patent application months or even years later. Likewise,
when filing one of our trademarks in a country where it is not covered, we could find that the trademark in question
is not available in that country. A new trademark would then need to be sought for the country in question or an
agreement negotiated with the prior holder of the trademark. We may not be able to prevent a disclosure of
information to third parties that could have an impact on our future intellectual property rights. Therefore, it is in no
way certain that our current and future applications for patents, trademarks and other intellectual property rights will
result in registrations.
Thirdly, the simple granting or registration of a patent, trademark or other intellectual property right does not
guarantee validity or enforceability. Our competitors may at any time contest the validity or enforceability of our or
our partners’ patents, trademarks or applications relating thereto before a court or in the context of other specific
procedures which, depending on the outcome of such disputes, could reduce their scope, result in their invalidation
or allow them to be circumvented by competitors. In addition, developments, changes or divergences in the
interpretation of the legal framework governing intellectual property in Europe, the United States or other countries
could allow competitors to use our or our partners’ inventions or intellectual property rights to develop or market our
products or technologies without financial compensation. Moreover, there are still certain countries that do not
protect intellectual property rights in the same way as in Europe and the United States, and the effective procedures
and rules necessary to ensure the defense of our rights may not exist in these countries. There is therefore no
certainty that our existing and future patents, trademarks and other intellectual property rights will not be disputed,
invalidated or circumvented, or that they will provide effective protection against competition.
Consequently, our rights to our owned or licensed patents, trademarks and related applications and other
intellectual property rights may not confer the protection expected against competition. We therefore cannot
guarantee with certainty that:
•we will be able to develop novel inventions for which a patent could be filed or issued;
•applications for patents and other property rights currently under review will actually result in the
granting of patents, trademarks or other registered intellectual property rights;
•patents or other intellectual property rights granted to us or our partners will not be contested,
invalidated or circumvented; or
•the scope of protection conferred by our or our partners’ patents, trademarks and intellectual property
rights is and will remain sufficient to protect us against competition.
Were these eventualities to occur, they could have a material adverse effect on our business and growth.
In addition, third parties (or even our employees) could use or attempt to use elements of our technologies
protected by an intellectual property right, which would create a detrimental situation for us. We may therefore be
compelled to bring legal or administrative proceedings against these third parties in order to enforce our intellectual
property rights (patents, trademarks, designs and models or domain names) in court.
Enforcing a claim that a party illegally infringed or misappropriated our intellectual property is difficult,
expensive and time-consuming, and the outcome is unpredictable. Any litigation or dispute, regardless of the
outcome, could lead to substantial costs, affect our reputation, negatively influence our income and financial
position and possibly not lead to the desired protection or sanction. Some competitors with more substantial
resources than us may be able to bear the costs of litigation more easily.
If we fail to comply with our obligations in any agreements under which we may license intellectual property
rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we
could lose rights that are important to our business.
Our ability to pursue the development of some of our drug-based candidates depends on the maintenance in
force of the licensing agreements entered into with various institutes. We have licenses granted by the CNRS, the
University of Montpellier and/or the Institut Curie for certain patents or patent co-ownership rights resulting from
38
cooperation with the CNRS, the University of Montpellier and the Institut Curie, which allowed obefazimod to be
developed and a chemical library of more than 2,200 small molecules to be generated.
These license contracts provide the possibility for the licensor to end an agreed exclusivity or terminate the
contracts in certain events, including the event of non-payment of fees, a dispute over the validity of the patents
licensed or a violation by us of our obligations.
We may from time to time be party to license or collaboration agreements with third parties to advance our
research or allow commercialization of current or future drug candidates. Such agreements may impose numerous
obligations, such as development, diligence, payment, commercialization, funding, milestone, royalty, sublicensing,
insurance, patent prosecution, enforcement and other obligations on us and may require us to meet development
timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products, in order to
maintain the licenses. In spite of our best efforts, our licensors might conclude that we have materially breached our
license agreements and might therefore terminate the license agreements, thereby removing or limiting our ability to
develop and commercialize products and technologies covered by these license agreements.
Any termination of these licenses, or if the underlying licensed rights fail to provide the intended exclusivity,
could result in the loss of significant rights and could harm our ability to commercialize our current or future drug
candidates, and competitors or other third parties would have the freedom to seek regulatory approval of, and to
market, products identical to ours and we may be required to cease our development and commercialization of
certain of our current or future drug candidates. Any of the foregoing could have a material adverse effect on our
competitive position, business, financial conditions, results of operations, and prospects.
Disputes may also arise between us and our licensors regarding intellectual property subject to a license
agreement, including:
•the scope of rights granted under the license agreement and other interpretation-related issues;
•whether and the extent to which our technology and processes infringe, misappropriate or otherwise
violate intellectual property rights of the licensor that is not subject to the licensing agreement;
•our right to sublicense patent and other rights to third parties under collaborative development
relationships;
•our diligence obligations with respect to the use of the licensed technology in relation to our
development and commercialization of our current or future drug candidates, and what activities
satisfy those diligence obligations;
•the priority of invention of any patented technology; and
•the ownership of inventions and know-how resulting from the joint creation or use of intellectual
property by our future licensors and us and our partners.
In addition, the agreements under which we may license intellectual property or technology from third parties
are likely to be complex, and certain provisions in such agreements may be susceptible to multiple interpretations.
The adverse resolution of any contract interpretation disagreement that may arise could narrow what we believe to
be the scope of our rights to the relevant intellectual property or technology or increase what we believe to be our
financial or other obligations under the relevant agreement, either of which could have a material adverse effect on
our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property
that we have licensed or may license prevent or impair our ability to maintain future licensing arrangements on
acceptable terms, we may be unable to successfully develop and commercialize the affected current or future drug
candidates, which could have a material adverse effect on our business, financial conditions, results of operations
and prospects.
We may be sued for infringing or misappropriating the intellectual property rights of third parties, and if we are,
such litigation could be costly and time consuming and could prevent or delay us from developing or
commercializing our drug candidates.
Our commercial success will also depend on our ability to develop products and technologies that do not
infringe the patents or other rights of third parties. It is important for the success of our business that we are able to
use our products and conduct research and development efforts leading to commercialization of our products
without infringing patents or other third-party rights.
We continue to carry out, as we have done to date, the preliminary studies that we consider necessary in view
of the above risks, before investing in the development of our various products and technologies. With the help of
39
intellectual property consulting and law firms, we monitor our competitors’ activity (particularly with respect to
patent filings).
We therefore cannot guarantee with certainty that:
•there are no prior patents or other intellectual property rights of third parties covering certain of our
products, methods, technologies, results or activities and that, consequently, third parties might bring
an action for infringement or violation of their rights against us with a view to obtaining damages and
interest and/or the cessation of our activities in the manufacture and/or commercialization of products,
methods and the like thus disputed;
•there are no trademark rights or other prior rights of third parties that could be the basis of an
infringement or liability action against us; and
•our domain names are not subject, on the part of third parties who have prior rights (for example
trademark rights), to a Uniform Domain-Name Dispute-Resolution Policy (“UDRP”) or similar policy,
or an infringement action.
In the event of intellectual property litigation, we may have to:
•stop developing, making, selling, offering for sale or using the product or products that depended on
the disputed intellectual property;
•obtain a license from the holder of the intellectual property rights, however, such a license may be
unobtainable or only be obtainable under unfavorable economic conditions for us; or
•revise the design of some of our products/technologies or, in the case of trademark applications,
rename our products to avoid infringing the intellectual property rights of third parties, which may
prove impossible or time-consuming and expensive, and could impact our marketing efforts.
Litigation can also result in an order to pay damages (including treble damages) and being subject to
injunctions.
Patent terms may be inadequate to protect our competitive position on our drugs for an adequate amount of time,
and we may seek to rely, but may not be able to rely, on other forms of protection, such as regulatory exclusivity.
Given the amount of time required for the development, testing and regulatory review of new drug candidates,
patents protecting such candidates might expire before or shortly after such candidates are commercialized. For
example, the certain patents protecting obefazimod’s composition of matter expire in 2030 and the certain patents
protecting obefazimod methods of use expire in 2035 which pose a risk to its successful commercialization. We
expect to seek extensions of patent terms in the United States and, if available, in other countries where we are
prosecuting patents. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984
permits a patent term extension of up to five years beyond the normal expiration of the patent, which is limited to the
approved indication (or any additional indications approved during the period of extension). However, the applicable
authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other
countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant
extensions to our patents, or may grant more limited extensions than we request. We may also seek to rely on other
forms of protection, such as regulatory exclusivity, but there can be no assurance that such other forms of protection
will be available or sufficient.
We will not seek to protect our intellectual property rights in all jurisdictions throughout the world and we may
not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek
protection.
Filing, prosecuting and defending patents on our drug candidates in all countries and jurisdictions throughout
the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United
States could be less extensive than those in the United States, assuming that rights are obtained in the United States.
Competitors may use our technologies in jurisdictions where we do not pursue and obtain patent protection to
develop their own products and further, may export otherwise infringing products to territories where we have patent
protection, but enforcement is not as strong as that in the United States. These products may compete with our drugs
and our patents or other intellectual property rights may not be effective or sufficient to prevent them from
competing. Even if we pursue and obtain issued patents in particular jurisdictions, our patent claims or other
intellectual property rights may not be effective or sufficient to prevent third parties from so competing.
40
In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as
the federal and state laws in the United States. Many companies have encountered significant problems in protecting
and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries,
particularly developing countries, do not favor the enforcement of patents and other intellectual property protection,
especially those relating to biopharmaceuticals or biotechnologies. This could make it difficult for us to stop the
infringement of our patents, if obtained, or the misappropriation of our other intellectual property rights. For
example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to
third parties. In addition, many countries limit the enforceability of patents against third parties, including
government agencies or government contractors. In these countries, patents may provide limited or no benefit.
Patent protection must ultimately be sought on a country-by-country basis, which is an expensive and time-
consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain
countries, and we will not have the benefit of patent protection in such countries.
Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our
efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or
interpreted narrowly, could put our patent applications at risk of not being issued and could provoke third parties to
assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies
awarded, if any, may not be commercially meaningful. In addition, changes in the law and legal decisions by courts
in the United States and foreign countries may affect our ability to obtain adequate protection for our technology and
the enforcement of our intellectual property. In addition, monitoring the unauthorized use of our products and
technology and the infringement of our intellectual property rights is challenging. We cannot guarantee with
certainty that we will be able to prevent, take legal action against and obtain compensation for infringement,
misappropriation or unauthorized use of our products and technologies, particularly in foreign countries where our
rights are less well protected because of the territorial scope of intellectual property rights. Accordingly, our efforts
to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial
advantage from the intellectual property that we develop or license.
Further, in Europe, a new unitary patent system took effect June 1, 2023, which significantly impacts
European patents, including those granted before the introduction of such a system. Under the unitary patent system,
European applications have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to
the jurisdiction of the Unitary Patent Court, or the UPC. As the UPC is a new court system, there is currently little
precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the
UPC will have the option of opting out of the jurisdiction of the UPC and remaining as national patents in the UPC
countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a single UPC-based
revocation challenge that, if successful, could invalidate the patent in all countries who are signatories to the UPC.
We cannot predict with certainty the long-term effects of any potential changes.
In addition, geo-political actions in the United States and in foreign countries could increase the uncertainties
and costs surrounding the prosecution or maintenance of our patent applications and the maintenance, enforcement
or defense of our issued patents. For example, the United States and foreign government actions related to Russia’s
invasion of Ukraine may limit or prevent filing, prosecution, and maintenance of patent applications in Russia.
Government actions may also prevent maintenance of issued patents in Russia. These actions could result in
abandonment or lapse of our patents or patent applications, resulting in partial or complete loss of patent rights in
Russia. If such an event were to occur, it could have a material adverse effect on our business. In addition, a decree
was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit
inventions owned by patentees from the United States without consent or compensation. Consequently, we would
not be able to prevent third parties from practicing our inventions in Russia or from selling or importing products
made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our
business, financial condition, results of operations and prospects may be adversely affected.
If our trademarks and trade names are not adequately protected by us or our partners that develop trademarks
for our future products, then we may not be able to build name or brand recognition in our markets of interest,
and our business may be adversely affected.
Our registered or unregistered trademarks and trade names and the registered or unregistered trademarks and
trade names that our partners will develop may be challenged, infringed, diluted, circumvented or declared generic
or determined to be infringing on other marks. We and our partners may not be able to protect our rights to these
trademarks and trade names, which we need to build name and brand recognition among potential partners or
customers in our markets of interest. We expect to rely on our partners to protect the trade names and trademarks
that they will develop, and they may not adequately protect such tradenames and trademarks, and we may have little
or no recourse in respect thereof. At times, competitors may adopt trademarks and trade names similar to ours,
thereby impeding our ability to build brand identity and possibly leading to market confusion. During the trademark
registration process, we may receive Office Actions from the USPTO or from comparable agencies in foreign
jurisdictions objecting to the registration of our trademark. Although we would be given an opportunity to respond
41
to those objections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable
agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark
applications and/or to seek the cancellation of registered trademarks. Opposition or cancellation proceedings may be
filed against our trademark applications or registrations, and our trademark applications or registrations may not
survive such proceedings. In addition, there could be potential trademark infringement claims brought by owners of
other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks.
Over the long term, if we are unable to establish name and brand recognition based on our trademarks, then we may
not be able to compete effectively and our business may be adversely affected.
Obtaining and maintaining patent protection depends on compliance with various procedural, document
submission, fee payment and other requirements imposed by governmental patent agencies, and our patent
protection could be reduced or eliminated for non-compliance with these requirements.
Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and
applications are required to be paid to the USPTO and various governmental patent agencies outside of the United
States in several stages over the lifetime of the patents and applications. The USPTO and various non-U.S.
governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other
similar provisions during the patent application process and after a patent has issued. There are situations in which
non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or
complete loss of patent rights in the relevant jurisdiction.
If we are unable to protect the confidentiality of our trade secrets and know-how, our business and competitive
position could be harmed.
In addition to seeking patent protection for our drug candidates, we also rely on trade secrets, including
unpatented know-how, technology and other proprietary information, to establish and maintain our competitive
position.
It is also important for us to protect against the unauthorized use and disclosure of our confidential
information, know-how and trade secrets. Unpatented and/or unpatentable technologies, processes, methods, know-
how and data are considered trade secrets that we seek to protect, in part, by entering into non-disclosure and
confidentiality agreements with parties who have access to them, such as our employees, collaborators, consultants,
advisors, university and/or institutional researchers and other third parties. We also have entered or seek to enter into
confidentiality and invention or patent assignment agreements with our employees, advisors and consultants.
In the context of collaboration, partnership or research contracts, or other types of cooperation between us and
researchers from academic institutions, and with other public or private entities, subcontractors, or any co-
contracting third parties, various information and/or products may be entrusted to them in order to conduct certain
tests and clinical trials. In such cases, we require that confidentiality agreements be signed. Furthermore, as a general
rule, we take care that the collaboration or research contracts that we are party to give us access to full ownership or
co-ownership of results and/or inventions resulting from the collaboration, or to an exclusive license based on these
results and/or inventions resulting from the collaboration.
Despite these efforts, counterparties may breach our agreements and disclose our proprietary information,
including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Our trade secrets
may also be obtained by third parties by other means, such as breaches of our physical or computer security systems.
Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-
consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less
willing or unwilling to protect trade secrets. Moreover, if any of our trade secrets were to be lawfully obtained or
independently developed by a competitor, we would have no right to prevent them, or those to whom they
communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be
disclosed to, or independently developed by, a competitor, our competitive position would be harmed and our
business may be adversely affected.
There can be no assurance that the agreements put in place to protect our technology and trade secrets and/or
the know-how being used will provide the protection sought or will not be violated, that we will have appropriate
solutions for such violations, or that our trade secrets will not be disclosed to or independently developed by our
competitors. In the context of contracts that we enter into with third parties, we sometimes take the precaution of
providing that they are not authorized to use third-party services or that they may only do so with our prior approval.
However, it cannot be ruled out that some of these co-contractors may nevertheless use third parties. In this event,
we have no control over the conditions under which third parties with which we do not contract protect their
confidential information, irrespective of whether we provide in our agreements with our co-contractors that they
undertake to pass on confidentiality obligations to their own co-contractors.
42
Such contracts therefore expose us to the risk of having the third parties concerned (i) claim the benefit of
intellectual property rights on our inventions or other intellectual property rights, (ii) fail to ensure the
confidentiality of unpatented innovations or improvements of our confidential information and know-how,
(iii) disclose our trade secrets to our competitors or independently develop these trade secrets and/or (iv) violate
such agreements, without our having an appropriate solution for such violations.
Consequently, our rights to our confidential information, trade secrets and know-how may not confer the
expected protection against competition and we cannot guarantee with certainty that:
•our knowledge and trade secrets will not be obtained, stolen, circumvented, transmitted or used
without our authorization;
•our competitors have not already developed similar technologies or products, or ones similar in nature
or purpose to ours;
•no co-contracting party will claim the benefit of all or part of the intellectual property rights relating to
inventions, knowledge or results that we hold in our own right or in co-ownership, or for which we
would be entitled to a license; or
•our employees will not claim rights or payment of additional compensation or fair price for inventions
in the creation of which they participated.
The occurrence of one or more of these risks could have a material adverse effect on our business, outlook,
financial position, income and growth.
Intellectual property rights do not address all potential threats to our competitive advantage.
The degree of future protection afforded by our intellectual property rights is uncertain because intellectual
property rights have limitations, and may not adequately protect our business, or permit us to maintain our
competitive advantage. The following examples are illustrative.
•Competitors may be able to formulate compositions that are similar to ours but that are not covered by
our intellectual property rights.
•Competitors may independently develop similar or alternative compositions or otherwise circumvent
any of our applications or registrations without infringing our intellectual property rights.
•We or any of our collaboration partners might not have been the first to conceive and reduce to
practice the inventions covered by the patents or patent applications that we own, license or will own
or license.
•We or any of our collaboration partners might not have been the first to file patent applications
covering certain of the patents or patent applications that we or they own or have licensed, or will own
or will have licensed.
•It is possible that any pending patent applications that we have filed, or will file, will not lead to issued
patents.
•Issued patents that we own may not provide us with any competitive advantage, or may be held invalid
or unenforceable, as a result of legal challenges by our competitors.
•Our competitors might conduct research and development activities in countries where we do not have
patent rights, or in countries where research and development safe harbor laws exist, and then use the
information learned from such activities to develop competitive products for sale in our major
commercial markets.
•Ownership of our patents or patent applications may be challenged by third parties.
•We may infringe on the patents of third parties or pending or future applications of third parties, if
issued, and the patents of third parties or pending or future applications of third parties, if issued, may
have an adverse effect on our business.
Risks Related to Legal and Compliance
Our business is subject to a restrictive and changing regulatory framework.
One of the major issues for a growing company like ours is to successfully develop, alone or with the help of
partners, products incorporating our technologies in an increasingly restrictive regulatory environment. The
pharmaceutical industry faces constant changes in its legal and regulatory environment and increased oversight by
43
the competent authorities, such as the National Agency for Medicines and Health Products Safety (“ANSM”) in
France, the EMA in the European Union, the FDA in the United States or the PMDA in Japan, and other regulatory
authorities in the rest of the world. At the same time, the public is demanding more guarantees regarding drug safety
and efficacy. This may at any time lead to a more restrictive regulatory environment for our drug candidates which
may have a material adverse effect on business, financial position, income, growth and outlook.
Health authorities oversee preclinical studies, clinical trials, the operations of pharmaceutical companies, and
drug manufacturing and commercialization. This increasing stringency of the legislative and regulatory framework
is common worldwide; however, requirements may vary from country to country. In particular, health authorities,
especially the ANSM, EMA, FDA and PMDA, have imposed increasingly burdensome requirements in terms of the
volume and quality of data required to demonstrate the efficacy and safety of a product. These increased
requirements may have thus reduced the number of products authorized in comparison to the number of applications
filed. The risk/benefit ratio of products on the market is also subject to continuous monitoring and periodic review
after their authorization. The delayed discovery of problems not identified at the research or initial assessment stage
can lead at any time to marketing restrictions, suspension of the marketing or withdrawal of the products from the
market, and to an increased risk of litigation.
Therefore, the authorization process is long and expensive; it can take many years and the result is not
predictable and likely to continuously evolve. Insofar as new legal or regulatory provisions would result in an
increase in the requirements and associated costs for obtaining and maintaining product marketing authorizations or
would limit the targeted indications for a product that a product targets or the economic value of a new product to its
inventor, the growth prospects for the pharmaceutical industry, and us, could be reduced. If we experience delays
completing, or if we terminate early, any of our clinical trials, or if we are required to conduct additional clinical
trials, the commercial prospects for our drug candidates may be harmed and our ability to generate product revenue
will be delayed. The occurrence of one or more of these risks could have a material adverse effect on our business,
outlook, financial position, income and growth.
We are subject to healthcare laws and regulations which may require substantial compliance efforts and could
expose us to criminal sanctions, civil and administrative penalties, contractual damages, reputational harm and
diminished profits and future earnings, among other penalties.
Healthcare providers, including physicians, and others will play a primary role in the recommendation and
prescription of our products, if approved. Our arrangements with such persons and third-party payors and our
general business operations will expose us to broadly applicable fraud and abuse and other healthcare laws and
regulations that may constrain the business or financial arrangements and relationships through which we research,
market, sell and distribute our drugs, if we obtain marketing approval. Restrictions under applicable U.S. federal,
state and foreign healthcare laws and regulations include, but are not limited to, the following:
•the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from
knowingly and willfully soliciting, offering, receiving or providing remuneration, including any
kickback, bribe or rebate, directly or indirectly, in cash or in kind, to induce or reward, or in return for,
either the referral of an individual for, or the purchase or lease, order or recommendation of, any item,
good, facility or service, for which payment may be made under federal healthcare programs such as
Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or
specific intent to violate it in order to have committed a violation;
•U.S. federal civil and criminal false claims laws and civil monetary penalties laws, including the civil
False Claims Act (“FCA”), which impose criminal and civil penalties, including those from civil
whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly
presenting, or causing to be presented, claims for payment that are false or fraudulent or making a false
statement to avoid, decrease, or conceal an obligation to pay money to the federal government. For
example, pharmaceutical companies have been prosecuted under the FCA in connection with their
alleged off-label promotion of drugs, purportedly concealing price concessions in the pricing
information submitted to the government for government price reporting purposes, and allegedly
providing free product to customers with the expectation that the customers would bill federal health
care programs for the product. In addition, the government may assert that a claim including items and
services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent
claim for purposes of the FCA;
•the U.S. federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which
created additional federal criminal statutes that impose criminal and civil liability for, among other
things, executing or attempting to execute a scheme to defraud any healthcare benefit program or
knowingly and willingly falsifying, concealing or covering up a material fact or making false
statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or
44
entity does not need to have actual knowledge of the healthcare fraud statute implemented under
HIPAA or specific intent to violate it in order to have committed a violation;
•HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act
(“HITECH”) and its implementing regulations, which impose certain requirements on covered entities
and their business associates, as well as their covered subcontractors, including mandatory contractual
terms, with respect to safeguarding the privacy, security and transmission of individually identifiable
health information;
•federal and state consumer protection and unfair competition laws, which broadly regulate marketplace
activities and activities that potentially harm consumers;
•U.S. federal transparency requirements under the Physician Payments Sunshine Act, enacted as part of
the Affordable Care Act (“ACA”), that require applicable manufacturers of covered drugs, devices,
biologics and medical supplies for which payment is available under Medicare, Medicaid or the
Children’s Health Insurance Program, with specific exceptions, to track and annually report to
Concerned Member States (“CMS”) payments and other transfers of value provided to physicians,
certain other healthcare providers (such as physicians assistants and nurse practitioners), and teaching
hospitals, and require certain manufacturers and group purchasing organizations to report annually
certain ownership and investment interests held by physicians or their immediate family members; and
•analogous state or foreign laws and regulations, such as state anti-kickback and false claims laws,
which may apply to items or services reimbursed by any third-party payor, including commercial
insurers, state marketing and/or transparency laws applicable to manufacturers that may be broader in
scope than the federal requirements, state laws that require biopharmaceutical companies to comply
with the biopharmaceutical industry’s voluntary compliance guidelines and the relevant compliance
guidance promulgated by the federal government and state laws governing the privacy and security of
health information in certain circumstances, many of which differ from each other in significant ways
and may not have the same effect as HIPAA, thus complicating compliance efforts.
Ensuring that our business arrangements with third parties comply with applicable healthcare laws and
regulations will likely be costly. It cannot be excluded that governmental authorities will conclude that our business
practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse
or other healthcare laws and regulations. If our operations were found to be in violation of any of these laws or any
other governmental regulations that may apply to us, we may be subject to significant civil, criminal and
administrative penalties, damages, fines, disgorgement, imprisonment, possible exclusion from government funded
healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits
and future earnings and curtailment of our operations, any of which could substantially disrupt our operations. If the
physicians or other providers or entities with whom we expect to do business are found not to be in compliance with
applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from
government funded healthcare programs. We may incur significant costs achieving and maintaining compliance with
applicable federal and state privacy, security, and fraud laws. Any action against us for violation of these laws, even
if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s
attention from the operation of our business.
Current and future health reform measures could adversely affect our business operations.
In the United States and some foreign jurisdictions there have been, and we expect there will continue to be,
several legislative and regulatory changes and proposed reforms of the healthcare system to contain costs, improve
quality, and expand access to care. For example, in March 2010, President Obama signed the ACA into law, which
substantially changed the way healthcare is financed by both governmental and private insurers and continues to
significantly impact the United States pharmaceutical industry.
There have been judicial, congressional and executive branch challenges to certain aspects of the ACA. For
example, on June 17, 2021, the United States Supreme Court dismissed a challenge on procedural grounds that
argued the ACA is unconstitutional in its entirety because the individual mandate was repealed by Congress.
Moreover, there have been a number of health reform initiatives by the Biden administration that have impacted the
ACA. For example, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (“IRA”), into
law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in
ACA marketplaces through plan year 2025. The IRA also eliminates the “donut hole” under the Medicare Part D
program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly-
established manufacturer discount program. It is unclear how other healthcare reform measures, if any, will impact
our business.
45
In addition, other legislative changes have been proposed and adopted in the United States since the ACA was
enacted. For example, on August 2, 2011, the Budget Control Act of 2011 was signed into law which among other
things, led to aggregate reductions in Medicare payments to providers. These reductions went into effect on April 1,
2013, and, due to subsequent legislative amendments, will remain in effect until 2032, unless additional
Congressional action is taken.
Additionally, there have been several recent U.S. presidential executive orders, congressional inquiries and
proposed and enacted legislation at the federal and state levels designed to, among other things, bring more
transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the
cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. For
example, on March 11, 2023, the American Rescue Plan Act of 2021 was signed into law, which eliminates the
statutory Medicaid drug rebate cap, currently set at 100% of a drug’s average manufacturer price, beginning January
1, 2024. In addition, the IRA, among other things, (1) directs the U.S. Department of Health and Human Services
("HHS") to negotiate the price of certain single-source drugs and biologics covered under Medicare and (2) imposes
rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation. The IRA
permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial
years. HHS has and will continue to issue and update guidance as these programs are implemented. These provisions
take effect progressively starting in fiscal year 2023, although the Medicare drug price negotiation program is
currently subject to litigation. It is currently unclear how the IRA will be implemented but is likely to have a
significant impact on the pharmaceutical industry. Further, in response to the Biden administration’s October 2022
executive order, on February 14, 2023, HHS released a report outlining three new models for testing by the Centers
for Medicare & Medicaid Services Innovation Center which will be evaluated on their ability to lower the cost of
drugs, promote accessibility and improve quality of care. It is unclear whether the models will be utilized in any
health reform measures in the future. Further, on December 7, 2023, the Biden administration announced an
initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On
December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency
Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of
a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not
previously been exercised, it is uncertain if that will continue under the new framework. We expect that additional
U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the
U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our
drug candidates or additional pricing pressures.
At the state level, legislatures have increasingly passed legislation and implemented regulations designed to
control pharmaceutical and biological product pricing, including price or patient reimbursement constraints,
discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in
some cases, designed to encourage importation from other countries and bulk purchasing. For example, on January
5, 2024, the FDA approved Florida’s Section 804 Importation Program ("SIP") proposal to import certain drugs
from Canada for specific state healthcare programs. It is unclear how this program will be implemented, including
which drugs will be chosen, and whether it will be subject to legal challenges in the United States or Canada. Other
states have also submitted SIP proposals that are pending review by the FDA. Any such approved importation plans,
when implemented, may result in lower drug prices for products covered by those programs. If healthcare policies or
reforms intended to curb healthcare costs are adopted, or if we experience negative publicity with respect to the
pricing of our products or the pricing of pharmaceutical drugs generally, the prices that we charge for any approved
products may be limited, our commercial opportunity may be limited and/or our revenues from sales of our products
may be negatively impacted.
We expect that other healthcare reform measures that may be adopted in the future, may result in more
rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved
product. Any reduction in reimbursement from Medicare or other government programs may result in a similar
reduction in payments from private payors. The implementation of cost containment measures or other healthcare
reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drug
candidates.
We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other
laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal
penalties, other remedial measures and legal expenses, which could adversely affect our business, results of
operations and financial condition.
We are subject to other laws and regulations governing our international operations, including regulations
administered by the governments of the United States, and authorities in the European Union and in Japan, including
applicable export control regulations, economic sanctions on countries and persons, customs requirements and
currency exchange regulations, collectively referred to as the trade control laws.
46
We are also subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act of 1977, as
amended (“FCPA”), which prohibits any U.S. individual or business from paying, offering, or authorizing payment
or offering of anything of value, directly or indirectly, to any foreign official, political party, or candidate for the
purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in
obtaining or retaining business, and other state and national anti-bribery and anti-money laundering laws in the
countries in which we conduct activities, including the French anti-corruption laws:
•Article 433-1 of the French Criminal Code (bribery of domestic public officials);
•Article 433-2 of the French Criminal Code (influence peddling involving domestic public officials);
•Article 434-9 of the French Criminal Code (bribery of domestic judicial staff);
•Article 434-9-1 of the French Criminal Code (influence peddling involving domestic judicial staff);
•Articles 435-1 and 435-3 of the French Criminal Code (bribery of foreign or international public
officials);
•Articles 435-7 and 435-9 of the French Criminal Code (bribery of foreign or international judicial
staff);
•Articles 435-2, 435-4, 435-8 and 435-10 of the French Criminal Code (active and passive influence
peddling involving foreign or international public officials and foreign or international judicial staff);
•Articles 445-1 and 445-2 of the French Criminal Code (bribery of private individuals); and
•French Law No. 2016-1691 of December 9, 2016 on Transparency, the Fight Against Corruption and
the Modernization of the Economy (Sapin 2 Law), which provides for numerous new obligations for
large companies such as the obligation to draw up and adopt a code of conduct defining and
illustrating the different types of behavior to be proscribed as being likely to characterize acts of
corruption or influence peddling, to set up an internal warning system designed to enable the
collections of reports from employees relating to the existence of conduct or situations contrary to the
company’s code of conduct, to set up accounting control procedures, whether internal or external,
designed to ensure that the books, registers and accounts are not used to conceal acts of corruption or
influence peddling, to set up a disciplinary system for sanctioning company employees in the event of
a breach of the company’s code of conduct or a system for monitoring and evaluating the measures
implemented.
The FCPA also obligates companies whose securities are listed in the United States to comply with accounting
provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of
the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal
accounting controls for international operations. Activities that violate the FCPA, even if they occur wholly outside
the United States, can result in criminal and civil fines, imprisonment, disgorgement, oversight, and debarment from
government contracts. The scope and enforcement of these laws is uncertain and subject to rapid change. Further,
enforcement bodies have increased their scrutiny of interactions between healthcare companies and healthcare
providers. This has resulted in an increase in the number of investigations, prosecutions, convictions and settlements
in the healthcare industry. Responding to investigations can be both resource and time consuming and can divert
management’s attention from the business. Any such investigation or settlement could increase our costs or
otherwise have a material adverse effect on our business, outlook, financial position, income and growth.
The FCPA and other anti-corruption laws are interpreted broadly and prohibit companies and their employees,
agents, contractors, and other collaborators from authorizing, promising, offering, or providing, directly or
indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage
third parties to sell our products outside the United States, to conduct clinical trials and/or to obtain necessary
permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with
officials and employees of government agencies or government-affiliated hospitals, universities, and other
organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors,
and other collaborators, even if we do not explicitly authorize or have actual knowledge of such activities.
There is no complete assurance that we will be effective in ensuring our compliance with all applicable anti-
corruption laws, including the FCPA, the French anti-corruption laws or other legal requirements, including trade
control laws. If we are not in compliance with the FCPA, the French anti-corruption laws and other anti-corruption
laws or trade control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and
remedial measures and legal expenses, which could have an adverse impact on our business, financial condition,
results of operations and liquidity. Likewise, any investigation of any potential violations of the FCPA, the French
anti-corruption laws, other anti-corruption laws or trade control laws by U.S. or other authorities could also have an
adverse impact on our reputation, our business, results of operations and financial condition.
47
In addition, changes in our products and drug candidates or changes in applicable export or import laws and
regulations may create delays in the introduction or provision of our products and drug candidates in other
jurisdictions, prevent others from using our products and drug candidates or, in some cases, prevent the export or
import of our products and drug candidates to certain countries, governments or persons altogether. Any limitation
on our ability to export or provide our products and drug candidates could adversely affect our business, financial
condition and results of operations.
Product liability and other lawsuits could divert our resources, result in substantial liabilities and reduce the
commercial potential of our drug candidates.
The risk that we may be sued on product liability claims is inherent in the development and commercialization
of our drug candidates. Side effects of, or manufacturing defects in, drugs that we develop could result in the
deterioration of a patient’s condition, injury or even death. For example, our liability could be sought after by
patients participating in the clinical trials in the context of the development of the therapeutic products tested and
unexpected side effects resulting from the administration of these drugs. In addition, we could face liability due to
undetected side-effects caused by the interaction of our drugs with other drugs following release of the drug
candidate to the market. Once a product is approved for sale and commercialized, the likelihood of product liability
lawsuits increases. Criminal or civil proceedings might be filed against us by patients, regulatory authorities,
biopharmaceutical companies and any other third party using or marketing our drugs. These actions could include
claims resulting from actions by our partners, licensees and subcontractors, over which we have little or no control.
These lawsuits may divert our management from pursuing our business strategy and may be costly to defend. In
addition, if we are held liable in any of these lawsuits, we may incur substantial liabilities, may be forced to limit or
forgo further commercialization of the affected products and may suffer damage to our reputation.
We could be exposed to the risk of liability claims during the clinical development of our products, in
particular product liability claims, related to the manufacture of therapeutic products and trials in humans and
animals. We could be held liable by patients participating in clinical trials as part of the development of the
therapeutic products tested for unexpected side effects resulting from the administration of these products.
We could also be held liable during the commercialization phase of our products. Criminal complaints or
lawsuits could be filed or brought against us by patients, regulatory agencies, pharmaceutical companies and any
other third parties using or marketing our products. These actions may include claims arising from acts of our
partners, licensees or subcontractors, over which we have little or no control. Physicians and patients may not
comply with any warnings that identify known potential adverse effects and patients who should not use our drug
candidates.
We maintain product liability insurance coverage for our clinical trials at levels which we believe are
appropriate for our clinical trials. Nevertheless, we cannot guarantee that the insurance policy taken out or the
contractually limited indemnification, if applicable, granted by our subcontractors will be sufficient to cover the
claims that could be brought against us or losses we may suffer.
If our liability, or that of our partners, licensees and subcontractors, was thereby activated, if we or our
partners, licensees and subcontractors were unable to obtain and maintain appropriate insurance coverage at an
acceptable cost or protect ourselves in any way against liability claims, this would seriously affect the
commercialization of our products and, more generally, have a material adverse effect on our business, income,
financial position and outlook for growth.
We are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations,
policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with
such obligations could lead to regulatory investigations or actions; litigation; fines and penalties; disruptions of
our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.
In the ordinary course of business, we (and others on our behalf) collect, receive, store, process, generate, use,
transfer, archive, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, processing)
personal data and other sensitive information, including proprietary and confidential business data, trade secrets,
intellectual property, sensitive third-party data, personal data/personal information, business plans, transactions, and
financial information (collectively, sensitive data).
Our data processing activities subjects us to numerous data privacy and security obligations, such as various
laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual
requirements, and other obligations relating to data privacy and security.
48
In the United States, federal, state, and local governments have enacted numerous data privacy and security
laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5
of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws). For example, the California
Consumer Privacy Act of 2018 (“CCPA”) requires businesses to provide specific disclosures in privacy notices and
honor requests of California residents to exercise certain privacy rights. The CCPA provides for civil penalties of up
to $7,500 per violation and allows private litigants affected by certain data breaches to recover significant statutory
damages. In addition, the California Privacy Rights Act of 2020 (“CPRA”), which becomes operative January 1,
2023, will expand the CCPA’s requirements, including applying to personal information of business representatives
and employees and establishing a new regulatory agency to implement and enforce the law.
Other states, such as Virginia, Colorado, Utah and Connecticut have also passed comprehensive privacy laws,
and similar laws are being considered in several other states, as well as at the federal and local levels. These
developments may further complicate compliance efforts and may increase legal risk and compliance costs for us
and the third parties upon whom we rely.
Outside the United States, an increasing number of laws, regulations, and industry standards may govern data
privacy and security. For example, among other laws, the European Union’s Regulation (EU) 2016/679 of 27 April
2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of
such data, as amended (“EU GDPR”), the United Kingdom’s GDPR (“UK GDPR”), Brazil’s General Data
Protection Law (Lei Geral de Proteção de Dados Pessoais, or “LGPD”) (Law No. 13,709/2018), Canada’s Personal
Information Protection and Electronic Documents Act (“PIPEDA”), and China’s Personal Information Protection
Law (“PIPL”) impose strict requirements for processing personal data.
The collection and use of personal health data in the European Union is governed by the provisions of the EU
GDPR. Under the EU GDPR, companies may face temporary or definitive bans on data processing and other
corrective actions; fines of up to €20 million or 4% of annual global revenue, whichever is greater; or private
litigation related to processing of personal data brought by classes of data subjects or consumer protection
organizations authorized at law to represent their interests. We also engage in clinical trial activities in other foreign
jurisdictions.
In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United
States or other third party countries in which local data privacy laws are less stringent due to limitations on cross-
border data flows. Europe and other jurisdictions have enacted laws requiring data to be localized or limiting the
transfer of personal data to other countries. In particular, the EEA and the United Kingdom (“UK”) have
significantly restricted the transfer of personal data to countries whose privacy laws it believes are inadequate. Other
jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer
laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and
UK to the United States in compliance with law, such as the Trans-Atlantic Data Privacy Framework or the EEA
and UK’s standard contractual clauses, being specified that these mechanisms of standard contractual clauses are
subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully
transfer personal data to the United States or other third party countries. If there is no lawful manner for us to
transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a
legally-compliant transfer are too onerous, we could face significant adverse consequences, including the
interruption or degradation of our operations, the need to relocate part of or all of our business or data processing
activities to other jurisdictions at significant expense, increased exposure to regulatory actions, substantial fines and
penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions
against our processing or transferring of personal data necessary to operate our business. Some European regulators
have prevented companies from transferring personal data out of Europe for allegedly violating the EU GDPR’s
cross-border data transfer limitations.
In addition to data privacy and security laws, we may be contractually subject to industry standards adopted by
industry groups and may become subject to such obligations in the future. Depending upon the context, we may also
be bound by other contractual obligations related to data privacy and security, and our efforts to comply with such
obligations may not be successful.
We publish and may publish privacy policies, marketing materials, and other statements, such as compliance
with certain certifications or self-regulatory principles, regarding data privacy and security. If these policies,
materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of
our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences.
Obligations related to data privacy and security are quickly changing, becoming increasingly stringent, and
creating regulatory uncertainty. Additionally, these obligations may be subject to differing applications and
interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these
49
obligations requires us to devote significant resources and may necessitate changes to our services, information
technologies, systems, and practices and to those of any third parties that process personal data on our behalf.
We may at times fail (or be perceived to have failed) in our efforts to comply with our data privacy and
security obligations. Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to
comply with such obligations, which could negatively impact our business operations. If we or the third parties on
which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security
obligations, we could face significant consequences, including but not limited to: government enforcement actions
(e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims);
additional reporting requirements and/or oversight; bans on processing personal data; and orders to destroy or not
use personal data. Any of these events could have a material adverse effect on our reputation, business, or financial
condition, including but not limited to: loss of customers; inability to process personal data or to operate in certain
jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend
any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.
Risks Related to Ownership of Our ADSs and Our Status as a Non-U.S. Company with Foreign Private
Issuer Status
There has been no market for our ADSs prior to our initial public offering of our ADSs in the United States, and
an active and liquid market for our securities may fail to develop, which could harm the market price of our
ADSs.
Although our ordinary shares have been traded on Euronext Paris since mid-2015, prior to our initial public
offering of our ADSs in the United States in October 2023 there was no public market on a U.S. national securities
exchange for our ADSs. An active trading market for our ADSs may never develop or be sustained. In the absence
of an active trading market for our ADSs, investors may not be able to sell their ADSs at a desired offering price or
at the time that they would like to sell.
If we do not achieve our projected development and commercialization goals in the timeframes we announce and
expect, our business will be harmed, and the price of our securities could decline as a result.
We sometimes estimate for planning purposes the timing of the accomplishment of various scientific, clinical,
regulatory and other product development objectives. These milestones may include our expectations regarding the
commencement or completion of scientific studies, clinical trials, the submission of regulatory filings, or
commercialization objectives. From time to time, we may publicly announce the expected timing of some of these
milestones, such as the completion of an ongoing clinical trial, the initiation of other clinical programs, receipt of
marketing approval, or a commercial launch of a product. The achievement of many of these milestones may be
outside of our control. All of these milestones are based on a variety of assumptions which may cause the timing of
achievement of the milestones to vary considerably from our estimates, including:
•our available capital resources or capital constraints we experience;
•the rate of progress, costs and results of our clinical trials and research and development activities,
including the extent of scheduling conflicts with participating clinicians and collaborators, and our
ability to identify and enroll patients who meet clinical trial eligibility criteria;
•our receipt of approvals by the European Commission, FDA and other regulatory agencies and the
timing thereof;
•other actions, decisions or rules issued by regulators;
•our ability to access sufficient, reliable and affordable supplies of compounds and raw materials used
in the manufacture of our drug candidates;
•the efforts of our collaborators with respect to the commercialization of our products; and
•the securing of, costs related to, and timing issues associated with, product manufacturing as well as
sales and marketing activities.
If we fail to achieve announced milestones in the timeframes we expect, the commercialization of our drug
candidates may be delayed, our business and results of operations may be harmed, and the trading price of the ADSs
may decline as a result.
50
We may be a “passive foreign investment company” for U.S. federal income tax purposes, which could result in
adverse U.S. federal income tax consequences to U.S. investors.
Generally, if, for any taxable year, at least 75% of our gross income is passive income (“income test”), or at
least 50% of the value of our assets (based on an average of the quarterly values of the assets during a taxable year)
is attributable to assets that produce passive income or are held for the production of passive income, including cash,
we would be characterized as a passive foreign investment company (“PFIC”) for U.S. federal income tax purposes.
For purposes of these tests, passive income includes, among other things, dividends, interest, and gains from the sale
or exchange of investment property and rents or royalties other than rents or royalties which are received from
unrelated parties in connection with the active conduct of a trade or business. Cash and cash equivalents are
generally treated as passive assets. Goodwill is treated as an active asset to the extent associated with business
activities that produce active income. For purposes of the PFIC rules, a non-U.S. corporation that owns, directly or
indirectly, at least 25% by value of the equity interests of another corporation or partnership is treated as if it held its
proportionate share of the assets of the other corporation or partnership, and received directly its proportionate share
of the income of the other corporation or partnership. Equity interests of less than 25% by value in any other
corporation or partnership are treated as passive assets, regardless of the nature of the other corporation or
partnership’s business.
If we are a PFIC for any taxable year in which a U.S. Holder (as defined in “Material United States Federal
Income and French Tax Considerations—Material U.S. Federal Income Tax Considerations for U.S. Holders”) holds
an ADS, certain adverse U.S. federal income tax consequences could apply to such U.S. Holder including increased
tax liability on disposition gains and certain “excess distributions” and additional reporting requirements. See
“Material United States Federal Income and French Tax Considerations—Material U.S. Federal Income Tax
Considerations for U.S. Holders—Passive Foreign Investment Company Rules.”
Based on our analysis of our financial statements, activities and relevant market and shareholder data, we do
not believe that we were a PFIC for the taxable year ended December 31, 2023. The determination of whether we
are a PFIC is a fact-intensive determination made on an annual basis and the applicable law is subject to varying
interpretation. Whether we are a PFIC for any taxable year will depend on the composition of our income and the
composition, nature and value of our assets from time to time (including the value of our goodwill, which may be
determined by reference to the value of our ADSs, which could fluctuate considerably). We currently do not
generate product revenues and therefore we may be a PFIC for any taxable year in which we do not generate
sufficient amounts of non-passive income to offset our passive income. As a result, there can be no assurance that
we will not be treated as a PFIC for the current or any future taxable year and our U.S. counsel expresses no opinion
with respect to our PFIC status for any prior, current or future taxable year. Even if we determine that we are not a
PFIC for a taxable year, there can be no assurance that the Internal Revenue Service, or the IRS, will agree with our
conclusion and that the IRS would not successfully challenge our position. Each U.S. holder is strongly urged to
consult its tax advisor regarding these issues and any available elections to mitigate such tax consequences.
If a United States person is treated as owning at least 10% of the value or voting power of our ADSs, such holder
may be subject to adverse U.S. federal income tax consequences.
If a United States person is treated as owning (directly, indirectly, or constructively) at least 10% of the
aggregate value or voting power of our ADSs, such person may be treated as a “United States shareholder” with
respect to each “controlled foreign corporation” in our group (if any), which may subject such person to adverse
U.S. federal income tax consequences. Our group currently includes one U.S. subsidiary corporation and, therefore,
under current law our current non-U.S. subsidiary and any future newly formed or acquired non-U.S. subsidiaries
that are treated as corporations for U.S. federal income tax purposes will be treated as controlled foreign
corporations, regardless of whether we are treated as a controlled foreign corporation. A United States shareholder
of a controlled foreign corporation generally is required to report annually and include in its U.S. taxable income its
pro rata share of “Subpart F income,” “global intangible low-taxed income,” and investments in U.S. property by
controlled foreign corporations, regardless of whether we make any distributions. An individual that is a United
States shareholder with respect to a controlled foreign corporation generally would not be allowed certain tax
deductions or foreign tax credits that would be available to a United States shareholder that is a U.S. corporation.
Failure to comply with these reporting obligations may subject a United States shareholder to significant monetary
penalties and may prevent the statute of limitations with respect to such shareholder’s U.S. federal income tax return
for the year for which reporting was due from starting. We cannot provide any assurances that we will assist
investors in determining whether we are treated as a controlled foreign corporation or whether any holder of our
ADSs is treated as a United States shareholder with respect to any such controlled foreign corporation or furnish to
any United States shareholders information that may be necessary to comply with the aforementioned reporting and
tax paying obligations. The United States Internal Revenue Service provided limited guidance on situations in which
investors may rely on publicly available information to comply with their reporting and tax paying obligations with
respect to foreign-controlled CFCs. Each U.S. holder of our ADSs should consult its advisors regarding the potential
application of these rules to an investment in our ADSs.
51
The rights of shareholders in companies subject to French corporate law differ in material respects from the
rights of shareholders of corporations incorporated in the United States.
We are a French company with limited liability. Our corporate affairs are governed by our by-laws and by the
laws governing companies incorporated in France. The rights of shareholders and the responsibilities of members of
our Board are in many ways different from the rights and obligations of shareholders in companies governed by the
laws of U.S. jurisdictions. For example, in the performance of its duties, our Board is required by French law to
consider the interests of our company, its shareholders, its employees and other stakeholders, rather than solely our
shareholders and/or creditors. It is possible that some of these parties will have interests that are different from, or in
addition to, your interests as a shareholder or holder of ADSs.
You may face difficulties protecting your interests, and your ability to protect your rights through the U.S. federal
courts may be limited because we are incorporated under the laws of France, all of our assets are in the
European Union and a majority of our directors and executive officers reside outside the United States.
We are constituted under the laws of France. A majority of our officers and directors reside outside the
United States. In addition, a substantial portion of their assets and our assets are located outside of the United States.
As a result, you may have difficulty serving legal process within the United States upon us or any of these persons.
You may also have difficulty enforcing, both in and outside of the United States, judgments you may obtain in
U.S. courts against us or these persons in any action, including actions based upon the civil liability provisions of
U.S. Federal or state securities laws. Furthermore, there is substantial doubt as to the enforceability in France against
us or against any of our directors and officers who are not residents of the United States, in original actions or in
actions for enforcement of judgments of U.S. courts, of liabilities based solely upon the civil liability provisions of
the U.S. federal securities laws. In addition, shareholders in French corporations may not have standing to initiate a
shareholder derivative action in U.S. federal courts.
As a result, our public shareholders may have more difficulty in protecting their interests through actions
against us, our management, our directors or our major shareholders than would shareholders of a corporation
incorporated in a jurisdiction in the United States.
The dual listing of our ordinary shares and the ADSs may adversely affect the liquidity and value of the ADSs.
Our ordinary shares are listed on Euronext Paris. Trading of the ADSs or ordinary shares in these markets will
take place in different currencies (U.S. dollars on Nasdaq and euros on Euronext Paris), and at different times
(resulting from different time zones, different trading days and different public holidays in the United States and
France). The trading prices of our ordinary shares on these two markets may differ due to these and other factors.
Any decrease in the price of our ordinary shares on Euronext Paris could cause a decrease in the trading price of the
ADSs on Nasdaq. Investors could seek to sell or buy our ordinary shares to take advantage of any price differences
between the markets through a practice referred to as arbitrage. Any arbitrage activity could create unexpected
volatility in both our share prices on one exchange, and the ordinary shares available for trading on the other
exchange. In addition, holders of ADSs will not be immediately able to surrender their ADSs and withdraw the
underlying ordinary shares for trading on the other market without effecting necessary procedures with the
depositary. This could result in time delays and additional cost for holders of ADSs. We cannot predict the effect of
this dual listing on the value of our ordinary shares and the ADSs. However, the dual listing of our ordinary shares
and the ADSs may reduce the liquidity of these securities in one or both markets and may adversely affect the
development of an active trading market for the ADSs in the United States.
Our by-laws and French corporate law contain provisions that may delay or discourage a takeover attempt.
Provisions contained in our by-laws and French corporate law could make it more difficult for a third party to
acquire us, even if doing so might be beneficial to our shareholders. In addition, provisions of our by-laws impose
various procedural and other requirements, which could make it more difficult for shareholders to effect certain
corporate actions. These provisions include the following:
•under French law, the owner of 90% of the share capital or voting rights of a public company listed on
a regulated market in a Member State of the European Union or in a state party to the EEA Agreement,
including from the main French stock exchange, has the right to force out minority shareholders
following a tender offer made to all shareholders;
•under French law, a non-resident of France as well as any French entity controlled by non-residents of
France may have to file a declaration for statistical purposes with the Bank of France (Banque de
France) within 20 working days following the date of certain direct foreign investments in us,
including any purchase of our ADSs. In particular, such filings are required in connection with
investments exceeding €15 million that lead to the acquisition of at least 10% of our share capital or
52
voting rights or cross such 10% threshold. See “Limitations Affecting Shareholders of a French
Company”;
•under French law, certain foreign investments in companies incorporated under French laws are
subject to the prior authorization from the French Minister of the Economy, where all or part of the
target’s business and activity relate to a strategic sector, such as energy, transportation, public health,
telecommunications, research and development in biotechnologies, activities relating to public health,
etc.;
•a merger (i.e., in a French law context, a share for share exchange following which our company
would be dissolved into the acquiring entity and our shareholders would become shareholders of the
acquiring entity) of our company into a company incorporated in the European Union would require
the approval of our Board as well as a two-thirds majority of the votes held by the shareholders
present, represented by proxy or voting by mail at the relevant meeting;
•a merger of our company into a company incorporated outside of the European Union would require
100% of our shareholders to approve it;
•under French law, a cash merger is treated as a share purchase and would require the consent of each
participating shareholder;
•our shareholders have granted and may grant in the future our Board broad authorizations to increase
our share capital or to issue additional ordinary shares or other securities, such as warrants, to our
shareholders, the public or qualified investors, including as a possible defense following the launching
of a tender offer for our shares;
•our shareholders have preferential subscription rights on a pro rata basis on the issuance by us of any
additional securities for cash or a set-off of cash debts, which rights may only be waived by the
extraordinary general meeting by a two-thirds majority vote of our shareholders or on an individual
basis by each shareholder;
•our Board has the right to appoint directors to fill a vacancy created by the resignation or death of a
director, subject to the approval by the shareholders of such appointment at the next shareholders’
meeting, which prevents shareholders from having the sole right to fill vacancies on our Board;
•our Board can be convened by our chairman, including upon request from our Chief Executive Officer
(directeur général), if the positions of Chief Executive Officer and Chairman of the Board are not held
by the same person, or, when no board meeting has been held for more than two consecutive months,
from directors representing at least one-third of the total number of directors;
•our Board meetings can only be regularly held if at least half of the directors attend either physically or
by way of videoconference or teleconference enabling the directors’ identification and ensuring their
effective participation in the Board’s decisions;
•our shares are registered or bearer, if the legislation so permits, according to the shareholder’s choice;
•approval of at least a majority of the votes held by shareholders present, represented by a proxy, or
voting by mail at the relevant ordinary shareholders’ general meeting is required to remove directors
with or without cause;
•advance notice is required for nominations to the Board or for proposing matters to be acted upon at a
shareholders’ meeting, except that a vote to remove and replace a director can be proposed at any
shareholders’ meeting without notice;
•our by-laws can be changed in accordance with applicable French laws and regulations;
•the crossing of certain thresholds must be disclosed and can impose certain obligations (including
filing a mandatory public tender offer);
•transfers of shares shall comply with applicable insider trading rules and regulations and, in particular,
with the EU Market Abuse Directive and Regulation dated April 16, 2014; and
•pursuant to French law, the sections of our by-laws relating to the number of directors and election and
removal of a director from office, may only be modified by a resolution adopted by two-thirds of the
votes of our shareholders present, represented by a proxy or voting by mail at the meeting.
53
Existing and potential investors in our ordinary shares or ADSs may have to request the prior authorization from
the French Ministry of Economy prior to acquiring an interest in our ordinary shares or ADSs.
Under French law, direct and indirect acquisition of control of all or part of a branch of activity, and
investments of more than 10% in companies like ours whose shares are admitted to trading on a French or EU
regulated market, by foreign individuals or entities (except, in the last case, EU/EEA investors) in a French company
deemed to be a strategic industry is subject to prior authorization of the French Ministry of Economy pursuant to
Articles L. 151-1 et seq. and R. 151-1 et seq. of the French Monetary and Financial Code. Industries and research
and development essential to the protection of public health fall within the scope of this regulation. If necessary to
protect strategic assets, the ministry may condition its authorization upon the commitment of the investor to certain
structural and behavioral remedies that are necessary for the maintain of strategic activities, knowledge and
intellectual property in France.
If an investment requiring the prior authorization of the French Minister of Economy is completed without
such authorization having been granted, the French Minister of Economy might order the relevant investor to
(i) submit a request for authorization, (ii) have the situation prior to the completion of the investment restored at its
own expense or (iii) amend the investment. Non-compliance with the authorization requirement or breach to the
conditions imposed may expose the relevant investor to a criminal fine which cannot exceed the greater of: (i) twice
the amount of the relevant investment, (ii) 10% of the annual turnover before tax of the target company and (iii)
€5 million (for an entity) or €1 million (for an individual). The French Minister of Economy may also adopt
precautionary measures it deems necessary to protect strategic sovereign assets, including the suspension of voting
rights or the prohibition or limitation of the distribution of dividends and remuneration attached to shares whose
ownership by the investor should have been subject to prior authorization.
The non-EU/EEA investors in French companies whose shares are admitted to trading on a French or EU
regulated market reaching the 10% threshold benefit from a “fast-track procedure” pursuant to which the investor is
exempt from the authorization request provided for in Article R. 151-5 of the Monetary and Financial Code,
provided that the investment project has been the subject of a prior simplified notification to the French Minister of
Economy, and the French Minister of Economy did not request to follow the standard notification process, the
transaction can proceed within ten working days following notification.
Failure to comply with such measures could result in significant consequences in the concerned investment.
Such measures could also delay or discourage a takeover or more broadly a foreign investment attempt, and we
cannot predict whether these measures will result in a lower or more volatile market price of our ADSs.
You may not be able to exercise your right to vote the ordinary shares underlying your ADSs.
Holders of ADSs may exercise voting rights with respect to the ordinary shares represented by the ADSs only
in accordance with the provisions of the deposit agreement. The deposit agreement provides that, upon receipt of
notice of any meeting of holders of our ordinary shares, the depositary will fix a record date for the determination of
ADS holders who shall be entitled to give instructions for the exercise of voting rights. Upon timely receipt of notice
from us, if we so request, the depositary shall distribute to the holders as of the record date (i) the notice of the
meeting or solicitation of consent or proxy sent by us and (ii) a statement as to the manner in which instructions may
be given by the holders.
Purchasers of ADSs may instruct the depositary of their ADSs to vote the ordinary shares underlying their
ADSs. Otherwise, purchasers of ADSs will not be able to exercise voting rights unless they withdraw the ordinary
shares underlying the ADSs they hold. However, a holder of ADSs may not know about the meeting far enough in
advance to withdraw those ordinary shares. If we ask for a holder of ADSs’ instructions, the depositary, upon timely
notice from us, will notify him or her of the upcoming vote and arrange to deliver our voting materials to him or her.
We cannot guarantee to any holder of ADSs that he or she will receive the voting materials in time to ensure that he
or she can instruct the depositary to vote his or her ordinary shares or to withdraw his or her ordinary shares so that
he or she can vote them. If the depositary does not receive timely voting instructions from a holder of ADSs, it may
give a proxy to a person designated by us to vote the ordinary shares underlying his or her ADSs. In addition, the
depositary and its agents are not responsible for failing to carry out voting instructions or for the manner of carrying
out voting instructions. This means that a holder of ADSs may not be able to exercise his or her right to vote, and
there may be nothing he or she can do if the ordinary shares underlying his or her ADSs are not voted as he or she
requested.
Purchasers of ADSs are not holders of our ordinary shares.
A holder of ADSs will not be treated as one of our shareholders and will not have direct shareholder rights.
French law governs our shareholder rights. The depositary will be the holder of the ordinary shares underlying ADSs
held by purchasers of ADSs. Purchasers of ADSs will have ADS holder rights. The deposit agreement among us, the
54
depositary and purchasers of ADSs, as ADS holders, and all other persons directly and indirectly holding ADSs, sets
out ADS holder rights, as well as the rights and obligations of the depositary.
A double voting right is attached to each registered ordinary share (except treasury shares) that is held in the
name of the same shareholder for at least two years. However, the ordinary shares underlying our ADSs will not be
entitled to double voting rights as the depositary will hold the ordinary shares underlying our ADSs in bearer form.
The right as a holder of ADSs to participate in any future preferential subscription rights or to elect to receive
dividends in shares may be limited, which may cause dilution to the holdings of purchasers of ADSs.
According to French law, if we issue additional securities for cash, current shareholders will have preferential
subscription rights for these securities on a pro rata basis unless they waive those rights at an extraordinary meeting
of our shareholders by a two-thirds majority vote or individually by each shareholder. However, ADS holders will
not be entitled to exercise or sell such rights unless we register the rights and the securities to which the rights relate
under the Securities Act or an exemption from the registration requirements is available. In addition, the deposit
agreement provides that the depositary will not make rights available to purchasers of ADSs unless the distribution
to ADS holders of both the rights and any related securities are either registered under the Securities Act or
exempted from registration under the Securities Act. Further, if we offer holders of our ordinary shares the option to
receive dividends in either cash or shares, under the deposit agreement the depositary may require satisfactory
assurances from us that extending the offer to holders of ADSs does not require registration of any securities under
the Securities Act before making the option available to holders of ADSs. We are under no obligation to file a
registration statement with respect to any such rights or securities or to endeavor to cause such a registration
statement to be declared effective. Moreover, we may not be able to establish an exemption from registration under
the Securities Act. Accordingly, ADS holders may be unable to participate in our rights offerings or to elect to
receive dividends in shares and may experience dilution in their holdings. In addition, if the depositary is unable to
sell rights that are not exercised or not distributed or if the sale is not lawful or reasonably practicable, it will allow
the rights to lapse, in which case you will receive no value for these rights.
Purchasers of ADSs may be subject to limitations on the withdrawal of the underlying ordinary shares.
Temporary delays in the cancellation of ADSs and withdrawal of the underlying ordinary shares may arise
because the depositary has closed its transfer books or we have closed our transfer books, the transfer of ordinary
shares is blocked to permit voting at a shareholders’ meeting or we are paying a dividend on our ordinary shares. In
addition, a holder of ADSs may not be able to cancel his or her ADSs and withdraw the underlying ordinary shares
when he or she owes money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in
order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary
shares or other deposited securities.
ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which
could result in less favorable outcomes to the plaintiffs in any such action.
The deposit agreement governing the ADSs representing our ordinary shares provides that, to the fullest extent
permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary
arising out of or relating to our shares, the ADSs or the deposit agreement, including any claim under the U.S.
federal securities laws.
If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether
the waiver was enforceable based on the facts and circumstances of that case in accordance with the applicable state
and federal law. To our knowledge, the enforceability of a contractual pre-dispute jury trial waiver in connection
with claims arising under the federal securities laws has not been finally adjudicated by the United States Supreme
Court. However, we believe that a contractual pre-dispute jury trial waiver provision is generally enforceable,
including under the laws of the State of New York, which govern the deposit agreement, by a federal or state court
in the City of New York, which has non-exclusive jurisdiction over matters arising under the deposit agreement. In
determining whether to enforce a contractual pre-dispute jury trial waiver provision, courts will generally consider
whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. We believe that this is the
case with respect to the deposit agreement and the ADSs. It is advisable that you consult legal counsel regarding the
jury waiver provision before entering into the deposit agreement.
If you or any other holders or beneficial owners of ADSs bring a claim against us or the depositary in
connection with matters arising under the deposit agreement or the ADSs, including claims under federal securities
laws, you or such other holder or beneficial owner may not be entitled to a jury trial with respect to such claims,
which may have the effect of limiting and discouraging lawsuits against us and the depositary. If a lawsuit is brought
against either or both of us and the depositary under the deposit agreement, it may be heard only by a judge or
55
justice of the applicable trial court, which would be conducted according to different civil procedures and may result
in different outcomes than a trial by jury would have, including results that could be less favorable to the plaintiffs in
any such action.
Nevertheless, if this jury trial waiver provision is not permitted by applicable law, an action could proceed
under the terms of the deposit agreement with a jury trial. No condition, stipulation or provision of the deposit
agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of
compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder.
As a foreign private issuer, we are exempt from a number of rules under the U.S. securities laws and are
permitted to file less information with the SEC than a U.S. public company. This may limit the information
available to holders of ADSs.
We are a foreign private issuer, as defined in the SEC’s rules and regulations and, consequently, we are not
subject to all of the disclosure requirements applicable to public companies organized within the United States. For
example, we are exempt from certain rules under the Exchange Act that regulate disclosure obligations and
procedural requirements related to the solicitation of proxies, consents or authorizations applicable to a security
registered under the Exchange Act, including the U.S. proxy rules under Section 14 of the Exchange Act. In
addition, our officers and directors are exempt from the reporting and “short-swing” profit recovery provisions of
Section 16 of the Exchange Act and related rules with respect to their purchases and sales of our securities.
Moreover, while we currently make annual and semi-annual filings with respect to our listing on Euronext Paris and
expect to file financial reports on an annual and semi-annual basis, we will not be required to file periodic reports
and financial statements with the SEC as frequently or as promptly as U.S. public companies and will not be
required to file quarterly reports on Form 10-Q or current reports on Form 8-K under the Exchange Act.
Accordingly, there will be less publicly available information concerning our company than there would be if we
were not a foreign private issuer.
As a foreign private issuer, we are permitted, and we expect, to follow certain home country practices in relation
to corporate governance matters that differ significantly from Nasdaq’s corporate governance standards. These
practices may afford less protection to shareholders than they would enjoy if we complied fully with the corporate
governance standards of the Nasdaq Global Market.
As a foreign private issuer listed on the Nasdaq Global Market, we are subject to Nasdaq’s corporate
governance standards. However, Nasdaq rules provide that foreign private issuers are permitted to follow home
country corporate governance practices in lieu of Nasdaq’s corporate governance standards, with certain exceptions,
as long as notification is provided to Nasdaq of the intention to take advantage of such exemptions. We intend to
rely on exemptions for foreign private issuers and follow French corporate governance practices in lieu of Nasdaq’s
corporate governance standards, to the extent possible. Certain corporate governance practices in France, which is
our home country, may differ significantly from Nasdaq corporate governance standards. For example, as a French
company, neither the corporate laws of France nor our by-laws require a majority of our directors to be independent
and we can include non-independent directors as members of our remuneration committee, and our independent
directors are not required to hold regularly scheduled meetings at which only independent directors are present.
We are also exempt from provisions set forth in Nasdaq rules which require an issuer to provide in its by-laws
for a generally applicable quorum, and that such quorum may not be less than one-third of the outstanding voting
stock. Consistent with French law, our by-laws provide that a quorum requires the presence of shareholders having
at least (i) 20% of the shares entitled to vote in the case of an ordinary shareholders’ general meeting or at an
extraordinary shareholders’ general meeting where shareholders are voting on a capital increase by capitalization of
reserves, profits or share premium, or (ii) 25% of the shares entitled to vote in the case of any other extraordinary
shareholders’ general meeting. If a quorum is not present, the meeting is adjourned. There is no quorum requirement
when an ordinary general meeting is reconvened, but the reconvened meeting may consider only questions which
were on the agenda of the adjourned meeting. When an extraordinary general meeting is reconvened, the quorum
required is 20% of the shares entitled to vote, except where the reconvened meeting is considering capital increases
through capitalization of reserves, profits or share premium. For these matters, no quorum is required at the
reconvened meeting. If a quorum is not present at a reconvened meeting requiring a quorum, then the meeting may
be adjourned for a maximum of two months.
As a foreign private issuer, we are required to comply with Rule 10A-3 of the Exchange Act, relating to audit
committee composition and responsibilities. Under French law, the audit committee may only have an advisory role
and appointment of our statutory auditors, in particular, must be decided by the shareholders at our annual meeting.
Therefore, our shareholders may be afforded less protection than they otherwise would have under Nasdaq’s
corporate governance standards applicable to U.S. domestic issuers. For an overview of our corporate governance
practices, see “Part II—Item 16G—Corporate Governance.”
56
We are an “emerging growth company” under the JOBS Act and will be able to avail ourselves of reduced
disclosure requirements applicable to emerging growth companies, which could make our ADSs less attractive to
investors.
We are an “emerging growth company,” as defined in the JOBS Act, and we intend to take advantage of
certain exemptions from various reporting requirements that are applicable to other public companies that are not
“emerging growth companies”, including not being required to comply with the auditor attestation requirements of
Section 404(b) of the Sarbanes-Oxley Act of 2002 (“Sarbanes-Oxley Act”), and exemptions from the requirements
of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute
payments not previously approved. In addition, Section 107 of the JOBS Act also provides that an emerging growth
company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act,
for complying with new or revised accounting standards. We will not take advantage of the extended transition
period provided under Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting
standards. Since IFRS makes no distinction between public and private companies for purposes of compliance with
new or revised accounting standards, the requirements for our compliance as a private company and as a public
company are the same.
We cannot predict if investors will find our ADSs less attractive because we may rely on these exemptions. If
some investors find our ADSs less attractive as a result, there may be a less active trading market for our ADSs and
the price of our ADSs may be more volatile. We may take advantage of these reporting exemptions until we are no
longer an emerging growth company. We will remain an emerging growth company until the earliest of (1) the last
day of the fiscal year in which we have total annual gross revenue of $1.235 billion or more; (2) the last day of our
fiscal year following the fifth anniversary of the date of the completion of our U.S. initial public offering and listing
on Nasdaq; (3) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous
three years; and (4) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.
We may lose our foreign private issuer status in the future, which could result in significant additional cost and
expense.
While we currently qualify as a foreign private issuer, the determination of foreign private issuer status is
made annually on the last business day of an issuer’s most recently completed second fiscal quarter and,
accordingly, the next determination will be made with respect to us on June 30, 2024. In the future, we could lose
our foreign private issuer status if we fail to meet the requirements necessary to maintain our foreign private issuer
status as of the relevant determination date. We will remain a foreign private issuer until such time that more than
50% of our outstanding voting securities are held by U.S. residents and any of the following three circumstances
applies: (i) the majority of our executive officers or directors are U.S. citizens or residents; (ii) more than 50% of our
assets are located in the United States; or (iii) our business is administered principally in the United States. For
additional information relating to our principal shareholders, see “Principal Shareholders.”
The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be
significantly more than costs we incur as a foreign private issuer. If we are not a foreign private issuer, we will be
required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are
more detailed and extensive in certain respects than the forms available to a foreign private issuer. We would be
required under current SEC rules to prepare our financial statements in accordance with U.S. GAAP, rather than
IFRS, and modify certain of our policies to comply with corporate governance practices associated with U.S.
domestic issuers. Such conversion of our financial statements to U.S. GAAP would involve significant time and
cost. In addition, we may lose our ability to rely upon exemptions from certain corporate governance requirements
on U.S. stock exchanges that are available to foreign private issuers such as the ones described herein and
exemptions from procedural requirements related to the solicitation of proxies.
General Risk Factors
We may not be successful in obtaining or maintaining necessary rights to product components and processes for
our development pipeline through acquisitions and in-licenses.
The growth of our business may depend in part on our ability to acquire, in-license or use third-party
proprietary rights. For example, our drug candidates may require specific formulations to work effectively and
efficiently, we may develop drug candidates containing our compounds and pre-existing pharmaceutical compounds,
or we may be required by the FDA or comparable foreign regulatory authorities to provide a companion diagnostic
test or tests with our drug candidates, any of which could require us to obtain rights to use intellectual property held
by third parties. In addition, with respect to any patents we may co-own with third parties, we may require licenses
to such co-owner’s interest to such patents. We may be unable to acquire or in-license any compositions, methods of
use, processes or other third-party intellectual property rights from third parties that we identify as necessary or
important to our business operations. In addition, we may fail to obtain any of these licenses at a reasonable cost or
57
on reasonable terms, if at all. Were that to happen, we may need to cease use of the compositions or methods
covered by those third-party intellectual property rights, and may need to seek to develop alternative approaches that
do not infringe on those intellectual property rights, which may entail additional costs and development delays, even
if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it
may be non-exclusive, which means that our competitors may also receive access to the same technologies licensed
to us. In that event, we may be required to expend significant time and resources to develop or license replacement
technology.
Additionally, we sometimes collaborate with academic institutions to accelerate our preclinical research or
development under written agreements with these institutions. In certain cases, these institutions provide us with an
option to negotiate a license to any of the institution’s rights in technology resulting from the collaboration. Even if
we hold such an option, we may be unable to negotiate a license from the institution within the specified timeframe
or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property
rights to others, potentially blocking our ability to pursue our program.
The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies
that may be more established or have greater resources than we do may also be pursuing strategies to license or
acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize
our drug candidates. More established companies may have a competitive advantage over us due to their size, cash
resources and greater clinical development and commercialization capabilities. In addition, companies that perceive
us to be a competitor may be unwilling to assign or license rights to us. There can be no assurance that we will be
able to successfully complete these types of negotiations and ultimately acquire the rights to the intellectual property
surrounding the additional drug candidates that we may seek to develop or market. If we are unable to successfully
obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we
have, we may have to abandon development of certain programs and our business financial condition, results of
operations and prospects could suffer.
The market price of our equity securities may be volatile, and purchasers of our ADSs could incur substantial
losses.
The market price for our ADSs may be volatile. The stock market in general and the market for
biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the
operating performance of particular companies. As a result of this volatility, investors may not be able to sell their
ADSs at or above the price originally paid for the security. The market price for our ADSs and ordinary shares may
be influenced by many factors, including:
•actual or anticipated fluctuations in our financial condition and operating results;
•actual or anticipated changes in our growth rate relative to our competitors;
•competition from existing products or new products that may emerge;
•announcements by us or our competitors of significant acquisitions, strategic partnerships, joint
ventures, collaborations, or capital commitments;
•failure to meet or exceed financial estimates and projections of the investment community or that we
provide to the public;
•issuance of new or updated research or reports by securities analysts;
•fluctuations in the valuation of companies perceived by investors to be comparable to us;
•share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;
•additions or departures of key management or scientific personnel;
•lawsuits threatened or filed against us, disputes or other developments related to proprietary rights,
including patents, litigation matters, and our ability to obtain patent protection for our technologies;
•changes to coverage policies or reimbursement levels by commercial third-party payors and
government payors and any announcements relating to coverage policies or reimbursement levels;
•announcement or expectation of additional debt or equity financing efforts;
•sales of our ordinary shares or ADSs by us, our insiders or our other shareholders; and
•general economic and market conditions.
58
These and other market and industry factors may cause the market price and demand for our ADSs to fluctuate
substantially, regardless of our actual operating performance, which may limit or prevent investors from readily
selling their ADSs and may otherwise negatively affect the liquidity of the trading market for our ADSs.
If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our
business, the price of our ADSs and their trading volume could decline.
The trading market for our ADSs depends in part on the research and reports that securities or industry
analysts publish about us or our business. If no or few securities or industry analysts cover our company, the trading
price for our ADSs would be negatively impacted. If one or more of the analysts who covers us downgrades our
equity securities or publishes incorrect or unfavorable research about our business, the price of our ADSs would
likely decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us
regularly, or downgrades our securities, demand for our ADSs could decrease, which could cause the price of our
ADSs or their trading volume to decline.
The requirements of being a U.S. public company may strain our resources and divert management’s attention.
We are required to comply with various corporate governance and financial reporting requirements under the
Sarbanes-Oxley Act, the Exchange Act, and the rules and regulations adopted by the SEC and the Public Company
Accounting Oversight Board. Further, compliance with various regulatory reporting requires significant
commitments of time from our management and our directors, which reduces the time available for the performance
of their other responsibilities. Our failure to track and comply with the various rules may materially adversely affect
our reputation, ability to obtain the necessary certifications to financial statements, lead to additional regulatory
enforcement actions, and could adversely affect the value of our ordinary shares or ADSs.
We may be at an increased risk of securities class action litigation.
Historically, securities class action litigation has often been brought against a company following a decline in
the market price of its securities. This risk is especially relevant for us because biotechnology and biopharmaceutical
companies have experienced significant share price volatility in recent years. If we were to be sued, it could result in
substantial costs, which could be insufficiently covered by insurance, and a diversion of management’s attention and
resources, which could harm our business.
We do not currently intend to pay dividends on our securities and, consequently, your ability to achieve a return
on your investment will depend on appreciation in the price of the ordinary shares and our ADSs. In addition,
French law may limit the amount of dividends we are able to distribute.
We have never declared or paid any cash dividends on our ordinary shares and do not currently intend to do so
for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Therefore,
you are not likely to receive any dividends on your ADSs for the foreseeable future and the success of an investment
in ADSs will depend upon any future appreciation in its value. Consequently, investors may need to sell all or part
of their holdings of ADSs after price appreciation, which may never occur, as the only way to realize any future
gains on their investment. There is no guarantee that the ADSs will appreciate in value or even maintain the price at
which our shareholders have purchased them. Investors seeking cash dividends should not purchase our ADSs.
Furthermore, certain of our debt instruments restrict the payment of dividends or require consent to pay dividends.
See “Part I—Item 8.A—Dividend Policy.”
Further, under French law, the determination of whether we have been sufficiently profitable to pay dividends
is made on the basis of our statutory financial statements prepared and presented in accordance with accounting
standards applicable in France. In addition, payment of dividends may subject us to additional taxes under French
law. Therefore, we may be more restricted in our ability to declare dividends than companies not based in France.
In addition, exchange rate fluctuations may affect the amount of euros that we are able to distribute, and the
amount in U.S. dollars that our shareholders receive upon the payment of cash dividends or other distributions we
declare and pay in euros, if any. These factors could harm the value of our ADSs, and, in turn, the U.S. dollar
proceeds that holders receive from the sale of our ADSs.
59
Item 4.Information on the Company.
A.History and Development of the Company
Our legal and commercial name is Abivax SA. We were incorporated as a société anonyme (limited liability
company) under the laws of France on December 4, 2013 and registered at the Paris Trade and Company Register on
December 27, 2013 under the number 799 363 718. Our principal executive offices are located at 7-11 boulevard
Haussmann 75009 Paris, France, and our telephone number is +33 (0) 1 53 83 09 63. We have one wholly owned
subsidiary, Abivax LLC, a Delaware limited liability company, formed on March 20, 2023. Our agent for service of
process in the United States is CT Corporation System, 1015 15th Street N.W., Suite 1000, Washington, D.C.
20005.
We have been listed on Euronext Paris since June 2015. In October 2023, we completed the initial public
offering of our ordinary shares in the form of ADSs on the Nasdaq Global Market, raising approximately $235.8
million in gross proceeds (equivalent to approximately €223.3 million based on the exchange rate then in effect).
We did not incur any material capital expenditures for the years ended December 31, 2023, 2022 and 2021.
The SEC maintains an Internet site that contains reports, proxy information statements and other information
regarding issuers that file electronically with the SEC. The address of that site is http://www.sec.gov. Our website
address is www.abivax.com. The reference to our website is an inactive textual reference only and information
contained in, or that can be accessed through, our website or any other website cited in this annual report is not part
of this annual report.
B.Business Overview
Overview
We are a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s
natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. We
are currently evaluating our lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults
with moderately to severely active ulcerative colitis (“UC”). We are also in the planning stages of initiating a Phase
2b clinical trial of obefazimod in patients with Crohn’s disease (“CD”), as well as evaluating other potential
inflammatory indications.
We focus on indications where existing treatments have left patients with significant unmet needs, and where
we believe our investigational agents have the potential to be meaningfully differentiated from currently available
therapies. The indications we target have substantial populations and represent large commercial opportunities,
pending regulatory approvals and successful commercialization. Our initial focus is on inflammatory bowel diseases
(“IBD”), chronic conditions involving inflammation of the gastrointestinal (“GI”) tract, of which the two most
common forms are UC and CD. As of 2022, an aggregate of approximately 2.9 million patients across the United
States, EU4 (France, Germany, Italy and Spain), the United Kingdom and Japan suffered from IBD, with 1.5 million
of these patients in the United States alone.
One of the primary goals of IBD therapy is to achieve durable clinical remission while simultaneously taking
into consideration a patient’s quality of life and concerns regarding potential side effects. Despite a number of
different therapies approved for UC and CD, the vast majority of these therapies require chronic administration via
injections or intravenous infusions, and may come with serious and concerning warnings, including, but not limited
to, risks of serious infections leading to hospitalizations or death and increased risks of various malignancies. A vast
majority of IBD patients do not achieve clinical remission with existing therapies, and a significant number of
patients will lose response over time, especially those patients on TNF-alpha inhibitor therapy where anti-drug
antibodies are very common. Further, despite the increased number of biosimilars, such as TNF-alpha inhibitor
therapies, becoming available for the treatment of IBD, biosimilars unfortunately do not alleviate any of the
potential side effect concerns that often cause patients to delay, or avoid altogether, stepping up to more advanced
therapies. In addition, although a small number of oral therapies have more recently been approved for the treatment
of IBD, these therapies also come with concerning potential side effects, which can discourage patients from
initiating treatment with advanced therapies. Therefore, there continues to be significant unmet need for novel oral
therapies with durable efficacy, improved safety profiles and minimal preinitiation requirements for patients with
moderately to severely active IBD. Moreover, we believe the IBD market has significant growth potential driven by
growing diagnosis of these diseases and increased penetration of oral treatments with improved benefit/risk profiles.
We believe our lead drug candidate, obefazimod, is differentiated from competing approaches for the
treatment of IBD via its novel mechanism of action. Obefazimod was demonstrated to specifically enhance the
expression of a single micro-RNA, miR-124, which plays a critical role in the regulation of the inflammatory
response. In the context of inflammation, miR-124 is a natural regulator of the inflammatory response, controlling
60
progression of inflammation and restoring homeostasis of the immune system, without causing broader
immunosuppression. In contrast to currently available advanced therapies, prescribed post-conventional therapies,
some of which target only a single cytokine or pathway, miR-124 modulates the expression of several key cytokines
and pathways. Modulating multiple inflammatory pathways simultaneously may lead to more durability of efficacy
results over the long-term, which is critical in lifelong conditions such as IBD, potentially differentiating
obefazimod from currently available IBD treatments.
In our Phase 2 clinical trials for the treatment of moderately to severely active UC, consistent with the
pharmacological effects observed in our preclinical studies, obefazimod demonstrated an onset of symptom relief by
day 8 of dosing, with meaningful reductions in rectal bleeding and stool frequency scores. In our induction Phase 2b
clinical trial, which included 252 patients, obefazimod met the primary endpoint of a statistically significant
reduction in Modified Mayo Score, a measure of disease activity relative to placebo. In addition, we observed high
rates of sustained and newly achieved clinical remission in the subsequent open-label maintenance extension trial of
up to two years of treatment, of which approximately 45% of patients were previously exposed to biologics or Janus
kinase (“JAK”) inhibitors. Greater than 90% of patients previously exposed to advanced therapy prior to enrollment
were highly refractory, having failed two advanced therapies.
In April 2023, we reported the results from the final analysis of our Phase 2b open-label maintenance trial,
including 217 patients of which 164 patients (76%) completed the second year of once-daily oral treatment with 50
mg obefazimod. At the conclusion of the second year of treatment, 114 of the 217 patients enrolled (53%) achieved
clinical remission and 158 patients (73%) achieved clinical response. Among the 98 bio-refractory patients,
66 patients (67%) had a clinical response, 38 patients (39%) were in clinical remission, 46 patients (47%) had
endoscopic improvement and 20 patients (20%) had endoscopic remission at week 96. Among the 124 patients that
achieved clinical response at the end of the 8-week induction period of the double-blind study, 82 patients (66%)
achieved clinical remission at week 48, mimicking the re-randomization of responders approach typically utilized in
Phase 3 maintenance trials. Of the 124 patients in clinical response at week 8, 74 patients (60%) achieved clinical
remission, 95 patients (77%) had clinical response, 79 patients (64%) achieved endoscopic improvement and 52
patients (42%) achieved endoscopic remission at week 96.
In September 2023, we reported an interim analysis of step-down dosing from 50 mg to 25 mg for the third
and fifth year of open-label maintenance treatment with obefazimod in UC patients. These patients were treated with
50 mg of oral, once-daily obefazimod for approximately four years in the Phase 2a clinical trial and approximately
two years in the Phase 2b clinical trial. Patients were eligible to enroll in the trial if they had a Mayo endoscopic
subscore of 0 or 1. Eligible patients were switched to 25 mg, and an interim analysis was performed at week 48 with
a cut-off date of July 31, 2023. Of the 71 eligible patients, 63 completed their 48-week visit. Among these patients,
53 out of 63 patients (84%) demonstrated disease control (stable or improved Modified Mayo Score). No new safety
signals were detected in UC patients treated up to five years with oral, once-daily obefazimod.
Obefazimod’s tolerability profile indicates potentially important clinical differentiation. As of November 30,
2023 (the last safety data cut-off date), 1,082 subjects have received obefazimod, according to various
administration schedules, in all completed and ongoing open-label clinical trials across all indications including 248
subjects for longer than 6 months and 226 subjects for longer than one year. Additionally, 146 subjects included in
the ABTECT program have received blinded obefazimod or placebo.
We initiated our pivotal Phase 3 clinical trials of obefazimod for the treatment of moderately to severely active
UC in October 2022, which consist of two induction trials (ABTECT-1 and ABTECT-2) and one ABTECT
maintenance trial. Top-line data from the ABTECT-1 and ABTECT-2 induction trials is expected to be announced
in the first quarter of 2025, and top-line data from the ABTECT maintenance trial is expected to be announced in the
first quarter of 2026. Our Investigational New Drug application (“IND”) for a Phase 2b clinical trial in patients with
CD was cleared by the FDA in the fourth quarter of 2023, and we expect to initiate enrollment in the third quarter of
2024. We intend to announce Phase 2b induction trial top-line results in the second half of 2026 with the objective to
demonstrate clinical response and tolerability profile consistent with that already observed in our clinical trials for
moderately to severely active UC. Based on the results from this Phase 2b clinical trial, if positive, we intend to
proceed to a Phase 3 clinical trial.
Our Pipeline
Our lead drug candidate, obefazimod, is in clinical development for the treatment of moderately to severely
active UC. We are continuing to develop obefazimod for the treatment of CD and are evaluating additional potential
inflammatory indications to pursue, subject to the availability of necessary resources and funding. In parallel, we are
in the process of generating follow-on compounds based on the miR-124 platform.
61
The chart below sets forth details relating to the current stages of development of our lead drug candidate:
(1)Decision subject to results of the Phase 3 monotherapy induction trials.
IBD Overview and Limitations of Existing Treatments
IBD, such as UC and CD, is a chronic life-long immune-mediated inflammatory condition of the GI tract with
many contributing factors, including genetic, environmental and immunologic. UC and CD are the two most
common forms of IBD and are characterized by dysregulation of lymphocytes contributing to inflammation. Both
UC and CD are chronic, relapsing, remitting, inflammatory conditions of the GI tract that begin most commonly
during adolescence and young adulthood. UC involves the innermost lining of the large intestine, and symptoms
include abdominal pain and diarrhea, frequently with blood and mucus. CD can affect the entire thickness of the
bowel wall and all parts of the GI tract from mouth to anus. CD symptoms include abdominal pain, diarrhea and
other more systemic symptoms, such as weight loss, nutritional deficiencies and fever.
IBD, as of 2022, affected approximately 1.5 million patients in the United States alone. As of 2022, the
prevalence of UC and CD in the United States were estimated at approximately 0.9 million and 0.6 million patients,
respectively. The prevalence of IBD in the EU4 and the United Kingdom is estimated at 1.2 million with
approximately 0.7 million patients with UC and 0.5 million patients with CD. As of 2022, an aggregate of
approximately 2.9 million patients across the United States, EU4, the United Kingdom and Japan suffered from IBD.
This figure is expected to grow to approximately 3.0 million patients by 2028.
One of the primary goals of IBD therapy is to achieve durable clinical remission while simultaneously taking
into consideration a patient’s quality of life and concerns regarding potential side effects. Despite a number of
different therapies approved for UC and CD, the vast majority of these therapies require chronic administration via
injections or intravenous infusions, and may come with serious and concerning warnings, including, but not limited
to, risks of serious infections leading to hospitalizations or death and increased risks of various malignancies. A vast
majority of IBD patients do not achieve clinical remission with existing therapies, and a significant number of
patients will lose response over time, especially those patients on TNF-alpha inhibitor therapy where anti-drug
antibodies are very common. Further, despite the increased number of biosimilars, such as TNF-alpha inhibitor
therapies, becoming available for the treatment of IBD, biosimilars unfortunately do not alleviate any of the
potential side effect concerns that often cause patients to delay, or avoid altogether, stepping up to more advanced
therapies. In addition, although a small number of oral therapies have more recently been approved for the treatment
of IBD, these therapies also come with concerning potential side effects, which can also discourage patients from
initiating treatment with advanced therapies. Therefore, there continues to be significant unmet need for novel oral
therapies with durable efficacy, improved safety profiles and minimal preinitiation requirements for patients with
moderately to severely active IBD. Moreover, we believe the IBD market has significant growth potential driven by
growing diagnosis of these diseases and increased penetration of oral treatments with improved benefit/risk profiles.
In 2022, pharmaceutical sales in IBD were $16.3 billion in the United States and $7.4 billion in the rest of the
world, totaling $23.7 billion worldwide. In 2028, pharmaceutical sales in IBD are estimated to be $17.5 billion and
$26.8 billion in the United States and worldwide, respectively. Worldwide sales in the UC market were $7.4 billion
in 2022 and are estimated to be $10.2 billion in 2028, while in the CD market worldwide sales reached $16.3 billion
in 2022 and are estimated to be $16.6 billion in 2028. We believe the IBD market has significant growth potential
62
driven by growing diagnosis of these diseases and increased penetration of oral treatments with improved benefit/
risk profiles. We believe the potential for oral agents to gain significant market share is supported by physician and
patient preference for the convenience of oral administration over injectable agents, increasing demand for therapies
with long-term efficacy profiles and the opportunity for potent and well-tolerated oral agents to expand the overall
segment of the moderately to severely active UC population undergoing treatment.
Medical treatment of IBD is typically divided into two types of therapy: induction and maintenance. Induction
therapy is used to reduce inflammation quickly (in three months or less) and maintenance therapy is used to sustain
that reduction. Patients with IBD are classified by the activity of their disease as either mild to moderately active or
moderately to severely active based on the level of symptoms experienced, inflammatory biomarkers and severity of
disease on endoscopy. The current standard of care for the treatment of patients with moderately to severely active
IBD is to reduce inflammation with anti-inflammatory agents. Patients with mild to moderately active IBD are
treated with so-called “conventional therapies” which are anti-inflammatory treatments that include:
aminosalicylates (e.g., 5-ASAs), immunosuppressants or immunomodulators (e.g., 6-mercaptopurine, methotrexate
and azathioprine) and corticosteroids.
Despite the widespread use of conventional therapies to treat mild to moderately active IBD, due to the
progressive and lifelong nature of both UC and CD, for many patients the severity of their disease progresses in
activity and are considered moderately to severely active. This requires patients and their physicians to consider
using more targeted therapies typically termed “advanced therapies.” The majority of advanced therapies require
chronic parenteral administration including TNF-alpha inhibitors (e.g., infliximab, adalimumab and golimumab),
Interleukin (“IL”)-12/23 inhibitor (ustekinumab), anti-integrin antibodies (vedolizumab) or IL-23 inhibitors
(mirikizumab). There are also two classes of oral treatments including JAK inhibitors (e.g., tofacitinib, filgotinib and
upadacitinib) and sphingosine-1-phosphate (“S1P”) receptor agonists (ozanimod). Although these therapies have
demonstrated efficacy in UC and/or CD, the majority of IBD patients do not achieve clinical remission, and a
significant number of patients lose response over time, especially those treated with TNF-alpha inhibitor therapies
where anti-drug antibodies are common. Due to mechanisms of action that are poorly understood, with each line of
advanced therapy that is exhausted, patients become less likely to respond to the next advanced therapy utilized in
the sequence of care.
Each of the advanced therapy classes are associated with notable side effect and safety tradeoffs that must be
considered before initiating treatment. For instance:
•TNF-alpha inhibitors: Boxed warnings for increased risk of serious infections leading to
hospitalizations or death and various forms of malignancies are noted in the United States prescribing
information with similar warnings in the European Medicines Agency (“EMA”) summary of product
characteristics (“SmPCs”).
•IL-12/23 inhibitors: Warnings in label for serious infections, tuberculosis, malignancies and posterior
reversible encephalopathy syndrome (PRES).
•Anti-integrin antibodies: Warnings in label for potential risk of Progressive Multifocal
Leukoencephalopathy (“PML”), gut specificity of vedolizumab may be connected with exacerbating or
causing extraintestinal manifestations.
•IL-23 inhibitors: Warnings in the EU for severe infections and risk of hepatic enzyme elevations
(mirikizumab not approved in the United States).
•JAK inhibitors: Boxed warnings for increased risk of serious infections leading to hospitalization or
death, higher rates of all-cause mortality, malignancies, cardiovascular death, myocardial infarction,
stroke and thrombosis appear in the United States prescribing information with similar warnings in the
EU.
•S1P receptor agonists: Warnings in label for infections, bradyarrhythmia and atrioventricular
conduction delays, liver injury and macular edema. These warnings result in multiple preinitiation
requirements prior to initiating therapy. Risk of PML also exists.
63
Patients and physicians must take into consideration the lifelong burden of chronic parenteral administration
for injectable agents and the potential safety warnings for all therapies when deciding which treatment, if any, to
initiate.
The following chart depicts the current UC treatment landscape:
For patients who do not or no longer respond to treatment, or experience complications, surgical treatment
may be necessary. Approximately 50% to 80% of CD patients and 10% to 30% of UC patients require surgery over
their lifetime. In light of the above, we believe that there is significant unmet medical need in the UC treatment
paradigm due to imperfect existing therapies with unfavorable clinical characteristics and limited efficacy that
frequently wanes over time. A general patient preference for oral agents over injectables suggests a potential
untapped market opportunity available for efficacious, well-tolerated oral therapies.
Our Strategy
Our primary goal is to develop and commercialize obefazimod for the treatment of inflammatory diseases,
starting with moderately to severely active UC and CD. We focus on indications with high unmet needs with
substantial commercial potential. To achieve our goal, we are pursuing the following key elements of our strategy:
•Advance obefazimod through pivotal clinical trials and establish obefazimod as a potential first-
line advanced therapy for IBD.
We believe that the strength of the data we have generated in our Phase 2 clinical trials, specifically
the potential to demonstrate rapid onset of action and durability of safety and efficacy results (as
evidenced by a clinical remission rate of 53%, clinical response rate of 73% and no new adverse safety
signals observed from our two-year Phase 2b open-label maintenance trial), if supported by the results
of our Phase 3 clinical trials, uniquely positions obefazimod as a potential first-line advanced therapy
choice for moderately to severely active UC, if approved. We believe our data, if supported by the
results of our Phase 3 clinical trials with an expected induction data-read out in the first quarter of
2025, well-positions obefazimod as a potential first-line advanced therapy choice for moderately to
severely active UC, if approved.
Based on the positive clinical data generated in our UC trials, preclinical studies in dextran sulfate
sodium (“DSS”) mouse model which provide support for pursuing further development in CD, and
underlying biological and mechanistic rationale, we plan to initiate a Phase 2b clinical trial in patients
with CD in the third quarter of 2024, with a planned top-line data read-out in the second half of 2026,
to potentially demonstrate outcomes consistent with those observed in our Phase 2 clinical trials for
moderately to severely active UC. CD causes long-lasting inflammation and ulcers in the digestive
tract, with fibrosis and stricturing, playing a key role in disease progression. It differs from UC in that
it affects the entire thickness of the bowel wall and all parts of the digestive tract from mouth to anus.
However, CD shares many of the underlying pathophysiological processes and clinical manifestations
of UC, and, as a result, the current treatment paradigm of CD is similar to UC, as described further
64
below. In addition, we believe that obefazimod’s clinical profile observed to-date lends itself to
potential combinations with existing or new therapies, which we are exploring.
•Potential Combination Therapy in IBD with obefazimod.
Currently available therapies have limited efficacy and durability that wanes over time, have extensive
pre-initiation requirements, carry significant safety and tolerability challenges (such as black box
safety warnings), and many of them are injectable biologics. We believe several of obefazimod’s
attributes make it a potentially attractive candidate to pair with other advanced treatments. First, the
oral route of administration is preferred by a majority of patients, potentially resulting in higher levels
of medication adherence. Further, obefazimod’s proposed mechanism of action harnesses the body’s
natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory
diseases. The novel mechanism of action of obefazimod potentially lends itself as complementary to
other oral or injectable agents with the potential of improving the induction and remission efficacy
over monotherapy. We have initiated a formal process evaluating oral and injectable combination
therapy candidate with obefazimod in UC. Preclinical data to support our decision-making on a
combination agent is expected during the second half of 2024.
•Leverage library of miR-124 enhancers to expand our pipeline in chronic inflammatory diseases.
Based on the mechanistic concept of obefazimod, we have launched a research and development
program to generate new potential drug candidates to strengthen our intellectual property portfolio on
the miR-124 platform and to identify additional drug candidates from our proprietary small molecule
library that includes additional miR-124 enhancers. We expect to announce an obefazimod follow-on
candidate selection during the third quarter of 2024.
•Opportunistically evaluate strategic partnerships to maximize the value of obefazimod and our
therapeutic pipeline.
We have discovered and are developing obefazimod as an innovative medicinal product and we
currently hold its worldwide rights. We intend to retain worldwide development and
commercialization rights for obefazimod. For certain geographies, we may opportunistically enter into
strategic partnerships to accelerate development activities in order to realize the commercial potential
of obefazimod as well as other assets in our pipeline. In connection with any potential strategic
partnership, we plan to pursue and receive upfront funding, milestone payments and future royalties
for these agreements.
Our Programs
Our lead drug candidate, obefazimod, is in clinical development for the treatment of moderately to severely
active UC. We are continuing to develop obefazimod for the treatment of CD and are evaluating additional potential
inflammatory indications to pursue, subject to the availability of necessary resources and funding. In parallel, we are
in the process of generating follow-on compounds based on the miR-124 platform.
Our Lead Drug Candidate for the Treatment of Inflammatory Diseases: Obefazimod
Obefazimod is an oral small molecule drug candidate in clinical development for the treatment of moderately
to severely active UC. We believe that obefazimod is the only small molecule drug candidate in clinical
development with a mechanism of action that was demonstrated to specifically enhance the expression of a single
micro-RNA, miR-124, which plays a critical role in the regulation of the inflammatory response.
In our induction Phase 2b clinical trial, which included 252 patients, obefazimod met the primary endpoint of
a statistically significant reduction in Modified Mayo Score, a measure of disease activity relative to placebo. We
have observed an onset of symptom relief by day 8 of dosing, with meaningful reductions in rectal bleeding and
stool frequency scores, consistent with the pharmacological effects observed in our preclinical studies, and high
rates of sustained and newly achieved clinical remission in the subsequent open-label maintenance extension trial of
up to two years of treatment, of which approximately 45% of patients were previously exposed to biologics or JAK
inhibitors. In April 2023, we reported the results from the final analysis of our Phase 2b open-label maintenance
trial, including 217 patients of which 164 patients (76%) completed the second year of once-daily oral treatment
with 50 mg obefazimod. At the conclusion of the second year of treatment, 114 of the 217 patients enrolled (53%)
achieved clinical remission and 158 patients (73%) achieved clinical response. Among the 98 bio-refractory patients,
66 patients (67%) had a clinical response, 38 patients (39%) were in clinical remission, 46 patients (47%) had
endoscopic improvement and 20 patients (20%) had endoscopic remission at week 96. Among the 124 patients that
achieved clinical response at the end of the 8-week induction period of the double-blind study, 82 patients (66%)
achieved clinical remission at week 48, mimicking the re-randomization of responders approach typically utilized in
Phase 3 maintenance trials. Of the 124 patients in clinical response at week 8, 74 patients (60%) achieved clinical
65
remission, 95 patients (77%) had clinical response, 79 patients (64%) achieved endoscopic improvement and 52
patients (42%) achieved endoscopic remission at week 96.
In September 2023, we reported an interim analysis of step-down dosing from 50 mg to 25 mg for the third
and fifth year of open-label maintenance treatment with obefazimod in UC patients. These patients were treated with
50 mg of oral, once-daily obefazimod for approximately four years in the Phase 2a clinical trial and approximately
two years in the Phase 2b clinical trial. Patients were eligible to enroll in the trial if they had a Mayo endoscopic
subscore of 0 or 1. Eligible patients were switched to 25 mg, and an interim analysis was performed at week 48 with
a cut-off date of July 31, 2023. Of the 71 eligible patients, 63 completed their 48-week visit. Among these patients,
53 out of 63 patients (84%) demonstrated disease control (stable or improved Modified Mayo Score). No new safety
signals were detected in UC patients treated up to five years with oral, once-daily obefazimod.
Furthermore, obefazimod’s tolerability profile indicates potentially important clinical differentiation. As of
November 30, 2023 (the last safety data cut-off date), 1,082 subjects have received obefazimod, according to various
administration schedules, in all completed and ongoing open-label clinical trials across all indications, including 248
subjects for longer than 6 months and 226 subjects for longer than one year. The most common treatment emergent
adverse event (“TEAE”) reported has been mild to moderate headache, which has been transient and manageable
with or without over-the-counter medications. Furthermore, at present and based on data from all completed or non-
blinded clinical trials with obefazimod, no increased rate of opportunistic infections or malignancies have been
observed. We expect to announce our UC extension trial data read-out after one and two years of continued
treatment with reduced dose of 25 mg of obefazimod in the third quarter of 2024.
We initiated our pivotal Phase 3 clinical trials of obefazimod for the treatment of moderately to severely active
UC in consultation with international regulators, including the U.S. Food and Drug Administration (the “FDA”), the
EMA, the Pharmaceuticals and Medical Devices Agency (“PMDA”) and the China Center for Drug Evaluation
(“CDE”). These pivotal Phase 3 clinical trials consist of two induction trials (ABTECT-1 and ABTECT-2) and one
ABTECT maintenance trial in doses of 25 mg and 50 mg across 36 countries in North America, Latin America,
Europe and Asia Pacific, involving 1,200 moderately to severely active UC patients in over 600 sites. Each of the
trials will be randomized, double-blind and placebo-controlled, using independent and central review of video-taped
endoscopies with the primary endpoint of clinical remission according to the Modified Mayo Score assessed at week
8 (induction) and at week 44 (maintenance), as recommended by the FDA. Enrollment of the first patient under this
program occurred on October 11, 2022. Top-line data from the ABTECT-1 and ABTECT-2 induction trials is
expected to be announced in the first quarter of 2025, and top-line data from the ABTECT maintenance trial is
expected to be announced in the first quarter of 2026. We currently expect to complete enrollment for our induction
trials in the fourth quarter of 2024.
Currently, the obefazimod safety database is supported by more than 1,000 subjects treated with obefazimod
across different indications, including UC patients, some of whom are in their fifth year of continuous daily dosing.
Summary of Obefazimod’s Mechanism of Action
We believe our lead drug candidate, obefazimod, is differentiated from competing approaches for the
treatment of IBD via its novel mechanism of action. Obefazimod was demonstrated to specifically enhance the
expression of a single micro-RNA, miR-124, which plays a critical role in the regulation of the inflammatory
response. In the context of inflammation, miR-124 is a natural regulator of the inflammatory response, controlling
progression of inflammation and restoring homeostasis of the immune system, without causing broader
immunosuppression. Once expressed, micro-RNA interact with specific mRNA targets and decrease their translation
into proteins to regulate specific pathways. By binding to the cap binding complex, a complex playing a role in
cellular RNA biogenesis, obefazimod enhances the selective splicing of a single long non-coding RNA to generate
the anti-inflammatory micro-RNA, miR-124, in immune cells. Importantly, obefazimod does not impact the splicing
of cellular messenger RNA.
By targeting key inflammatory mRNA players such as STAT3 and MCP1, miR-124, a known anti-
inflammatory micro-RNA, regulates inflammation by decreasing macrophages and downregulating the translation of
pro-inflammatory cytokines and chemokines, such as TNF-alpha, IL-6, MCP-1 and IL-17, as well as Th17+ cells, to
control overactive immune stimulation seen in chronic inflammatory diseases. This downregulation thereby
regulates the inflammatory process and suggests broad potential as a novel anti-inflammatory therapeutic agent.
66
The following charts provide schematics of obefazimod’s mechanism of action at both a protein-level (direct
downregulation) and cellular-level (indirect downregulation):
In a DSS mouse model, we observed that administration of DSS enhances the expression of pro-inflammatory
cytokines in colonic tissue and Th17 cells in lymph nodes and that the treatment of these mice with obefazimod
reduced the level of pro-inflammatory cytokines and Th17 cells back to their normal level. Interestingly, when we
treated healthy mice with obefazimod, we did not observe any effect on Th17 cells in the lymph node and on
67
cytokine levels in the colonic tissue, which we believe illustrates that regulation via enhanced expression of
miR-124 has an effect only when these pathways are dysregulated, as shown below:
Laboratory analysis of the Phase 2b clinical trial at week 8 showed a highly statistically significant
enhancement of expression of miR-124 in rectal tissue in patients treated with obefazimod, compared to baseline.
The median increases were 13-fold for the 25 mg group, 25-fold for the 50 mg group and 25-fold for the 100 mg
group, while no enhanced expression was observed in the placebo group (1.02-fold increase), indicative of the
positive pharmacological effect of obefazimod. Downstream effects of enhancement of expression of miR-124 have
been demonstrated by the reduction in IL-17 and Il-23 levels in the blood and rectal biopsies of patients treated with
obefazimod. The following charts depict those results:
68
In contrast to currently available advanced therapies, prescribed post-conventional therapies, some of which
target only a single cytokine or pathway, miR-124 modulates the expression of several key cytokines and pathways.
Restoring multiple inflammatory pathways simultaneously to homeostatic level may lead to more durability of
efficacy results over the long-term, which is critical in lifelong conditions such as IBD, potentially differentiating
obefazimod from currently available IBD treatments.
Obefazimod in UC
UC Overview
UC, one of the most common forms of IBD, is a chronic inflammatory disease of the large intestine or colon,
that affects the lining of the colon and causes small sores or ulcers. UC is the result of several factors that are not yet
well understood. Abnormal inflammatory response, genetics, microbiome and environmental factors all contribute to
UC. UC can occur at any age, though most people are diagnosed aged 20 to 30, and men and women are equally
likely to be affected. UC can affect people of any racial or ethnic group. UC symptoms can vary, depending on the
severity of inflammation and where it occurs. Signs and symptoms may include diarrhea, rectal bleeding, abdominal
pain and cramping, weight loss, fatigue and fever, substantially impacting the quality of life of patients with this
debilitating disease. There were an estimated 4.1 million prevalent cases of UC globally in 2022.
During the 12 months ended May 2023, we estimate that there were approximately 776,000 patients treated
for UC in the United States. Of those patients, approximately 594,000 patients received conventional therapies;
approximately 285,000 patients were maintained on conventional therapy, approximately 193,000 patients received
steroids only and approximately 116,000 patients could not be controlled with conventional therapies. The
remaining 182,000 patients received some form of advanced therapies, which we believe represented approximately
$5.3 billion of sales in the United States; approximately 43,000 patients were new to advanced therapy,
approximately 51,000 patients received suboptimal results or recently switched from other forms of therapy and
approximately 88,000 patients were maintained on advanced therapy.
Existing Therapies and Their Limitations
The current UC treatment approach is influenced by multiple factors, including disease severity, previous
response to treatment, side effects and co-morbidities. Both existing conventional therapies as well as advanced
therapies, including approved products and drug candidates in development, face significant room for improvement
in efficacy, safety and tolerability, and convenience from dosing and route of administration standpoints as
discussed below.
Conventional Therapies for UC
Aminosalicylates (5-ASAs) are used as a first-line therapy in mildly to moderately active UC. Corticosteroids
are used primarily during induction therapy and are effective for reducing symptoms, but do not address mucosal
healing which limit their ability to modify and improve the underlying cause of disease. In addition, there are safety
considerations with extended corticosteroid use, including lowered quality of life, bone loss, weight gain and
cardiovascular complications. As a result, corticosteroids are used primarily as a bridge to manage symptoms until
69
immunomodulators or biologic agents become effective and enable mucosal healing. Oral immunosuppressants (e.g.
azathioprine, 6-mercatopurine and methotrexate) have not been effective as induction agents and are generally used
for steroid-sparing or as an adjunctive therapy for reducing immunogenicity against biologic agents. Oral
immunosuppressants are also associated with known toxicities such as drops in white blood cell counts and
increased risk for infection.
Given the above insufficiencies of these conventional therapies, patients suffering from mild UC may evolve
towards moderate and severe forms requiring the use of advanced therapies.
Advanced Therapies for UC
Advanced therapies for UC include biological agents as well as emerging oral molecules. Biological agents
such as TNF-alpha inhibitors (including infliximab, adalimumab and golimumab), IL-12/23 inhibitors (such as
ustekinumab) or IL-23 inhibitors, which specifically block certain inflammatory factors involved in UC. Biological
agents also include gut-specific anti-integrin antibodies (such as vedolizumab and natalizumab). New oral molecules
acting on certain pathways of the inflammation include JAK inhibitors (including tofacitinib and upadacitinib) – or,
on the trafficking of inflammatory cells such as S1P receptor agonists (e.g., ozanimod).
However, these therapies often only have moderate efficacy that may wane over time, as patients stop
responding or do not respond at all to these treatments and thus require new therapeutic management options. For
patients who do not or no longer respond to treatment, or experience complications, surgical treatment may be
necessary. Approximately 10% to 30% of UC patients require surgery over their lifetime.
In addition, while TNF-alpha inhibitors and JAK inhibitors and newer biological agents, including anti-
integrin antibodies, IL-12/23 inhibitors and IL-23 inhibitors, have generally improved the care of moderate to
severely active IBD (JAK inhibitors specifically in UC), these are all anti-inflammatory agents with safety and
tolerability concerns. These include increased risks for cancers, infections and blood clots due to their systemic
impact and resulting effects on the immune system outside of the GI tract. In addition, prolonged treatment with
biological therapies can lead to anti-drug antibody development by patients’ immune systems which may lead to
gradual waning of therapeutic efficacy and patients needing to switch to other biological agents. Furthermore,
biological agents require injections or intravenous infusions, resulting in patient inconvenience and burden, which
often negatively impacts patient compliance. Injections can also lead to injection-related events such as sciatica,
neuralgia, neuropathic pain and peripheral neuropathy.
In September 2021, the FDA published strict warnings about increased risk of serious heart-related events,
cancer, blood clots and death for JAK inhibitors that treat certain chronic inflammatory conditions (including UC).
In January 2023, the EMA stated recommendations to minimize the risk of serious side effects with JAK inhibitors
used to treat several chronic inflammatory disorders, noting that these side effects include cardiovascular conditions,
blood clots, cancer and serious infections which were adopted by the European Commission in March 2023.
Recently, there have been efforts to develop drug candidates targeting novel mechanisms, such as S1P
receptor agonists and TL1A inhibitors. S1P agonists, while offering convenient oral dosing, have not achieved
meaningful commercial adoption. Ozanimod and other S1P agonists work by blocking capacity of lymphocytes to
egress from lymph nodes, thereby reducing the number of lymphocytes in peripheral blood, which can lead to
increased susceptibility to infections. Furthermore, Ozanimod, in its UC Study 1 which assessed efficacy during the
induction period, achieved 18% clinical remission in all patients at week 10, with only 10% of patients with prior
exposure to TNF-alpha inhibitors showing clinical remission. TL1A inhibitors have garnered interest from those
seeking newer targets and agents with differentiated clinical profile. While Merck-Prometheus and Pfizer-Roivant
have generated promising early Phase 2 data in both biologics-experienced and biologics-naïve patients, neither
have initiated Phase 3 clinical trials and do not have long-term safety and efficacy data beyond 56 weeks.
In summary, we believe that there is significant unmet medical need in the UC treatment paradigm due to
imperfect existing therapies with unfavorable clinical characteristics and limited efficacy that frequently wanes over
time.
Obefazimod is being developed as a once-daily, oral medication which, combined with its observed
tolerability to date, would represent a meaningfully differentiated clinical profile from existing therapies. We believe
this may position obefazimod as a potential first-line advanced therapy choice for both prescribers and patients, if
approved.
70
Our Market Opportunity: UC
The estimated market opportunity for UC was approximately $7.4 billion in worldwide sales in 2022 and is
expected to reach $10.2 billion in worldwide sales in 2028. In 2022, there were 4.1 million prevalent cases of UC
worldwide. In the United States, EU4, the United Kingdom and Japan, there were 2.0 million prevalent cases of UC,
of which 1.3 million of these cases in G7 countries were treated with 5-ASAs or advanced therapies. In addition,
approximately 76% of patients suffering from UC in the United States were covered by commercial insurance, with
approximately 20% and 3% covered by Medicare and Medicaid, respectively. The UC market has significant growth
potential driven by increasing incidence of the disease as well as the development of innovative oral therapeutics.
We believe the potential for oral agents to gain significant market share is supported by physician and patient
preference for the convenience of oral administration over injectable agents, increasing demand for therapies with
long-term efficacy profiles and the opportunity for potent and well-tolerated oral agents to expand the overall
segment of the moderately to severely active UC population undergoing treatment.
Clinical Trial Results of Obefazimod in Moderately to Severely Active UC
As of November 30, 2023 (the last safety data cut-off date), 1,082 subjects have received obefazimod,
according to various administration schedules, in all completed and ongoing open-label clinical trials across all
indications, including 248 subjects for longer than 6 months and 226 subjects for longer than one year. The most
common TEAE reported has been mild to moderate headache, which has been transient and manageable with or
without over-the-counter medications. Furthermore, at present and based on data from all completed or non-blinded
clinical trials with obefazimod, no increased rate of opportunistic infections or malignancies have been observed.
We are conducting Phase 3 clinical trials in moderately to severely active UC in the United States, Europe, Asia
Pacific and Latin America.
Phase 2a Clinical Trial with Obefazimod for the Treatment of Moderately to Severely Active UC
The induction Phase 2a clinical trial was a randomized trial of an 8-week placebo-controlled, double-blind
induction phase followed by an open-label long term extension trial. It was completed in September 2018. This
proof-of-concept trial enrolled 32 adult patients who had been diagnosed with moderately to severely active UC for
at least 12 weeks and who failed or were intolerant to conventional treatments (50%) or biologics (50%). Patients
who completed the induction phase were eligible to continue in the open-label extension trial.
In the induction phase, patients were randomized two-to-one to a once-daily orally-administered 50 mg dose
of obefazimod or placebo for eight weeks. In the long-term extension, all patients received a once-daily orally-
administered 50 mg dose of obefazimod.
This double-blind, placebo-controlled trial follows a standard study design in this indication for which a dose
response as well as placebo effect can be frequently observed. The 50 mg daily dose was selected on the basis of the
safety data accumulated for this dose.
71
The trial design of our Phase 2a clinical trial for obefazimod in patients with moderately to severely active UC
is depicted below:
Overview of Primary Endpoints of Induction Phase 2a Clinical Trial with Obefazimod for the Treatment of UC
The primary endpoint in the induction Phase 2a clinical trial was safety, assessed as the rate of TEAEs. The
primary endpoint in the induction phase, evaluation of safety and tolerability of obefazimod, was met. The most
frequently reported adverse events reported in the 50 mg group were GI disorders and headache. GI disorders were
experienced by 35% of subjects in the obefazimod group and 22% of subjects in the placebo group. These included
abdominal pain, abdominal pain upper, anal fissure, anorectal discomfort, dyspepsia and nausea for the obefazimod
group and abdominal pain and diarrhea for the placebo group. Headache was experienced by 17% of subjects in the
obefazimod group and 0% in the placebo group. Headaches occurred early and were transient (lasting only a few
days), mainly mild or moderate (grade 1 or 2) and manageable with or without over-the-counter medications. No
serious adverse events related to treatment were observed.
The following table provides an overall summary of TEAEs by treatment group:
AE = adverse event; TEAE = treatment-emergent adverse event
72
Overview of Secondary Endpoints of Induction Phase 2a Clinical Trial with Obefazimod for the Treatment of UC
The following table depicts secondary efficacy endpoints of our Phase 2a clinical trial with obefazimod in
moderately to severely active UC at week 8:
1.POC Study was not powered for efficacy
ITT = Intent-to-treat; PP = Per Protocol
The secondary endpoints in the induction Phase 2a clinical trial included the proportion of patients achieving
clinical remission at week 8 as compared to placebo, change from baseline to week 8 in total Modified Mayo Score
(which is based on stool frequency, rectal bleeding, physician global assessment and endoscopic subscore), rate of
endoscopic improvement, clinical response rate, as well as miR-124 expression in the rectal tissue of the patients.
Overview of Additional Follow-Up Data from Long Term Extension Portion of Phase 2a Clinical Trial with
Obefazimod for the Treatment of Moderately to Severely Active UC
For the long-term extension, the primary objective was long term safety of obefazimod. Additional efficacy
endpoints included clinical and endoscopic rates of response and remission. Overall, 32 patients were enrolled in the
induction phase, 23 patients were randomized to obefazimod, and nine patients were randomized to placebo.
Of the 29 patients who completed the induction phase (20 patients for obefazimod and nine patients for
placebo), 22 patients continued their treatment into the long-term extension.
In October 2019, we announced the 12-month data from this Phase 2a proof-of-concept trial. This open-label
maintenance trial was conducted in 22 patients, of which 19 completed the first year of treatment. At 12 months, an
endoscopy was performed in 16 of the 19 patients to evaluate the rate of clinical remission, and 12 of the 16
evaluable patients (75%) were observed to achieve clinical remission. Obefazimod was also observed to maintain
enhanced expression of miR-124 throughout the 12 months of the trial. At month 12, mean change in Mayo Score
was observed at -2.6 points compared to the maintenance baseline. Median fecal calprotectin decreased from
153.1 microg/g (baseline) to 27.9 microg/g and 31.6 microg/g at week 52 and month 24, respectively.
The following table depicts secondary efficacy endpoints of our Phase 2a clinical trial with obefazimod in
moderately to severely active UC at 24 and 48 months:
73
Phase 2b Clinical Trial with Obefazimod for the Treatment of UC
Overview of Induction Phase 2b Clinical Trial with Obefazimod for the Treatment of UC
The induction Phase 2b clinical trial for the treatment of moderately to severely active UC was conducted in
252 patients enrolled at 130 trial sites across 15 European countries, Canada and the United States. It was completed
in April 2021. The trial was a randomized, double-blind and placebo-controlled 16-week induction trial with a
primary efficacy endpoint at week 8 involving four treatment groups (receiving an oral once-daily 25 mg, 50 mg or
100 mg dose of obefazimod or placebo). Endoscopies were read centrally and blinded, by independent reviewers.
Electronic patient diaries were used to enhance the reliability of the collection of stool frequency, rectal bleedings,
and other patient reported outcomes-all efficacy endpoints were set according to FDA guidance.
The following chart depicts the design of our Phase 2b clinical trial with obefazimod in moderately to severely
active UC:
Between August 13, 2019 and April 16, 2021, 252 patients were randomly allocated to obefazimod 100 mg
(n=64), obefazimod 50 mg (n=63), obefazimod 25 mg (n=61) or placebo (n=64).
Baseline characteristics were well-balanced among the treatment groups, indicating a moderately to severely
active UC population. At screening, 49% of patients had an inadequate response, loss of response, or intolerance to
TNF-alpha inhibitors, vedolizumab, other biologics and/or JAK inhibitors treatments, while the other patients were
refractory to conventional treatments only. Enrolled patients suffered from longstanding UC with an overall mean
disease duration of 8.05 years and 71% of the patients had a severe disease profile (baseline Modified Mayo Score
of 7 to 9 points).
The following table depicts the baseline characteristics of our Phase 2b clinical trial:
74
*Percentages based on number of patients with previous exposure to biologics/JAK inhibitors
Overview of Primary Endpoints of Induction Phase 2b Clinical Trial with Obefazimod for the Treatment of UC
Modified Mayo Score: In the full analysis set (“FAS”), corresponding to an ITT analysis, the primary endpoint
was met at week 8 (statistically significant reduction of Modified Mayo Score) with -2.9 (95% CI -3.4 to -2.5) for
the obefazimod 100 mg group, -3.2 (-3.7 to -2.7) for the obefazimod 50 mg group, -3.1 (-3.6 to -2.6) for the
obefazimod 25 mg group, and -1.9 (-2.4 to -1.5) for placebo group. The magnitude of the difference in Modified
Mayo Score from baseline was significantly greater in all three obefazimod groups compared with placebo
(p=0.0039 for obefazimod 100 mg vs placebo, p=0.0003 for obefazimod 50 mg vs placebo, and p=0.0010 for
obefazimod 25 mg vs placebo).
Clinical Response, Clinical Remission and Endoscopic Improvement: Furthermore, rates of clinical response
and clinical remission at week 8 in the FAS were higher in the three obefazimod dosage groups than with placebo.
Although there is no apparent dose response in clinical remission, we observe that there is a trend for the most
objective measure which is the endoscopic improvement score. In addition, we also see the same trend for the
bionaive population. The subgroup of patients who were refractory to one or more second line therapies showed
results that were consistent with the overall analysis for clinical response and clinical remission at week 8. Rates of
endoscopic improvement at week 8 were also higher in the obefazimod dosage groups than in the placebo group in
the FAS. Change in fecal calprotectin from baseline in the FAS was greater in all obefazimod groups than with
placebo.
The following tables depict the changes of the primary endpoint from baseline in Modified Mayo Score at
week 8:
(1)ANCOVA model for change from baseline MMS at week 8 which includes baseline MMS as a covariate and treatment, previous exposure
to biological drugs or JAK inhibitors as fixed effects and a random error term.
(2)p-values are based on nonparametric ANCOVA using ranked data.
(3)MMS is the sum of assessment scores (0-3) of mucosal appearance on endoscopy, stool frequency, and rectal bleeding.
(4)n = number of patients in the category with data available for baseline and week 8 visit.
75
The following tables depict the secondary efficacy endpoint results at week 8:
(1)Clinical remission (per Modified Mayo Score) is defined as stool frequency subscore (SFS) ≤1, rectal bleeding subscore (RBS) of 0 and
endoscopic subscore ≤1.
(2)Clinical response (per Adapted Mayo Score) is defined as a decrease from baseline in the Modified Mayo Score ≥2 points and ≥30 percent
from baseline, plus a decrease in RBS ≥1 or an absolute RBS ≤1.
(3)Endoscopic improvement is defined as endoscopic subscore ≤1 without friability.
(4)n = number of patients that met the respective endpoint.
(5)N = number of patients in the relevant analysis set.
(6)Delta = arithmetic difference rounded to nearest full percentage.
We also conducted sub-group analyses of biologics / JAK-naïve and biologics / JAK-experienced patients, the
results of which are displayed below:
*Trial not powered for statistical significance for sub-group analysis.
(1)n = Number of patients in the category with data available for baseline and week 8 visit.
(2)MMS is the sum of assessment scores (0-3) of mucosal appearance on endoscopy, stool frequency, and rectal bleeding.
76
*Trial not powered for statistical significance for sub-group analysis.
(1)Endoscopic improvement is defined as endoscopic subscore ≤1 without friability.
(2)n = number of patients that met the respective endpoint.
(3)N = number of patients in the relevant analysis set.
(4)Delta = arithmetic difference rounded to nearest full percentage.
Overview of Maintenance Phase 2b Clinical Trial with Obefazimod for the Treatment of UC
Of the 222 patients who completed the 16-week Phase 2b induction trial, 217 patients (98%) enrolled in the
subsequent open-label maintenance trial to evaluate the induction Phase 2b clinical trial long-term safety and
efficacy profile of obefazimod for up to two years, irrespective of treatments or treatment outcome during the
induction phase.
At week 48, of those 217 patients who received a 50 mg once-daily oral dosing with obefazimod, 178 patients
(82%) had clinical response, 119 patients (55%) were in clinical remission, 133 patients (61%) had endoscopic
improvement and 72 patients (33%) had endoscopic remission. Moreover, 38 patients were in sustained clinical
remission and 107 patients showed sustained clinical response. A total of 71 patients exhibited de novo clinical
response and 81 patients exhibited de novo clinical remission. Among the 98 bio-refractory patients, 66 patients
(67%) had a clinical response, 38 patients (39%) were in clinical remission, 46 patients (47%) had endoscopic
improvement and 20 patients (20%) had endoscopic remission at week 96. These results demonstrate the long-term
clinical response of obefazimod in patients who were refractory to conventional treatments, as well as patients who
were previously exposed to treatment with biologics and/or JAK inhibitors.
At week 96, of the 49 patients who were in clinical remission at the end of the induction phase, 33 patients
(67%) remained in clinical remission. Of the 168 patients who were not in clinical remission at the end of the
induction phase, 81 patients (48%) exhibited de novo clinical remission. Furthermore, the clinical remission rate for
patients who did not show at least a clinical response at the end of the 8-week induction phase was 43%
(40 patients). Of the patients included in the maintenance trial, 164 patients (75%) completed two years of once-
daily oral dosing with 50 mg obefazimod. Thirty patients dropped out during the first year of treatment. Six patients
did not qualify for the second year due to non-response after the first year of treatment, and 17 patients dropped out
during the second year. These patients were all considered as treatment failures in the intent-to-treat analysis.
Of all 217 patients who entered the Phase 2b open-label maintenance trial, regardless of their status at the end
of the 8-week induction period, 119 patients (55%) achieved clinical remission at week 48 and 114 patients (53%)
achieved clinical remission at week 96. Among the 124 patients who achieved clinical response at the end of the 8-
77
week induction period of the double-blind study, 82 patients (66%) achieved clinical remission at week 48,
mimicking the re-randomization of responders approach typically utilized in Phase 3 maintenance trials, and 74
patients (60%) achieved clinical remission at week 96. This comparison is shown below:
(1)217/222 eligible patients enrolled into open label maintenance study.
(2)Irrespective of patient outcome at the end of the 8-week induction phase.
(3)n = Number of patients that met the respective endpoint.
(4)N = Number of patients in the relevant analysis set.
(5)124 patents achieved clinical response at end of 8-week induction phase.
(6)From week 48 to week 96, 19 patients began experiencing symptoms of UC again (i.e., were not in clinical remission anymore), and
14 patients achieved clinical remission.
The below table depicts the types of adverse events observed from our Phase 2b clinical trial:
During the induction and the maintenance treatments of the Phase 2b clinical trial, the safety and tolerability
profile observed was consistent with previous findings and no new adverse safety signals were observed. As of
November 30, 2023 (the last safety data cut-off date), 1,082 subjects have received obefazimod, according to various
administration schedules, in all completed and ongoing open-label clinical trials across all indications, including 248
subjects for longer than 6 months and 226 subjects for longer than one year.
Overview of Phase 2 Open-Label Trial to Evaluate Long-Term Safety and Efficacy of Obefazimod at 25 mg
In September 2023, we reported an interim analysis of step-down dosing from 50 mg to 25 mg for the third
and fifth year of open-label maintenance treatment with obefazimod in UC patients.
78
These patients were treated with 50 mg of oral, once-daily obefazimod for approximately four years in the
Phase 2a clinical trial and approximately two years in the Phase 2b clinical trial. Patients were eligible to enroll in
the trial if they had a Mayo endoscopic subscore of 0 or 1. Eligible patients were switched to 25 mg, and an interim
analysis was performed at week 48 with a cut-off date of July 31, 2023.
(1)ABX464-108 Interim Analysis Outputs as of July 31, 2023.
(2)n = Number of patients that met the respective endpoint.
(3)N = Number of patients in the relevant analysis set.
Of the 71 eligible patients, 63 completed their 48-week visit. Among these patients, 53 out of 63 patients
(84%) demonstrated disease control (stable or improved Modified Mayo Score). No new safety signals were
detected in UC patients treated up to five years with oral, once-daily obefazimod.
Phase 3 Clinical Trials and Regulatory Pathway in UC
We are working with IQVIA, a global premier contract research organization, to conduct the Phase 3 clinical
trials with obefazimod in moderately to severely active UC, following consultations with regulatory agencies,
including FDA, EMA, CDE and PMDA.
79
These pivotal Phase 3 clinical trials consist of two induction trials (ABTECT-1 and ABTECT-2) and the
subsequent ABTECT maintenance trial investigating obefazimod at doses of 25 mg and 50 mg across 36 countries
in North America, Latin America, Europe and Asia Pacific, involving 1,200 moderately to severely active UC
patients in over 600 sites. Each of the trials will be randomized, double-blind and placebo-controlled, using
independent and central review of the video-taped endoscopies with the primary endpoint of clinical remission
according to the Modified Mayo Score assessed at week 8 (induction) and at the end of the 44-week maintenance
trial (total 52 weeks), as recommended by the FDA.
The Modified Mayo Score evaluates UC disease activity, based on three parameters: stool frequency, rectal
bleeding and endoscopic evaluation. Each parameter of the score ranges from zero (normal or inactive disease) to
three (severe activity). The patient rates stool frequency score (“SFS”) and rectal bleeding score (“RBS”) daily. The
endoscopy subscore is evaluated by a central reader (who is blinded to any clinical information about the patient)
from an endoscopy that is performed at the trial site. The inclusion criteria based on FDA guidance for moderately to
severely active UC is active disease defined by a Modified Mayo Score ≥ 5 with (RBS) ≥ 1 and endoscopy subscore
of 2 or 3 (confirmed by central reader). The primary endpoint for induction and maintenance is clinical remission
defined as SFS of 0 or 1 and not greater than baseline and RBS = 0 and endoscopy subscore of 0 or 1. At week 8,
secondary endpoints include endoscopic improvement, clinical response, symptomatic remission and histologic-
endoscopic mucosal improvement (“HEMI”). At week 44 of the maintenance trial, secondary endpoints include
endoscopic improvement, symptomatic remission, corticosteroid-free clinical remission, sustained clinical
remission, HEMI and endoscopic remission. After week 44, a long-term extension trial will follow for eligible and
willing subjects for an additional for up to 4 years, or until the commercialization of obefazimod, whichever occurs
first.
The following chart depicts the design of our Phase 3 clinical trial with obefazimod in moderately to severely
active UC:
Enrollment of the first patient under this program in the United States occurred on October 11, 2022. Top-line
data from the ABTECT-1 and ABTECT-2 induction trials is expected to be announced in the first quarter of 2025,
and top-line data from the ABTECT maintenance trial is expected to be announced in the first quarter of 2026.
The following chart depicts our recently completed and expected upcoming milestones for our Phase 3 clinical
trials of obefazimod for moderately to severely active UC:
80
Additional Clinical Trials Completed with Obefazimod
In addition, four Phase 1 clinical trials have recently been completed to assess the tolerability and safety
profile of obefazimod: (i) a Phase 1 heart rhythm (QT interval) trial, for which we enrolled 120 healthy volunteers;
(ii) a Phase 1 clinical trial of drug-drug interactions, for the purposes of providing further information on any
possible interactions of obefazimod with other drugs, for which we enrolled 60 healthy volunteers; (iii) a Phase 1
absorption, distribution, metabolism and excretion trial for the purposes of generating additional data to further
evaluate the safety profile of obefazimod, for which we enrolled 12 healthy volunteers; and (iv) a Phase 1 clinical
trial conducted in Japanese subjects to further evaluate pharmacokinetics and tolerability of obefazimod in this
population, for which we enrolled 48 healthy volunteers. The results of these Phase 1 clinical trials provide
supportive data for our further clinical development and New Drug Application (“NDA”) submission. Furthermore,
additional Phase 1 clinical trials to support NDA submission are planned. While we have decided not to pursue
additional clinical work in RA at this point, we have completed a Phase 2a clinical trial in patients with RA, where
we saw encouraging proof-of-concept data supporting obefazimod’s potential role in addressing inflammatory
conditions beyond IBD.
Obefazimod in CD
CD Overview
CD is a chronic inflammatory condition that can affect the GI tract from mouth to anus but typically affects
the colon and last section of the ileum (terminal ileum). Although considered in the same category of IBD as UC, the
inflammation occurs across the bowel wall which leads to different complications including stricture and fistula
formation. CD affects about 3.2 per 1,000 people in Europe, North America and the United Kingdom. Collectively,
we estimate there are approximately 1.1 million CD patients in G7 countries. Of these patients, approximately
0.5 million patients (or approximately 44%) are estimated to be diagnosed with moderately to severely active CD,
with approximately 0.6 million patients (or approximately 56%) diagnosed with mildly to moderately active
CD. While this disease is diagnosed at any age, onset is more common among adolescents and young
adults. Patients typically present with abdominal pain, diarrhea, fatigue and weight loss. In cases of bowel
obstruction, patients will also experience bloating and vomiting. The likelihood of having surgery mostly due to
bowel obstruction within the lifetime of a CD patient is approximately 80%. Besides bowel complications, patients
can experience extra-intestinal manifestations (“EIMs”), which impact the skin, eye and joints primarily. The
prevalence rate of EIMs is approximately 24% in all IBD patients, 27% in UC patients, but as high as 35% in CD
patients.
Existing Therapies and Their Limitations
Similar to existing UC treatments, patients may receive oral immunosuppressants, such as azathioprine and
methotrexate as well as short courses of corticosteroids. In cases of moderately to severely active CD, the options for
advanced therapy include very commonly prescribed TNF-alpha inhibitors, anti-integrin antibodies, IL-12/23
inhibitors, IL-23 inhibitors and JAK inhibitors. Therapies such as TNF-alpha inhibitors, IL-12/23 inhibitors or IL-23
inhibitors are injectable agents, representing a significant commercial disadvantage due to patients’ and prescribers’
preference for the convenience of oral therapies. JAK inhibitors are accompanied by safety warnings due to
increased risk of adverse events such as infection, cancer or blood clots.
Induction remission rates for these existing therapies are less than 50% and maintenance remission rates often
decrease over time. There remains unmet needs for more effective and durable therapy, including those with more
convenient delivery methods (as there are no approved oral therapies for first-line use in the United States), durable
efficacy, treatment of patients who have failed biologic agents, improved mucosal healing, improved treatment for
fistulizing CD and improved corticosteroid free remission. We believe obefazimod’s differentiated clinical profile,
including dosing as a once-daily, oral therapy as well as its demonstrated tolerability and durability to date, position
it favorably as a potential first-line advanced therapy option for patients and prescribers, if approved.
Our Market Opportunity: CD
The estimated market opportunity for CD was approximately $16.3 billion in worldwide sales in 2022 and is
expected to reach $16.6 billion in worldwide sales in 2028. In 2022, approximately $11.4 billion of sales came from
the United States and all moderately to severely active CD sales came exclusively from injectable products. Similar
to the UC market, we believe oral agents represent a significant commercial opportunity, particularly if such
therapeutics can provide long-term safety and efficacy profiles comparable to injectable agents.
81
Proposed Obefazimod CD Development Program
Due to the pathophysiological and clinical similarities of CD and UC, we plan to initiate a Phase 2b clinical
trial in patients with CD in the third quarter of 2024 to potentially demonstrate outcomes consistent with those
observed in our Phase 2 clinical trials for moderately to severely active UC. We believe the nonclinical and Phase 1
data generated in our UC clinical trials are sufficient to support initiation of this Phase 2b trial in CD. We filed an
IND in the fourth quarter of 2023 to initiate a single-dose Phase 2a proof-of-concept trial. Following further
consultation, the FDA permitted us to use a more efficient path in the dose exploration Phase 2b design. We intend
to announce Phase 2b induction trial top-line results in the second half of 2026. Based on the results from this Phase
2b clinical trial, we intend to proceed to Phase 3 clinical trials.
The following chart depicts the design of our Phase 2b clinical trial with obefazimod in CD:
Potential Combination Therapy for the Treatment of IBD with Obefazimod as the Cornerstone
Despite the development of various advanced targeted therapies for IBD over the past 20 years, a single agent
with transformational efficacy remains elusive. Although cross-trial efficacy comparisons must be interpreted with
caution, induction of clinical remission rates have currently reached a placebo-adjusted therapeutic ceiling up to
30%. Improved efficacy of combination therapy with thiopurines and TNF-alpha inhibitors has been well described
(SONIC and UC-SUCCESS) but did not breach the aforementioned efficacy ceiling. Emerging data utilizing dual
advanced targeted therapy affecting complementary mechanisms of action indicate a potential path to higher
efficacy rates. The first trial utilizing this strategy (VEGA) randomized patients to three parallel treatment groups:
(1) dual combination therapy with guselkumab (IL-23 inhibitor) plus golimumab (TNF-alpha inhibitor); (2)
guselkumab alone; or (3) golimumab alone. At the end of the 12-week induction period, a greater proportion of
patients randomized to dual combination therapy achieved clinical remission (approximately 47%) compared to
either monotherapy treatment arms (guselkumab at approximately 25%; golimumab at approximately 24%).
Importantly, adverse events, serious adverse events and infection rates were comparable among treatment groups.
We believe synergistic improvements that may be achieved with advanced combination therapy should be
balanced with patient adherence to multiple biologic injections and safety considerations associated with immune
suppression. Several of obefazimod’s attributes make it a potentially attractive candidate to pair with other advanced
treatments. First, the oral route of administration is preferred by a majority of patients, potentially resulting in higher
levels of medication adherence. Further, obefazimod’s proposed mechanism of action harnesses the body’s natural
regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. The novel
mechanism of action of obefazimod potentially lends itself as complementary to other oral or injectable agents with
the potential of improving the induction and remission efficacy over monotherapy. We believe the current clinical
results we have observed with obefazimod including a lack of safety signals up to 96 weeks of treatment support
development as an agent to be used in potential combination therapy.
We have initiated a formal process evaluating oral and injectable combination therapy candidate with
obefazimod in UC. Preclinical data to support our decision-making on a combination agent is expected during the
second half of 2024.
82
Follow-On Compounds Program
Based on the mechanistic concept of obefazimod, a research and development program is currently ongoing to
generate new potential drug candidates to strengthen our intellectual property portfolio on the miR-124 platform.
The first follow-on drug candidate is expected to be selected during the third quarter of 2024.
Manufacturing and Supply
Obefazimod
Our lead compound, obefazimod, is manufactured using commercially available, widely used raw materials
and common chemical engineering and synthetic processes. Obefazimod is formulated as an oral solid capsule. We
have successfully scaled-up active pharmaceutical ingredients and drug product processes, and we have a large
supply of active pharmaceutical ingredients and capsules available for clinical trials.
We outsource all manufacturing operations and rely on European and North American third-party CMOs to
supply clinical trials and finalize the development of obefazimod. These operations are designed to be in compliance
with the standards imposed by Good Manufacturing Practice (“GMP”). We believe our outsourcing strategy and
internal organization allow us to focus our resources on the development of different drug candidates and the
management of third parties, without investing in expensive manufacturing facilities and equipment. All third parties
are assessed under our quality system and agreements are in place to compel compliance and we maintain
agreements with manufacturers which include confidentiality and intellectual property provisions to protect
proprietary rights.
We are in the process of further optimizing and scaling up our supply chain for obefazimod to ensure capacity
for our expected commercial supply, if the FDA or foreign regulatory authority approved. In addition, we are in
process of establishing a second source manufacturer for obefazimod to ensure continuity of product supply.
Competition
We compete with companies that have drugs on the market or are developing drug candidates for chronic
inflammatory disease. The biotechnology and pharmaceutical industries are highly competitive and subject to
significant and rapid technological change, as researchers learn more about chronic inflammatory diseases and
develop new technologies and treatments.
Significant competitive factors in our industry include: (i) product efficacy and safety; (ii) quality and breadth
of an organization’s technology; (iii) skill of an organization’s employees and its ability to recruit and retain key
employees; (iv) timing and scope of regulatory approvals; (v) government reimbursement rates for, and the average
selling price of, pharmaceutical products; (vi) the availability of raw materials and qualified manufacturing capacity;
(vii) manufacturing costs; intellectual property and patent rights and their protection; and (viii) sales and marketing
capabilities. Given the intense competition in our industry, we cannot assure you that even if we are able to
successfully develop any products, that they will have a higher benefit-risk profile or better cost effectiveness
compared to products developed or introduced by our competitors. Our competitors in the chronic inflammatory
disease field are primarily large pharmaceuticals companies including, but not limited to, AbbVie, Eli Lilly,
Johnson & Johnson, Pfizer and Takeda. Several lines of research are being developed to improve the treatment of
IBD. Many companies are working to develop new, more effective and better tolerated treatments with more
practical formulations, especially small molecules administered orally, better accepted than monoclonal antibodies
that require administration by injection or intravenous infusions.
The molecules in development have various mechanisms of action and are primarily: (i) TNF-alpha inhibitors;
(ii) IL-12/23 inhibitors; (iii) anti-integrin antibodies; (iv) IL-23 inhibitors; (v) JAK inhibitors; (vi) S1P receptor
agonists; or (vii) TL1A inhibitors.
In the TNF-alpha treatment class, Remicade® (Janssen) was first approved by the FDA in 1998. In 2012, the
European Commission approved AbbVie’s Humira® for the treatment of pediatric patients aged six to 17 years with
severe active CD who have an inadequate response, are intolerant or have contraindications to conventional therapy.
IL-12/23 inhibitors entered the UC market in 2019 as ustekinumab (Johnson & Johnson’s Stelara®). In 2021,
AbbVie filed an authorization application with FDA and EMA for risankizumab (Anti-IL-23—Skyrizi®) for the
treatment of moderately to severely active CD and a Phase 3 clinical trial in patients with UC is underway.
Etrolizumab, a selective anti-alpha-4/beta-7 monoclonal antibody developed by Roche/Genentech, recently
failed in Phase 3 for CD after failing in Phase 3 in UC in 2020. The anti-integrin class is currently represented by
83
vedolizumab/Entyvio® and natalizumab/Tysabri®. We are also aware of Morphic Therapeutic’s MORF-057 and
Protagonist Therapeutics/Johnson & Johnson’s PN-943 currently in development. The anti-integrin drugs work by
preventing the leukocytes to move from the blood vessels to sites of inflammation. They block the action of integrin
on the surface of circulating immune cells and endothelial cell adhesion molecules, thereby inhibiting the
interactions between leukocytes and intestinal blood vessels. Natalizumab and vedolizumab block alpha4-integrin
and alpha4beta7-integrin respectively. These drugs are injectable (Humanized mAb).
In 2021, Eli Lilly reported that mirikizumab (Anti-IL-23) generated data in a Phase 3 maintenance trial in
patients with UC that led to the submission of an authorization request to regulatory agencies. Phase 3 clinical trials
in CD are also underway with mirikizumab. All these drugs are injectable (Humanized mAb). IL-23 is a regulator of
T-helper (Th)-17 cell. IL-23 prevents regulatory T-cell response in the intestine, and therefore increases
inflammation in the gut. Anti-interleukins targeting the IL-23 have been shown to be effective for induction and
maintenance of remission in patients with moderate-severe UC.
The JAK correspond to four intracellular tyrosine kinases: JAK1, JAK2, JAK3 and tyrosine kinase 2.
Inhibition of the JAK-STAT signal channel makes it possible to block the production of pro-inflammatory
cytokines, including TNF-alpha, to block other pathways of inflammation and to regulate innate and adaptive
immunity. Thus, several cytokines and several inflammation pathways are blocked simultaneously, unlike TNF-
alpha inhibitors, which only have a single target. In September 2021, FDA published a black box warning, requiring
pharmaceutical companies to provide a warning for increased risk of serious cardiac events, cancer, blood clots and
death linked to JAK inhibitor treatments used for the treatment of certain IBD, including UC. Consequently, these
treatments are only accessible to patients who do not respond to any other available treatment and who have certain
well-defined conditions. In the JAK inhibitor class, to our knowledge the following products are authorized or in
advanced development:
•Pfizer’s tofacitinib (Xeljanz®) is a non-selective JAK inhibitor. It obtained marketing approval in UC
in June 2018. In September 2021, the FDA concluded that there was a high risk of serious side effects
following a randomized clinical trial conducted to assess the safety of tofacitinib. Consequently, the
molecule will be used as a third line treatment in patients who meet specific criteria.
•Gilead and Galapagos’ filgotinib (Jyseleca®) is a selective JAK1 inhibitor. Since November 2021,
filgotinib has been approved for the treatment of UC in the European Union (the “EU”). Authorization
requests have also been submitted to the UK Medicines and Healthcare products Regulatory Agency
(“MHRA”) and the Japanese PMDA for the treatment of moderately to severely active UC. A Phase 3
clinical trial in patients with CD is also underway.
•AbbVie’s upadacitinib (Rinvoq®), which is also a selective JAK1 inhibitor, was approved by the FDA
in March 2022 for the treatment of moderately to severely active UC. EMA authorization for the
treatment of moderately to severely active UC was granted in July 2022. A Phase 3 clinical trial in
patients with CD is currently underway.
S1P receptor agonists allow sequestration of activated lymphocytes in lymph nodes and thus reduce their
circulation in the GI tract. Ozanimod (Zeposia®) is a S1P receptor modulator that is selective for the S1P1 and S1P5
receptors. It was approved by the FDA and EMA for the treatment of moderately to severely active UC in 2021.
Phase 3 clinical trials are currently being conducted to assess the efficacy of ozanimod in CD. Top-line results of a
Phase 3 induction trial of ARENA Pharmaceuticals’ Etrasimod for the treatment of UC were announced in March
2022 and the primary endpoint, as well as the key secondary endpoints were reached; a Phase 2/3 clinical trial is
currently being conducted in CD. In addition, in October 2023, Ventyx Biosciences announced results from its
Phase 2 clinical trial of VTX002 in UC.
We are also aware of other types of treatments currently under various stages of development, such as
NImmune Biopharma’s omilancor (a Lanthionine Synthetase C-Like 2 activator) as well as tyrosine kinase 2
inhibitors from Bristol Myers Squibb’s Sotyktu (deucravacitinib – approved in the EU) and Ventyx Biosciences’
VTX 958.
Furthermore, TL1A inhibitors have garnered interest from those seeking newer targets and agents with
differentiated clinical profile. While PRA023 (Merck-Prometheus) and RVT-3101 (Pfizer-Roivant) have generated
promising early Phase 2 data in both biologics-experienced and biologics-naïve patients, neither have initiated Phase
3 clinical trials and do not have long-term safety and efficacy data beyond 56 weeks.
Our competitors may also succeed in obtaining European Commission, FDA or other regulatory approvals for
their drug candidates more rapidly than us, which could place us at a significant competitive disadvantage. Market
acceptance of our drug candidates will depend on a number of factors, including: (i) potential advantages over
existing or alternative therapies or tests; (ii) the actual or perceived safety of similar classes of products; (iii) the
84
effectiveness of our sales, marketing, and distribution capabilities; and (iv) the scope of any approval provided by
the FDA or foreign regulatory authorities.
We anticipate that we will face intense and increasing competition as new drugs and therapies enter the market
and advanced technologies become available.
Government Regulation
Companies operating in the pharmaceutical industry are subject to increased scrutiny by the competent
authorities and must deal with an ever-changing and increasingly restrictive legal and regulatory environment.
The development of drugs involves several stages: research and development, preclinical tests, clinical trials,
authorization, manufacturing and commercialization.
All of these stages are subject to specific requirements that impose substantial and onerous constraints,
compliance with which is ensured by various national, regional (in the EU, the EMA) or federal (in the United
States, the FDA) authorities.
Failure to comply with these regulations may be subject to fines, to the suspension or withdrawal of the
authorizations and certifications required to perform pharmaceutical activities, to the seizure or withdrawal of
products from the market, or to partial or total suspension of their manufacturing. Regulatory authorities may also
withdraw marketing authorizations (“MAs”) previously granted or reject MA applications (“MAAs”) and initiate
legal proceedings, and their outcome remains uncertain.
Although the regulatory constraints may differ from a country to another, development of therapeutic products
for human use must comply with requirements shared by all developed countries. The steps to be completed before
obtaining an MA in the EU and in the United States are generally as follows:
•conduct of preclinical laboratory tests and studies in animals, in accordance with Good Laboratory
Practice (“GLP”);
•conduct of clinical trials in humans to demonstrate the safety and efficacy of the product for each
considered indication, in accordance with Good Clinical Practice (“GCP”), if necessary after
authorization by a competent authority and an ethics committee;
•preparation and submission of an MAA to the competent authority, in order to market the product;
•inspection by the competent authority of the manufacturing facilities in which the product and/or its
ingredients are manufactured to assess compliance with Good Manufacturing Practices (“GMP”);
•inspection by the competent authority of establishments distributing medicinal products in order to
assess their compliance with Good Distribution Practice (“GDP”); and
•if needed, commitment by the applicant to comply with post-MA requirements.
Due to these regulatory constraints, the development and approval process of a drug candidate for
commercialization, which varies according to its nature, complexity and novelty, usually extends over several years.
EU Regulation
Preclinical Studies
Within all EU Member States, preclinical studies include laboratory evaluation of the composition, purity and
stability of the active pharmaceutical ingredient and the formulated product, as well as studies to evaluate the
tolerance (toxicological studies), activity and behavior of the product candidate in vitro and in animals (in vivo).
The conduct of preclinical studies is subject to legal and regulatory provisions. Non-clinical studies are
performed to demonstrate the health or environmental safety of new chemical or biological substances. Non-clinical
(pharmaco-toxicological) studies must be conducted in compliance with GLP, as set forth in EU Directive 2004/10/
EC (unless otherwise justified for certain particular medicinal products – e.g., radio-pharmaceutical precursors for
radio-labelling purposes). In particular, non-clinical studies, both in vitro and in vivo, must be planned, performed,
monitored, recorded, reported and archived in accordance with the GLP principles, which define a set of rules and
criteria for a quality system for the organizational process and the conditions for non-clinical studies. These GLP
standards reflect the Organization for Economic Co-operation and Development requirements.
85
Preclinical studies are a prerequisite for the initiation of clinical trials in humans: all the results of these trials
are submitted to the regulatory authorities at the same time as the application to initiate clinical trials. However,
while preclinical tests must be performed prior to conducting clinical trials in humans, certain long-term preclinical
tests, such as tests on reproductive toxicity and carcinogenicity, may continue after the submission of an application
to initiate clinical trials.
Clinical Trials in Humans
The various phases of clinical trials in the EU are subject to significant regulatory controls. They must be
conducted in accordance with EU and national regulations, the standards adopted by the International Conference on
Harmonization (“ICH”) and GCP.
Directive no. 2001/20/EC on the conduct of clinical trials sought to harmonize the regulatory framework for
clinical trials in the EU, setting out common rules for the monitoring and authorization of clinical trials in the EU.
To reduce disparities between the transpositions by the Member States, Regulation 536/2014 on clinical trials on
medicinal products for human use and repealing Directive 2001/20/EC, was adopted on April 16, 2014. This
regulation aims to further harmonize and streamline the clinical trial authorization process, simplify adverse event
reporting procedures, improve the supervision of clinical trials, and increase the transparency of clinical trials. This
regulation became applicable on January 31, 2022. However, it provides for a three-year transition period (i.e.,
clinical trials for which an application was submitted in accordance with Directive no. 2001/20/EC before
January 31, 2022, will continue to be subject to the Directive provisions for a period of three years). Furthermore,
sponsors having submitted a clinical trial under the Directive until January 31, 2023 may remain governed by the
Directive until January 31, 2025. By that date, all ongoing trials will become fully subject to the provisions of the
Regulation 536/2014.
Under the clinical trials regulation, the sponsor may submit its application for a clinical trial authorization to
one or several Member States, in which case the evaluation of Part I of the dossier (scientific part) is carried out
according to a coordinated procedure. In this framework, the sponsor must submit a single application for
authorization via the portal associated with the EU database (“CTIS”), comprising a common scientific part
evaluated jointly by all the EU Member States in which the trial will be carried out (with one of the Member States
concerned acting as rapporteur Member State) and a national part covering the ethical aspects of the trial, evaluated
independently by each Member State.
The conclusion of the rapporteur Member State with regard to Part I of the assessment report is deemed to be
the conclusion of all Member States concerned. However, the Member States concerned may disagree with this
conclusion for a number of limited reasons, for example when they consider that participation in the clinical trial
would lead to a subject receiving a treatment inferior to that of normal clinical practice on their territory. The
Member State concerned may then refuse the clinical trial on its territory.
A “single” decision covering the conclusions of the Part I and Part II evaluations is issued by each of the
Member States concerned and is notified to the sponsor on the dedicated European portal.
The sponsor of a clinical trial conducted in the EU notifies through the EudraVigilance database without delay
and at the latest within the deadlines set by the clinical trials regulation, of all relevant information on suspected
serious and unexpected adverse reactions to the investigational medicinal product. If the competent bodies
concerned consider that the adverse effects outweigh the benefits for the participants, they may require the
immediate suspension or early termination of the trial at any time.
In addition, the sponsor must submit through CTIS once a year, for the duration of the clinical trial, an Annual
Safety Report (ASR) for each investigational drug used in the clinical trial.
Finally, the EU framework applicable to clinical trials has also been significantly strengthened with
Regulation (EU) 2016/679 of the European Parliament and of the Council of April 27, 2016, on the protection of
natural persons with regard to the processing of personal data and on the free movement of such data, and repealing
Directive 95/46/EC (General Data Protection Regulation, “GDPR”), which entered into force on May 25, 2018. This
regulation has significantly increased EU citizens’ rights by giving them more control over their personal data. Thus,
depending on the type of personal data processing carried out during clinical trials and the nature of such trials, it
might be necessary to carry out formalities by the local Data Protection Authority, in addition to seeking formal
informed consent which must be obtained from each clinical trial subject.
86
Responsibility of the Sponsor and Insurance Obligation of the Sponsor
In the EU, the sponsor shall indemnify the subject of the trial in case of damage arising as a consequence of
the research, unless he proves that the damage does not result from his fault or the fault of any other person
intervening in the trial. In the EU, Member States generally require a sponsor to have an insurance covering its civil
liability and the liability of any person intervening in the research. In addition, any breach to the provisions
concerning clinical trials may lead to significant administrative, criminal and/or reputational penalties.
Marketing Approval
Within the EU, marketing of medicinal products is governed by EU regulations (including but not limited to
Directive 2001/83/EC and Regulation 726/2004/EU).
On April 26, 2023, the European Commission issued proposals for a revision of the current legal framework.
Although the proposal is subject to adoption by EU institutions, which become effective upon adoption, this new
framework, which in particular aims at granting timely access to patients for safe, effective and affordable medicines
and at enhancing supply of medicines, may significantly amend general principles described above, notably
timelines and market exclusivity periods.
In the EU, medicinal product candidates can only be commercialized after obtaining an MA. To obtain
regulatory approval of a product candidate under EU regulatory systems, we must submit an MAA. The process for
doing this depends, among other things, on the nature of the medicinal product. There are two types of MAs:
•“Centralized MAs” are granted by the European Commission through the centralized procedure based
on the opinion of the Committee for Medicinal Products for Human Use (“CHMP”) of the EMA. The
MA issued under this procedure is valid in all EU Member States.
•The centralized procedure is compulsory for some types of medicinal products such as biotechnology
products, designated orphan medicinal products, products containing a new active substance indicated
for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes or autoimmune and viral
diseases, advanced therapy medicinal products (such as gene therapy, somatic cell therapy and tissue
engineered products). The centralized procedure is optional for products containing a new active
substance that has not yet been authorized in the EU or for products which present a significant
therapeutic, scientific or technical innovation or are of interest for the public health in the EU.
•“National MAs” are issued at a national level by the competent authorities of the concerned Member
States. They are valid only on their territory. National MAs can be issued for products that do not fall
within the mandatory scope of the centralized procedure. Medicinal products which have not received
a national MA in any of the Member States, may be authorized through the decentralized procedure.
This procedure enables the simultaneous issuance of national MAs in several EU countries. Under the
decentralized procedure, an identical dossier is submitted to the competent authorities of each of the
Member States in which an MA is sought. One of these Member States is designated by the applicant
to act as the Reference Member State (“RMS”). The competent authority of the RMS drafts an
assessment report and prepares an SmPC, a package leaflet and a draft labelling, which are sent to the
other Member States involved in the procedure, known as the Concerned Member States (“CMS”), for
approval. If the CMS do not raise any objections based on a potential serious risk to public health,
regarding the assessment, the SmPC, the labelling or the packaging proposed by the RMS, a national
MA is granted for the product in all Member States involved in the procedure (i.e., in the RMS and the
CMS). Where a product has already been authorized for marketing in an EU Member State, this
national MA can be recognized in another member state through the mutual recognition procedure. In
this procedure, the Member State which issued the initial MA, known as the RMS, must prepare an
assessment report on the medicinal product or update any existing report. This report is sent to the
CMS, together with the approved SmPC and the labelling and package leaflet. Unless an objection
based on a potential serious risk to public health is raised, the CMS issue(s) a national MA for the
product, the terms of which are identical to the MA granted by the RMS.
Depending on the procedure used, the EMA or the national competent authority(ies) must, before granting a
MA, make an assessment of the benefit/risk ratio of the product based on scientific criteria of quality, safety of use
and efficacy. Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the EMA is
210 days, excluding clock stops. In exceptional cases, the CHMP might perform an accelerated review of an MAA
in no more than 150 days (not including clock stops). Innovative products that target an unmet medical need and are
expected to be of major public health interest may be eligible for a number of expedited development and review
programs, such as the Priority Medicines (“PRIME”) scheme, which provides incentives similar to the breakthrough
therapy designation in the U.S. In March 2016, the EMA launched an initiative, the PRIME scheme, a voluntary
scheme aimed at enhancing the EMA’s support for the development of medicines that target unmet medical needs. It
87
is based on increased interaction and early dialogue with companies developing promising medicines, to optimize
their product development plans and speed up their evaluation to help them reach patients earlier. Product
developers that benefit from PRIME designation can expect to be eligible for accelerated assessment but this is not
guaranteed. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not
limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and
other development program elements, and accelerated MAA assessment once a dossier has been submitted.
Importantly, a dedicated contact and rapporteur from the CHMP is appointed early in the PRIME scheme facilitating
increased understanding of the product at EMA’s committee level. An initial meeting initiates these relationships
and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and
regulatory strategies.
Moreover, in the EU, a conditional MA may be granted by the European Commission for a period of one year
and is renewable annually.
A conditional MA is granted in the absence of sufficient clinical data to obtain an ordinary MA if the
following requirements are met: (i) the medicinal product is intended to treat, prevent or diagnose a fatal or seriously
debilitating disease, (ii) it fulfils to an unmet medical need, (iii) its benefit/risk ratio is, on the basis of the available
data, positive, (iv) it is likely that the applicant will be able to provide the required comprehensive post-MA clinical
data and (v) in terms of public health, the benefits of the product’s immediate availability to patients outweigh the
risks inherent to the lack of sufficient clinical data.
The granting of a conditional MA is accompanied by specific obligations, in particular relating to the
completion of clinical trials, the performance of new studies and the collection of pharmacovigilance data in order to
confirm the benefit/risk ratio of the product. Once the pending studies are provided, it can become a “standard” MA.
MAs may also be granted under exceptional circumstances to medicinal products for which a complete
evaluation file cannot be provided when the product’s indication is too rarely encountered and reasonably prevents
the provision of comprehensive evidence, when the current state of scientific knowledge prevents the provision of
such data or when the collection of the necessary data would be unethical. This MA is close to the conditional MA
as it is reserved to medicinal products to be approved for severe diseases or unmet medical needs and the applicant
does not hold the complete data set legally required for the grant of a MA. However, unlike the conditional MA, the
applicant does not have to provide the missing data and will never have to. Although the MA “under exceptional
circumstances” is granted definitively, the risk-benefit balance of the medicinal product is reviewed annually and the
MA is withdrawn in case the risk-benefit ratio is no longer favorable.
However, despite the granting of a MA, both the MA holder and the competent authorities may decide to
withdraw (voluntarily or compulsorily) a product from the market or a MA, when it appears that the product
presents more risks than benefits for the patients.
Data and Marketing Exclusivity
In the EU, new products authorized for marketing (i.e., reference products) generally receive eight years of
data exclusivity and an additional two years of market exclusivity upon MA. If granted, the data exclusivity period
prevents generic and biosimilar applicants from relying on the preclinical and clinical trial data contained in the
dossier of the reference product when applying for a generic or biosimilar MA in the EU during a period of eight
years from the date on which the reference product was first authorized in the EU. The market exclusivity period
prevents a successful generic or biosimilar applicant from commercializing its product in the EU until ten years have
elapsed from the initial MA of the reference product in the EU. The overall ten-year market exclusivity period can
be extended to a maximum of eleven years if, during the first eight years of those ten years, the MA holder obtains
an authorization for one or more new therapeutic indications, which, during the scientific evaluation prior to their
authorization, are held to bring a significant clinical benefit in comparison with existing therapies. However, there is
no guarantee that a product will be considered by the EU’s regulatory authorities to be a new chemical or biological
entity, and products may not qualify for data exclusivity.
Pediatric Development
In the EU, MAAs for new medicinal products must include the results of studies conducted in the pediatric
population, in compliance with a Pediatric Investigation Plan (“PIP”) agreed with the EMA’s Pediatric Committee
(“PDCO”). The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of
the medicinal product for which MA is being sought. The PDCO can grant a deferral of the obligation to implement
some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the
product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the PDCO when
these data is not needed or appropriate because the product is likely to be ineffective or unsafe in children, the
88
disease or condition for which the product is intended occurs only in adult populations, or when the product does not
represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the MA is obtained in
all the EU member states and study results are included in the product information, even when negative, the product
is eligible for six months’ supplementary protection certificate extension (if any is in effect at the time of approval)
or, in the case of orphan pharmaceutical products, a two-year extension of the orphan market exclusivity is granted.
Manufacturing and Distribution-related Requirements
To ensure patients’ safety, the manufacturing, distribution and import of active pharmaceutical ingredients and
finished products into the EU are also subject to extensive requirements and both MA holders and manufacturers of
medicinal products are subject to comprehensive regulatory oversight by the EMA, the European Commission and/
or the competent regulatory authorities of the Member States.
Medicines (including their active substances) must be manufactured in accordance with GMP requirements.
These regulations govern manufacturing processes and procedures, and notably provide for requirements relating to
the implementation of quality systems to control and ensure the quality of materials and products. Manufacturing
activities must be performed only within companies holding valid licenses from the competent regulatory authorities
of the Member States which is issued following an inspection of the concerned facilities. In addition, routine
inspections are conducted on a regularly basis to ensure that compliance is maintained.
Distributors must also comply with very strict requirements, including good distribution practices (“GDP”).
These regulations provide for strict requirements including the implementation of an effective quality system and
adequate procedures to ensure the quality of the products all over the distribution chain and efficiently respond to
claims, recalls, and risks of falsification, or the use of appropriate facilities, equipment and personnel. Similarly to
manufacturing, distribution activities are subject to a prior approval from the competent regulatory authorities of the
Member States which is issued following an inspection of the concerned facilities which aims at ensuring that the
establishment complies with the applicable regulations. Routine inspections are also conducted on a regularly basis.
Finally, the import of active pharmaceutical ingredients and medicines into the EU must also be authorized in
advance, in order to ensure that the products are manufactured and distributed in accordance with standards at least
equivalent to those existing for the EU market.
Failure to comply with the above requirements may be sanctioned by the suspension or withdrawal of the
manufacturing/distribution/import authorization, civil, criminal or administrative penalties, or the withdrawal of the
concerned active ingredients and finished products from the market.
Post-Approval Requirements
Pharmacovigilance Requirements
The MA holder must establish and maintain a pharmacovigilance system and designate a Qualified Person
Responsible for Pharmacovigilance (“QPPV”) who is responsible for the establishment and maintenance of that
system, and oversees the safety profiles of medicinal products and any emerging safety concerns. The main
obligations of the QPPV include prompt reporting of suspected serious adverse reactions and submission of periodic
pharmacovigilance update reports (“PSURs”).
All new MAA must include a risk management plan (“RMP”) describing the risk management system that the
company will put in place and setting out measures to prevent or minimize the risks associated with the medicinal
product. The regulatory authorities may also issue an MA subject to the fulfillment of specific obligations. These
risk reduction measures or post-authorization obligations may consist, in particular, of reinforced safety monitoring,
more frequent submission of PSURs, the conduct of additional clinical trials or the performance of post-
authorization safety studies.
Advertising Requirements
In the EU, the advertising and promotion of medicinal products is also subject to laws concerning promotion
of medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial
practices. The general principles applicable to the advertising of medicines, which is broadly defined as any form of
door-to-door information, canvassing activity or inducement designed to promote the prescription, supply, sale or
consumption of medicinal products, are established by EU directives.
Any advertising or promotion of a medicinal product must comply with its approved SmPC. Consequently,
any promotion of off-label promotion is prohibited. Indeed, the advertising must encourage the rational use of
89
medicines by presenting them objectively without exaggeration and thus, must not be misleading. Direct-to-
consumer advertising of prescription medicines is also prohibited in the EU. Although general requirements for
advertising and promotion of medicinal products are established under EU directives, the details are governed by
regulations in each Member State and can differ from one country to another.
Depending on the Member States, advertising-related regulatory requirements may be sanctioned notably by
fines, suspension or withdrawal of regulatory authorizations, medicinal products recalls, medicinal products
seizures, operating restrictions and even criminal and/or civil prosecution and significant fines.
The aforementioned EU rules are generally applicable in the European Economic Area (“EEA”) which
consists of the 27 EU member states plus Norway, Liechtenstein and Iceland.
Coverage and Reimbursement
In the EU, pricing and reimbursement systems widely vary from one country to another and remain
exclusively the responsibility of the Member States.
Thus, Member States may restrict the range of medicines for which their national health insurance system
provides reimbursement and to control the price of medicines for human use, provided that time limits for review of
a reimbursement application provided in Directive 89/105/EEC of 21 December 1988 must be complied with.
Some Member States use a system of positive and negative lists, whereby medicines can only be marketed
after a reimbursement price has been agreed. Others may require additional studies comparing the cost-effectiveness
of a medicinal product to existing therapies in order to obtain approval for reimbursement or pricing. Finally,
Member States can agree to a set price or, instead, allow companies to set their own prices while having their profits
monitored and controlled (e.g., control of the quantity of prescriptions).
Over the last few years, many EU Member States have increased the amount of rebates applied to medicinal
products, and these efforts may continue as Member States exercise greater control over their healthcare spending
due to often large debts. The downward pressure on healthcare costs in general, including medicinal products subject
to mandatory prescription, has become considerable. Changing political, economic and regulatory conditions can
complicate price negotiations. This price negotiation can continue after reimbursement has been achieved and is
generally subject to periodic reviews. Finally, reference prices used by various EU Member States and parallel trade
(i.e., arbitrage by distributors between low and high price Member States) may also lead to further price reductions.
On December 13, 2021, Regulation No 2021/2282 on Health Technology Assessment (“HTA”) amending
Directive 2011/24/EU, was adopted. While the Regulation entered into force in January 2022 it will only begin to
apply from January 2025 onwards, with preparatory and implementation-related steps to take place in the interim.
Once the Regulation becomes applicable, it will have a phased implementation depending on the concerned
products. This regulation intends to boost cooperation among EU Member States in assessing health technologies,
including new medicinal products, and providing the basis for cooperation at the EU level for joint clinical
assessments in these areas. The regulation will permit EU Member States to use common HTA tools,
methodologies, and procedures across the EU, working together in four main areas, including joint clinical
assessment of the innovative health technologies with the most potential impact for patients, joint scientific
consultations whereby developers can seek advice from HTA authorities, identification of emerging health
technologies to identify promising technologies early, and continuing voluntary cooperation in other areas.
Individual EU Member States will continue to be responsible for assessing non-clinical (e.g., economic, social,
ethical) aspects of health technology, and making decisions on pricing and reimbursement.
Other Healthcare Laws
Relationships between the pharmaceutical industry and healthcare professionals are subject to national
restrictions and regulations in order to avoid any incentive to prescribe drugs that is not justified by the patient’s
state of health and profile.
For example, in France, relations between companies producing and/or marketing health products or providing
services associated with these products, regardless of their nationality and/or the location of their registered office,
and healthcare professionals practicing in France are governed by the “anti-gift” and “transparency” laws.
The purpose is to ensure that healthcare professionals, in their choice of a medicinal product, equipment or
service, are guided solely by medical information and considerations.
90
By way of principle, under the French anti-gift law, persons providing health services, manufacturing or
marketing healthcare products are prohibited from promising or offering advantages, in cash or in kind, either
directly or indirectly, to healthcare professionals practicing in France, students intending to enter such professions or
associations of these individuals, including learned societies and national professional councils.
The list of benefits that do that do not qualify as “advantages” under the anti-kickback regulation is very
limited and includes, for example, benefits that relate to the exercise of the beneficiary’s profession and of negligible
value, which may not exceed the amounts provided for by a Ministerial Order.
By way of exception, above-mentioned health stakeholders may provide advantages to the healthcare
professionals/associations mentioned above, subject to the conclusion of a written agreement and to a prior
declaration to or approval from the authority to which the concerned beneficiary belongs.
This exception is however limited to specific situations mainly including:
•The remuneration, compensation and expenses for research activities, research promotion, scientific
evaluation, consultancy, provision of services or commercial promotion, provided that the
remuneration is proportionate to the service provided and that the compensation or expenses do not
exceed the costs actually incurred by the persons concerned;
•Donations and gifts, in cash or in kind, exclusively intended to finance research activities, the
promotion of research or scientific evaluation; or
•Hospitality offered during events of an exclusively professional or scientific nature, or during events
promoting healthcare products or services, provided that this hospitality is of a reasonable level,
strictly limited to the main purpose of the event and to healthcare professionals (excluding students);
When failing to comply with these regulations, in addition to a significant risk to their reputation, the
companies and professionals concerned may be subject to significant criminal penalties and, in the case of the latter,
disciplinary penalties.
The French transparency provision, for its part, provides citizens with access to certain information on a
website so that they can more objectively assess the relationships between health actors (i.e., a broad list including
healthcare professionals, associations of healthcare professionals, students, associations of users of the health
system, health establishments, academic institutions, foundations, learned societies and societies or advisory bodies
involved in the health product or health services sector, etc.) and companies producing or marketing health products
or providing services associated with these products. Under the terms of this regulation, the companies concerned
must disclose the main information relating to their relationships with healthcare professionals, such as
compensation or benefits paid, and agreements entered into. Companies that knowingly fails to disclose such
information may be subject to criminal penalties.
UK Regulation
Since the end of the Brexit transition period on January 1, 2021, Great Britain (“GB”) (England, Scotland and
Wales) has not been directly subject to EU laws. However, under the terms of the Ireland/Northern Ireland Protocol,
EU laws have generally applied to Northern Ireland. On February 27, 2023, the UK government and the European
Commission reached a political agreement on the so-called “Windsor Framework” which is intended to revise the
Ireland/Northern Ireland Protocol in order to address some of the perceived shortcomings in its operation. The
agreement was adopted at the Withdrawal Agreement Joint Committee on March 24, 2023. If the changes are
adopted in the form proposed, medicinal products to be placed on the market in the UK will be authorized solely in
accordance with UK laws. Northern Ireland would be reintegrated back into a UK-only regulatory environment
under the authority of the MHRA with respect to all medicinal products. The implementation of the Windsor
Framework would occur in various stages, with new arrangements relating to the supply of medicines into Northern
Ireland anticipated to take effect in 2025.
The EU laws that have been transposed into United Kingdom (“UK”) law through secondary legislation
remain applicable in Great Britain. However, new EU legislation that was either adopted or entered into application
after Brexit such as the EU CTR is not applicable in Great Britain. The UK regulatory framework in relation to
clinical trials is derived from previously existing EU legislation (as implemented into UK law, through secondary
legislation). On January 17, 2022, the UK MHRA launched an 8-week consultation on reframing the UK legislation
for clinical trials. The consultation closed on March 14, 2022, and aims to streamline clinical trial approvals, enable
innovation, enhance clinical trials transparency, enable greater risk proportionality and promote patient and public
involvement in clinical trials. The outcome of the consultation is being closely watched and will determine whether
the UK chooses to align with the (EU) CTR or diverge from it. Under the terms of the Ireland/Northern Ireland
91
Protocol, provisions of the EU CTR which relate to the manufacture and import of investigational medicinal
products and auxiliary medicinal products currently apply in Northern Ireland.
Since January 1, 2021, the MHRA has been the sole regulatory of medicines and medical devices in GB and
for medicinal products that are not authorized through the centralized procedure in Northern Ireland. The MHRA
has introduced changes to national licensing procedures, including procedures to prioritize access to new medicines
that will benefit patients, including a 150-day assessment and a rolling review procedure. All existing EU MAs for
centrally authorized products were automatically converted or grandfathered into UK MAs, effective in GB (only),
free of charge on January 1, 2021, unless the MA holder opted-out. In order to use the centralized procedure to
obtain an MA that will be valid throughout the EEA, companies must be established in the EEA. Therefore, since
Brexit, companies established in the UK can no longer use the EU centralized procedure for authorization of
medicinal products intended to be marketed in the UK. In order to obtain a UK MA to commercialize products in the
UK, an applicant must be established in the UK and must follow one of the UK national authorization procedures or
one of the remaining post-Brexit international cooperation procedures to obtain an MA to commercialize products in
the UK. Until December 31, 2023, the MHRA may rely on a decision taken by the European Commission on the
approval of a new (centralized procedure) MA when reviewing an application for authorization of a medicinal
product to be supplied in GB. Depending on the nature and intended therapeutic purpose of the medicinal product,
the MHRA may, alternatively, use its own decentralized or mutual recognition procedures which enable the MHRA
to have regard to MAs approved in EU Member States, Iceland, Liechtenstein, and Norway when granting an MA in
the UK or GB. From the first quarter of 2024, a new international recognition framework should be in place with an
aim to extend the countries whose assessments the MHRA will take into account. The UK government will need to
adopt new legislation to introduce this route.
There is no pre-MA orphan designation procedure. Applications for orphan designation are made at the same
time as an application for MA and the MHRA will review applications for orphan designation in parallel to the
corresponding MA application. The criteria are essentially the same, but have been tailored for the market (i.e., the
prevalence of the condition in GB, rather than the EU, must not be more than five in 10,000). Should an orphan
designation be granted, the period or market exclusivity will be set from the date of first approval of the product in
GB.
U.S. Government Regulation
In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, (“FDCA”)
and its implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with
applicable federal, state, and local statutes and regulations requires the expenditure of substantial time and financial
resources. Failure to comply with the applicable U.S. requirements at any time during the product development
process, approval process, or after approval, may subject an applicant to a variety of administrative or judicial
sanctions, such as the FDA’s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical
hold on a clinical trial, issuance of warning letters, product recalls, product seizures, total or partial suspension of
production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or
criminal penalties.
The process required by the FDA before a drug may be marketed in the United States generally involves the
following:
•Completion of preclinical laboratory studies, animal studies and formulation studies in compliance
with the FDA’s GLP regulations, and other applicable regulations;
•Submission to the FDA of an IND which must become effective before human clinical trials may
begin;
•Approval by the Institutional Review Board (“IRB”) or ethics committee, at each clinical site before
each trial may be initiated;
•Performance of adequate and well-controlled human clinical trials, in accordance with GCP
requirements to establish the safety and effectiveness of the proposed drug product for each indication;
•Submission to the FDA of an NDA;
•Satisfactory completion of an FDA advisory committee review, if applicable;
•Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the
product is produced to assess compliance with current good manufacturing practice (“cGMP”)
requirements and to assure that the facilities, methods and controls are adequate to preserve the drug’s
identity, strength, quality and purity, and of potential inspection of selected clinical investigation sites
to assess compliance with GCPs; and
92
•FDA review and approval of the NDA.
Preclinical Studies and INDs
Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as
animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical
studies, together with manufacturing information, analytical data and any available clinical data or literature, among
other things, to the FDA as part of an IND. Some preclinical studies may continue even after the IND is submitted.
An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises
concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In
such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin.
As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.
Clinical Trials
Clinical trials involve the administration of the investigational drug to human patients under the supervision of
qualified investigators in accordance with GCP requirements, which include, among other things, the requirement
that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical
trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be
used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any
subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, the IRB(s)
competent for the institution(s) participating in the clinical trial must review and approve the plan for any clinical
trial before it commences. Information about certain clinical trials must be submitted within specific timeframes to
the National Institutes of Health for public dissemination on their www.clinicaltrials.gov website.
While the IND is active, progress reports detailing the results of the clinical trials and nonclinical studies
performed since the last progress report, among other information, must be submitted at least annually to the FDA
and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected
adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar
drugs, findings from animal or in vitro testing suggesting a significant risk to humans, and any clinically important
increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator
brochure. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various
grounds, including a finding that the research patients are being exposed to an unacceptable health risk. Similarly, an
IRB can suspend or terminate approval of a clinical trial if the clinical trial is not being conducted in accordance
with the IRB’s requirements or if the drug has been associated with unexpected serious harm to patients. In addition,
some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a
data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may
move forward at designated check points based on access to certain data from the trial.
For purposes of FDA approval, human clinical trials are generally conducted in three sequential phases that
may overlap or be combined:
•Phase 1: The drug candidate is initially introduced into healthy human subjects and tested for safety,
dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early
indication of its effectiveness.
•Phase 2: The drug candidate is administered to a limited patient population with a specified disease or
condition to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of
the drug candidate for specific targeted diseases and to determine dosage tolerance and appropriate
dosage.
•Phase 3: The drug candidate is administered to an expanded patient population to further evaluate
dosage, to provide substantial evidence of efficacy and to further test for safety, generally at multiple
geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall
risk-benefit ratio of the drug candidate and provide an adequate basis for product labeling.
Post-approval trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing
approval. These trials are used to, among other things, gain additional experience from the treatment of patients in
the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical
trials as a condition of approval of an NDA.
Concurrent with clinical trials, companies usually complete additional animal studies and must also develop
additional information about the chemistry and physical characteristics of the drug and finalize a process for
manufacturing the product in commercial quantities in accordance with GMPs. The manufacturing process must be
93
capable of consistently producing quality batches of the drug candidate and, among other things, the manufacturer
must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate
packaging must be selected and tested, and stability studies must be conducted to demonstrate that the drug
candidate does not undergo unacceptable deterioration over its shelf life.
Marketing Approval
Assuming successful completion of the required clinical testing, the results of the preclinical studies and
clinical trials, together with detailed information relating to the product’s chemistry, manufacture, controls and
proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market
the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial
application user fee. Under the Prescription Drug User Fee Act guidelines that are currently in effect, the FDA has a
goal of ten months from the date of “filing” of a standard NDA for a new molecular entity to review and act on the
submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the
FDA has approximately two months to make a “filing” decision.
In addition, under the Pediatric Research Equity Act of 2003, as amended and reauthorized, certain NDAs or
supplements to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the
claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each
pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the
request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the
product for use in adults, or full or partial waivers from the pediatric data requirements.
The FDA also may require submission of a Risk Evaluation and Mitigation Strategy (“REMS”) plan to ensure
that the benefits of the drug outweigh its risks. The REMS plan could include Medication Guides (FDA approved
patient labeling to be provided to patients when the drug is dispensed), physician communication plans, assessment
plans, or Elements to Assure Safe Use, such as restricted distribution methods, patient registries, or other risk
minimization tools.
The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before
accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The
FDA may request additional information rather than accept an NDA for filing. In this event, the application must be
resubmitted with the additional information. The resubmitted application is also subject to review before the FDA
accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The
FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the
facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product’s
continued safety, quality and purity.
The FDA may refer an application for a novel drug to an Advisory Committee. An Advisory Committee is a
panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a
recommendation as to whether the application should be approved and under what conditions. The FDA is not
bound by the recommendations of an Advisory Committee, but it considers such recommendations carefully when
making decisions.
Before approving an NDA, the FDA typically will inspect the facility or facilities where the commercial
product would be manufactured. The FDA will not approve an application unless it determines that the
manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent
production of the product within required specifications. Additionally, before approving an NDA, the FDA may
inspect one or more clinical trial sites to verify the clinical data submitted in the NDA, and to assure compliance
with GCP requirements.
After evaluating the NDA and all related information, including the Advisory Committee recommendation, if
any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an
approval letter, or, in some cases, a Complete Response Letter. An approval letter authorizes commercial marketing
of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that
the review cycle of the application is complete, and the application will not be approved in its present form, and
describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such
as an additional clinical trial or other significant and time-consuming requirements related to clinical trials,
nonclinical studies or manufacturing. If a CRL is issued, the sponsor must resubmit the NDA, addressing all of the
deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the
FDA may decide that the NDA does not satisfy the criteria for approval.
94
Even if the FDA approves a product, it may limit the approved indications for use of the product, require that
contraindications, warnings or precautions be included in the product labeling, require that post-approval studies,
including Phase 4 clinical trials, be conducted to further assess a drug’s safety after approval, require testing and
surveillance programs to monitor the product after commercialization, or impose other conditions, including
distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect
the potential market and profitability of the product. The FDA may at any time prevent or limit further marketing of
a product based on the results of post-marketing studies or surveillance programs. After initial approval, some types
of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling
claims, are subject to further testing requirements and FDA review and approval.
Post-Approval Requirements
Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing
regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting,
product sampling and distribution, the submission of advertising and promotion, and reporting of adverse
experiences with the product. After approval, most changes to the approved product, such as adding new indications
or other labeling claims are subject to prior FDA review and approval. There also are continuing, annual program
user fee requirements for any marketed products, as well as new application fees for certain supplemental
applications.
The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For
example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further
assess and monitor the product’s safety and effectiveness after commercialization.
In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved
drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic
unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to
the manufacturing process are strictly regulated and often require prior FDA approval before being implemented.
FDA regulations also require manufacturers to investigate and correct of any deviations from cGMP requirements
and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the
sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area
of production and quality control to maintain cGMP compliance.
Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements
and standards is not maintained or if problems occur after the product reaches the market. Later discovery of
previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or
with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions
to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess
new safety risks; or imposition of distribution or other restrictions under a REMS program.
Other potential consequences include, among other things:
•Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product
from the market or product recalls;
•Fines, warning letters or holds on post-approval clinical trials;
•Refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or
revocation of product approvals;
•Product seizure or detention, or refusal to permit the import or export of products; or
•Injunctions or the imposition of civil or criminal penalties.
The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the
market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the
approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion
of unapproved uses (“off-label” uses), and a company that is found to have improperly promoted off-label uses may
be subject to significant liability. Physicians may prescribe legally available products for uses that are not described
in the product’s labeling and that differ from those tested by us and approved by the FDA. The FDA does not
regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer’s
communications on the subject of off-label use of their products.
95
Marketing Exclusivity
Market exclusivity provisions under the FDCA can delay the submission or the approval of certain marketing
applications. The FDCA provides a five-year period of non-patent data exclusivity within the United States to the
first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA
has not previously approved any other new drug containing the same active moiety, which is the molecule or ion
responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review
an abbreviated new drug application (“ANDA”), or an NDA submitted under Section 505(b)(2) (“505(b)(2) NDA”)
submitted by another company for another drug based on the same active moiety, regardless of whether the drug is
intended for the same indication as the original innovative drug or for another indication, where the applicant does
not own or have a legal right of reference to all the data required for approval. However, an application may be
submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents
listed with the FDA by the innovator NDA holder.
The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an
existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by
the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications,
dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug
received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving
ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use.
Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant
submitting a full NDA would be required to conduct, or obtain a right of reference to, all of the preclinical studies
and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.
Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric
exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if
a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written
request does not require the sponsor to undertake the described clinical trials.
Coverage and Reimbursement
Sales of our drug candidates, if approved, will depend, in part, on the extent to which such products will be
covered by third-party payors, such as government health care programs, commercial insurance and managed
healthcare organizations. These third-party payors determine which medications they will cover and establish
reimbursement levels. In addition, these third-party payors are increasingly limiting coverage or reducing
reimbursements for medical products and services. In the United States, no uniform policy of coverage and
reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products
can differ significantly from payor to payor. In addition, the U.S. government and state legislatures have continued
implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements
for substitution of generic products. Patients who are prescribed medications for the treatment of their conditions,
and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated
with their prescription drugs. Patients are unlikely to use our products unless coverage is provided and
reimbursement is adequate to cover all or a significant portion of the cost of our products. As a result, adoption of
price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing
controls and measures, could further limit our net revenue and results. Decreases in third-party reimbursement for
our drug candidates or a decision by a third-party payor to not cover our drug candidates could reduce physician
usage of our drug candidates, once approved, and have a material adverse effect on our sales, results of operations
and financial condition. Additionally, we or our collaborators may develop companion diagnostic tests for use with
our drug candidates. We or our collaborators will be required to obtain coverage and reimbursement for these tests
separate and apart from the coverage and reimbursement we seek for our drug candidates, once approved. Similar
challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply
to companion diagnostics.
Other Healthcare Laws
We will also be subject to other healthcare regulation and enforcement by the U.S. federal government and the
states in which we will conduct our business once our drug candidates are approved. Failure to comply with these
laws, where applicable, can result in the imposition of significant administrative, civil, and criminal penalties. The
laws that may affect our ability to operate in the United States include:
•The federal healthcare programs’ Anti-Kickback Statute, which prohibits, among other things, persons
from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or
indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or
96
recommendation of, any good or service for which payment may be made under federal healthcare
programs such as the Medicare and Medicaid programs;
•Federal false claims act laws, including the civil False Claims Act, which prohibit, among other things,
individuals or entities from knowingly presenting, or causing to be presented, claims for payment from
Medicare, Medicaid, or other third-party payors that are false or fraudulent;
•The federal health care fraud statutes, which created additional federal criminal statutes that impose
criminal and civil liability for, among other things, executing or attempting to execute a scheme to
defraud any healthcare benefit program or knowingly and willingly falsifying, concealing or covering
up a material fact or making false statements relating to healthcare matters;
•The Physician Payments Sunshine Act, which requires manufacturers of drugs, devices, biologics, and
medical supplies to report annually to the Centers for Medicare & Medicaid Services, information
related to payments and other transfers of value to physicians (defined to include doctors, dentists,
optometrists, podiatrists and chiropractors), other health care professionals (such as physicians
assistants and nurse practitioners), and teaching hospitals, as well as and ownership and investment
interests held by physicians and their immediate family members;
•The U.S. federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which
created additional federal criminal statutes that impose criminal and civil liability for, among other
things, executing or attempting to execute a scheme to defraud any healthcare benefit program or
knowingly and willingly falsifying, concealing or covering up a material fact or making false
statements relating to healthcare matters; and
•HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act
(“HITECH”), which governs the conduct of certain electronic healthcare transactions and protects the
security and privacy of protected health information.
In addition, many states have similar laws and regulations, such as anti-kickback and false claims laws that
may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under
Medicaid and other state programs. Further, certain states enacted laws that require: pharmaceutical companies to
comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance
promulgated by the federal government; drug manufacturers to report information related to payments and other
transfers of value to physicians and other healthcare providers or marketing expenditures; the reporting of
information related to drug pricing; the registration of pharmaceutical sales representatives. Certain states have also
enacted legislation to govern the privacy and security of health information, many of which differ from each other in
significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. Additionally, to the
extent that our product is sold in a foreign country, we may be subject to similar foreign laws. Violation of any of
these laws or any other governmental regulations, may result in significant civil, criminal and administrative
penalties, damages, fines, disgorgement, imprisonment, possible exclusion from government funded healthcare
programs, such as Medicare and Medicaid, contractual damages, reputational harm, and diminished profits and
future earnings.
Healthcare Reform
The enactment of the Affordable Care Act (“ACA”) has substantially changed healthcare financing and
delivery by both governmental and private insurers, and significantly impacted the pharmaceutical industry. The
ACA, among other things, established an annual, nondeductible fee on any entity that manufactures or imports
certain specified branded prescription drugs and biologic agents, revised the methodology by which rebates owed by
manufacturers to the state and federal government for covered outpatient drugs under the Medicaid Drug Rebate
Program are calculated, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid
Drug Rebate Program, extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals
enrolled in Medicaid managed care organizations, and provided incentives to programs that increase the federal
government’s comparative effectiveness research.
Since its enactment, there have been judicial and congressional challenges to certain aspects of the ACA. Most
recently, on June 17, 2021, the United States Supreme Court dismissed a challenge on procedural grounds that
argued the ACA is unconstitutional in its entirety because the individual mandate was repealed by Congress. In
addition, there have been a number of health reform initiatives by the Biden administration that have impacted the
ACA. For example, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (“IRA”), into
law, which among other things, extends enhanced subsidies for individuals purchasing health insurance coverage in
ACA marketplaces through plan year 2025. The IRA also eliminates the “donut hole” under the Medicare Part D
program beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly
established manufacturer discount program.
97
Other legislative changes have been proposed and adopted since the ACA was enacted. For example, on
August 2, 2011, the Budget Control Act of 2011 was signed into law which among other things, led to aggregate
reductions in Medicare payments to providers. These reductions went into effect on April 1, 2013, and, due to
subsequent legislative amendments, will remain in effect until 2032 unless additional Congressional action is taken.
In addition, there has been heightened governmental scrutiny over the manner in which manufacturers set
prices for their marketed products. For example, there have been several congressional inquiries and proposed bills
designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing
and manufacturer patient programs, and reform government program reimbursement methodologies for drug
products. For example, on March 11, 2021, the American Rescue Plan Act of 2021 was signed into law, which
eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug’s average manufacturer price,
beginning January 1, 2024. In addition, the IRA, among other things, (1) directs HHS to negotiate the price of
certain single-source drugs and biologics covered under Medicare and (2) imposes rebates under Medicare Part B
and Medicare Part D to penalize price increases that outpace inflation. These provisions take effect progressively
starting in fiscal year 2023, although the Medicare drug price negotiation program is currently subject to litigation.
Further, the Biden administration released an additional executive order on October 14, 2022, directing HHS to
submit a report within 90 days on how the Center for Medicare and Medicaid Innovation (“CMMI”) can be further
leveraged to test new models for lowering drug costs for Medicare and Medicaid beneficiaries. In response, on
February 14, 2023, HHS released a report outlining three new models for testing by the CMMI which will be
evaluated on their ability to lower the cost of drugs, promote accessibility, and improve quality of care. It is unclear
whether the models will be utilized in any health reform measures in the future. Further, on December 7, 2023, the
Biden administration announced an initiative to control the price of prescription drugs through the use of march-in
rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology
published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights
which for the first time includes the price of a product as one factor an agency can use when deciding to exercise
march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under
the new framework. At the state level, legislatures are increasingly passing legislation and implementing regulations
designed to control pharmaceutical and biological product pricing, including price or patient reimbursement
constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency
measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. For
example, on January 5, 2024, the FDA approved Florida’s Section 804 Importation Program ("SIP") proposal to
import certain drugs from Canada for specific state healthcare programs. It is unclear how this program will be
implemented, including which drugs will be chosen, and whether it will be subject to legal challenges in the United
States or Canada. Other states have also submitted SIP proposals that are pending review by the FDA. Any such
approved importation plans, when implemented, may result in lower drug prices for products covered by those
programs.
We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which
could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could
result in reduced demand for our drug candidates or additional pricing pressures.
Intellectual Property
Our success will depend upon our ability to obtain and maintain patents and other intellectual property for our
drug candidates in the United States and internationally, including composition-of-matter, pharmaceutical
composition, synthesis process, method of manufacture and method of treatment, as well as patent and other
intellectual property and proprietary protection for our novel discoveries and other important technology inventions
and know-how.
One of our strategies is also to file new patents that could extend obefazimod’s intellectual property protection
in the United States to 2039 and to generate new intellectual property through the protection of potential follow-on
compounds.
In addition to patents, we rely upon unpatented trade secrets, know-how, and continuing technological
innovation to develop and maintain our competitive position. We protect our proprietary information, in part, using
confidentiality agreements with our commercial partners, collaborators, employees and consultants and invention
assignment agreements with our employees. We also have confidentiality agreements or invention assignment
agreements with our commercial partners and selected consultants. Despite these measures, any of our intellectual
property and proprietary rights could be challenged, invalidated, circumvented, infringed or misappropriated, or
such intellectual property and proprietary rights may not be sufficient to permit us to take advantage of current
market trends or otherwise to provide competitive advantages. In addition, such confidentiality agreements and
98
invention assignment agreements can be breached and we may not have adequate remedies for any such breach. For
more information, please see “Risk Factors—Risks Related to Intellectual Property.”
The term of individual patents depends upon the legal term of the patents in the countries in which they are
obtained. In most countries in which we are seeking patent protection for our drug candidates, the patent term is 20
years from the earliest date of filing a non-provisional patent application. In the United States, the term of a patent
may be lengthened by a patent term adjustment, which provides for term extension in the case of administrative
delays at the United States Patent and Trademark Office in granting a patent, or may be shortened if a patent is
terminally disclaimed over another patent with an earlier expiration date. Furthermore, in the United States, the term
of a patent covering an FDA approved drug may be eligible for patent term extension (“PTE”) under the Hatch-
Waxman Amendments as compensation for the loss of patent term during the FDA regulatory review process. The
period of extension may be up to five years beyond the expiration of the patent but cannot extend the term of a
patent beyond a total of 14 years from the date of product approval. Only one patent covering a single FDA-
approved product among those eligible for an extension may be extended. In the future, if any of our drug candidates
receives FDA approval, we expect to apply for a PTE, if available, to extend the term of a patent covering such
approved drug product. We also expect to seek PTEs in any jurisdictions where they are available, however, there is
no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such an
extension should be granted, and even if granted, the length of such an extension. See “Item 3.D. Risk Factors—
Risks Related to Intellectual Property — Our ability to commercialize our drug candidates may decrease if we are
unable to protect our intellectual property rights or if these rights are insufficient for our purposes."
Patents
All the patents and patent applications covering obefazimod are co-owned with the French National Centre for
Scientific Research (the “CNRS”), the University of Montpellier, and the Institut Curie, except U.S. patent
10,464,903 and U.S. patent 10,745,357, as described below.
Obefazimod
As of December 31, 2023, the principal patent rights related to obefazimod, include:
•U.S. patent 10,017,498, which is directed to the composition of matter of obefazimod generically and
specifically and to a pharmaceutical composition comprising it. This patent is also granted in Europe
and several other countries (Australia, Brazil, Canada, China, Hong Kong, Cuba, India, Japan, South
Korea, Mexico, Russia, South Africa) and has an expiry date of 2030, not including patent term
adjustment or any potential PTE.
•U.S. patent 10,975,063, which is directed specifically to obefazimod (composition of matter), free base
and salts of obefazimod, a pharmaceutical composition comprising it, a process for preparing it and a
method for treating HIV infection. This patent has an expiry date of 2030, not including patent term
adjustment or any potential PTE.
•U.S. patent 10,435,370, which is directed to methods of treating inflammatory diseases including UC
and CD by obefazimod generically and specifically. This patent is also granted in Europe and several
other countries.
•U.S. continuation patent 11,649,211 is directed to the method of treating inflammatory diseases
including UC and CD by obefazimod specifically. Divisional U.S. patents protect methods of treating
additional inflammatory diseases (U.S. patent 10,981,874 and U.S. patent 11,649,210). These patents
have an expiry date of 2035, not including patent term adjustment or any potential PTE.
•U.S. patent 10,464,903 and U.S. patent 10,745,357, which are directed to a synthesis process for
manufacturing obefazimod and derivatives thereof, a polymorphic form of the free base of obefazimod
and crystalline forms of various salts of obefazimod. These patents have an expiry date of 2037, not
including patent term adjustment or any potential PTE. A corresponding European patent has also been
granted. These patents are solely owned by us.
•Further indications are also protected by other patents: U.S. patent 9,827,237, which is directed to the
method of treating Human Leukemia virus infection. This patent is also granted in Europe and several
other countries and has an expiry date of 2034. U.S. patent 9,145,367, which is directed to the method
of treating AIDS by obefazimod generically and specifically. This patent is also granted in Europe and
several other countries and has an expiry date of 2030. U.S. patent 9,108,919, which is directed to the
method of treating cancer by obefazimod generically and specifically. This patent is also granted in
Europe and several other countries and has an expiry date of 2030. Another patent application directed
to a method of treating cancer has been filed worldwide in 2019. U.S. patent 10,806,729 which is
99
directed to the method of treating HIV resistant patients by obefazimod generically and specifically.
This patent is also granted in Europe and other countries and has an expiry date of 2036.
•U.S. patent applications 17/416,856 and 17/416,679, which are respectively directed to the method of
treating other inflammatory diseases and cancer by obefazimod generically and specifically or its N-
glucuronide metabolite have been filed in 2019, as well as counterpart applications in other countries.
•U.S. patent application 17/913,063, which is directed to the method of treating Coronaviridae infection
by obefazimod generically and specifically or its N-glucuronide metabolite has been filed in 2021, as
well as counterpart applications in other countries.
•U.S. patent application 17/796,834, which is directed to the amorphous solid dispersion (ASD) of
obefazimod, its method of preparation, pharmaceutical composition and method of treating
inflammatory disease, cancer and viral diseases therewith has been filed in 2021, as well as counterpart
applications in other countries.
•U.S. patent application 17/793,133, which is directed to co-crystals and salts of obefazimod,
pharmaceutical composition and method of treating inflammatory disease, cancer and viral diseases
therewith has been filed in 2021, as well as counterpart applications in other countries.
•U.S. patent application18/284,253, which is directed to a synthesis process for manufacturing
obefazimod and derivatives thereof and was filed in 2022.
•Two PCT international patent applications filed in 2023 were published underWO23/135207 directed
to combinations products with obefazimod respectively with etrasimod and Rinvoq.
Trademarks and Domain Names
We own a number of registered and pending trademarks and registered domain names. The URL for our
website, as well as a number of domain names including the wording “abivax” or “obefazimod.” “Abivax” is a
registered trademark of our company in Australia, Brazil, Canada, Cuba, the EU, France, India, South Africa, the
United Kingdom and the United States. The “Abivax” trademark is pending in Canada, China, India, Japan, Mexico,
South Africa, South Korea and the United States.
C.Organizational Structure
Abivax SA is the parent company of Abivax, LLC, a wholly-owned subsidiary organized in Delaware, United
States.
D.Property, Plants and Equipment.
100
Our corporate headquarters is located in Paris, France, where we occupy approximately 765 m² of office space
that we sublease. We lease an additional 279 m² of office space in Boston, Massachusetts. We believe our existing
facilities meet our current needs.
Item 4A. Unresolved Staff Comments.
Not applicable.
101
Item 5.Operating and Financial Review and Prospects
You should read the following discussion of our financial condition and results of operations in conjunction
with our financial statements and the related notes thereto included elsewhere in this Annual Report on Form 20-F.
In addition to historical information, the following discussion and analysis contains forward-looking statements that
reflect our plans, estimates and beliefs. Our actual results and the timing of events could differ materially from those
anticipated in the forward-looking statements. Factors that could cause or contribute to these differences include
those discussed below and elsewhere in this annual report, particularly in the sections titled “Item 3.D—Risk
Factors” and “Special Note Regarding Forward-Looking Statements.”
Overview
We are a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s
natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. We
are currently evaluating our lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults
with moderately to severely active ulcerative colitis (“UC”). We are also in the planning stages of initiating a Phase
2b clinical trial of obefazimod in patients with Crohn’s disease (“CD”), as well as evaluating other potential
inflammatory indications.
We focus on indications where existing treatments have left patients with significant unmet needs, and where
we believe our investigational agents have the potential to be meaningfully differentiated from currently available
therapies. The indications we target have substantial populations and represent large commercial opportunities,
pending regulatory approvals and successful commercialization. Our initial focus is on inflammatory bowel diseases
(“IBD”), chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common
forms are UC and CD.
We believe our lead drug candidate, obefazimod, is differentiated from competing approaches for the
treatment of IBD via its novel mechanism of action. Obefazimod was demonstrated to specifically enhance the
expression of a single micro-RNA, miR-124, which plays a critical role in the regulation of the inflammatory
response. In the context of inflammation, miR-124 is a natural regulator of the inflammatory response, controlling
progression of inflammation and restoring homeostasis of the immune system, without causing broader
immunosuppression. In contrast to currently available advanced therapies, prescribed post-conventional therapies,
some of which target only a single cytokine or pathway, miR-124 modulates the expression of several key cytokines
and pathways. Modulating multiple inflammatory pathways simultaneously may lead to more durability of efficacy
results over the long-term, which is critical in lifelong conditions such as IBD, potentially differentiating
obefazimod from currently available IBD treatments.
We were incorporated as a société anonyme on December 4, 2013 and, in 2014, we acquired Splicos,
Wittycell and Zophis by means of a universal transfer of assets and liabilities (Transmission Universelle du
Patrimoine (“TUP”)). We have been listed on Euronext Paris since June 26, 2015, and on the Nasdaq Global Market
since October 24, 2023.
On March 20, 2023, our United States-based subsidiary Abivax LLC (the “Subsidiary”) was formed as a
limited liability company under the laws of the State of Delaware. The Subsidiary hosts our operations in the United
States. We have prepared audited consolidated financial statements as of and for the year ended December 31, 2023.
As of December 31, 2023, the Subsidiary’s contribution to our consolidated results of operations was a net operating
loss of €5.3 million.
Since our inception in 2013, we have devoted substantially all of our efforts to organizing and staffing our
company, business planning, raising capital, establishing our intellectual property portfolio, acquiring or discovering
drug candidates, research and development activities for obefazimod and other compounds, establishing
arrangements with third parties for the manufacture of our drug candidates and component materials, and providing
general and administrative support for these operations. We do not have any products approved for sale and have not
generated any revenue from product sales or otherwise. We do not expect to generate significant revenue from
product sales or royalties unless and until our drug candidates are approved for marketing and successfully
commercialized.
We have incurred significant operating losses since inception, and we expect to continue to incur significant
expenses and operating losses for the foreseeable future. Our ability to generate product revenue sufficient to
achieve profitability will depend heavily on the successful development and eventual commercialization of
102
obefazimod and any future drug candidates. For the years ended December 31, 2023, 2022 and 2021, we reported
net losses of €147.7 million, €60.7 million and €42.5 million, respectively. As of December 31, 2023, we carried
forward accumulated tax losses of €459.8 million. We expect to continue to incur net operating losses for at least the
next several years, and we do not anticipate achieving profitability in the future unless we obtain regulatory
approvals necessary to commercialize obefazimod and any additional drug candidates that we may pursue in the
future. We expect that our research and development expenses, general and administrative expenses, and capital
expenditures will increase substantially in connection with our ongoing activities, particularly if and as we:
•continue to advance our existing drug candidates through clinical development;
•timely and successfully complete clinical development of obefazimod, our clinical-stage drug
candidate;
•seek and maintain regulatory and marketing approvals for obefazimod and any future drug candidates
for which we successfully complete clinical trials;
•continue the preclinical and clinical development of our drug candidates;
•expand the scope of our current clinical trials for our drug candidates;
•begin new clinical trials for our drug candidates;
•develop, scale and validate our commercial manufacturing capabilities for our drug candidates;
•establish a sales, marketing and distribution infrastructure to commercialize any drugs for which we
may obtain regulatory and marketing approval for which we have not entered into a collaboration with
a third-party;
•seek to discover, identify and validate additional drug candidates;
•acquire or in-license other drug candidates and technologies;
•make milestone, royalty or other payments under in-license or collaboration agreements;
•obtain, maintain, protect, enforce and expand our intellectual property portfolio;
•manufacture, or have manufactured, non-clinical, clinical and potentially commercial supplies of
obefazimod and any future drug candidates;
•attract new and retain existing clinical, scientific, operational, financial and management personnel;
and
•incur additional legal, accounting, and other costs associated with operating as a dual-listed French and
U.S. public company.
Our net losses may fluctuate significantly from period to period, depending on the timing of expenditures
related to our research and development activities.
We will not generate revenue from product sales unless and until we successfully complete clinical
development and obtain regulatory approval for a drug candidate. In particular, following the issuance of royalty
certificates in September 2022 and other royalties that may become payable under our royalty agreements, the
payment of royalties in the event of commercialization of obefazimod would result in a decrease in cash flows
generated by sales of the product, which could have an unfavorable impact on our financial position, particularly at
the beginning of the commercialization phase. In addition, if we obtain regulatory approval for a drug candidate and
do not enter into a third-party commercialization partnership, we expect to incur significant expenses related to
developing our commercialization capability to support product sales, marketing, manufacturing and distribution
activities.
As a result, we will need substantial additional funding to support our continuing operations and pursue our
growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to
finance our operations through equity offerings, debt financings or other capital sources, which could include
collaborations, strategic alliances or additional licensing arrangements. We may be unable to raise additional funds
or enter into such arrangements when needed, on favorable terms, or at all. Our failure to raise capital or enter into
such agreements as, and when, needed, could have a material adverse effect on our business, results of operations
and financial condition, including requiring us to have to delay, reduce or eliminate product development or future
commercialization efforts. The amount and timing of our future funding requirements will depend on many factors,
including the successful advancement of obefazimod or any future drug candidates. Our ability to raise additional
funds may also be adversely impacted by potential worsening global economic conditions and disruptions to and
volatility in the credit and financial markets in the United States and worldwide, such as those resulting from the
ongoing war in Ukraine.
103
Due to the numerous risks and uncertainties associated with development of treatment of chronic
inflammatory diseases, we are unable to predict the timing or amount of increased expenses or when or if we will be
able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become
profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be
unable to continue our operations at planned levels and be forced to reduce or terminate our operations.
Principal Factors Affecting Our Results of Operations
The following factors have affected, and we expect will continue to affect, our results of operations.
Research and Development Activities
Research and development activities are central to our business. Since our inception, most of our resources
have been allocated to research and development and it accounts for the majority of our operating expenses. For the
year ended December 31, 2023, research and development expenses accounted for 78% of our total operating
expenses, as compared to 87% (excluding goodwill impairment loss) and 90% for the years ended December 31,
2022 and 2021 respectively. Drug candidates in later stages of clinical development generally have higher
development costs than those in earlier stages of clinical development, primarily due to the increased size and
duration of later-stage clinical trials. Accordingly, we expect that our research and development expenses will
increase in the foreseeable future as we seek to advance the development of our drug candidates. The successful
development of our drug candidates remains highly uncertain.
At this time, we cannot accurately determine or estimate the nature, timing and costs of the research and
development activities that will be necessary to complete the remainder of the development of obefazimod, and we
may never succeed in obtaining regulatory approval for obefazimod or any future drug candidates we may develop.
The duration, costs and timing of clinical trials and the development of our drug candidates will depend on
numerous risks and uncertainties associated with clinical development, including risks and uncertainties related to:
•the scope, progress, outcome and expenses of our clinical trials and other research and development
activities;
•the length of time required to enroll suitable patients and successful patient enrollment in, and the
initiation and completion of, clinical trials;
•the results of our clinical trials;
•the timing, receipt and terms of any marketing approvals from applicable regulatory authorities;
•the establishment of commercial manufacturing capabilities or making arrangements with third-party
manufacturers;
•the expense of filing, prosecuting, maintaining, defending and enforcing patent claims and other
intellectual property rights;
•changing government regulation;
•launching commercial sales of our drug candidates, if and when approved, whether alone or in
collaboration with others;
•maintaining a continued acceptable safety profile of the drug candidates following regulatory approval;
•the ability to market, commercialize and achieve market acceptance for obefazimod or any other drug
candidate that we may develop in the future; and
•significant competition and rapidly changing technologies within the biopharmaceutical industry.
A change in the outcome of any of these variables with respect to the development of any of our drug
candidates could significantly change the costs and timing associated with the development of that drug candidate.
The actual probability of success for our drug candidates will be affected by a variety of factors, including the safety
and efficacy of our drug candidates, investment in our clinical programs, manufacturing capability and competition
with other products and drug candidates. As a result of these variables, we are unable to determine the duration and
completion costs of our research and development projects or when and to what extent we may generate revenue
from the commercialization and sale of our drug candidates.
104
Regulatory Approval and Market Acceptance of our Drug Candidates
We may never succeed in achieving regulatory approval for any of our drug candidates. We may obtain
unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some drug
candidates or focus on others. A change in the outcome of any of these factors with respect to the development of
drug candidates that we are developing could result in a significant change in the costs and timing associated with
the development of such drug candidates. For example, if the EMA or the FDA or other regulatory authority were to
require us to conduct non-clinical studies and clinical trials beyond those that we currently anticipate will be
required for the completion of clinical development, or if we experience significant delays in enrollment in any
clinical trials, we could be required to spend significant additional financial resources and time on the completion of
clinical development.
Equity and Debt Financing
At this stage, we have not generated any revenue from sales of products or otherwise, and we do not expect to
do so unless and until we successfully complete development of, obtain marketing approval for, and successfully
commercialize, one or more of our drug candidates. Until such time that we can generate substantial revenue from
sales of products, if ever, we expect to finance our operating activities through a combination of equity offerings,
debt financings and government or other third-party funding. However, we may be unable to raise additional funds
or enter into such arrangements when needed on favorable terms, or at all, which would have a negative impact on
our financial condition and could force us to delay, limit, reduce or terminate our development programs or
commercialization efforts or grant to others the rights to develop or market drug candidates that we would otherwise
prefer to develop and market ourselves. Failure to receive additional funding could cause us to cease operations, in
part or in full.
Acquisition of Prosynergia
On April 1, 2022, we acquired 100% of the share capital of Prosynergia with the aim of strengthening our
research and development portfolio, for an amount of €3.25 million. On December 12, 2022, we completed the
merger with Prosynergia through a TUP and all of Prosynergia’s assets and liabilities were transferred to us.
Following the merger, Prosynergia was dissolved. Accordingly, as Prosynergia was dissolved in December 2022, we
did not prepare consolidated financial statements as of December 31, 2022.
Impact of the Ukraine/Russia Hostilities on our Business
In February 2022, Russia invaded Ukraine. The conflict has already had major implications for the global
economy and the rate of inflation, particularly in relation to the supply of energy, raw materials and food products.
The global scale of this conflict cannot be predicted at this stage. We, therefore, cannot rule out an adverse impact of
this conflict on our business, including in terms of access to raw materials, logistics, the performance of clinical
trials and in relation to any future financing we may seek.
The long-term safety and efficacy extension of the Phase 2b maintenance trial of obefazimod in moderately to
severely active UC is our only clinical trial with patients currently enrolled in Ukraine. The Phase 2b 12-month
assessment was carried out in all the Ukrainian patients before the war broke out and these patients are therefore
included in the one-year maintenance results that were reported on April 6, 2022. Ukrainian patients who completed
the two-year Phase 2b maintenance trial have been transitioned to the long-term safety and efficacy trial that is still
on-going. None of these sites are located in the Crimea Region of Ukraine, the so-called Donetsk People’s Republic,
or the so-called Luhansk People’s Republic. We are also evaluating the possibility to include a few Ukrainian sites
in the western part of Ukraine in the ABTECT Phase 3 clinical trials.
Together with our CRO, we are making considerable efforts to ensure the follow-up of patients who are
unable to come to the study centers. Monitoring takes place through a remote monitoring system that was
established and used successfully during the COVID-19 pandemic.
105
A.Operating Results
Comparison of Years Ended December 31, 2021, 2022 and 2023
The following table sets forth our results of operations for the years ended December 31, 2021, 2022 and 2023.
(In thousands of euros) | Year ended December 31, 2021 | Year ended December 31, 2022 | Year ended December 31, 2023 | % 2022 Change | % 2023 Change |
Other operating income ............................ | €11,961 | €4,583 | €4,621 | (62)% | 1% |
Total operating income .................................... | 11,961 | 4,583 | 4,621 | (62)% | 1% |
Sales and marketing expenses ................... | — | — | (6,431) | — | — |
Research and development expenses ........ | (47,781) | (48,295) | (103,176) | 1% | 114% |
General and administrative expenses ....... | (5,580) | (7,492) | (22,390) | 34% | 199% |
Goodwill impairment loss ......................... | — | (13,632) | — | —% | (100)% |
Total operating expenses .................................. | (53,361) | (69,419) | (131,997) | 30% | 90% |
Operating income (loss) ................................... | (41,400) | (64,836) | (127,376) | 57% | 96% |
Financial expenses .................................... | (3,561) | (7,022) | (27,875) | 97% | 297% |
Financial income ...................................... | 2,509 | 11,118 | 7,511 | 343% | (32)% |
Financial income (loss) ..................................... | (1,052) | 4,096 | (20,364) | (489)% | (597)% |
Net loss before tax ............................................. | (42,452) | (60,740) | (147,740) | 43% | 143% |
Income Tax ................................................ | — | — | — | — | — |
Net loss for the period ...................................... | €(42,452) | €(60,740) | €(147,740) | 43% | 143% |
Total Operating Income
For the year ended December 31, 2023, our total operating income was €4.6 million, as compared to €4.6
million for the year ended December 31, 2022, a decrease of €0.0 million, or 1%, as detailed below.
For the year ended December 31, 2022, our total operating income was €4.6 million, as compared to €12.0
million for the year ended December 31, 2021, a decrease of €7.4 million, or 62%, as detailed below.
Other Operating Income
The following table sets forth our other operating income for the years ended December 31, 2023, 2022 and
2021.
(In thousands of euros) | Year ended December 31, 2021 | Year ended December 31, 2022 | Year ended December 31, 2023 | % 2022 Change | % 2023 Change |
CIR (Research Tax Credits) ........................................... | €4,204 | €4,476 | €4,493 | 6 | — |
Subsidies ........................................................................ | 7,722 | 29 | 81 | (100)% | 179% |
Other .............................................................................. | 36 | 78 | 47 | 117% | (40)% |
Total other operating income ...................................... | €11,962 | €4,583 | €4,621 | (62)% | 1% |
106
For the year ended December 31, 2023, our other operating income was €4.6 million, as compared to €4.6
million for the year ended December 31, 2022, a decrease of €0.0 million, or 1%. There was no significant variation
during the period, as detailed below.
For the year ended December 31, 2022, our other operating income was €4.6 million, as compared to €12.0
million for the year ended December 31, 2021, a decrease of €7.4 million, or 62%. This decrease was primarily due
to a 100% decrease in subsidies.
Research Tax Credits
For the year ended December 31, 2023, we recognized research tax credits for our research and development
projects of €4.5 million, as compared to €4.5 million for the year ended December 31, 2022, an increase of
€0.0 million, or —%. Although research and development expenses increased by 114% between 2022 and 2023,
there was no significant variation during the period due to the maximum amount of eligible outsourced research and
development expenses being capped and internal research and development costs being stable.
For the year ended December 31, 2022, we recognized research tax credits for our research and
development projects of €4.5 million, as compared to €4.2 million for the year ended December 31, 2021, an
increase of €0.3 million, or 6%. This increase was primarily due to a slight increase in research and development
expenses.
Subsidies
For the year ended December 31, 2023, our subsidy income was €80,909 as compared to €29,000 for the year
ended December 31, 2022. There was no significant variation for 2023.
For the year ended December 31, 2022, our subsidy income was €29,000, as compared to €7.7 million for
the year ended December 31, 2021. This decrease was primarily due to there being no new subsidy entitlement in
2022.
For the year ended December 31, 2021, we recorded a €7.7 million subsidies income, mainly composed by
subsidies received from Bpifrance for the obefazimod COVID-19 Program. This subsidy was initially recorded as a
conditional advance in 2020 and as subsidy in 2021, following the waiver received from Bpifrance in April 2021
after the termination of trial in March 2021. As a result, we terminated our related financing agreement with
Bpifrance in March 2021, recording in 2021 an income of €4.5 million, corresponding to the carrying amount of the
advance at this date, as a result of Bpifrance’s agreement to waive the conditions of the advance. In addition, for the
year ended December 31, 2021, we recorded income of €3.3 million reflecting additional payments received from
Bpifrance to reimburse additional expenses incurred until the termination date.
Total Operating Expenses
For the year ended December 31, 2023, our total operating expenses were €132.0 million, as compared to
€69.4 million for the year ended December 31, 2022, an increase of €62.6 million, or 90%. This increase was
primarily due to an increase in research and development expenses of €54.9 million and an increase in general and
administrative expenses by €14.9 million, partially offset by the absence of goodwill impairment loss as of
December 31, 2023 (compared to €13.6 million as of December 31, 2022).
For the year ended December 31, 2022, our total operating expenses were €69.4 million, as compared to
€53.4 million for the year ended December 31, 2021, an increase of €16.1 million, or 30%. This increase was
primarily due to an increase in goodwill impairment loss and in general and administrative expenses.
Sales and Marketing Expenses
For the year ended December 31, 2023, our total sales and marketing expenses were €6.4 million. We did not
incur any sales and marketing expenses in 2022. These expenses consist primarily of consulting costs associated
with market research, re-branding of our company in preparation of our U.S. initial public offering and listing on
107
Nasdaq, as well as an early team build out in preparation for our future sales and commercialization efforts in the
U.S.
Research and Development Expenses
The following table sets forth our research and development expenses by drug candidate and therapeutic
indication for the years ended December 31, 2023, 2022 and 2021.
(In thousands of euros) | Year ended December 31, 2021 | Year ended December 31, 2022 | Year ended December 31, 2023 | % 2022 Change | % 2023 Change |
Obefazimod ..................................................... | €43,979 | €45,024 | €97,869 | 2% | 117% |
Ulcerative Colitis .................................... | 20,684 | 38,555 | 83,788 | 86% | 117% |
Crohn’s Disease ...................................... | 136 | 1 | 2,735 | — | — |
Rheumatoid Arthritis ............................... | 2,422 | 848 | 368 | (65)% | (57)% |
Covid-19 ................................................. | 1,171 | (768) | 11 | (166)% | (101)% |
Obefazimod Other Indication .................. | 433 | 68 | 169 | (84)% | 148% |
Transversal activities .............................. | 19,132 | 6,321 | 10,798 | (67)% | 71% |
ABX196 ............................................................ | 1,198 | 693 | 50 | (42)% | (93)% |
ABX711 ............................................................ | — | 287 | 604 | —% | 111% |
Others .............................................................. | 2,604 | 2,291 | 4,653 | (12)% | 103% |
Research and development expenses ............ | €47,781 | €48,295 | €103,176 | 1% | 114% |
For the year ended December 31, 2023, our research and development expenses were €103.2 million, as
compared to €48.3 million for the year ended December 31, 2022, an increase of €54.9 million, or 114%. This
increase was primarily due to a €45.2 million, or 117%, increase in expenses related to our UC clinical program,
driven by the progression of Phase 3 clinical trials for obefazimod in UC (where Phase 3 clinical trial costs were
significantly higher than in Phase 2), a €2.7 million increase in expenses related to our CD clinical program, driven
by planning costs incurred for the Phase 2b CD trial, and a €4.5 million, or 71%, increase in transversal activities
related to the overall expansion of the research and development headcount to support our organizational growth and
the issuance of new equity awards to officers and employees in research and development.
For the year ended December 31, 2022, our research and development expenses were €48.3 million, as
compared to €47.8 million for the year ended December 31, 2021, an increase of €0.5 million, or 1%. This increase
was primarily due to the €17.9 million, or 86%, increase in obefazimod for UC expenses, as we completed our Phase
2b clinical trial in early 2022 and initiated our Phase 3 clinical trial in the first half of 2022, with the first patient in
the United States enrolled in October 2022, as well as an increase of €0.3 million related to commencing
development of our novel drug candidate ABX711. This increase was offset by a decrease of €12.8 million in
transversal activities following the completion of our existing studies and no new studies on these projects began in
2022, a decrease of €1.9 million in COVID-19 research expenses and a decrease of €1.6 million in expenses related
to our rheumatoid arthritis clinical trial.
General and Administrative Expenses
108
(In thousands of euros) | Year ended December 31, 2021 | Year ended December 31, 2022 | Year ended December 31, 2023 | % 2022 Change | % 2023 Change |
Personnel costs .................................................. | 2,320 | 1,403 | 13,104 | (40)% | 834% |
Consulting and professional fees ....................... | 2,026 | 2,624 | 6,393 | 30% | 144% |
Other general and administrative expenses ....... | 1,233 | 3,466 | 2,893 | 181% | (17)% |
General and administrative expenses ............ | 5,580 | 7,492 | 22,390 | 34% | 199% |
For the year ended December 31, 2023, our general and administrative expenses were €22.4 million, as
compared to €7.5 million for the year ended December 31, 2022, an increase of €14.9 million, or 199%. This
increase was primarily due to an increase in personnel costs of €11.7 million, or 834%, resulting from the issuance
of new equity awards to our officers and employees, management changes that occurred during the period and an
increased G&A headcount to support the expansion of the company, as well as increased legal and professional fees
and other costs associated with operating as a dual-listed public company.
For the year ended December 31, 2022, our general and administrative expenses were €7.5 million, as
compared to €5.6 million for the year ended December 31, 2021, an increase of €1.9 million, or 34%. This increase
was primarily due to an increase in other general and administrative expenses, as well as increases in consulting, and
professional fees. The €2.2 million, or 181%, increase in other general and administrative expenses in 2022 was
primarily due to increased expenses related to financial and legal consulting fees. These increases were partially
offset by a decrease in personnel costs, mainly due to a reversal of share-based compensation expenses.
Goodwill Impairment Loss
For the year ended December 31, 2023, we did not record any goodwill impairment loss, as compared to
€13.6 million for the year ended December 31, 2022.
For the year ended December 31, 2022, we recorded a goodwill impairment loss of €13.6 million, as
compared to no goodwill impairment loss for the year ended December 31, 2021. The goodwill impairment loss was
primarily related to an impairment test conducted with respect to the ABX196 cash-generating unit as a result of
significant external changes in the hepatocellular carcinoma treatment landscape, which are expected to require a
new, lengthy, heavy and risky internal development process (use of a combination of compounds). As such, while
we considered the option of entering into a licensing partnership to fund the completion of the clinical development
of ABX196, we made the decision to freeze the development program for ABX196 in the treatment of
hepatocellular cancer, which led to full impairment of ABX196 goodwill.
Operating Income (Loss)
For the year ended December 31, 2023, our net operating loss was €127.4 million, as compared to a net
operating loss of €64.8 million for the year ended December 31, 2022, an increase of €62.5 million, or 96%. This
increase was primarily due to an increase of €54.9 million in research and development expenses, an increase of
€14.9 million in general and administrative expenses and the recognition of €6.4 million of sales and marketing
expenses. These increases were partially offset by the absence of goodwill impairment, as compared to the €13.6
million loss recorded in 2022.
For the year ended December 31, 2022, our net operating loss was €64.8 million, as compared to a net
operating loss of €41.4 million for the year ended December 31, 2021, an increase of €23.4 million, or 57%. This
increase was primarily due to an increase in goodwill impairment charges, a decrease in other operating income, as
well as an increase in general and administrative expenses.
109
Financial Income (Loss)
For the year ended December 31, 2023, our net financial loss was €20.4 million, as compared to a net
financial income of €4.1 million and a financial loss of €1.1 million for the years ended December 31, 2022 and
2021.
For the year ended December 31, 2023, our net financial loss was mainly driven by interest expenses of €3.9
million in relation to the Kreos / Claret OCABSA and the Heights Convertible Notes and €8.9 million in relation to
our royalty certificates, a €3.0 million increase in the fair value of derivatives, transaction costs amounting to €1.9
million, a net €3.2 million loss on de-recognition of the OCEANE bonds and the recognition of the Heights
convertible notes, and foreign exchange losses of €5.6 million (including the €3.2 million non-cash impact of the
year-end revaluation of U.S. dollar-denominated cash and cash equivalents). These costs were partially offset by an
interest income of €2.4 million in relation to the invested proceeds from our U.S. initial public and listing on
Nasdaq, a decrease in the fair value of the Heights Convertible Notes by €3.2 million and a decrease in derivatives
fair value by €1.0 million.
For the year ended December 31, 2022, our net financial income was mainly a result of a €4.1 million
decrease in the fair value of derivatives (mainly due to the decrease in our share price over the period) and a
€1.4 million decrease in other liabilities at fair value through profit or loss (mainly in Prosynergia earn-out liability),
which was partially offset by an increase in interest expenses of €3.7 million in relation to the Kreos bonds and
€2.6 million in relation to our OCEANE bonds.
For the year ended December 31, 2021, our net financial loss was mainly a result of interest expenses of
€2.3 million in relation to the Kreos bonds and €1.1 million in relation to our OCEANE bonds, partially offset by a
€2.4 million decrease in the fair value of derivatives. The decrease in the fair value of derivatives is mainly due to
the decrease in our share price over the period. See “—Liquidity and Capital Resources.”
Income Taxes
For each of the years ended December 31, 2023, 2022 and 2021, our income tax charge was zero.
Net Loss
For the year ended December 31, 2023, our net loss for the period was €147.7 million, as compared to
€60.7 million for the year ended December 31, 2022, an increase of €87.0 million, or 143%.
For the year ended December 31, 2022, our net loss for the period was €60.7 million, as compared to
€42.5 million for the year ended December 31, 2021, an increase of €18.3 million, or 43%.
B.Liquidity and Capital Resources
Sources of Liquidity
We have incurred substantial operating losses since inception and expect to continue to incur significant
operating losses for the foreseeable future and may never become profitable. For the years ended December 31,
2023 2022, and 2021, we reported net losses of €147.7 million, €60.7 million and €42.5 million, respectively. As of
December 31, 2023, we carried forward accumulated tax losses of €459.8 million.
Since inception, we have financed our operations through the issuance of ordinary shares with gross aggregate
proceeds of €557.2 million, of which €130.0 million of gross proceeds were from offerings of our ordinary shares on
Euronext Paris in February 2023, €223.3 million of gross proceeds were from offering of our ordinary shares in the
form of ADS on the Nasdaq Global Market as well as ordinary shares in Europe (including France) and countries
outside of the United States in a private placement in October 2023, bank borrowings and structured loans for
€125.0 million, reimbursements of CIR in an amount of €31.1 million, subsidies received from Bpifrance (including
€13.5 million of subsidies and €6.6 million of conditional advances) and royalty certificates in an amount of
€2.9 million. Based on (a) our existing cash and cash equivalents of €251.9 million and other short-term investments
of €9.0 million as of December 31, 2023, (b) drawdown of the second tranche of the Kreos / Claret Financing,
110
amounting to €25.0 million in gross proceeds received on March 28, 2024, and (c) the expected reimbursement of
the CIR from 2023 in the second half of 2024 amounting to €4.5 million, we expect to be able to fund our forecasted
cash flow requirements into the fourth quarter of 2025. This takes into account our assumption that R&D
expenditure will be substantially increased in 2024 driven by the progression of the Phase 3 clinical trials of
obefazimod in UC and the initiation of the Phase 2b trial for CD in 2024. Under these assumptions and based on our
current clinical plan, we would have sufficient funds to finance our operations through the announcement of our top-
line data from the Phase 3 ABTECT-1 and ABTECT-2 induction trials for UC.
We expect we will be able to extend our financing horizon beyond the fourth quarter of 2025 through the
available drawdowns of the third tranche of the Kreos / Claret Financing and the second tranche of the Heights
Financing, which collectively could amount up to €65.0 million in gross proceeds and additional dilutive and non-
dilutive financing, which could include a combination of capital increase, venture loans and convertible bonds.
Based on the above and the actions we have taken, management has concluded that the substantial doubt about
our ability to continue as a going concern has been alleviated beyond 12 months from issuance of the accompanying
financial statements, and the accompanying financial statements have been prepared on a going concern basis.
Capital Increases
Our operations have been financed primarily by capital increases from our founders and investors, net
proceeds from the initial public offering of our ordinary shares on Euronext Paris in France in 2015, and additional
follow-on capital increases, including the initial public offering of our ordinary shares in the form of ADS on the
Nasdaq Global Market in 2023. We have not yet commercialized any of our drug candidates, which are in various
phases of clinical development, and we do not expect to generate revenue from sales of any products for several
years, if at all. Until such time as we can generate significant revenue from product sales, if ever, we expect to
finance our operations through the sale of equity, debt financings or other capital sources, including potential
collaborations with other companies or other strategic transactions.
The following table sets forth our main capital increases carried out during the years ended December 31,
2021, 2022 and 2023:
(In thousands of euros) | Gross proceeds amount |
Capital increase from issuance of ordinary shares - July 30, 2021 . . . . . . . . . . . . . . . . . . . . . | €60,001 |
Capital increase from issuance of ordinary shares - September 2, 2022 . . . . . . . . . . . . . . . . . | €46,231 |
Capital increase from issuance of ordinary shares - February 23, 2023 . . . . . . . . . . . . . . . . .. | €130,000 |
Initial Public Offering (Nasdaq) - October 24, 2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. | €223,300 |
On July 27, 2021, we received gross proceeds of €60.0 million from the issuance of 1,964,031 ordinary shares
at a subscription price of €30.55 per share. The proceeds were primarily used to finance the progress of obefazimod
clinical trials in chronic inflammatory diseases, for general corporate purposes, payments with respect to, and
redemption of, certain existing indebtedness, and advancement of ABX196 for the treatment of hepatocellular
carcinoma.
On September 7, 2022, we received gross proceeds of €46.2 million from the issuance of 5,530,000 ordinary
shares at a subscription price of €8.36 per share, and the issuance of royalty certificates of €2.9 million, for a total
financing of €49.2 million. See “Item 10.C. Material Contracts—Financing Arrangements—Royalty Certificates.”
On March 1, 2023, we received gross proceeds of €130.0 million from the issuance of 20,000,000 ordinary
shares at a subscription price of €6.50 per share. The proceeds were primarily used to finance the progress of
obefazimod clinical trials in chronic inflammatory diseases and for general corporate purposes (research and
development expenses and loans maturities payments).
On October 24, 2023, we received gross proceeds of €223.3 million from the issuance of 20,325,500 ordinary
shares (including ordinary shares in the form of ADSs) at a price of €10.99 per share in connection with our U.S.
initial public offering. The proceeds were primarily used to finance the progress of obefazimod clinical trials in
chronic inflammatory diseases and for general corporate purposes (research and development expenses and loans
maturities payments).
111
Equity Line
We entered into an equity line agreement with Kepler Cheuvreux in September 2017. In accordance with the
terms of this agreement, Kepler Cheuvreux, acting as financial intermediary and guarantor, committed to subscribe
for 970,000 ordinary shares, at its option in line with a schedule lasting no longer than 24 months, at an issuance
price based on an average market price weighted according to the volumes traded over the two trading days
preceding each issue, less a maximum discount of 7.0%.
We renewed this financing line and entered into an agreement on September 30, 2019, with Kepler
Cheuvreux, who committed to subscribe for 730,000 ordinary shares (corresponding to the number of shares
unsubscribed as of September 30, 2019, and granted under the previous agreement) under the same terms and
conditions for a period of 24 months.
On September 24, 2021, we extended the agreement for an additional 12-month period with respect to the
unsubscribed shares at that date. This agreement was terminated on September 30, 2022.
Research Tax Credits
From our inception to December 31, 2023, we have benefited from refunds of CIRs in a total amount of
€31.1 million. In August 2021, we received CIRs of €2.6 million with respect to the year ended December 31, 2020.
In October 2022, we received CIRs of €4.2 million with respect to the year ended December 31, 2021. In November
2023, we received CIRs of €4.5 million with respect to the year ended December 31, 2022.
Bpifrance—Conditional Advances and Subsidies
We have received several conditional advances and subsidies from Bpifrance since our inception. Funds
received from Bpifrance in the form of conditional advances are recognized as financial liabilities, as we have a
contractual obligation to reimburse Bpifrance for such conditional advances in cash based on a repayment schedule.
Each award of an advance is made to help fund a specific development milestone. Subsidies are non-repayable
grants, which are recognized in the financial statements when there exists reasonable assurance that we will comply
with the conditions attached to the subsidies and the subsidies will be received.
The following table sets forth the monies granted by and received from Bpifrance as of December 31, 2023.
As of December 31, 2023 | |||
(In thousands of euros) | Contract status | Amount awarded | Amount collected |
Conditional advances ................................................ | €26,387 | €6,609 | |
Carena ............................................................... | Ongoing | €3,830 | €2,187 |
RNP-VIR ........................................................... | Ongoing | €6,298 | €4,032 |
Ebola .................................................................. | Stopped | €390 | €390 |
COVID-19 (1) .................................................... | Stopped | €15,869 | — |
Subsidies ..................................................................... | €7,475 | €13,524 | |
Carena ............................................................... | Ongoing | €1,397 | €1,187 |
RNP-VIR ........................................................... | Ongoing | €2,112 | €1,123 |
Ebola .................................................................. | Stopped | — | — |
COVID-19 (1) .................................................... | Stopped | €3,967 | €11,214 |
Total ............................................................................ | €33,862 | €20,133 | |
(1)Following the termination of the study in March 2021, the conditional advance of €6.3 million paid in 2020
was reclassified as a subsidy, following the waiver received from Bpifrance to repay the conditional advance.
See “—Bpifrance – COVID-19.”
112
Bpifrance—CARENA Contract
As part of the development of therapeutic and diagnostic solutions targeting alternative splicing and RNA
interference in the fields of virology (HIV-AIDS, HTLV-1) and metabolism (obesity), SPLICOS, which we acquired
in October 2014, entered into a Master Support Agreement and a conditional advance contract on December 2013
for the “CARENA” Strategic Industrial Innovation Project (“CARENA project”), with Bpifrance. Under this
contract, we are eligible to receive up to €3.8 million in conditional advances to develop a therapeutic HIV treatment
program with obefazimod. As of December 31, 2023, we had received €2.2 million of conditional advances, of
which €1.2 million was received in December 2013, €1.0 million in September 2014 and €29,000 in June 2016. The
repayment of these funds is spread from the date on which the repayments are called by Bpifrance.
Bpifrance—RNP-VIR Contract
As part of the CARENA project, focused on the clinical development of a drug molecule and demonstrating
the validity of an innovative therapeutic approach targeting viral RNPs, we entered into a Master Support
Agreement with Bpifrance, as well as a beneficiary agreement dated March 21, 2017, with conditional advances for
the “RNP-VIR” structuring research and development project for competitiveness. Under the RNP-VIR contract, we
are eligible to receive up to €6.3 million in conditional advances to develop methods for the discovery of new
molecules for the treatment of viral infectious diseases through the development of the “Modulation of RNA
biogenesis” platform. As of December 31, 2023, we had received €4.0 million of conditional advances, of which
€1.8 million was received in September 2017, €0.3 million in August 2018 and €1.9 million in November 2019. The
repayment of these funds is spread from the date on which the repayments are called by Bpifrance.
Bpifrance—Ebola
The Bpifrance and Occitanie Region joint support agreement was entered into on June 2, 2017 and provides
for conditional advances for a total amount of €0.4 million (€0.1 million from the Languedoc Roussillon Midi
Pyrénées Region and €0.3 million from Bpifrance) for the Ebola program. All funds under this contract were
received. In September 2019, we terminated this program due to the imminent licensing of a competing vaccine for
this indication, as well as changes in the macroeconomic climate for public funding. The reimbursement of the
conditional advance is spread over the period from September 2019 to June 2024.
Bpifrance—COVID-19
On June 22, 2020, we entered into agreements with Bpifrance setting out the conditions for aid to contribute to
the financing of the development of obefazimod as a potential therapeutic option for the treatment of COVID-19
patients at risk of developing a severe form of the disease.
This financing covered the conduct of a “miR-AGE” international clinical trial as well as all additional
clinical, preclinical, regulatory and industrial work to enable registration and accelerated access to obefazimod in the
COVID-19 indication. The “miR-AGE” clinical trial was conducted under our sole responsibility, in collaboration
with the University Hospital of Nice, which was tasked with the financial and administrative coordination of the
study, with the rest of the work being borne by us.
The maximum amount of aid available under the framework agreement was €36.0 million, of which
€19.8 million was allocated directly to us (reflecting €15.9 million in conditional advances and €4.0 million in
grants). Bpifrance’s participation was paid according to the achievement of certain phases and milestones during the
development program for the COVID-19 Program, broken down as follows:
•grants for a maximum total amount of €20.1 million, including €4.0 million for us (or a grant rate of
16% of planned expenditure) and €16.2 million for the University Hospital of Nice (or a grant rate of
100% of planned expenditure); and
•conditional advances for a maximum total amount of €15.9 million for us (or a rate of 64% of total
planned expenditure).
As of December 31, 2020, we had received a grant of €1.6 million and net proceeds from the conditional
advance of €6.3 million. In view of the results of the study and the recommendations of the Data and Safety
Monitoring Board, we terminated the study on March 5, 2021. As Bpifrance had recorded the project as
unsuccessful, we recognized an income of €4.5 million (discounted amount) as a result of Bpifrance’s agreement to
waive the conditions of the advance as of June 30, 2021.
As of December 31, 2021, we had also received an additional payment covering expenses incurred until the
termination date amounting to €3.3 million.
113
Indebtedness
For a description of material financing agreements, see "Item 10.C. Material Contracts."
Historical Changes in Cash Flows
The following table sets forth our cash inflows and outflows for the years ended December 31, 2023, 2022 and
2021.
(In thousands of euros) | Year ended December 31, 2021 | Year ended December 31, 2022 | Year ended December 31, 2023 | Change 2022 | Change 2023 |
Net cash flows (used in) operating activities ............ | (45,048) | (53,936) | (97,130) | 20% | 80% |
Net cash flows from (used in) investing activities ... | (6,232) | (12,026) | (8,095) | 93% | (33)% |
Net cash flows provided by (used in) financing activities ............................................................... | 82,679 | 32,211 | 335,290 | (61)% | 941% |
Effect of movements in exchange rates on cash held ...................................................................... | — | — | (5,072) | — | — |
Net increase (decrease) in cash and cash equivalents .......................................................... | 31,399 | (33,751) | 224,992 | (207)% | (767)% |
Cash and cash equivalents at the beginning of the period ............................................................ | 29,302 | 60,701 | 26,950 | 107% | (56)% |
Cash and cash equivalents at the end of the period .................................................................. | 60,701 | 26,950 | 251,942 | (56)% | 835% |
Operating Activities
For the year ended December 31, 2023, cash used in operating activities was €97.1 million, as compared to
€53.9 million for the year ended December 31, 2022, an increase of €43.2 million, or 80%.
For the year ended December 31, 2022, cash used in operating activities was €53.9 million, as compared to
€45.0 million for the year ended December 31, 2021, an increase of €8.9 million, or 20%.
For the year ended December 31, 2023, cash used in operating activities is attributable to increased R&D
spend driven by the progression of the UC Phase 3 clinical trial, increased headcount to support the expansion of the
overall organization, including a newly created sales and marketing department, increased legal and professional
fees and other infrastructure costs associated with operating as a dual-listed public company and changes in working
capital.
For the year ended December 31, 2022, cash used in operating activities mainly reflected our net loss of
60.7 million and was primarily used for our research and development efforts (€48.3 million) as a result of
progression of our portfolio development (partially offset by the elimination of the amortization of intangibles and
depreciation of property and equipment on the ABX196 cash generating unit), enhanced by an increase in
derivatives and liabilities fair value of €10.8 million, a decrease in trade payables of €2.4 million and offset by an
increase in interest expenses of €7.0 million.
For the year ended December 31, 2021, cash used in operating activities mainly reflected our net loss of
€41.4 million and was primarily used for our research and development efforts (€47.8 million) as a result of
progression of our portfolio development and net non-cash expense of €1.9 million.
Investing Activities
For the year ended December 31, 2023, cash used in investing activities was €8.1 million. and was mainly due
to a €9.0 million investment in a 6-month term deposit and the payment of additional long-term CRO advances
amounting to €1.6 million, partially offset by interests received amounting to €2.4 million.
114
For year ended December 31, 2022, cash used in investing activities was €12.0 million and was mainly
composed of (i) CRO contracts advances for clinical trials which have to be recovered at the end of the trials,
amounting to €12.2 million, and by (ii) the completion of the acquisition of Prosynergia in 2022 and the remaining
payment of the acquisition price of €2.9 million, partially offset by (iii) the non-recurring €3.3 million advance
repayment from University Hospital of Nice as part of the COVID-19 Program clinical trial.
For the year ended December 31, 2021, cash used in investing activities was €6.2 million, and was mainly
composed by the €4.0 million advance payment to the University Hospital of Nice as part of the COVID-19
Program clinical trial, as well as our entry in 2021 of a €1.4 million loan agreement to fund the acquisition of
Prosynergia and an advance payment made with respect to the acquisition of €0.3 million. The loan was made to
allow early repayment by Prosynergia of its existing indebtedness. For accounting purposes, this loan is considered
as a prepayment for the acquisition of Prosynergia’s assets.
Financing Activities
For the year ended December 31, 2023, cash from financing activities was €335.3 million, which consisted of
net proceeds from a capital raise with Euronext Paris of €123.3 million (including transaction costs of €6.7 million),
a capital raise of €202.0 million of net proceeds (including transaction costs of €21.3 million) from our U.S. initial
public offering and listing on Nasdaq (including transaction costs and underwriting commissions of €28.1 million),
net proceeds of the August 2023 drawdown of the first tranches of the Kreos / Claret Financing and the Heights
Financing, collectively amounting to €27.2 million (net of repayments of all outstanding amounts that remained due
under the First KC Agreement, the Second KC Agreement and the OCEANE bonds), partially offset by repayments
under the First KC Notes and the Second KC Notes (in an amount of €5.0 million), PGE (in an amount of €1.3
million) and interest paid (in an amount of €5.3 million).
For the year ended December 31, 2022, cash from financing activities was €32.2 million, which consisted
primarily of €46.2 million of net proceeds from a capital increase (including transaction costs of €3.3 million), net
proceeds from the issuance of the royalty certificates in an amount of €2.9 million, partially offset by €13.4 million
of repayments under the First KC Notes and the Second KC Notes and interest paid.
For the year ended December 31, 2021, cash from financing activities was €82.7 million, which consisted
primarily of €60.0 million of net proceeds from a capital increase (including transaction costs of €4.2 million),
€8.1 million of net proceeds from the exercise of share warrants (BSA) under the equity line agreement, €1.5 million
of net proceeds from the exercise of other share warrants (BSA), and net proceeds from the issuance of the
OCEANE bonds in an amount of €24.9 million, partially offset by €7.4 million of repayments under the First KC
Notes and the Second KC Notes and interest paid.
115
Material Cash Requirements
Contractual Obligations and Loans
The following table sets forth aggregate information about material contractual obligations as of December 31,
2023.
The commitment amounts in the table below are associated with contracts that are enforceable and legally
binding and that specify all significant terms, including, fixed or minimum services to be used, fixed, minimum or
variable price provisions, and the approximate timing of the actions under the contracts. Future events could cause
actual payments to differ from these estimates. All amounts except the retirement benefits in the table below are
presented gross and are undiscounted.
As of December 31, 2023 | As of December 31, 2023 | As of December 31, 2023 | |
Less than | More than | ||
(In thousands of euros) | 1 year | 1 year | Total |
Financial debt obligations .......................... | 17,762 | 60,584 | 78,346 |
Lease obligations ....................................... | 406 | 169 | 575 |
Retirements benefits .................................. | — | 629 | 629 |
Off-balance sheet obligations .................... | 201,777 | — | 201,777 |
Total .......................................................... | 219,946 | 61,382 | 281,327 |
In the ordinary course of our business, we regularly use the services of subcontractors and enters into research
and partnership arrangements with various CROs and with public-sector partners or subcontractors, who conduct
clinical trials and studies in relation to the drug candidates. Off-balance sheet obligations in the table above are
commitments related to these research and partnership agreements. They are classified at less than one year maturity
in the absence of a fixed schedule in contracts, in case of multiple-year contracts, such as CRO contracts. CRO
contracts include payments that are conditional to the completion of future development milestones.
Our material cash requirements in the above table do not include potential future royalty payments related to
the royalty certificates, amounting to 2% of the future net sales of obefazimod (worldwide and for all indications).
The amount of royalties that may be paid under the royalty certificates is capped at €172.0 million in the aggregate.
Royalty payments are expected to take place before the expiry date of the certificates, which is 15 years after their
issuance date (September 2, 2037).
As of December 31, 2023, our contractual obligations and loans were €281.3 million comprising financial debt
obligations of €78.3 million (in turn, comprising €30.9 million with respect of the Kreos / Claret OCABSA, €36.7
million with respect to Heights Convertible Notes, €6.8 million of conditional advances from Bpifrance and
€3.9 million with respect to the PGE) and off-balance sheet obligations of €201.8 million with respect to purchase
obligations.
Operating Capital and Capital Expenditures Requirements
We have incurred substantial operating losses since inception and expect to continue to incur significant
operating losses for the foreseeable future and may never become profitable. For the year ended December 31, 2023,
we recorded a net loss of €147.7 million.
Our present and future funding requirements will depend on many factors, including, among other things:
•the size, progress, timing, and completion of our preclinical studies and clinical trials;
•the number of potential new drug candidates we identify and decide to develop;
•the costs involved in filing patent applications and maintaining and enforcing patents or defending
against claims or infringements raised by third parties;
•the time and costs involved in obtaining regulatory approval for our drug candidates and any delays we
may encounter as a result of evolving regulatory requirements or adverse results with respect to any of
these drug candidates;
116
•selling and marketing activities undertaken in connection with the anticipated commercialization of
obefazimod and any other current or future drug candidates and costs involved in the creation of an
effective sales and marketing organization;
•the amount of revenue, if any, we may derive either directly or in the form of milestones or royalty
payments from our existing or future partnership or collaboration agreements; and
•the severity, duration and impact of the Russia/Ukraine war, which may continue to adversely impact
our business and clinical trials.
See “Risk Factors—Risks Related to our Financial Position and Need for Additional Capital” for additional
risks associated with our substantial capital requirements.
C.Research and Development, Patents and Licenses, Etc.
For a discussion of our research and development activities, see “Item 4.B—Business Overview” and “Item
5.A—Operating Results.”
D.Trend Information
For a discussion of trends, see “Item 4.B—Business Overview,” “Item 5.A—Operating Results” and “Item
5.B—Liquidity and Capital Resources.”
E.Critical Accounting Estimates
Our audited financial statements as of, and for the years ended, December 31, 2023, 2022 and 2021 were
prepared in accordance with International Financial Reporting Standards (“IFRS”), as issued by the International
Accounting Standards Board (“IASB”), and IFRS as adopted by the Europeran Union ("EU") regulation n
°1606/2022 of July 19, 2022.
A description of accounting policies and estimates along with a description of the recently-issued accounting
pronouncements that may potentially impact our financial position and results of operations is disclosed in Notes 4
and 2 respectively to our financial statements as of and for the year ended December 31, 2023, appearing elsewhere
in this Annual report. We did not have to change our accounting policies or make retrospective adjustments as a
result of adopting these standards, which include the following:
•Amendments to IAS 1 Presentation of Financial Statements and IFRS Practice Statement 2 –
Disclosure of Accounting Policies;
•Amendments to IAS 8 – Definition of Accounting Estimates;
•Amendments to IAS 12 – Deferred Tax related to Assets and Liabilities arising from a Single
Transaction;
•IFRS 17 – Insurance Contracts and related amendments.
We did not elect for early application of the new standards, amendments and interpretations, which were
issued but not mandatory as of January 1, 2023. Our assessment of the impacts resulting from the application of
these recently issued accounting pronouncements is described in Note 2 to our financial statements as of and for the
year ended December 31, 2023, appearing elsewhere in this Annual Report on Form 20-F.
117
Item 6.Directors, Senior Management and Employees
A.Directors and Senior Management
The following table sets forth the name, age and position of each of our executive officers and directors as of
the date of this Annual Report on Form 20-F. The business address of our executive officers and directors is our
principal executive offices located at 7-11 boulevard Haussmann, 75009 Paris, France.
Name | Age | Position(s) |
Executive Officers | ||
Marc de Garidel .............................................................. | 65 | Chief Executive Officer and Director, Chairman of the Board |
Didier Blondel ................................................................ | 60 | Chief Financial Officer and Board Secretary |
Sheldon Sloan ................................................................. | 65 | Chief Medical Officer |
Michael Ferguson ........................................................... | 46 | Chief Commercial Officer |
Pierre Courteille .............................................................. | 55 | Chief Business Officer |
Didier Scherrer ................................................................ | 54 | Chief Scientific Officer |
Ida Hatoum ..................................................................... | 49 | Chief People Officer |
Directors* | ||
June Lee .......................................................................... | 57 | Independent Director, Chair of the Appointments and Compensation Committee |
Troy Ignelzi .................................................................... | 55 | Independent Director, Chair of the Audit Committee |
Carol L. Brosgart ............................................................ | 72 | Independent Director |
Corinna zur Bonsen-Thomas .......................................... | 64 | Independent Director, Member of the Audit Committee and the Appointments and Compensation Committee |
Kinam Hong (Sofinnova Partners) ................................. | 50 | Director, Member of the Audit Committee and the Appointments and Compensation Committee |
Philippe Pouletty (Truffle Capital) ................................. | 65 | Director, Member of the Appointments and Compensation Committee |
Camilla Soenderby .......................................................... | 52 | Independent Director, Member of the Appointments and Compensation Committee |
*Independence criteria assessed in accordance with the definition provided in the Middlenext Code of Corporate
Governance
Executive Officers
Marc de Garidel has been our Chief Executive Officer and Chairman of the Board since May 5, 2023 and has
more than 40 years of experience in the pharmaceutical and biotechnology sector, including 12 years of experience
as Chief Executive Officer of pharmaceutical and biotechnology companies. Between July 2021 and April 2023, he
served as Chief Executive Officer of CinCor Pharma and led its successful sale for up to $1.8 billion, subject to the
achievement of certain milestones, to AstraZeneca in February 2023. Between September 2020 and May 2021,
Mr. de Garidel served as Chief Executive Officer of AZTherapies. From April 2018 until August 2020, he was Chief
Executive Officer of Corvidia Therapeutics and led its sale to Novo Nordisk for $2.1 billion in total consideration.
Mr. de Garidel was the Chief Executive Officer of Ipsen between November 2010 and July 2016, overseeing the
development of its U.S. presence. Prior to that, he worked for Amgen and Eli Lilly in jobs of increasing
responsibilities and in various markets, including the United States and Europe. Mr. de Garidel has served as
chairman of the board of directors of Ipsen since 2010 and has been a member of the board of directors of Claris Bio
since 2020. He holds a degree in Civil Engineering from the Ecole des Travaux Publics in Paris, a Master’s degree
118
in International Management from Thunderbird Global School Management and an executive MBA from Harvard
Business School. We believe that Mr. de Garidel is qualified to serve on our Board because of his experience as an
executive and member of the boards of companies in the life sciences industry.
Didier Blondel has been our Chief Financial Officer and Board Secretary since January 2017. From January
2012 to December 2016, he was Chief Financial Officer at Sanofi Pasteur MSD, a Lyon-based joint-venture between
Sanofi and Merck and a European leader in human vaccines. Prior to that, over a 20-year period, Mr. Blondel held a
wide range of senior finance positions at Sanofi, in Commercial Operations and then research and development,
where he became global research and development Chief Financial Officer. He started his career as an auditor at
PricewaterhouseCoopers, after graduating with a Master’s degree in Business and Administration from the
Commercial Institute of Nancy, a leading French business school. Mr. Blondel also holds a Master’s degree in
Finance and Accounting from Nancy II University, as well as a Graduate Diploma in Finance and Accounting.
Sheldon Sloan has been our Chief Medical Officer since March 2023. He has over 30 years of experience in
academia and the biopharmaceutical industry, with an extensive track record in the field of gastroenterology and
IBD. From March 2022 to January 2023, Dr. Sloan was Program Lead for etrasimod UC at Pfizer. From November
2019 to March 2022, Dr. Sloan worked for Arena Pharmaceuticals. Between September 1997 and October 2019, Dr.
Sloan held different leadership positions at Johnson and Johnson in Medical Affairs, Research and Development,
and Science Policy, including Global Medical Affairs Leader for IBD, leading the global launch strategy and
execution for CD and UC for Stelara. He holds a Doctor of Medicine from Rush Medical College, Chicago and a
Master of Bioethics from the University of Pennsylvania.
Michael Ferguson has been our Chief Commercial Officer since April 2023. He has over 22 years of
experience in the biopharmaceutical industry, with an extensive track record in the field of Gastroenterology (GI)
and IBD. From August 2019 through May 2022, Mr. Ferguson served as Vice President Global Commercial
Marketing and Planning and specifically as Global Commercial Lead for etrasimod across all GI Indications at
Arena Pharmaceuticals. From March 2007 to August 2019, he held various leading commercial leadership positions
at Shire/Takeda. Mr. Ferguson holds both a B.S. and an MBA in Finance from the Pennsylvania State University as
well as a post graduate degree in Pharmaceutical Marketing from St. Joseph’s University, Philadelphia.
Pierre Courteille has been our Chief Business Officer since May 2023. Prior to this appointment, he served
as our Chief Commercial Officer and Vice President Business Development. Mr. Courteille has over 25 years of
experience in marketing, sales and business development within the pharmaceutical industry (13 years based in
Japan). Prior to joining us in April 2015, he was Senior VP sales and marketing for Guerbet as well as Chief
Executive Officer of MEDEX (medical devices company owned by Guerbet) from 2012. From 2009, Mr. Courteille
served as VP Sales for Asia, Latin America and EMEA and met the ambitious objective of optimizing commercial
performance across these three regions. As President of Guerbet Japan and VP for Guerbet Asia, Mr. Courteille has
successfully managed the roll-out of its Japanese subsidiary and led the development of other branches in Asia. Mr.
Courteille holds a pharmacy degree and MBA (with Honors) from The University of Chicago Booth School of
Business.
Didier Scherrer has been our Chief Scientific Officer since August 2023. Prior to this appointment, he served
as our Vice President of Research and Development. Mr. Scherrer has extensive experience in the development of a
portfolio of therapeutics in oncology, viral diseases and autoimmune / inflammatory diseases. Prior to joining our
company in March 2009, he performed a combined role of Chief Executive Officer and Scientific Director at Splicos
from September 2009. He also has experience from prior roles as Associate Director (Capability Pathways –
Discovery Enabling Capabilities and Sciences) of the Research Department of AstraZeneca and as Head of Research
at LFB Biotechnologies. Mr. Scherrer has a Ph.D. in Molecular Pharmacology from Université Louis Pasteur
(Strasbourg I). He completed his post-doctoral studies at Harvard Medical School and then at the Stanford
University School of Medicine.
Ida Hatoum has been our Chief People Officer and Chief Compliance Officer since June 2023. Ms. Hatoum
has over 25 years experience in People Operations, Organizational Design and Build in the Biotech Industry. Prior
to joining Abivax, Ms. Hatoum was the SVP and Head of People Talent and Culture for CinCor Pharma where she
was integral in the organizational build and subsequent merger and acquisition negotiations. She also has experience
from prior roles as the Head of Organizational Development. Ms. Hatoum holds a bachelor's degree in pharmacy
from The University of Toledo in Ohio.
Directors
June Lee has been one of our independent directors since July 2023. Dr. Lee has served as a venture partner at
5AM Venture Management, LLC since July 2022. Dr. Lee was most recently Founder and Chief Executive Officer
of Esker Therapeutics until September 2021. Dr. Lee previously served as the Executive Vice President and Chief
119
Development Officer of MyoKardia, Inc. from January 2019 to June 2020, and was the Chief Operating Officer
from February 2017 until January 2019, and the Chief Development Officer from October 2017 to January 2019.
From April 2011 until February 2017, Dr. Lee served on the faculty of the University of California, San Francisco,
or UCSF, where she was director of the Catalyst program at the Clinical and Translational Science Institute and a
professor in the School of Medicine, and was responsible for overall strategy and operations for enabling and
supporting translational research at the university. Catalyst is an internal UCSF accelerator for therapeutics, devices,
diagnostics, and digital health technologies. Prior to UCSF, Dr. Lee was a disease area lead, early clinical
development, at Genentech, Inc. from 2006 to 2011, where she was responsible for all strategy and activities as well
as management of staff, budget, and resource allocation in the early clinical development group in multiple
therapeutic areas. Dr. Lee served as a Medical Director in the clinical development group at Genentech, Inc. from
2004 to 2006, where she was responsible for clinical activities for licensed product of the company. She currently
serves on Johns Hopkins University Center for Therapeutic Translation’s Advisory Board, serves on the board of
directors of Tenaya Therapeutics Inc, Eledon Pharmaceuticals Inc. and GenEdit, is a member of the Scientific
Advisory Board for Foresite Labs, and previously served as a member of the board of directors of CinCor Pharma,
Inc. Dr. Lee holds a B.A. in chemistry from Johns Hopkins University and an M.D. from the University of
California, Davis. We believe that Dr. Lee is qualified to serve on our Board because of her experience as an
investor and member of the boards of companies in the life sciences industry.
Troy Ignelzi has been one of our independent directors since July 2023. Mr. Ignelzi has served as the Chief
Financial Officer of Karuna Therapeutics, Inc. since March 2019. Prior to that, Mr. Ignelzi was the Chief Financial
Officer of scPharmaceuticals Inc. from March 2016 to February 2019, and provided consulting services to
scPharmaceuticals Inc. in February and March 2016. Mr. Ignelzi previously served as Chief Financial Officer and as
a member of the executive leadership teams at Juventas Therapeutics Inc., a privately held biotechnology company,
from October 2014 to February 2016. From October 2013 to October 2014, Mr. Ignelzi served as Senior Vice
President—Operations and Business Development of Pharmalex GmbH. Prior to Pharmalex, Mr. Ignelzi was Vice
President—Business Development at Esperion Therapeutics, Inc., a public pharmaceutical company, from January
2009 to September 2013. Mr. Ignelzi served as Vice President, Business Development & Strategic Planning at Insys
Therapeutics, Inc., a specialty pharmaceutical company, from February 2007 to February 2009. Previously, Mr.
Ignelzi had served as a specialty senior sales representative at Eli Lilly from February 2002 to August 2005. Mr.
Ignelzi currently serves as a member of the board of directors of Vedanta Biosciences, Inc. and previously served as
a member of the board of directors of CinCor Pharma, Inc. Mr. Ignelzi has a B.S. in accounting from Ferris State
University. We believe that Mr. Ignelzi is qualified to serve on our Board because of his experience as an executive
and member of the boards of companies in the life sciences industry.
Carol L. Brosgart has been one of our independent directors since January 2018. She has held several
executive management positions, notably those of Chief Medical Officer at Alios (now J&J), from February 2011 to
August 2011, and Senior Vice President and Medical Director at the Children’s Hospital and Research Center in
Oakland, California from December 2009 to January 2011. She held several executive management positions at
Gilead Sciences (Vice President Clinical Research, Vice President Medical Affairs, Vice President Public Health
and Strategy) between 1998 and 2009. She has served as a member of the board of directors of Galmed
Pharmaceuticals, a clinical stage drug development biopharmaceutical company for liver, metabolic and
inflammatory diseases, since 2017, and Enochian Biosciences, a biotechnology company committed to developing
advanced allogenic cell and gene therapies, since 2020. Dr. Brosgart also serves as a director on the board of Mirum
Pharmaceuticals, a clinical stage drug development biopharmaceutical company for rare liver diseases, since 2021.
Dr. Brosgart is the chair of the scientific advisory board at Hepion Pharmaceuticals, formerly ContraVir, a biotech
company operating in the area of NASH, HBV, HCV and HDV in the field of HBV cures. She is also a consultant at
Dynavax and several biotech companies working in the fields of liver diseases and infectious diseases. In addition,
Dr. Brosgart currently sits on the board of the Hepatitis B Foundation, the Management Committee of the National
Viral Hepatitis Roundtable, the Executive Committee of the Forum for Collaborative Research and the Management
Committee of the HBV Cure Forum. She is also a clinical professor of medicine, biostatistics and epidemiology in
the Global Health Sciences Department of the University of California, San Francisco. Dr. Brosgart holds a degree
in Community Medicine from UC Berkeley and earned a Doctor of Medicine from UC San Francisco. We believe
that Dr. Brosgart is qualified to serve on our Board because of her extensive experience as an executive and as a
member of the boards of companies in the life sciences industry and her medical background.
Corinna zur Bonsen-Thomas served as our Chair between August 2022 and May 2023 and has been one of
our independent directors since June 2017. Since April 2020, Ms. zur Bonsen-Thomas has held the position of
Managing Director and Chief Executive Officer of RetInSight GmbH, a company which she co-founded in
April 2020 and specializes in ophthalmic imaging. Ms. zur Bonsen-Thomas was General Counsel for Smart
Reporting GmbH from February 2017 to December 2022. From 1999 to 2015, she served as a member of the
Supervisory Board of Baxter AG, an Austrian company. She has more than thirty years of international professional
experience in the pharmaceutical, biopharmaceutical, medical and biotechnology industries. Ms. zur Bonsen-
Thomas received her First Law State Examination from Ludwig Maximilian Universitaet and her Second Law State
120
Examination from the Bavarian Ministry of Justice. We believe that Ms. zur Bonsen-Thomas is qualified to serve on
our Board because of her extensive professional experience in the life sciences industry.
Kinam Hong has served as the permanent representative of Sofinnova Partners on our Board since September
2019. He has served as the partner responsible for Sofinnova’s strategy of crossover and growth investment in late
development stage companies at Sofinnova Partners since January 2017. He has served as the permanent
representative of Sofinnova Partners on the board of directors of CytoImmune Therapeutics, Inc. since July 2021
and as an observer then board member of Limflow SA since April 2018. Prior to Sofinnova Partners, Dr. Hong spent
ten years as an investor and research analyst covering the biotechnology sector. Dr. Hong co-led the Exane Equinox
Fund, a global healthcare fund investing in public biotech companies. He also worked at Citigroup investment
research where he focused on small- and midcap biotechnology companies. Before his investment career, Dr. Hong
worked in new product development at Sanofi, a multinational pharmaceutical company, where he held positions in
business development and strategic/new product marketing. Dr. Hong is a doctor and scientist who holds a Bachelor
of Science degrees in molecular biology/biochemistry and a Doctor of Medicine from the University of Florida. He
also holds a Chartered Financial Analyst and a Master of Business Administration from INSEAD, France. We
believe that Dr. Hong is qualified to serve on our Board because of his extensive experience as an investor and as a
member of the boards of companies in the life sciences industry.
Philippe Pouletty, MD has served as a director since December 2013 and is our founder, as well as founder
or co-founder of Carbios, Carmat, Vexim, Symetis, Affluent Medical, SpikImm and more than a dozen other
biotechnology and medical technology companies of Truffle Capital, several being listed or were acquired. He was
the Chairman of France Biotech from 2001 to 2006 and from 2007 to 2009, the French association of biotech
companies and Vice-Chairman of Europabio from 2002 to 2006, the European federation of biotechnologies. Dr.
Pouletty is a member of the board of directors or the chairman of several biotechnology and medical device
companies in Europe. Dr. Pouletty, acting as permanent representative of Truffle Capital, has served as director of
Pharnext SA, from April 2016 to October 2021, Carmat SA, from April 2021 to July 2021, and Deinove SA, from
2009 to 2021. Dr. Pouletty holds a Doctor of Medicine from Université Paris VI and was a Post-doctoral fellow at
Stanford University and is a permanent member of the hall of fame of inventors of Stanford University. We believe
that Dr. Pouletty is qualified to serve on our Board because of his extensive experience as founder and member of
the boards of companies in the life sciences industry, his medical background and his experience as an executive of
several biotechnology organizations.
Camilla Soenderby has been one of our independent directors since March 2024. Currently, Ms. Soenderby
is a member of the Board of Directors for the investment company BB Biotech and the two biotech companies, F2G
and Affibody. In addition, she is a member of Novo Holdings Advisory Group and industrial advisor for the private
equity group EQT. Most recently, Ms. Soenderby served as Chief Patient Value and Product Strategy Officer for
Takeda Pharmaceutical Co Ltd. from 2019 to 2020. Ms. Soenderby led and oversaw Global Product Strategy at
Shire from March 2018 until its acquisition by Takeda. Prior to joining Shire, Ms. Soenderby was Region Head for
Roche Pharma with profit and loss responsibility for 11 countries in Central, South and Eastern Europe. Prior to that,
she worked as General Manager for Abbott (now AbbVie), first in Sweden and later in the United Kingdom. She
also held several operational and strategic roles of increasing responsibility at Schering Plough in Asia Pacific,
including General Manager for Taiwan. Ms. Soenderby began her career as a management consultant at McKinsey
& Company focusing on the bio-pharmaceutical and medical device industries. Ms. Soenderby holds a MSc in
Political Science from the University of Copenhagen. We believe that Ms. Soenderby is qualified to serve on our
Board because of her extensive experience as an executive and as a member of the boards of companies in the life
sciences industry.
Diversity of the Board of Directors
Board Diversity Matrix (As of December 31, 2023) | ||||
Total Number of Directors | 8 | |||
Female | Male | Non-Binary | Did Not Disclose Gender | |
Part I: Gender Identity | ||||
Directors | 4 | 4 | 0 | 0 |
Part II: Demographic Background | ||||
African American or Black | ||||
Alaskan Native or Native American | ||||
Asian | 1 | |||
121
Hispanic or Latinx | ||||
Native Hawaiian or Pacific Islander | ||||
White | 3 | 3 | ||
Two or More Races or Ethnicities | ||||
LGBTQ+ | ||||
Did Not Disclose Demographic Background | 1 | |||
Family Relationships
There are no family relationships among any of our executive officers or directors.
B.Compensation
Compensation of Chief Executive Officer
The following table sets out the compensation awarded to our Chief Executive Officer in the applicable
period:
Year ended December 31, | ||
2022 | 2023 | |
(€) | (€) | |
Marc de Garidel—Chief Executive Officer and Chairman from May 5, 2023 | ||
Fixed compensation ................................................................................... | N/A | 359,274 |
Variable annual compensation .................................................................. | N/A | 217,582 |
Variable multi-year compensation ............................................................. | N/A | — |
Exceptional variable compensation ........................................................... | N/A | — |
Remuneration allocated due to mandate as director ................................. | N/A | — |
Benefits in kind ........................................................................................... | N/A | 28,496 |
Total .......................................................................................................... | N/A | 605,353 |
Hartmut Ehrlich—Chief Executive Officer until May 5, 2023 (2) | ||
Fixed compensation ................................................................................... | 321,906 | 111,773 |
Variable annual compensation(1) ................................................................ | 193,144 | 64,381 |
Variable multi-year compensation ............................................................. | — | — |
Exceptional variable compensation ........................................................... | — | — |
Remuneration allocated due to mandate as director ................................. | — | — |
Benefits in kind ........................................................................................... | 8,880 | 3,083 |
Total .......................................................................................................... | 523,930 | 179,238 |
(1)Variable compensation paid for the financial year corresponds to the amount due for the previous year.
(2) Do not include departure indemnity equal to €1,209,825.
The aggregate compensation paid and benefits in-kind granted by us to our current executive officers and
directors, including share-based compensation, for the years ended December 31, 2023 and 2022 were €9.8 million
and €1.0 million, respectively. For both years, we did not allocate any amounts to be set aside or accrued to provide
pension, retirement or similar benefits to our directors or executive officers.
122
Compensation of Directors
The following table sets out the compensation awarded to our directors in the applicable period:
Year ended December 31, | ||
2022 | 2023 | |
(€) | (€) | |
Corinna zur Bonsen-Thomas ............................................................................... | 19,620 | 135,160 |
Joy Amundson(1) ................................................................................................... | 20,710 | 7,630 |
Jean-Jacques Bertrand(2) ....................................................................................... | 8,015 | 3,080 |
Santé Holdings SRL (permanent representative to the Board: Paolo Rampulla)(3) .......................... | 14,875 | 32,083 |
Truffle Capital (permanent representative to the Board: Christian Pierret)(4) .......................... | 7,735 | 1,400 |
Carol L. Brosgart ................................................................................................. | 18,530 | 39,967 |
Sofinnova Partners (permanent representative to the Board: Kinam Hong) ....... | 10,200 | 41,000 |
June Lee(1) ............................................................................................................. | N/A | 35,244 |
Troy Ignelzi(2) ....................................................................................................... | N/A | 44,327 |
Philippe Pouletty(4) ................................................................................................ | N/A | 35,000 |
Total .................................................................................................................... | 99,685 | 374,890 |
(1)As of July 2023, Ms. Amundson resigned from our Board, and Dr. Lee was appointed to our Board.
(2)As of July 2023, Mr. Bertrand resigned from our Board, and Mr. Ignelzi was appointed to our Board.
(3)As of March 28, 2024, Santé Holdings SRL resigned from our Board, and Ms. Soenderby was appointed to
our Board.
(4)On May 5, 2023, Dr. Pouletty resigned from his personal office as director and became Truffle Capital’s
representative to the Board in replacement of Mr. Pierret.
At the general meeting of shareholders held on June 9, 2022, our shareholders approved a package of
attendance fees and the compensation policy applicable to the chairperson of the Board and the Chief Executive
Officer. For the fiscal year ended December 31, 2023, none of the amounts set aside or accrued to provide pension,
retirement or similar benefits to our employees was attributable to our executive officers.
The following table sets forth the AGAs allocated to the chairperson and chief executive officer as of
December 31, 2023:
Chairperson & CEO | Allocation date | Type of AGAs | Number of AGAs allocated | Subscription price | Acquisition period |
Marc de Garidel .......... | July-11-2023 | Free Shares 2023-1 | 1,382,796 | N/A | Minimum of 1 year (*) |
Total ........................... | 1,382,796 |
(*)Acquisition Periods shall be as follows:
•For 212,738 Free Shares 2023-1: the Acquisition Period shall end on the first (1st) anniversary of the
allocation date;
•For 638,214 Free Shares 2023-1: the Free Shares 2023-1 shall progressively be definitively acquired
on a monthly basis over a period of three (3) years starting after the first (1st) anniversary of the
allocation date (i.e. 17,728 Free Shares 2023-1 per month except for the last month of the three-year
period where 17,734 Free Shares 2023-1 shall be acquired). The duration of the Acquisition Period of
these Free Shares 2023-1 shall be calculated accordingly;
•For 212,738 Free Shares 2023-1: the Acquisition Period shall end on the latest date between (i) the
first (1st) anniversary of the allocation date, and (ii) the date on which a specific performance
condition is fulfilled (condition 1);
123
•For 106,369 Free Shares 2023-1: the Acquisition Period shall end on the latest date between (i) the
first (1st) anniversary of the allocation date, and (ii) the date on which a specific performance
condition is fulfilled (condition 2);
•For 106,369 Free Shares 2023-1: the Acquisition Period shall end on the latest date between (i) the
first (1st) anniversary of the allocation date, and (ii) the date on which a specific performance
condition is fulfilled (condition 3);
•For 106,368 Free Shares 2023-1: the Acquisition Period shall end on the first (1st) anniversary of the
allocation date subject to the completion, prior to such date, of a specific performance condition
(condition 4).
Provisions or Allocations to Pay Pensions, Retirement or Other Benefits for Directors and Management
For the fiscal year ended December 31, 2023, none of the amounts set aside or accrued to provide pension,
retirement or similar benefits to our employees was attributable to our administrative, supervisory or management
bodies. We have not set aside any provisions to pay pensions, retirement and other benefits for corporate directors.
The directors’ compensation does not include any profit-sharing plans.
Employment Agreements
We have entered into employment agreements with each of our executive officers, except for our Chief
Executive Officer, who is a corporate officer (mandataire social) with whom we have entered into a management
contract.
Our Chief Executive Officer has been appointed for a term lasting until the end of the Board meeting
following the general meeting of shareholders held to approve the financial statements for the year ending December
31, 2026. He has also been appointed as Chairman of the Board for a term lasting until the end of the Board meeting
following the general meeting of shareholders held to approve the financial statements for the year ending December
31, 2024. In case of termination of the Chief Executive Officer as a result of (i) non-renewal, (ii) revocation except
for gross negligence or willful misconduct and/or (iii) resignation justified by invalidity or health issues or Mr. de
Garidel’s definitive retirement (a “Qualifying Departure”), Mr. de Garidel shall be entitled to a severance payment
equal to 12 months of the higher of either (i) the monthly average fixed remuneration and variable remuneration
received by Mr. de Garidel during the 12-month period preceding the effective date of the Qualifying Departure, or
(ii) the monthly average fixed remuneration received by Mr. de Garidel during the 12-month period preceding the
effective date of the Qualifying Departure plus 1/12th of the variable remuneration for the financial year
immediately preceding the date of the Qualifying Departure, irrespective of the date of payment of that variable
remuneration.
In February 2023, we entered into an offer letter with Dr. Sloan. Dr. Sloan may terminate his employment
with us without good reason (as defined in his offer letter), and we may terminate his employment with us without
cause (as defined in his offer letter) upon four months of notice. If Dr. Sloan’s employment is terminated by us
without cause or Dr. Sloan resigns with good reason (as defined in his offer letter), then he will be entitled to receive
severance pay in an amount equal to (i) six months of his then-current base compensation, (ii) prorated portion of the
variable compensation and (iii) any premiums for healthcare plans provided by us (including any eligible COBRA
coverage) for the earlier of a period of six months from the date of termination and the date on which Dr. Sloan
becomes eligible to receive such benefits with a new employer. The offer letter also includes a non-competition
provision lasting during and for six months following his employment with us.
In April 2023, we entered into an offer letter with Mr. Ferguson. Mr. Ferguson may terminate his employment
with us without good reason (as defined in his offer letter), and we may terminate his employment with us without
cause (as defined in his offer letter) upon four months of notice. If Mr. Ferguson’s employment is terminated by us
without cause or Mr. Ferguson resigns with good reason (as defined in his offer letter), then he will be entitled to
receive severance pay in an amount equal to (i) six months of his then-current base compensation, (ii) prorated
portion of the variable compensation and (iii) any premiums for healthcare plans provided by us (including any
eligible COBRA coverage) for the earlier of a period of six months from the date of termination and the date on
which Mr. Ferguson becomes eligible to receive such benefits with a new employer. The offer letter also includes a
non-competition provision lasting during and for six months following his employment with us.
In May 2023, we entered into an executive employment agreement with Ms. Hatoum. Ms. Hatoum may
terminate her employment with us without good reason (as defined in her offer letter) upon thirty days of notice, and
we may terminate her employment with us without cause (as defined in her offer letter). If Ms. Hatoum’s
employment is terminated by us without cause or Ms. Hatoum resigns with good reason (as defined in her offer
letter), then she will be entitled to receive severance pay in an amount equal to (i) twelve months of her then-current
124
base compensation, (ii) the variable compensation and (iii) any premiums for healthcare plans provided by us
(including any eligible COBRA coverage) for the earlier of a period of twelve months from the date of termination
and the date on which Ms. Hatoum becomes eligible to receive such benefits with a new employer, as well as twelve
months of accelerated vesting of the unvested portion of any outstanding equity awards. If Ms. Hatoum’s
employment is terminated by us without cause or Ms. Hatoum resigns with good reason (as defined in her offer
letter) within three months before or twelve months after a change in control of the company, then she will be
entitled to receive severance pay in an amount equal to (i) twelve months of her then-current base compensation, (ii)
a prorated portion of the variable compensation and (iii) any premiums for healthcare plans provided by us
(including any eligible COBRA coverage) for the earlier of a period of twelve months from the date of termination
and the date on which Ms. Hatoum becomes eligible to receive such benefits with a new employer, as well
accelerated vesting of the unvested portion of any outstanding equity awards. The offer letter also includes a non-
competition provision lasting during and for twelve months following her employment with us.
Each of our executive officers has agreed to maintain the confidentiality of any confidential information, both
during and after the employment/management agreement expires or is earlier terminated. In addition, they are
subject to loyalty and confidentiality obligations and certain of them are bound by a non-solicitation covenant that
prohibits such executive officer from soliciting our customers, or soliciting or hiring our executive employees and
those of our employees working in the same team as our executive officer, during his or her employment/office and
for one year after the termination of his or her employment/office.
Free Shares (AGA)
We entered into a transition protocol with Dr. Hartmut Ehrlich, our previous Chief Executive Officer,
according to which he was granted by a Board decision on July 11, 2023 100,000 free shares that are subject to the
achievement of specific performance conditions.
Moreover, pursuant to a Board decision on July 11, 2023, we have allocated a total number of 1,382,796 free
shares (AGA) to Mr. Marc de Garidel, as our current Chief Executive Officer, to which performance conditions and
presence conditions apply. In particular, 106,369 out of these 1,382,796 free shares (AGA) vested upon the
successful completion of our initial public offering of our ADSs in the United States.
On September 28, 2023, certain of our officers and employees were allocated 985,750 free shares (AGA) in
the aggregate, the vesting of which is subject to certain conditions. Subject to remaining employed with us, each
such officer or employee’s free shares (AGA) will be vested as follows: (i) 50% at the end of a two-year period from
the allocation date, (ii) 25% at the end of a three-year period from the allocation date and (iii) 25% at the end of a
four-year period from the allocation date. Of the 985,750 free shares (AGA), 254,250 free shares (AGA) are subject
to an additional vesting condition that was satisfied upon the successful completion of our initial public offering of
our ADSs in the United States.
Transition Protocol
In connection with Dr. Hartmut Ehrlich’s retirement as Chief Executive Officer, we entered into a transition
protocol with Dr. Ehrlich in April 2023. Pursuant to the transition protocol, Dr. Ehrlich remained our employee on a
part-time basis until December 31, 2023 in a capacity as advisor to the new Chief Executive Officer against payment
of a total compensation of €100,000, and we paid Dr. Hartmut Ehrlich a departure indemnity equal to €1,209,825. In
addition, Dr. Ehrlich was granted by a Board decision on July 11, 2023 100,000 free shares that are subject to the
achievement of specific performance conditions.
Limitations on Liability and Indemnification
Under French law, provisions of by-laws that limit the liability of directors are prohibited. However, French
law allows sociétés anonyme to contract for and maintain liability insurance against civil liabilities incurred by any
of their directors and officers involved in a third-party action, provided that they acted in good faith and within their
capacities as directors or officers of Abivax SA. Criminal liability cannot be indemnified under French law, whether
directly by us or through liability insurance.
We maintain liability insurance for our directors and officers, including insurance against liability under the
Securities Act and we intend to enter into agreements with our directors and executive officers to provide
contractual indemnification. With certain exceptions and subject to limitations on indemnification under French law,
these agreements will provide for indemnification for damages and expenses including, among other things,
attorneys’ fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or
proceeding arising out of his or her actions in that capacity.
125
These agreements may discourage shareholders from bringing a lawsuit against our directors and executive
officers for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of
derivative litigation against directors and executive officers, even though such an action, if successful, might
otherwise benefit us and our shareholders. Furthermore, a shareholder’s investment may be adversely affected to the
extent we pay the costs of settlement and damage awards against directors and officers pursuant to these insurance
agreements.
Certain of our non-employee directors may, through their relationships with their employers or partnerships,
be insured and/or indemnified against certain liabilities in their capacity as members of our Board.
In any underwriting agreement we enter into in connection with the sale of ordinary shares (including in the
form of ADSs) being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our
directors, our officers and persons who control us within the meaning of the Securities Act against certain liabilities.
Equity Incentives
We believe our ability to grant equity incentives is a valuable and necessary compensation tool that allows us
to attract and retain the best personnel for positions of substantial responsibility, provides additional incentives to
employees and promotes the success of our business. Due to French corporate law and tax considerations, we have
historically granted several different equity incentive instruments to our executive officers, Board members and
employees, including founder's share warrants (BCE), share warrants (BSA) and free shares (AGA).
Our Board's authority to grant these equity incentive instruments and the aggregate amount authorized to be
granted under these instruments must be approved by a two-thirds majority of the votes held by our shareholders
present, represented or voting by authorized means, at the relevant extraordinary shareholders’ meeting. Once
approved by our shareholders, our Board can grant share warrants (BSA) for up to 18 months, and stock options
and/or free shares (AGA) for up to 38 months from the date of the applicable shareholders’ approval. The authority
of our Board to grant equity incentives may be extended or increased only by extraordinary shareholders’ meetings.
As a result, we typically request that our shareholders authorize new pools of equity incentive instruments at every
annual shareholders’ meeting.
Founder's Share Warrants (BCE)
Founder’s share warrants (BCE) have traditionally been granted to certain of our employees who were French
tax residents because the warrants carry favorable tax and social security treatment for French tax residents. Similar
to options, founder’s share warrants (BCE) entitle a holder to exercise the warrant for the underlying vested shares at
an exercise price per share determined by our Board and at least equal to the fair market value of an ordinary share
on the date of grant. However, unlike options, the exercise price per share is fixed as of the date of implementation
of the plans pursuant to which the warrants may be granted, rather than as of the date of grant of the individual
warrants.
Our shareholders, or pursuant to delegations granted by our shareholders, our Board, determines the recipients
of the warrants, the dates of grant, the number and exercise price of the founder’s share warrants (BCE) to be
granted, the number of shares issuable upon exercise and certain other terms and conditions of the founder’s share
warrants (BCE), including the period of their exercisability and their vesting schedule.
As of December 31, 2023, we had issued several types of founder’s share warrants (BCE) as follows:
Category | BCE- 2014-1 | BCE- 2014-2 | BCE- 2014-3 | BCE- 2014-4 | BCE- 2014-5 | BCE- 2014-6 | BCE- 2014-7 | BCE- 2015-9 (G) | BCE- 2015-9 (S) | BCE- 2015-9 (D) | BCE- 2015-9 (C) | BCE- 2016-1 | BCE- 2017-1 | BCE- 2017-2 | BCE 2017-3 | BCE- 2017-4 | BCE- 2017-5 |
Expiration date | 11/03/ 2024 | 11/03/ 2024 | 11/03/ 2024 | 11/03/ 2024 | 11/03/ 2024 | 11/03/20 24 | Null and void | Null and void | Null and void | Null and void | Null and void | 7/11/202 6 | 23/01/20 27 | 20/11/20 27 | 20/11/20 27 | 20/11/20 27 | 20/11/20 27 |
Subscription or purchase price (€) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Exercise price per share (€) | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 12.5 | 17.79 | 17.79 | 17.79 | 17.79 | 7.44 | 6.39 | 11.14 | 11.14 | 11.14 | 11.14 |
Exercise conditions | Note (1) | Note (2) | Achieve ment of objective s Note (3) | Achieve ment of objective s Note (4) | Achieve ment of objective s Note (5) | Note (6) | Achieve ment of objective s Note (7) | Achieve ment of objective s Note (8 | Achieve ment of objective s Note (9) | Achieve ment of objective s Note (10 | Achieve ment of objective s Note (11 |
126
Number of shares subscribed | 275,000 | 275,000 | 76,300 | 98,400 | 2,800 | 19,700 | 0 | 0 | 0 | 0 | 0 | 40,006 | 374 | 0 | 48,426 | 1 | 3,000 |
Beneficiaries (remaining number of shares that can be subscribed) | |||||||||||||||||
Marc de Garidel | |||||||||||||||||
Other | 22,495 | 67,000 | 67,373 | 64,374 | |||||||||||||
Cumulative number of cancelled or lapsed BCEs | 0 | 0 | 626 | 0 | 169 | 328 | 1,650 | 33,687 | 67,374 | 33,687 | 67,374 | 21,499 | 0 | 37,500 | 52,635 | 0 | 0 |
BCEs outstanding as of 31/12/2023 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 22,495 | 67,000 | 112,500 | 0 | 67,373 | 64,374 |
BCEs exercisable at 31/12/2023* | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 22,495 | 67,000 | 112,500 | 0 | 67,373 | 64,374 |
Category | BCE-2018-1 | BCE-2018-2 | BCE 2018-3 | BCE-2018-4 | BCE-2018-5 |
Expiration date ............................................................................................... | 15/03/2028 | 21/05/2028 | 20/11/2028 | 14/05/2028 | 14/05/2028 |
Subscription or purchase price (€) ............................................................... | 0 | 0 | 0 | 0 | 0 |
Exercise price per share (€) ........................................................................... | 8.96 | 8.96 | 7.33 | 7.33 | 7.33 |
Terms of exercise ............................................................................................ | Note (12) | Achievement of objectives Note (13 | Achievement of objectives Note (14) | Achievement of objectives Note (15 | Note (16) |
Number of shares subscribed ........................................................................ | 6,930 | 44,916 | 16,843 | 0 | 5,750 |
Beneficiaries (number of shares that can be subscribed) | |||||
Marc de Garidel ............................................................................................. | |||||
Others .............................................................................................................. | 11,980 | 16,844 | 16,843 | 6,000 | |
Cumulative number of cancelled or lapsed BCEs ....................................... | 3,090 | 22,458 | 0 | 0 | 10,250 |
BCEs outstanding at December 31, 2023 ..................................................... | 11,980 | 0 | 16,844 | 16,843 | 6,000 |
BCEs exercisable at December 31, 2023* .................................................... | 11,980 | 0 | 16,844 | 16,843 | 6,000 |
(*) The number of shares to which the exercise of the BSAs and BCEs entitles the holder has been multiplied by
100 for all BSAs and BCEs issued prior to the division by 100 of the nominal value of the shares, decided by our
general meeting on February 20, 2015. According to the exercise conditions provided in the notes below and
assuming that performance objectives have been achieved.
(1) Service condition fully fulfilled on the date hereof.
(2) Service condition fully fulfilled on the date hereof. BCE 2014-2 has a warrant to share ratio of 1:100.
(3) BCE 2014-4 has a warrant to share ratio of 1:100. 246 BCE-2014-4 are exercisable subject to a service condition, which is fully fulfilled
on the date hereof. 369 BCE-2014-4 are exercisable exclusively in the event of the achievement of qualitative and/or quantitative objectives (non-
market conditions), as set by the Board on September 8, 2014.
(4) 197 BCE-2014-6 are exercisable subject to a service condition, which is fully fulfilled on the date hereof. 328 BCE-2014-6 are
exercisable exclusively in the event of the achievement of qualitative and/or quantitative objectives (non-market conditions), as set by the Board
on September 8, 2014 and revised on November 20, 2017.
(5) 50% of the BCE-2014-7 granted to each beneficiary are exercisable subject to a presence condition, which is fully fulfilled on the date
hereof. 50% of the BCE-2014-7 are exercisable exclusively in the event of the achievement of qualitative and/or quantitative objectives (non-
market conditions), as set by the Board on September 8, 2014.
(6) Service condition fully fulfilled on the date hereof.
(7) 33,687 BCE-2017-1 are exercisable subject to a service condition, which is fully fulfilled on the date hereof, 16,844 BCE-2017-1 are
exercisable exclusively in the event of achievement of the qualitative objectives (non-market conditions) set by the Board, and 16,843
BCE-2017-1 are exercisable exclusively in the event of achievement of the quantitative targets (market conditions) set by the Board.
(8) 75,000 BCE-2017-2 are exercisable subject to a service condition, which is fully fulfilled on the date hereof: and 75,000 BCE-2017-2 are
exercisable exclusively in the event of the achievement of qualitative objectives (non-market conditions) set by the Board.
(9) 50,531 BCE-2017-3 are exercisable subject to a service condition, which is fully fulfilled on the date hereof, and 50,530 BCE-2017-3 are
exercisable exclusively in the event of the achievement of qualitative objectives (non-market conditions) set by the Board.
(10) 33,687 BCE-2017-4 are exercisable subject to a service condition, which is fully fulfilled on the date hereof, and 33,687 BCE-2017-4 are
exercisable exclusively in the event of the achievement of qualitative objectives (non-market conditions) set by the Board.
127
(11) 16,843 BCE-2017-5 are exercisable subject to a service condition, which is fully fulfilled on the date hereof, and 16,844 BCE-2017-5 are
exercisable exclusively in the event of the achievement of qualitative objectives (non-market conditions) set by the Board.
(12) Service condition fully fulfilled on the date hereof.
(13) 33,686 BCE-2018-2 are exercisable subject to a service condition, which is fully fulfilled on the date hereof, and 33,686 BCE-2018-2 are
exercisable exclusively in case of achievement of qualitative objectives (non-market conditions) set by the Board.
(14) 16,843 BCE-2018-3 are exercisable subject to a service condition, which is fully fulfilled on the date hereof, and 16,844 BCE-2018-3 are
exercisable exclusively in the event of the achievement of qualitative objectives (non-market conditions) set by the Board.
(15) 8,422 BCE-2018-4 are exercisable subject to a service condition, which is fully fulfilled on the date hereof, and 8,421 BCE-2018-4 are
exercisable exclusively in the event of the achievement of qualitative objectives (non-market conditions) set by the Board.
(16) Service condition fully fulfilled on the date hereof.
General note: all of our BCE plans provide for specific cases of acceleration resulting in the exercise of said BCEs in
the event of the occurrence of specific events and in particular in the event of a change of control of us.
Share Warrants (BSA)
Share warrants (BSA) have historically been granted to our non-employee directors and consultants that
regularly work in partnership with us. Similar to options, share warrants (BSA) entitle a holder to exercise the
warrant for the underlying vested shares at an exercise price per share determined by our Board and at least equal to
the fair market value of an ordinary share on the date of grant. However, unlike options, the exercise price per share
is fixed as of the date of implementation of the plans pursuant to which the warrants may be granted, rather than as
of the date of grant of the individual warrants.
As of December 31, 2023, we had issued several types of share warrants (BSA) as follows:
Category | BSA-2014- 1 | BSA-2014- 2 | BSA-2014- 3 | BSA-2014 -4 | BSA-2014- 5 | BSA-2014- 6 | BSA-2014- 7 | BSA-2015- 9 | BSA-2015 - 11- Santé Holdings S | BSA-2015- 12 | BSA-2017- 1 | BSA-2018- 1 | BSA-2018- 2 |
Date of general meeting | 11/03/2014 | 11/03/2014 | 11/03/2014 | 11/03/2014 | 11/03/2014 | 11/03/2014 | 11/03/2014 | 20/02/2015 | 20/02/201 5 | 20/02/2015 | 23/06/2017 | 23/06/2017 | 23/06/2017 |
Date of Board meeting | 21/02/2014 | 21/02/2014 | 21/02/2014 | 21/02/2014 | 21/02/2014 | 21/02/2014 | 21/02/2014 | 14/09/2015 | 04/12/201 5 | 04/12/2015 | 18/09/2017 | 22/01/2018 | 14/05/2018 |
Date of decision of the Chief Executive Officer | |||||||||||||
Total number of shares that may be subscribed or purchased (*) : | |||||||||||||
Santé Holding SRL ......... | 96,924 | ||||||||||||
Corinna zur Bonsen- Thomas ............................. | 16,400 | ||||||||||||
Carol L. Brosgart ............ | 16,400 | ||||||||||||
Others ............................... | 0 | 0 | 0 | 84,160 | 45,900 | 0 | 0 | 0 | 16,400 | 0 | |||
(*) The number of shares to which the exercise of the BSAs and BCEs entitles the holder has been multiplied by 100 for all BSAs and BCEs
issued prior to the division by 100 of the nominal value of the shares, decided by our general meeting on February 20, 2015. Consequently, BSA
2014-3, BSA 2014-4 and BSA 2014-5 have a warrant to share ratio of 1:100.
128
Category | BSA-2014- 1 | BSA-2014- 2 | BSA-2014- 3 | BSA-2014-4 | BSA- 2014-5 | BSA- 2014-6 | BSA- 2014-7 | BSA- 2015-9 | BSA- 2015-11- Santé Holding SRL | BSA- 2015-12 | BSA- 2017-1 | BSA- 2018-1 | BSA- 2018-2 |
Starting date for exercising options .... | According to the achievement of criteria (see Terms of exercise) | According to the achievement of criteria (see Terms of exercise) | According to the achievement of criteria (see Terms of exercise) | According to the achievement of criteria (see Terms of exercise) | According to the achievement of criteria (see Terms of exercise) | 11/03/2014 | 11/03/2014 | 14/09/2015 | 10/12/2015 | 04/12/2016 | 18/09/2017 | 22/01/2018 | 14/05/2018 |
Expiry date. .............. | 11/03/2024 | 11/03/2024 | 11/03/2024 | 11/03/2024 | 11/03/2024 | 11/03/2024 | 11/03/2024 | 14/09/2025 | 04/12/2025 | 04/12/2025 | 18/09/2027 | 22/01/2028 | 14/05/2028 |
or at the end of a period of 90 days following the date on which the beneficiary ceases to work for us | or at the end of 90 days following the expiration of the beneficiary’s mandate | ||||||||||||
Subscription or purchase price (€) .... | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 2.07 | 1.78 | 1.78 | 1.29 | 0.9 | 0.73 |
Exercise price per share (€) .................... | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 20.73 | 17.79 | 17.79 | 11.57 | 8.05 | 6.6 |
Terms of exercise ..... | Note (1) | Achievement of objectives Note (2) | Achievement of objectives Note (3) | Note (4) | Note (5) | Note (6) | Note (7) | Note (8) | |||||
Number of shares subscribed ................. | 39,400 | 44,800 | 98,000.00 | 47,340 | 22,950.00 | 5,200 | 8,100 | 0 | 0 | 0 | 0 | 16,400 | 0 |
Cumulative number of BSA or BCE cancelled or lapsed ... | 0 | 229 | 264 | 0 | 328 | 0 | 0 | 122,274 | 0 | 65,600 | 0 | 16,400 | 32,800 |
BSAs as of December 31, 2023 ... | 0 | 0 | 0 | 842 | 229,5 | 0 | 0 | 0 | 96,924 | 16,400 | 16,400 | 16,400 | 0 |
BSA potentially exercisable as of December 31 2023,* . | 0 | 0 | 0 | 842 | 229,5 | 0 | 0 | 0 | 96,924 | 16,400 | 16,400 | 16,400 | 0 |
(*) The number of shares to which the exercise of the BSAs and BCEs entitles the holder has been multiplied by 100 for all BSAs and BCEs
issued prior to the division by 100 of the nominal value of the shares, decided by our general meeting on February 20, 2015. According to the
exercise conditions provided in the notes below and assuming that the objectives have been achieved.
(1) Progressive vesting in time fully vested on the date hereof.
(2) 263 BSA-2014-4 are exercisable at any time as from March 11, 2014. 1,052 BSA-2014-4 are exercisable exclusively in the event of the
achievement of qualitative and/or quantitative objectives (non-market conditions), as set by the Board on September 8, 2014.
(3) Exercisable by their beneficiary according to the exercise conditions set by the Board on September 8, 2014.
(4) Progressive vesting in time fully vested on the date hereof.
(5) Progressive vesting in time fully vested on the date hereof.
(6) Progressive vesting in time fully vested on the date hereof.
(7) Progressive vesting in time fully vested on the date hereof.
(8) Progressive vesting in time fully vested on the date hereof.
General note: all of our BSA plans provide for specific cases of acceleration resulting in the exercise of said BSAs in
the event of the occurrence of specific events and in particular in the event of a change of control of us.
Free Shares (AGA)
Free ordinary shares (AGA) are employee equity incentive instruments pursuant to which the beneficiaries are
granted, for free, the possibility to receive our ordinary shares under certain conditions.
As of December 31, 2023, we had issued free shares (AGA) as follows:
129
Plan name | Free ordinary share plan AGA 2023-1 |
General Meeting date | June 5, 2023 |
Board of Directors decision | July 11, 2023 |
Free ordinary shares granted by the Board of Directors | 1,382,796 |
Duration of vesting period | •212,738 ordinary shares shall vest on July 11, 2024; •638,214 the ordinary shares shall progressively vest on a monthly basis over a period of three (3) years starting after July 11, 2024 (i.e. 17,728 ordinary shares per month except for the last month of the three-year period where 17,734 ordinary shares shall vest); •531,844 ordinary shares shall vest on the latest date between (i) July 11, 2024, and (ii) the date on which the relevant performance conditions are fulfilled. |
Date of availability | All ordinary shares vesting before July 11, 2025 shall be subject to a lock-up period ending on July 11, 2025. Ordinary shares vesting after July 11, 2025 are not subject to a lock-up period. |
Free ordinary shares fully vested as of December 31, 2023 | 0 |
Free ordinary shares being vested as of December 31, 2023 | 1,382,796 |
Free ordinary shares lapsed as of December 31, 2023 | 0 |
Employment conditions | For all of the ordinary shares, the vesting is subject to the beneficiary of the plan remaining, on the vesting date, the Chief Executive Officer (CEO) of the Company. For 531,844 ordinary shares, the vesting is subject to the achievement of various performance conditions. For 106,369 of these 531,844 ordinary shares, the vesting of the ordinary shares was subject to the successful completion of the initial public offering of the Company’s shares (or depositary receipts representing any such shares) on the NASDAQ stock exchange in New York allowing the Company to raise an amount of gross proceeds at least equal to one hundred million dollars ($100,000,000). Such performance condition has been fulfilled |
Plan name | Free ordinary share plan AGA 2023-2 |
General Meeting date | June 5, 2023 |
Board of Directors decision | July 11, 2023 |
Free ordinary shares granted by the Board of Directors | 100,000 |
Duration of vesting period | •25% of the allocated ordinary shares shall vest on July 11, 2024; and •75% of the allocated ordinary shares shall vest on the latest date between (i) July 11, 2024, and (ii) the date on which the performance condition is fulfilled. |
Date of availability | Each ordinary share vesting before July 11, 2025 shall be subject to a lock-up period ending on July 11, 2025. Ordinary shares vesting after July 11, 2025 are not subject to a lock-up period. |
Free ordinary shares fully vested as of December 31, 2023 | 0 |
Free ordinary shares being vested as of December 31, 2023 | 100,000 |
Free ordinary shares lapsed as of December 31, 2023 | 0 |
Performance and employment conditions | The vesting of the ordinary shares is not subject to a presence condition. 75% of the allocated ordinary shares are subject to the fulfillment of a performance condition. |
130
Plan name | Free ordinary share plan AGA 2023-3 |
General Meeting date | June 5, 2023 |
Board of Directors decision | September 28, 2023 |
Free ordinary shares granted by the Board of Directors | 731,500 |
Duration of vesting period | •50% of the ordinary shares allocated shall vest on September 28, 2025; •25% of the ordinary shares allocated shall vest on September 28, 2026; and •25% of the ordinary shares allocated shall vest on September 28, 2027. |
Date of availability | The ordinary shares are not subject to a lock-up period once vested. |
Free ordinary shares fully vested as of December 31, 2023 | 0 |
Free ordinary shares being vested as of December 31, 2023 | 731,500 |
Free ordinary shares lapsed as of December 31, 2023 | 0 |
Performance and employment conditions | For all of the ordinary shares, the vesting is subject to the beneficiary of the plan retaining, on an ongoing basis, the status of corporate officer or employee of the Company and/or one of its direct and/or indirect subsidiaries, as applicable. |
Plan name | Free ordinary share plan AGA 2023-4 |
General Meeting date | June 5, 2023 |
Board of Directors decision | September 28, 2023 |
Free ordinary shares granted by the Board of Directors | 254,250 |
Duration of vesting period | Subject to the successful completion of a performance condition linked to the initial public offering of the Company’s shares (or depositary receipts representing any such shares) on the NASDAQ stock exchange in New York: •50% of the ordinary shares allocated shall vest on September 28, 2025; •25% of the ordinary shares allocated shall vest on September 28, 2026; and •25% of the ordinary shares allocated shall vest on September 28, 2027. |
Date of availability | The ordinary shares are not subject to a lock-up period once vested. |
Free ordinary shares fully vested as of December 31, 2023 | 0 |
Free ordinary shares being vested as of December 31, 2023 | 254,250 |
Free ordinary shares lapsed as of December 31, 2023 | 0 |
Performance and employment conditions | For all of the ordinary shares, the vesting is subject to the beneficiary of the plan retaining, on an ongoing basis, the status of corporate officer or employee of the Company and/or one of its direct and/or indirect subsidiaries, as applicable. In addition, the vesting of the ordinary shares was subject to the successful completion of the initial public offering of the Company’s shares (or depositary receipts representing any such shares) on the NASDAQ stock exchange in New York allowing the Company to raise an amount of gross proceeds at least equal to two hundred million dollars ($200,000,000). Such performance condition has been fulfilled. |
131
Plan name | Free ordinary share plan AGA 2023-5 |
General Meeting date | June 5, 2023 |
Board of Directors decision | December 1, 2023 |
Free ordinary shares granted by the Board of Directors | 132,750 |
Duration of vesting period | •50% of the ordinary shares allocated shall vest on December 1st, 2025; •25% of the ordinary shares allocated shall vest on December 1st, 2026; and •25% of the ordinary shares allocated shall vest on December 1st, 2027. |
Date of availability | The ordinary shares are not subject to a lock-up period once vested. |
Free ordinary shares fully vested as of December 31, 2023 | 0 |
Free ordinary shares being vested as of December 31, 2023 | 132,750 |
Free ordinary shares lapsed as of December 31, 2023 | 0 |
Performance and employment conditions | For all of the ordinary shares, the vesting is subject to the beneficiary of the plan retaining, on an ongoing basis, the status of corporate officer or employee of the Company and/or one of its direct and/or indirect subsidiaries, as applicable. |
General note: all of our AGA plans provide for specific cases of acceleration resulting in the vesting of said AGAs
in the event of the occurrence of specific events and in particular in the event of a change of control of us.
C.Board Practices
Board Composition
Our Board currently consists of eight members. The rules of procedure of our Board set the principles guiding
the composition of the Board. The most recent version of this document was adopted by our Board in April 2021
and subsequently amended in September 2023.The Board has established two permanent, specialized committees to
assist the Board in its work: (1) the audit committee and (2) the appointments and compensation committee. The
Board has also established an ad hoc committee, the scientific committee. Subject to available exemptions the
composition and functioning of all of our committees will comply with applicable requirements of the French
Commercial Code, the Exchange Act, the Nasdaq Global Market and SEC rules and regulations.
In accordance with French law, committees of our Board only has an advisory role and can only make
recommendations to our Board. As a result, decisions will be made by our Board taking into account non-binding
recommendations of the relevant Board committee. Since May 5, 2023, our Board has been chaired by our Chief
Executive Officer, Mr. de Garidel, who represents us vis-à-vis third parties in his capacity as Chief Executive
Officer.
All members of the Board may serve for a maximum of four years, expiring at the end of the shareholders’
meeting called to approve the financial statements from the previous year and held during the year in which the term
expires. Members of the Board may be re-elected. They may be dismissed at any time by a decision of the ordinary
general meeting of shareholders. The composition of our Board is described below:
Current Position | Year of Initial Appointment | Term Expiration Year(1) | |
Marc de Garidel | Chairman | 2023 (as Director and Chairman) | 2025 |
Corinna zur Bonsen-Thomas | Director | 2017 | 2025 |
June Lee | Director | 2023 | 2026 |
Troy Ignelzi | Director | 2023 | 2026 |
132
Truffle Capital (permanent representative to the Board: Philippe Pouletty) | Director | 2013 | 2025 |
Carol L. Brosgart | Director | 2018 | 2026 |
Sofinnova Partners (permanent representative to the Board: Kinam Hong) | Director | 2019 | 2026 |
Camilla Soenderby | Director | 2024 | 2025 |
(1) The mandates expire at the annual shareholders’ meeting approving the financial statements closed on
December 31 of the previous year.
During the fiscal year ended December 31, 2023, the Board met 16 times. The average attendance rate of the
directors was approximately 98%.
Non-voting Board Members / Observers
Pursuant to our by-laws, the General Meeting or the Board may appoint non-voting board members (or
observers). To date, no non-voting directors / observers have been appointed.
Director Independence
As a foreign private issuer, under the listing requirements and rules of Nasdaq, we are not required to have
independent directors on our Board, except to the extent that our audit committee is required to be consistent with
independence requirements. In determining whether a director is an independent director, our Board considers the
relationships that each non-employee director has with the Board and all other facts and circumstances that our
Board deems relevant in determining the director’s independence, including the number of ordinary shares
beneficially owned by the director and his or her affiliated entities, if any.
Based upon information requested from, and provided by, each director concerning such director’s
background, employment and affiliations, including family relationships, our Board has determined that all of our
directors, except for Marc de Garidel, qualify as “independent directors” as defined under applicable rules of the
Nasdaq Global Market and the independence requirements contemplated by the Exchange Act.
Furthermore, our Board has determined that, under the criteria of the Middlenext Code of Corporate
Governance, five of our directors are “independent directors”: June Lee, Troy Ignelzi, Corinna zur Bonsen-Thomas,
Carol L. Brosgart, and Camilla Soenderby. The Middlenext Code sets out the five following criteria justifying the
independence of directors, characterized by the absence of any significant financial, contractual or family
relationship likely to affect their independence of judgment:
•they must not be a salaried employee or corporate officer of us or our group and must not have held
such a position within the last five years;
•they must not be in a significant business relationship with us or our group (e.g., client, supplier,
competitor, provider, creditor, banker, etc.) within the last two years;
•they must not be a reference shareholder or hold a significant number of voting rights;
•they must not have close relationships or family ties with any of our corporate officer or reference
shareholder; and
•they must not have been our auditor within the last six years.
Conflicts of Interest Among the Management and Supervisory Bodies and Executive Management
Our Chairperson and Chief Executive Officer, our Chief Financial Officer and Board Secretary and our
directors are direct or indirect shareholders or holders of securities giving access to our share capital. See
“Compensation and Benefits—Compensation of Chief Executive Officer.”
Service agreements entered into with Board members
There are no existing service contracts between the Company and its subsidiaries on the one hand, and any
Board member on the other, providing for benefits upon termination of employment.
Board Committees
Audit Committee
133
Mission and Responsibilities
The audit committee monitors issues relating to the elaboration and control of accounting and financial
information as provided for by French law and by our by-laws and by the rules of procedure of the Board. It then
formulates recommendations to the Board in its task of permanent control of our management. It also issues
recommendations in relation to the proposed statutory auditors.
The audit committee is responsible for:
•monitoring the preparation and development of accounting and financial information and, where
appropriate, formulating recommendations in this respect to ensure its accuracy;
•reviewing the efficiency of the internal control and risk management systems;
•ensuring proper legal oversight of the preparation of the annual financial statements and financial
statements by the statutory auditors; and
•selecting and ensuring the independence of the statutory auditors.
The audit committee is also responsible for approving:
•non-audit services provided by the statutory auditors (including the permitted level of fees); and
•all budgets for statutory audits and other engagements provided by the statutory auditors.
The audit committee further controls the services provided by the auditors in relation to what is permitted by
law or regulation.
The audit committee is responsible for formulating recommendations regarding the statutory auditors
proposed for nomination by the General Meeting of Shareholders and/or during the renewal of their term.
Within this context, the audit committee may examine our annual financial statements in the form that they are
presented to the Board, hear the opinions of the statutory auditors and the finance director and receive
communications in relation to their analysis work and their conclusions.
The audit committee may use external experts at our expense, after approval of the chairperson of the Board or
the audit committee or of the Chief Executive Officer, and render any expert reports to the Board.
The audit committee may hear any director and carry out any internal or external audit on any subject it
considers relevant to its mission. The chairperson of the audit committee shall inform the Board in advance. In
particular, the audit committee has the power to interview the persons involved in the preparation of the accounts or
in their control (administrative and financial director and the main managers of the financial department).
Composition and Compensation
The audit committee and chairperson of the audit committee are appointed by the Board from members of the
Board, excluding executive directors, with finance or accounting skills and at least one member must be independent
in accordance with the provisions of the Middlenext Code. Members of the audit committee are appointed for a
fixed period of time, which may not exceed the duration of their terms of office as director and may be revoked by
the Board at any time and without reason. Appointments are renewable without limitation. The audit committee is
composed of at least two members and members receive no compensation other than attendance fees. Their duties
on the audit committee may be taken into account in determining the allocation of such attendance fees.
The current members of the audit committee are Troy Ignelzi, Corinna zur Bonsen-Thomas and Kinam Hong
(representing Sofinnova Partners). The current chairperson of the audit committee is Mr. Ignelzi.
The committee may invite any person, internal or external to us, to take part in its meetings and its work.
Our Board has determined that each of the members of our audit committee is independent within the meaning
of the applicable listing rules and the independence requirements contemplated by Rule 10A-3. Committee members
must be competent in financial or accounting matters and at least one member must be independent in accordance
with the provisions of the Middlenext Code. Our Board has further determined that Mr. Ignelzi is an “audit
committee financial expert” as defined by SEC rules and regulations and that Mr. Ignelzi qualifies as financially
sophisticated under the applicable exchange listing rules.
134
Conditions of Functioning
The audit committee meets when the chairperson of the audit committee, at least two members of the audit
committee, the chairperson of the Board or the Chief Executive Officer deems useful and at least twice per year,
particularly before publication of the financial statements. The committee may be convened by any means 24 hours
before the meeting by the chairperson of the audit committee or of the Board or any individual to whom one of them
shall have delegated the necessary authority. The committee meets at the registered office or in any other place
specified in the notice of the meeting. It may also meet by video conference or by any means of telecommunication
as specified in the internal regulation of the Board.
To deliberate validly, at least half of the members of the committee must be present. At meetings, one member
of the audit committee may be represented by another audit committee member and the audit committee’s
recommendations are adopted by simple majority. Upon completion of each meeting, if the members deem it
necessary, meeting minutes may be prepared. The chairperson of the audit committee regularly reports to the Board
on the committee’s work and immediately report any difficulty encountered.
Appointments and Compensation Committee
Mission and Responsibilities
The appointments and compensation committee makes recommendations to the Board in relation to the
nomination of, and compensation for, executive directors and the operational and functional management, and with
regard to appointments and compensation policy and internal profit sharing. In particular, the appointments and
compensation committee:
•provides recommendations and proposals to the Board concerning the appointment, in particular in the
research of a balanced representation of men and women on the Board, compensation, retirement and
provident scheme, supplementary pension benefits, benefits in kind, various financial rights of our
managers and executive officers, the allocation of share warrants (BSA), founder’s share warrants
(BCE), free shares (AGA), share subscription or share purchase options, for the benefit of our
employees, managers or consultants and, where applicable, its subsidiaries, in accordance with legal
provisions;
•defines the methods for determining the variable portion of the compensation of corporate officers and
monitors its application;
•proposes a general policy for awarding share warrants (BSA), founder’s share warrants (BCE), free
shares (AGA) and options to subscribe or purchase shares, and determines the frequency thereof,
depending on the categories of beneficiaries;
•examines the system of for the allocation of directors’ fees among the members of the Board,
particularly according to their participation in our committees; and
•expresses its opinion to senior management about the compensation of the principal senior executives.
The appointments and compensation committee is also involved in discussing each independent director’s
qualifications upon his or her nomination and during the exercise of his or her term of office, as applicable.
Composition and Compensation
The appointments and compensation committee is composed of at least two members. The chairperson of the
compensation committee and the committee’s members are appointed by the Board from members of the Board.
Members are appointed for a fixed period of time, which may not exceed, as applicable, the duration of their term of
office as director and may be revoked by the Board at any time and without reason. Their appointments shall be
renewable without limitation.
The chairperson of the Board, if not a member of the appointments and compensation committee, may be
invited to participate in the appointments and compensation committee’s meetings. The appointments and
compensation committee shall invite him/her to present its proposals. He/she shall not have the right to vote and
shall not be present during the deliberations relating to his/her own situation.
The current members of the appointments and compensation committee are June Lee, Philippe Pouletty
(representing Truffle Capital), Kinam Hong (representing Sofinnova Partners) and Camilla Soenderby. The current
chairperson of the appointments and compensation committee is Dr. Lee.
135
The appointments and compensation committee may invite any person, internal or external to us, to take part
in its meetings and its work.
Appointments and compensation committee members shall receive no compensation other than attendance
fees. Their duties on the compensation committee may be taken into consideration in determining the allocation of
such attendance fees.
Conditions of Functioning
The appointments and compensation committee meets when the chairperson of the appointments and
compensation committee, at least two members of the appointments and compensation committee, the chairperson
of the Board or the Chief Executive Officer deems useful and at least once a year. The appointments and
compensation committee may be convened by any means, 24 hours before the meeting, by the chairperson of the
appointments and compensation committee or of the Board, or any individual to whom one of them shall have
delegated the authority necessary for the convocation.
The committee meets at the registered office or in any other place specified in the notice of the meeting. It
may also meet by video conference or by any means of telecommunication, as specified in the internal regulation of
the Board.
To deliberate validly, at least half of the members of the committee must be present. A member of the
appointments and compensation committee may be represented by another appointments and compensation
committee member and the appointments and compensation committee’s recommendations are adopted by simple
majority. Upon completion of each meeting, if the members deem it necessary, meeting minutes may be prepared.
The appointments and compensation committee chairperson reports regularly to the Board on the
appointments and compensation committee’s work and shall immediately report any difficulty encountered.
Scientific Committee
Mission and Responsibilities
The scientific committee was created by a decision by the Board on September 27, 2018.
The role of the scientific committee is to:
•examine specific scientific questions submitted to it;
•make recommendations for determining the general guidelines to be adopted in the scientific field; and
•make recommendations for defining our priorities in the field of research and development and the
means for achieving such objectives.
The committee meets at least once a year.
It works in collaboration with the Chief Executive Officer, who may request its opinion on subjects related to
its mission. At the request of the Board, the chairperson of the scientific committee reports on the committee’s work
to the Board.
Composition
The scientific committee is composed of at least four members appointed by the Board upon proposal of the
Chief Executive Officer. The members of the scientific committee do not have to be members of the Board.
The current members of the scientific committee are Prof. Ian McGowan, MD, PhD, (Chairman); Prof.
Christian Bréchot; Prof. Christoph Huber; Prof. Jürgen Rockstroh; Prof. Christian Trepo; Prof. Lawrence R.
Stanberry; Prof. Luc Teyton; and Claude Bertrand.
The composition of the scientific committee is currently under review in light of our needs for the continued
development of our clinical programs.
D.Employees
136
As of December 31, 2023, we had 61 full-time employees, consisting of 40 within the research and
development department 14 within the general administrative department and 7 within the sales and marketing
department. Our employees based in France are subject to the national collective bargaining agreement for the
pharmaceutical industry (the convention collective nationale de l’industrie pharmaceutique). We believe that we
maintain good relations with our employees. As of December 31, 2023, 34 full-time employees were based in
France and 27 full-time employees were based in the United States.
We rely on skilled, experienced and innovative employees to conduct the operations of our company. We are
committed to building an outstanding, committed team and we focus on a culture that values a focus on scientific
innovation, inclusion, collaboration and equity. We focus on recruiting, retaining and developing employees from a
diverse range of backgrounds to conduct our research, development, clinical, commercial, marketing and market
access activities. We recognize that recruiting, motivating and retaining talented employees is vital to our success.
The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the
granting of stock-based and cash-based compensation awards, in order to increase shareholder value and the success
of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives.
We aim to create an equitable, inclusive and empowering environment in which our employees can grow and
advance their careers, with the overall goal of developing, expanding and retaining our workforce to support our
current pipeline and future business goals. Employees are encouraged to attend scientific, clinical and technological
meetings and conferences and have access to broad resources they need to be successful.
E.Share Ownership
For information regarding the share ownership of our directors and executive officers, see “Item 6.B—
Compensation” and “Item 7.A—Major Shareholders and Related Party Transactions.”
F.Disclosure of a Registrant’s Action to Recover Erroneously Awarded Compensation
None.
137
Item 7.Major Shareholders and Related Party Transactions
A.Major Shareholders
The following table and accompanying footnotes set forth information with respect to the beneficial ownership
of our ordinary shares as of February 29, 2024 for:
•each beneficial owner, known by us, of more than 5% of our outstanding ordinary shares;
•each of our directors and executive officers individually; and
•all of our directors and executive officers as a group.
Beneficial ownership is determined in accordance with the rules of the SEC. These rules generally attribute
beneficial ownership of securities to persons who possess sole or shared voting power or investment power with
respect to those securities and include ordinary shares that can be acquired within 60 days of February 29, 2024. The
percentage ownership information shown in the table below is based upon 62,917,662 ordinary shares outstanding as
of February 29, 2024 (excluding 11,156 treasury shares issued by us as of February 29, 2024).
Except as otherwise indicated, all of the shares reflected in the table are ordinary shares and all persons listed
below have sole voting and investment power with respect to the shares beneficially owned by them, subject to
applicable community property laws. The information is not necessarily indicative of beneficial ownership for any
other purpose.
In computing the number of ordinary shares beneficially owned by a person and the percentage ownership of
that person, we deemed outstanding ordinary shares subject to options and warrants held by that person that are
immediately exercisable or exercisable within 60 days of February 29, 2024. We did not deem these shares
outstanding, however, for the purpose of computing the percentage ownership of any other person. Beneficial
ownership representing less than 1% is denoted with an asterisk (*).
138
The information in the table below is based on information known to us or ascertained by us from public
filings made by the shareholders (which may be in the form of ADSs). Except as otherwise indicated in the table
below, addresses of the directors, executive officers and named beneficial owners are in care of Abivax SA,
7-11 boulevard Haussmann, 75009 Paris, France. Our major shareholders do not have any special voting rights.
Name of Beneficial Owner | Number of Ordinary Shares Beneficially Owned | Percentage of Ordinary Shares Benefic ially Owned | Percentage of Voting Power+ |
5% Shareholders: | |||
TCG Crossover(1) ..................................................................... | 6,056,596 | 9.63% | 8.66% |
Entities managed by Truffle Capital(2) ..................................... | 4,865,007 | 7.73% | 12.84% |
Sofinnova Crossover(3) ............................................................. | 5,264,739 | 8.37% | 9.94% |
Invus(4) ...................................................................................... | 5,569,364 | 8.85% | 7.97% |
Deep Track Capital(5) ............................................................... | 4,297,438 | 6.83% | 6.10% |
Entities affiliated with Venrock(6) ............................................ | 3,611,570 | 5.74% | 5.17% |
Directors and Officers: | |||
Marc de Garidel(7) .................................................................... | 38,145 | * | * |
Didier Blondel(8) ....................................................................... | 67,374 | * | * |
Pierre Courteille(9) .................................................................... | 67,374 | * | * |
Didier Scherrer(10) .................................................................... | 35,773 | * | * |
Sheldon Sloan ............................................................................ | — | — | — |
Michael Ferguson ...................................................................... | — | — | — |
Ida Hatoum ................................................................................ | — | — | — |
June Lee ..................................................................................... | — | — | — |
Troy Ignelzi ............................................................................... | — | — | — |
Carol L. Brosgart(11) ................................................................ | 16,400 | * | * |
Corinna zur Bonsen-Thomas(12) .............................................. | 16,400 | * | * |
Kinam Hong (representing Sofinnova Partners)(13) ................. | 5,264,739 | 8.37% | 9.94% |
Paolo Rampulla (representing Santé Holdings SRL)(14) .......... | 838,465 | 1.33% | 2.06% |
Philippe Pouletty (representing Truffle Capital)(15) ................. | 5,140,007 | 8.17% | 13.63% |
All directors and officers as a group (14 persons) ..................... | 11,484,677 | 18.18% | 25.90% |
*Represents beneficial ownership of less than 1%.
+A double voting right is attached to each registered ordinary share (except treasury share) that is held in the name of the same shareholder
for at least two years.
(1)These securities are held by TCG Crossover Fund I, L.P. (“TCG Crossover I”). TCG Crossover GP I, LLC (“TCG Crossover GP I”) is the
general partner of TCG Crossover I. Chen Yu is the sole managing member of TCG Crossover GP I and holds voting and dispositive
power with respect to the securities held by TCG Crossover I. The principal business address of each of TCG Crossover GP I, TCG
Crossover I and Dr. Yu is 705 High St., Palo Alto, CA 94301, United States.
(2)Consists of (i) 2,213,333 ordinary shares held by FCPR Truffle Capital II (“Truffle Capital II”), (ii) 1,160,804 ordinary shares held by
FCPI UFF Innovation 7 (“UFF Innovation 7”), (iii) 119,000 ordinary shares held by FCPI UFF Innovation 15 (“UFF Innovation 15”),
(iv) 171,600 ordinary shares held by FCPI Fortune 4 (“FCPI Fortune 4”), (v) 91,973 ordinary shares held by FCPI Fortune 3 (“FCPI
Fortune 3”), (vi) 157,100 ordinary shares held by FCPI UFF Innovation 12 (“UFF Innovation 12”), (vii) 193,900 ordinary shares held by
FCPI UFF Innovation 8 (“UFF Innovation 8”), (viii) 103,400 ordinary shares held by FCPI UFF Innovation 14 (“UFF Innovation 14”),
(ix) 84,983 ordinary shares held by FCPI Truffle Fortune 5 (“FCPI Fortune 5”), (x) 54,120 ordinary shares held by FCPI UFF
Innovation 16 (“UFF Innovation 16”), (xi) 16,394 ordinary shares held by FCPI Truffle Innocroissance 2015 (“Truffle Innocroissance
2015”), (xii) 36,400 ordinary shares held by Truffle Developpement (“Truffle Developpement”), (xiii) 197,000 ordinary shares held by
FCPI BioMedTech (“BioMedTech”) and (xiv) 265,000 ordinary shares held by FCPI Truffle Medeor (“Truffle Medeor”). Truffle Capital
II, UFF Innovation 7, UFF Innovation 15, FCPI Fortune 4, FCPI Fortune 3, UFF Innovation 12, UFF Innovation 8, UFF Innovation 14,
FCPI Fortune 5, UFF Innovation 16, Truffle Innocroissance 2015, Truffle Developpement, BioMedTech, and Truffle Medeor are
managed by Truffle Capital (“Truffle Capital” and together the “Truffle Entities”), itself controlled at 36.85% (of the share capital)
respectively by Dr. Philippe Pouletty, a member of our Board, and Mr. Bernard-Louis Roques. The principal business address of the
Truffle Entities is 5 rue de la Baume, 75008, Paris, France.
(3)The information in this footnote is based on a Schedule 13G filed with the SEC on October 30, 2023 by Sofinnova Crossover I SLP and
related entities and persons and the company’s records. Consists of 5,264,739 ordinary shares held by Sofinnova Crossover I SLP
139
(“Sofinnova Crossover”). Sofinnova Crossover is controlled by Sofinnova Partners (“Sofinnova Partners” and together the “Sofinnova
Entities”). Each of Antoine Papiernik, Cedric Moreau, Kinam Hong, a member of our Board, Joseph Anderson and Jacques Theurillat is a
member of the investment committee of Sofinnova Crossover and may be deemed to have shared voting and investment control over the
shares held by Sofinnova Crossover. Each of such individuals disclaims beneficial ownership of such shares except to the extent of their
pecuniary interest therein. The principal business address of the Sofinnova Entities is 7-11 boulevard Haussmann, 75009 Paris, France.
(4)Consists of 5,569,364 ordinary shares directly held by Invus Public Equities, L.P. (“Invus PE”). Invus Public Equities Advisors, LLC
(“Invus PE Advisors”), controls Invus PE, as its general partner and accordingly, may be deemed to beneficially own the ordinary shares
held by Invus PE. The Geneva branch of Artal International S.C.A. (“Artal International”), controls Invus PE Advisors, as its managing
member and accordingly, may be deemed to beneficially own the ordinary shares held by Invus PE. Artal International Management S.A.
(“Artal International Management”), as the managing partner of Artal International, controls Artal International and accordingly, may be
deemed to beneficially own the ordinary shares that Artal International may be deemed to beneficially own. Artal Group S.A. (“Artal
Group”), as the sole stockholder of Artal International Management, controls Artal International Management and accordingly, may be
deemed to beneficially own the ordinary shares that Artal International Management may be deemed to beneficially own. Westend S.A.
(“Westend”), as the parent company of Artal Group, controls Artal Group and accordingly, may be deemed to beneficially own the
ordinary shares that Artal Group may be deemed to beneficially own. Stichting Administratiekantoor Westend (the “Stichting”), as
majority shareholder of Westend, controls Westend and accordingly, may be deemed to beneficially own the ordinary shares that Westend
may be deemed to beneficially own. Mr. Amaury Wittouck, as the sole member of the board of Stichting, controls the Stichting and
accordingly, may be deemed to beneficially own the ordinary shares that the Stichting may be deemed to beneficially own. The principal
business address for Invus PE and Invus PE Advisors is 750 Lexington Avenue, 30th Floor, New York, NY 10022. The principal business
address for Artal International, Artal International Management, Artal Group, Westend and Mr. Wittouck is Valley Park, 44, Rue de la
Vallée, L-2661, Luxembourg. The principal business address for the Stichting is Claude Debussylaan, 46, 1082 MD Amsterdam, the
Netherlands.
(5)The information in this footnote is based on a Schedule 13G filed with the SEC on October 30, 2023 by Deep Track Capital, LP and
related entities and persons and the company’s records. Consists of 4,297,438 ordinary shares held by Deep Track Biotechnology Master
Fund, Ltd. (“Deep Track Fund”) acting on behalf of funds it manages. Deep Track Fund is controlled by Deep Track Capital GP, LLC.
The latter is controlled by Mr. David Kroin who is also its managing member. The principal business address of the Deep Track Entities is
200 Greenwich Avenue 3rd Floor, Greenwich, CT 06830, United States.
(6)The information in this footnote is based on a Schedule 13G/A filed with the SEC on February 14, 2024 by Venrock Healthcare Capital
Partners III, L.P. and related entities and persons and the company’s records. Consists of (i) 2,800,204 ordinary shares held by Venrock
Healthcare Capital Partners EG, L.P. (“VHCP EG”), (ii) 737,581 ordinary shares held by Venrock Healthcare Capital Partners III, L.P.
(“VHCP III”) and (iii) 73,785 ordinary shares held by VHCP Co-Investment Holdings III, LLC (“VHCP Co-Investment”). VHCP
Management III, LLC (“VHCPM”) is the sole general partner of VHCP III and the sole manager of VHCP Co-Investment. VHCP
Management EG, LLC (“VHCPM EG”) is the sole general partner of VHCP EG. Dr. Bong Koh and Nimish Shah are the voting members
of VHCPM and VHCPM EG. The principal business address of the Venrock Entities is 7 Bryant Park, 23rd Floor, New York, NY 10018,
United States.
(7)Consists of 38,145 ordinary shares held as of February 29, 2024.
(8)Consists of (a) 374 ordinary shares held as of February 29, 2024 and (b) up to 67,000 ordinary shares issuable upon the exercise of
options and warrants that are immediately exercisable or exercisable within 60 days of February 29, 2024.
(9)Consists of (a) one ordinary share held as of February 29, 2024 and (b) up to 67,373 ordinary shares issuable upon the exercise of options
and warrants that are immediately exercisable or exercisable within 60 days of February 29, 2024.
(10)Consists of 35,773 ordinary shares held as of February 29, 2024.
(11)Consists of up to 16,400 ordinary shares issuable upon the exercise of options and warrants that are immediately exercisable or
exercisable within 60 days of February 29, 2024.
(12)Consists of up to 16,400 ordinary shares issuable upon the exercise of options and warrants that are immediately exercisable or
exercisable within 60 days of February 29, 2024.
(13)Consists of 4,064,739 ordinary shares held by Sofinnova Crossover, as described in footnote 4 above. Kinam Hong, a member of our
Board, is a member of the investment committee of Sofinnova Crossover and may be deemed to have shared voting and investment
control over the shares held by Sofinnova Crossover, as described in footnote 4 above.
(14)Consists of (a) 741,541 ordinary shares held as of February 29, 2024 and (b) up to 96,924 ordinary shares issuable upon the exercise of
options and warrants that are immediately exercisable or exercisable within 60 days of February 29, 2024. Effective as of March 28, 2024,
Santé Holdings SRL resigned from our board of directors.
(15)Consists of (a) 275,000 ordinary shares held as of February 29, 2024 and (b) 4,865,007 ordinary shares held by the Truffle Entities, as
described in footnote 1 above. Dr. Philippe Pouletty, a member of our Board, controls Truffle Capital and may be deemed to have shared
voting and investment control over the shares held by the Truffle Entities, as described in footnote 1 above.
As of December 31, 2023, to the best of our knowledge, we estimate that 10,589,234 of our outstanding
ordinary shares (including ordinary shares in the form of ADSs) were held by eight shareholders of record in the
United States. The actual number of holders is greater than these numbers of record holders, and includes beneficial
owners whose ordinary shares or ADSs are held in street name by brokers and other nominees. This number of
holders of record also does not include holders whose shares may be held in trust by other entities.
B.Related Party Transactions
Since January 1, 2023, we have engaged in the following transactions with our directors, executive officers
and holders of more than 5% of our outstanding voting securities and their affiliates, which we refer to as to our
related parties.
Issuances of Securities
We issued 20,000,000 ordinary shares in a private placement on February 23, 2023 and 20,325,500 ordinary
shares in the U.S. Offering on October 24, 2023. The following table summarizes the ordinary shares acquired in
140
connection with these offerings by our executive officers, directors and holders of more than 5% of our outstanding
voting securities.
Entities affiliated with Truffle Capital | Sofinnova Crossover | TCG Crossover | Entities affiliated With Venrock | Deep Track Capital | Invus | ||
Private placement in 2023 ........... | Number of ordinary shares purchased (#) | — | 1,535,000 | 2,650,000 | 1,150,000 (1) | 2,000,000 | 2,150,000 |
Purchase price per share (€) | — | 6.50 | 6.50 | 6.50 | 6.50 | 6.50 | |
U.S. Initial Public Offering in 2023 | Number of ordinary shares purchased (#) | 265,000(2) | 1,200,000 | 1,100,000 | 700,000(3) | 1,750,000 | 1,500,000 |
Purchase price per share (€) | 10.99 | 10.99 | 10.99 | 10.99 | 10.99 | 10.99 |
(1)Consists of (i) 817,420 ordinary shares subscribed by VHCP EG, (ii) 302,335 ordinary shares subscribed by
VHCP III, and (iii) 30,245 ordinary shares subscribed by VHCP Co-Investment.
(2)Consists of (i) 265,000 ordinary shares subscribed by Truffle Medeor, which is controlled by Truffle
Capital, itself controlled at 39.66% (of the share capital) respectively by Dr. Philippe Pouletty, a member of
our Board, and Mr. Bernard-Louis Roques. The principal business address of the Truffle Entities is 5 rue de
la Baume, 75008, Paris, France.
(3)Consists of 700,000 ordinary shares subscribed by Venrock Healthcare Capital Partners EG, L.P.
We further issued one ordinary share on June 2, 2021 to the benefit of Mr. Pierre Courteille, our Chief
Business Officer. Following his exercise of one BCE 2017-4, he holds one ordinary share at an issue price per share
equal to €11.14.
We further issued 18,400 ordinary shares on January 20, 2023 to the benefit of Mr. Didier Scherrer, our Chief
Scientific Officer. Following his exercise of 184 BCE-2014-4, he holds 18,400 ordinary shares at an issue price per
share equal to €0.01.
Arrangements with our Directors and Executive Officers
Director and Executive Officer Compensation
We are parties to employment agreements and other compensation arrangements, including equity
compensation arrangements, with our directors and executive officers in the ordinary course of business. See
“Compensation and Benefits—Compensation of Chief Executive Officer” for information regarding compensation
of the Directors and Executive Officers.
Related Person Transaction Policy
We comply with French law regarding approval of transactions with related parties. In particular, in
accordance with article L.225-38 and seq. of the French Commercial Code, transactions with our general managers,
directors, shareholders holding more than 10% of the voting rights of the company and any company controlling a
shareholder holding more than 10% of our voting rights, other than transactions in the ordinary course of business
and at arm’s length, are (i) subject to a prior approval by the Board, (ii) reported to the statutory auditors who must
then prepare a report on such transaction, and (iii) ratified by the our shareholders at the annual general meeting.
In addition, we have adopted a related-party transaction policy that sets forth our procedures for the
identification, review, consideration and approval or ratification of related-party transactions. For purposes of our
policy only, a related-party transaction is defined as (1) any individual or series of financial transactions,
arrangements or relationships (including any indebtedness or guarantee of indebtedness), in which we and any
related parties are, were or will be participants, or otherwise have a direct or indirect interest, or (2) any agreement
or similar transaction under French law which falls within the scope of Article L. 225-38 of the French Commercial
141
Code. For purposes of this policy, a related party is any person who is or at any time since the beginning of the our
last fiscal year was, a director, director nominee, executive officer, beneficial owner of more than 5% of any class of
our voting securities or any immediate family member(s) of the foregoing persons, or any firm, corporation or other
entity in which any of the foregoing persons is employed or is a partner or principal or in a similar position or in
which such person has more than a 5% beneficial ownership interest. Under the policy, related-party transactions
must be reported to us by the relevant related parties. If a transaction has been identified as a related-party
transaction, management must present information regarding the related-party transaction to our Board for review,
consideration and approval or ratification. Regarding certain transactions, our Board may appoint an independent
expert whenever the signing of a related person transaction is likely to have a material impact on our balance sheet
or results. In this case, this expert review will be mentioned in the special report of the statutory auditors and
disclosed to the public subject, as the case may be, to any information likely to adversely affect trade secret. Our
Board may also seek the opinion of the audit committee and/or of the independent statutory auditors if there is any
doubt about the qualification of a related person transaction subject to his evaluation. When submitted to our
Board’s review, the persons who have a direct or indirect interest in the transaction shall not participate in its review.
C.Interests of Experts and Counsel
Not applicable.
142
Item 8.Financial Information
A.Consolidated Statements and Other Financial Information
Financial Statements
Our consolidated financial statements are included at the end of this annual report, starting at page F-1.
Legal Proceedings
From time to time, we may be involved in various claims and legal proceedings relating to claims arising out
of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are
likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse
impact on us because of defense and settlement costs, diversion of management resources and other factors.
Dividend Policy
We have never declared or paid any cash dividends on our ordinary shares. We do not have any present plan
to pay any cash dividends on our equity securities in the foreseeable future. We currently intend to retain all of our
available funds and any future earnings to operate and expand our business. For as long as any amount is
outstanding under the Kreos / Claret Financing, we are not permitted to declare or make any dividend without
consent from KC or Claret. In the event a dividend is made or declared, the terms and conditions of the OCABSAs
and BSAs issued to KC and Claret and the terms and conditions of the convertible notes issued to Heights provide
for an adjustment of the conversion ratio. We do not anticipate paying cash dividends on our equity securities in the
foreseeable future and intend to retain all available funds and any future earnings for use in the operation and
expansion of our business, given our state of development.
Subject to the requirements of French law and our by-laws, dividends may only be distributed from our
distributable profits, plus any amount held in our available reserves, which are those reserves other than the legal
and statutory reserves and the revaluation surplus.
If we pay any dividends, we will pay our ADS holders to the same extent as holders of our ordinary shares,
subject to the terms of the deposit agreement, including deduction in respect of the fees and expenses payable
thereunder. See “Description of American Depositary Shares” for further information. Cash dividends on our
ordinary shares, if any, will be paid in euros and converted into U.S. dollars with respect to ADSs, as provided in the
deposit agreement.
B.Significant Changes
Please see Note 3.4 Subsequent Events, included in the audited consolidated financial statements included
elsewhere in this Form 20-F. Other than the events included in this note, no significant changes have occurred.
143
Item 9.The Offer and Listing
A.Offer and Listing Details
Our ADSs have been listed on the Nasdaq Global Market under the symbol “ABVX” since October 20, 2023.
Prior to that date, there was no public trading market for our ADSs. Our ordinary shares have been trading on
Euronext Paris under the symbol “ABVX” since June 2015. Prior to that date, there was no public trading market for
our ordinary shares.
B.Plan of Distribution
Not applicable.
C.Markets
For information regarding the stock exchanges and regulated markets on which our ADSs and ordinary shares
are listed, see “Item 9.A. Offer and Listing Details.
D.Selling Shareholders
Not applicable.
E.Dilution
Not applicable.
F.Expenses of the Issue
Not applicable.
144
Item 10.Additional Information.
A.Share capital
Not applicable.
B.Memorandum and articles of association
The information set forth in Exhibit 2.1 is incorporated herein by reference.
C.Material contracts
Kreos / Claret Financing Agreements
On August 20, 2023, we entered into the Framework Subscription Agreement with KC and Claret, as the
Secured Lenders. Under this Framework Subscription Agreement, we may draw up to €75 million in structured debt
financing in three tranches of €25 million in aggregate principal amount each, as further described below.
The first tranche, with an aggregate principal amount of €25 million, takes the form of senior secured
convertible bonds with warrants attached, which we refer to as the Kreos / Claret OCABSA. We drew the first
tranche on August 21, 2023. On the same date, we repaid all outstanding amounts that remained due under the First
KC Agreement and the Second KC Agreement. The Kreos / Claret OCABSA are convertible into ordinary shares at
any time from their issuance at the request of their holders at a fixed conversion price of €21.2209, subject to
standard adjustments, including anti-dilution and dividend protections.
The second tranche, with an aggregate principal amount of €25 million, takes the form of senior secured non-
convertible bonds. We drew the second tranche on March 28, 2024. The drawdown of the second tranche was
subject to a maximum 10% Debt-To-Market Capitalization Ratio at the time of drawdown. The “Debt-To-Market
Capitalization Ratio” is calculated, on any relevant date, by dividing (i) our indebtedness (including amounts due
under the Kreos / Claret Financing, but excluding amounts due under the Heights Financing), by (ii) our market
capitalization calculated by multiplying the number of our outstanding ordinary shares by the closing price of our
ordinary shares on such relevant date.
The third tranche, with an aggregate principal amount of €25 million, takes the form of senior secured non-
convertible bonds and may be drawn before July 31, 2024, subject to satisfaction of customary closing conditions.
The drawdown of the third tranche is subject to a maximum 10% Debt-To-Market Capitalization Ratio at the time of
drawdown and is conditional on our raising of a minimum of $125 million in gross proceeds through a listing on
Nasdaq before June 30, 2024 (which was achieved in October 2023).
Interest on the Kreos / Claret OCABSA accrues annually at a rate of 9% payable in quarterly installments. The
Kreos / Claret OCABSA’s maturity date is March 31, 2027 and the final repayment date is January 1, 2027.
A variable interest rate of 7.5% plus European Central Bank Base Rate (subject to a minimum interest rate of
2.5% and a maximum interest rate of 4%) applies to each of the second and third tranches. These two tranches will
be repaid monthly through March 31, 2027, after a deferred repayment of the principal (i) until October 1, 2024, for
the second tranche, or February 1, 2025, if the conditions to draw the third tranche are met, and (ii) until February 1,
2025, for the third tranche.
The Kreos / Claret Financing provides for certain restrictive covenants (subject to customary exceptions),
which include, among other things, restrictions on the incurrence of indebtedness, cross-default, the distribution of
dividends and the grant of security interests. As security for the Kreos / Claret Financing, the Secured Lenders
benefit from the grant of first-ranking collateral on our principal tangible and intangible assets, including pledges
over our business (fonds de commerce) as a going concern and intellectual property rights in our lead drug
candidate, as well as pledges over our bank accounts and receivables. Such securities apply to all tranches of the
Kreos / Claret Financing.
As part of the Kreos / Claret Financing, we have issued warrants to the Secured Lenders for a global
subscription price of €1.00, giving them the right to subscribe to up to 214,198 new ordinary shares at an exercise
price of €18.6744.
In the context of one of the conditions for the drawdown of the third tranche of the Kreos / Claret Financing
being met (raising of a minimum of $125 million in gross proceeds through a listing on Nasdaq before June 30,
2024), we issued on November 2, 2023, 405,831 additional warrants to KC and Claret for a global subscription price
of €1.00 giving them the right to subscribe to up to 405,831 new ordinary shares at an exercise price of €9.8563.
The warrants issued to the Secured Lenders can be exercised over a period of seven years from their issuance
date or up until the date of the successful closing of a tender offer for our ordinary shares, whichever is earlier. At
145
the time of exercise of the warrants, the holders of the warrants are eligible to sell part of their warrants to us in
accordance with a put option agreement to allow for a cashless exercise of the warrants.
The Kreos / Claret OCABSA, the non-convertible bonds and the warrants issued in the framework of the
Kreos / Claret Financing will not be listed on any market. The agreements relating to the Kreos / Claret Financing
are governed by French law.
Prior KC Agreements
On July 24, 2018, we entered into the First KC Agreement for €20 million venture loan agreement with KC.
The financing consists of two tranches of structured debt financing: (i) a total principal amount of First Tranche A
Notes of €10 million, comprised of (x) €8 million in non-convertible bonds issued in July 2018 and (y) €2 million in
convertible bonds issued in August 2018 and (ii) a total principal amount of First Tranche B Notes of €10 million,
comprised of (x) €8 million in non-convertible bonds and (y) €2 million in convertible bonds, each issued in May
2019.
On October 12, 2020, we entered into the Second KC Agreement for bonds issue agreement with KC,
pursuant to which we issued bonds in a total principal amount of Second Tranche A Notes of €15 million, comprised
of (i) a €10 million tranche and Second Tranche B Notes of €5 million, with an option to issue Second Tranche C
Notes of an additional €5 million.
On August 21, 2023, we repaid all outstanding amounts that remained due under the First KC Agreement and
the Second KC Agreement.
Heights Convertible Notes
On August 20, 2023, we entered into the Heights Subscription Agreement with Heights. Under the Heights
Subscription Agreement, we may draw up to €75 million of the Heights Convertible Notes in two tranches of €35
million and €40 million, respectively, as further described below.
The first tranche in aggregate principal amount of €35 million was drawn on August 24, 2023. On the same
date, we repaid all amounts due under the OCEANE bonds. The Heights Convertible Notes are convertible into
ordinary shares at any time from their issuance at the request of the holder at a fixed conversion price set at
€23.7674, subject to standard adjustments, including anti-dilution and dividend protections.
The second tranche in aggregate principal amount of up to €40 million may be drawn during the period from
the date immediately following the three-month anniversary of the issuance of the first tranche to the first-year
anniversary of the issuance of the first tranche. It may be drawn in up to two separate closings.
The amount available for drawdown under the second tranche will be determined based on our market
capitalization (based on seven (7) of the ten (10) trading days immediately preceding such drawdown) (“Average
Market Capitalization”) and the average daily valued traded of our ordinary shares (“ADVT”) over the three-month
period preceding the drawdown, as follows:
Average Market Capitalization | ADVT | Maximum Cumulated Amount Outstanding Under Both First and Second Tranches of the Heights Financing |
At least €700,000,000 | At least €900,000 | €45,000,000 |
At least €850,000,000 | At least €1,250,000 | €55,000,000 |
At least €1,000,000,000 | At least €1,500,000 | €65,000,000 |
Interest on the Heights Convertible Notes accrues annually at a rate of 6% payable in quarterly installments in
cash or, at our option, in ordinary shares.
The Heights Convertible Notes will be repaid through sixteen quarterly installment payments, beginning three
months after their issuance date (corresponding, for the first tranche, to a final repayment date on August 24, 2027).
Installments are payable in cash or, at our option, in ordinary shares.
Any interest or installment payments in shares will be made on the basis of a share price equal to 90% of the
Market Price of our ordinary shares at the time of payment. “Market Price” refers to the arithmetic average of the
daily VWAP for our ordinary shares on the two (2) days with the lowest daily VWAPs out of the five (5) trading
days immediately preceding the applicable date, but in no event greater than the VWAP of our ordinary shares on
the applicable date. The Market Price may not be higher than the applicable conversion price. Issuances of ordinary
shares may not be made at a price lower than a 15% discount to the 15-day VWAP at the time of the decision to
issue the Heights Convertible Notes (i.e., €14.4303 per ordinary share for the first tranche).
Upon the occurrence of certain events (including a change of control of Abivax, a free float event or a
delisting of our ordinary shares on Euronext Paris), any noteholder will have the option to require us to redeem all,
and no less than all, of its Heights Convertible Notes at par plus accrued but unpaid interest. In the event that our
146
ordinary shares are targeted by a public offer (in cash or in securities, in cash and securities, etc.) which may result
in a change of control or filed following a change of control, upon conversion of the Heights Convertible Notes, we
shall (i) deliver new ordinary shares at the conversion price, and (ii) pay a cash amount equal to the sum of the
remaining coupons scheduled until the maturity date, and any accrued interest.
The terms and conditions of the Heights Convertible Notes include a standard negative pledge providing that
any security granted in favor of other borrowed debt or debt instruments should also be granted in favor of the
Heights Convertible Notes on an equal basis (with the exception of the securities issued pursuant to the Kreos /
Claret Financing, as described above).
The Heights Financing is a senior, unsecured financing. The convertible bonds of the Heights Financing will
not be listed on any market. The agreements relating to the Heights Financing are governed by French law.
OCEANE Bonds
On July 30, 2021, we issued €25 million 6% convertible senior unsecured and unsubordinated bonds due July
30, 2026 corresponding to 654,621 OCEANE bonds. The OCEANE bonds were exchangeable, at the option of the
bondholders, for new or existing shares and bear interest at a rate of 6% per annum, payable semi-annually on
January 30 and July 30 of each year, beginning January 30, 2022. On August 24, 2023, we repaid all amounts due
under the OCEANE bonds.
Royalty Certificates
On August 31, 2022, we issued €2.9 million in royalty certificates (the “Royalty Certificates”).
The terms and conditions of the Royalty Certificates provide holders with the right to royalties equal to 2% of
the future net sales of obefazimod (worldwide and for all indications) following its commercialization. The amount
of royalties that may be paid under the Royalty Certificates is capped at €172 million (the “Royalty Cap”). The
Royalty Certificates do not provide for any dividend rights, coupon payments or any other additional financial rights
other than the right to royalties. In particular, the Royalty Certificates do not grant any financial rights in respect of
any other products that may be developed by us beyond obefazimod.
The Royalty Certificates have a term of 15 years and do not provide for an accelerated repayment in case of a
change of control. We may at any time repay the Royalty Certificates in full by paying an amount equal to the
Royalty Cap minus any royalties paid prior to such reimbursement. The Royalty Certificates are subject to a one-
year lock-up, after which they will become freely transferable by each holder thereof in whole, but not in part. The
Royalty Certificates are not listed nor assigned an ISIN.
Share Purchase Agreement
On April 1, 2022, we entered into a share purchase agreement pursuant to which we acquired 100% of the
capital and voting rights of Prosynergia S.à.r.L, a Luxembourg biotech company, registered in the Luxembourg
Trade and Companies Register under no. B257479, with registered offices located at 241 route de Longwy – 1941
Luxembourg City, Luxembourg for consideration of €3.25 million (the “Prosynergia Agreement”).
On December 1, 2021, we granted a loan to Prosynergia, for €1,400,000. On December 12, 2022, we
completed a merger with Prosynergia through a Transmission Universelle du Patrimoine (“TUP”) and all of
Prosynergia’s assets and liabilities were transferred to us. Following the merger, Prosynergia was dissolved. See
Note 3.2 to our audited financial statements as of and for the years ended December 31, 2021, 2022 and 2023
included in this Annual Report on Form 20-F.
IQVIA Master Services Agreement
On December 17, 2018, we entered into a master services agreement with IQVIA Ltd (“IQVIA”) for the
provision of clinical trial services, research and other services for individual clinical trials on human beings (the
“IQVIA Master Services Agreement”), as amended on September 9, 2022.
Pursuant to the IQVIA Master Services Agreement and underlying Work Order, IQVIA agreed to perform
certain services on our behalf as we request, subject to IQVIA’s acceptance of the services and related budget in the
applicable Work Order, including, but not limited to, strategic planning, expert consultation, clinical trial services,
statistical programming and analysis, data processing, data management, regulatory, project management,
pharmacovigilance, central laboratory services, clinical pharmacology services, electrocardiogram services and
device services. In consideration therefore, we agreed to pay IQVIA an agreed set of fees based on our requests, as
set forth in the applicable Work Order. We have the right to terminate the IQVIA Master Services Agreement or
requested work without cause and at any time upon 45 days’ written notice. We and IQVIA each have the right to
terminate the IQVIA Master Services Agreement in the event of a breach by the other party, if such breach has not
been substantially cured within the 30-day period. We have the right to terminate the IQVIA Master Services
Agreement and/or any Work Order with immediate effect by written notice and without any liability whatsoever in
case IQVIA becomes debarred.
147
Pursuant to the IQVIA Master Services Agreement and a study specific Work Order executed with IQVIA,
IQVIA is responsible for coordinating our Phase 3 clinical trial for obefazimod in moderately to severely active UC.
Evotec Drug Discovery Services Agreement
On September 1, 2017, we entered into a drug discovery services agreement with Evotec International GmbH
(“Evotec”), pursuant to which Evotec provides drug discovery services to us, in order to have optimized leads
obtained for various viral indications for further developments within the context of a global collaborative program
and to any further development programs under which we would require the assistance of Evotec in the provision of
services (the “Evotec Drug Discovery Services Agreement”). Under the Evotec Drug Discovery Services
Agreement, Evotec must provide its services in accordance with common industry standard of current established
practices by suitably qualified staff, using equipment in an agreed premises, under allocated timelines agreed
between the parties and in compliance with all relevant legislation. Evotec may not subcontract its obligations to us
other than to an affiliate without our express prior written consent.
In consideration for services provided, we are required to pay Evotec an agreed set of fees as agreed in the
relevant project description relating to such services. To the extent additional projects are completed under the
agreement, additional amounts may be payable to Evotec, but they are not determinable as of the date of this Annual
Report on Form 20-F. We own, and Evotec assigns to us to the extent permissible under applicable law, all
intellectual property rights conceived, discovered, invented or made by Evotec in connection with the provision of
drug discovery services. No milestone payments or royalties are payable pursuant to the Evotec Drug Discovery
Services Agreement. No drug candidate has currently been discovered pursuant to this agreement.
We have the right to terminate Evotec Drug Discovery Services Agreement or any project without cause at
any time upon 60 days’ written notice. We and Evotec each have the right to terminate any ongoing project upon 20
days’ written notice for a breach by the other party, if such breach has not been remedied within the 20-day period.
Delpharm Agreement
On November 24, 2016, we entered into a manufacturing agreement with Delpharm Lille S.A.S.
(“Delpharm”), pursuant to which Delpharm produces batches of capsules containing obefazimod required to carry
out clinical trials (the “Delpharm Agreement”). The Delpharm Agreement renews automatically for successive
periods of one year until either party notifies the other of its intention not to renew the agreement. The agreement is
still in effect on the date hereof. Either party may terminate the agreement upon serious breach or a serious non-
execution of the agreement by the other party. Abivax may also terminate the Delpharm Agreement at any time,
subject to certain reimbursement obligations to Delpharm.
Seqens Agreement
On March 11, 2016, we entered into a clinical batch development and production agreement with “Produits
Chimiques Auxiliaires et de Synthèse” (“Seqens”), under which Seqens provides services relating to the
development and production of active ingredients, including obefazimod (the “Seqens Agreement”). The Seqens
Agreement was amended on March 2, 2021, in connection with our UC Phase 3 clinical trials. In accordance with
the Seqens Agreement, in consideration for services provided, we are required to pay Seqens an agreed set of fees as
agreed in the relevant Work Order.
The Seqens Agreement remains in full force and effect until the earlier of (i) the execution of an agreement for
the commercial manufacturing by Seqens of obefazimod under Phase IV, such agreement to be negotiated between
Seqens and us in good faith, (ii) the failure to reach such a Phase IV agreement or (iii) the failure to obtain all
marketing approval by the FDA and other relevant regulators in Europe.
According to the Seqens Agreement, either party may terminate the agreement in the event of the other party’s
failure to perform one or more of its obligations. This termination shall only become effective one month after the
issuance by the complaining party of a registered letter with acknowledgement of receipt setting out the reasons for
the complaint, unless within this period the defaulting party has fulfilled its obligations or has provided proof of an
impediment due to force majeure. The termination may take effect without delay by simple written notification in
case of fraud or intentional fault by the party in default.
According to the Seqens Agreement, we have the right to postpone or terminate any pending work at any time
upon 30 days prior written notice, subject to payment to Seqens of the sums due in proportion to the actual progress
of the work on the day of receipt by Seqens of its notification, as well as any costs incurred prior to such receipt by
Seqens that would be non-revocable and not subject to reallocation within a reasonable time.
State-Guaranteed Loan
On June 11, 2020, we obtained non-dilutive financing from Société Générale in the form of a €5 million State-
guaranteed loan (the “State-guaranteed loan”). The State-guaranteed loan had an initial duration of 12 months
(subject to a five-year extension option) and accrues interest at a rate of 0.25% with repayment of principal falling
due in June 2021. The State-guaranteed loan was immediately made available to us in June 2020. In March 2021, we
entered into an amendment to the State-guaranteed loan, which extended the repayment date of the State- guaranteed
148
loan by five years until June 2026 with a one-year deferral of principal repayment, with the following conditions: (i)
a revised interest rate of 0.58% per annum, excluding insurance and State-guaranteed premium; and (ii) a State-
guaranteed premium of €0.1 million to be paid by installments over the contract period starting in June 2021. The
State-guaranteed loan includes certain customary covenants and prepayment provisions, as well as a negative
covenant restricting the disposal of assets representing more than 50% of the gross value of our fixed assets.
Royalties Agreement
On December 18, 2008, we entered into an agreement with (i) the CNRS, (ii) the University of Montpellier,
and (iii) the Institut Curie, which sets out financial conditions under which we can use any intellectual property
rights and research results derived from certain research collaboration programs we had with the CNRS, the
University of Montpellier, and the Institut Curie and which have now been terminated (the “Royalties Agreement”).
Pursuant to the Royalties Agreement, the CNRS and the Institut Curie are entitled to receive milestone
payments, as well as royalty payments on global net sales of products using the intellectual property rights and
research results jointly developed with them (including obefazimod) (each, a “Qualifying Product”). The amounts of
the milestone payments for each Qualifying Product are limited and not material compared to the amount of the
expected royalties.
In case we commercialize directly a Qualifying Product (either (i) implementing the jointly developed patents
and the jointly developed know-how or (ii) only implementing the jointly developed know-how), royalties due under
the Royalties Agreement are in the low single-digit percentages subject to an annual minimum.
In the event we commercialize a Qualifying Product by way of a license granted to a third-party, we may elect
(i) to pay royalties calculated in the same manner as if we were commercializing the Qualifying Product directly, or
(ii) to pay royalties (high single-digit to low double-digit percentages) calculated based on the revenues we receive
under the license granted to the third-party. We must notify the CNRS regarding which royalty amount we elect to
pay at the same time that the third-party grants the license.
For the avoidance of doubt, the Royalties Agreement does not include any cap on the total payments which
may be due by us under such Royalties Agreement.
The Royalties Agreement survives until the expiration of the underlying intellectual property rights (without
any termination rights to either party).
D.Exchange Controls
Under current French foreign exchange control regulations there are no limitations on the amount of cash
payments that we may remit to residents of foreign countries. Laws and regulations concerning foreign exchange
controls do, however, require that all payments or transfers of funds made by a French resident to a non-resident
such as dividend payments be handled by an accredited intermediary. All registered banks and substantially all
credit institutions in France are accredited intermediaries.
E.Taxation
The summary set forth below describes certain French and U.S. federal income tax consequences relating to
the purchase, ownership and disposition of the ADSs to U.S. Holders (as defined below) as of the date hereof. This
summary does not represent a detailed description of the tax consequences applicable to a U.S. Holder that is
subject to special treatment under the U.S. federal tax laws, including, without limitation:
•certain financial institutions;
•traders in securities who use a mark-to-market method of tax accounting;
•dealers in securities or currencies;
•persons holding ADSs as part of a hedging transaction, “straddle,” wash sale, conversion transaction or
integrated transaction or persons entering into a constructive sale with respect to the ADSs;
•regulated investment companies;
•insurance companies;
•real estate investment trusts, grantor trusts or other trusts;
•persons whose “functional currency” for U.S. federal income tax purposes is not the U.S. dollar;
•expatriates of the United States;
149
•tax exempt entities, including “individual retirement accounts” and “Roth IRAs”;
•entities or arrangements classified as partnerships or other pass-through entities for U.S. federal
income tax purposes (and investors therein);
•persons that received ADSs as compensation for the performance of services;
•persons that own or are deemed to own ten percent or more of our shares (by vote or value); and
•persons holding ADSs in connection with a trade or business, permanent establishment, or fixed base
outside the United States.
This summary is for general information only. Prospective Investors considering the purchase,
ownership or disposition of the ADSs are advised to consult their own tax advisers concerning the French and
U.S. federal income tax consequences in light of their particular facts and circumstances, as well as any
consequences arising under the laws of any other taxing jurisdiction.
French Income Tax Considerations
The following describes the material French income tax consequences to U.S. Holders (as defined below) of
purchasing, owning and disposing of our ADSs and, unless otherwise noted, this discussion is the opinion of
Dechert, our French tax counsel, insofar as it relates to matters of French tax law and legal conclusions with respect
to those matters.
This discussion does not purport to be a complete analysis or listing of all potential tax effects of the
acquisition, ownership or disposition of our ADSs to any particular investor, and does not discuss tax considerations
that arise from rules of general application or that are generally assumed to be known by investors. All of the
following is subject to change. Such changes could apply retroactively and could affect the consequences described
below.
In 2011, France introduced a comprehensive set of new tax rules applicable to French assets that are held by or
in foreign trusts. These rules, among other things, provide for the inclusion of trust assets in the settlor’s net assets
for purpose of applying the former French wealth tax (replaced by the French real estate wealth tax as from
January 1, 2018), for the application of French gift and death duties to French assets held in trust, for a specific tax
on capital on the French assets of foreign trusts not already subject to the former French wealth tax (replaced by the
French real estate wealth tax as from January 1, 2018) and for a number of French tax reporting and disclosure
obligations. The following discussion does not address the French tax consequences applicable to ADSs held in
trusts. If ADSs are held in trust, the grantor, trustee and beneficiary are urged to consult their own tax adviser
regarding the specific tax consequences of acquiring, owning and disposing of ADSs.
The description of the French income tax and real estate wealth tax consequences set forth below is based on
the Convention Between the Government of the United States of America and the Government of the French
Republic for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on
Income and Capital of August 31, 1994 which came into force on December 30, 1995 (as amended by any
subsequent protocols, including the protocol of January 13, 2009, or the "Treaty") and the tax guidelines issued by
the French tax authorities in force as of the date of this Annual Report on Form 20-F.
For the purposes of this discussion, the term “U.S. Holder” means a beneficial owner of ADSs that is (or is
treated as), for U.S. federal income tax purposes: (1) an individual who is a U.S. citizen or resident, (2) a corporation
or other entity that is treated as a corporation for U.S. federal income tax purposes, created or organized in or under
the laws of the United States or any state thereof, including the District of Colombia, (3) otherwise subject to U.S.
federal income taxation or (4) a trust, if a court within the United States is able to exercise primary supervision over
its administration and one or more U.S. persons have the authority to control all of the substantial decisions of such
trust or has a valid election in effect under applicable U.S. Treasury Regulations to be treated as a United States
person.
If a partnership (or any other entity treated as partnership for U.S. federal income tax purposes) holds ADSs,
the tax treatment of the partnership and a partner in such partnership generally will depend upon the status of the
partner and the activities of the partnership. If a U.S. Holder is a partnership or a partner in a partnership that holds
ADSs, such holder is urged to consult its own tax adviser regarding the specific tax consequences of acquiring,
owning and disposing of securities.
This discussion applies only to investors that hold our ADSs as capital assets that have the U.S. dollar as their
functional currency, that are entitled to Treaty benefits under the “Limitation on Benefits” provision contained in the
150
Treaty, and whose ownership of the ADSs is not effectively connected to a permanent establishment or a fixed base
in France. Certain U.S. Holders (including, but not limited to, U.S. expatriates, partnerships or other entities
classified as partnerships for U.S. federal income tax purposes, banks, insurance companies, regulated investment
companies, tax-exempt organizations, financial institutions, persons subject to the alternative minimum tax, persons
who acquired the securities pursuant to the exercise of employee share options or otherwise as compensation,
persons that own (directly, indirectly or by attribution) 5% or more of our voting stock or 5% or more of our
outstanding share capital, dealers in securities or currencies, persons that elect to mark their securities to market for
U.S. federal income tax purposes and persons holding securities as a position in a synthetic security, straddle or
conversion transaction) may be subject to special rules not discussed below.
U.S. Holders are urged to consult their own tax advisers regarding the tax consequences of the purchase,
ownership and disposition of securities in light of their particular circumstances, especially with regard to the
“Limitations on Benefits” provision.
Estate and Gift Taxes and Transfer Taxes
In general, a transfer of securities by gift or by reason of death of a U.S. Holder that would otherwise be
subject to French gift or inheritance tax, respectively, will not be subject to such French tax by reason of the
Convention between the Government of the United States of America and the Government of the French Republic
for the Avoidance of Double Taxation and the Prevention of Fiscal Evasion with Respect to Taxes on Estates,
Inheritances and Gifts, dated November 24, 1978 (as amended by any subsequent protocols, including the protocol
of December 8, 2004), unless (i) the donor or the transferor is domiciled in France at the time of making the gift or
at the time of his or her death, or (ii) the securities were used in, or held for use in, the conduct of a business through
a permanent establishment or a fixed base in France.
Financial Transactions Tax
Pursuant to Article 235 ter ZD of the French Tax Code (Code général des impôts) (the “FTC”), purchases of
certain securities issued by a French company, including ordinary shares (which may be in the form of ADSs),
which are listed on a regulated market of the EU or an exchange market formally acknowledged by the Minister of
Economy, after consultation opinion from the AMF (in each case within the meaning of the French Monetary and
Financial Code (the “FMFC”)) are subject in France to a 0.3% tax on financial transactions (the “TFT”), provided
inter alia that the issuer’s market capitalization exceeds €1 billion as of December 1 of the year preceding the
taxation year.
The Nasdaq Global Market, on which ADSs are listed, is not currently acknowledged by the French Minister
of Economy, but it may change in the future.
Moreover, a list of French relevant companies whose market capitalization exceeds €1 billion as of
December 1 of the year preceding the taxation year is published annually by the French State. The last version of
such list was dated December 20, 2023 (BOI-ANNX-000467). It did not include Abivax SA as its market
capitalization did not exceed €1.0 billion.
Purchases of our ADSs may thus be subject to the TFT if (1) Abivax SA’s market capitalization exceeds
€1.0 billion, and (2) the Nasdaq Global Market is acknowledged by the French Minister of Economy.
Registration Duties
In the case where the TFT is not applicable, (1) transfers of shares issued by a French company which are
listed on a regulated or organized market within the meaning of the FMFC are subject to uncapped registration
duties at the rate of 0.1% if the transfer is evidenced by a written statement (“acte”) executed either in France or
outside France, whereas (2) transfers of shares issued by a French company which are not listed on a regulated or
organized market within the meaning of the FMFC are subject to uncapped registration duties at the rate of 0.1%
notwithstanding the existence of a written statement.
As ordinary shares of Abivax SA are listed on Euronext Paris, which is a regulated market within the meaning
of the FMFC, their transfer should be subject to uncapped registration duties at the rate of 0.1% only if such transfer
is evidenced by a written agreement. Although the official guidelines published by the French tax authorities are
silent on this point (BOI-ENR-DMTOM-40-10-10-12/09/2012), ADSs should remain outside of the scope of the
aforementioned 0.1% registration duties.
151
Real Estate Wealth Tax
Since January 1, 2018, the French wealth tax (impôt de solidarité sur la fortune) has been repealed and
replaced by the French real estate wealth tax (impôt sur la fortune immobilière).
The scope of such new tax is narrowed to real estate assets (and certain assets deemed to be real estate assets)
or rights, held directly or indirectly through one or more legal entities and whose net taxable assets amount at least
to €1,300,000.
Broadly, subject to provisions of double tax treaties and to certain exceptions, individuals who are not
residents of France for tax purposes within the meaning of Article 4 B of the FTC, are subject to real estate wealth
tax (impôt sur la fortune immobilière) in France in respect of the portion of the value of their shares of our company
representing real estate assets (Article 965, 2° of the FTC). Some exceptions are provided by the FTC. For instance,
any participations representing less than 10% of the share capital of an operating company and shares representing
real estate for the professional use of the company considered shall not fall within the scope of the French real estate
wealth tax (impôt sur la fortune immobilière). Under the Treaty (the provisions of which should be applicable to this
new real estate wealth tax (impôt sur la fortune immobilière) in France), the French real estate wealth tax (impôt sur
la fortune immobilière) will however generally not apply to securities held by an eligible U.S. Holder who is a U.S.
resident, as defined pursuant to the provisions of the Treaty, provided that such (i) U.S. Holder (a) does not own
directly or indirectly more than 25% of the issuer’s financial rights and (b) that the ADSs do not form part of the
business property of a permanent establishment or fixed base in France and (ii) that the issuer’s assets do not consist
in at least 50 percent of real property located in France, or that the issuer’s shares do not derive at least 50 percent of
their value, directly or indirectly, from real property located in France.
U.S. Holders are advised to consult their own tax advisor regarding the specific tax consequences which may
apply to their particular situation with respect to such French real estate wealth tax (impôt sur la fortune
immobilière).
Taxation of Dividends
Dividends paid by a French corporation to non-residents of France are generally subject to French withholding
tax at a rate of currently (i) 25% for dividends paid to legal persons which are not French tax residents, and (ii)
12.8% for dividends paid to individuals who are not French tax residents. Dividends paid by a French corporation in
a non-cooperative State or territory, as defined in Article 238-0 A of the FTC, other than those states or territories
mentioned in 2° of 2 bis of the same Article 238-0 A will generally be subject to French withholding tax at a rate of
75%. However, eligible U.S. Holders entitled to Treaty benefits under the “Limitation on Benefits” provision
contained in the Treaty who are U.S. residents, as defined pursuant to the provisions of the Treaty, will not be
subject to this 12.8%, 25% or 75% withholding tax rate, but may be subject to the withholding tax at a reduced rate
(as described below).
Under the Treaty, the rate of French withholding tax on dividends paid to an eligible U.S. Holder who is a
U.S. resident as defined pursuant to the provisions of the Treaty and the beneficial owner of these dividends, and
whose ownership of the ordinary shares (which may be in the form of ADSs) is not effectively connected with a
permanent establishment or fixed base that such U.S. Holder has in France, is generally reduced to 15%, or to 5% if
such U.S. Holder is a corporation and owns directly or indirectly at least 10% of the share capital of the issuer; such
U.S. Holder may claim a refund from the French tax authorities of the amount withheld in excess of the Treaty rates
of 15% or 5%, if any.
For U.S. Holders that are not individuals but are U.S. residents, as defined pursuant to the provisions of the
Treaty, the requirements for eligibility for Treaty benefits, including the reduced 5% or 15% withholding tax rates
contained in the “Limitation on Benefits” provision of the Treaty, are complicated, and certain technical changes
were made to these requirements by the protocol of January 13, 2009. U.S. Holders are advised to consult their own
tax advisers regarding their eligibility for Treaty benefits in light of their own particular circumstances.
Dividends paid to an eligible U.S. Holder may immediately be subject to the reduced rates of 5% or 15%
provided that:
•such holder establishes before the date of payment that it is a U.S. resident under the Treaty by
completing and providing the depositary with a treaty form (Form 5000) in accordance with French
guidelines (BOI-INT-DG-20-20-20-20-12/09/2012); or
•the depositary or other financial institution managing the securities account in the U.S. of such U.S.
Holder provides the French paying agent with a document listing certain information about the U.S.
Holder and its ordinary shares or ADSs and a certificate (BOI-LETTRE-000138-28/07/2014) whereby
152
the financial institution managing the U.S. Holder’s securities account in the United States takes full
responsibility for the accuracy of the information provided in the document.
Otherwise, dividends paid to a U.S. Holder, if such U.S. Holder is a legal person, will be subject to French
withholding tax at the rate of 25%, or 75% if paid in a non-cooperative State or territory (as defined in Article 238-0
A of the FTC, but other than those states or territories mentioned in 2° of 2 bis of the same Article 238-0 A), and
then reduced at a later date to 5% or 15%, provided that such holder duly completes and provides the French tax
authorities with the treaty forms Form 5000 and Form 5001 before December 31 of the second calendar year
following the year during which the dividend is paid.
Certain qualifying pension funds and certain other tax-exempt entities are subject to the same general filing
requirements as other U.S. Holders except that they may have to supply additional documentation evidencing their
entitlement to these benefits.
Since the withholding tax rate applicable under French domestic law to U.S. Holders who are individuals does
not exceed the cap provided in the Treaty (i.e., 15%), the 12.8% rate shall apply, without any reduction provided
under the Treaty.
Besides, please note that pursuant to Article 235 quater of the FTC (introduced by the French finance bill
No. 2019-1479 for 2020) and under certain conditions, a corporate U.S. Holder which is in a tax loss position for the
fiscal year during which the dividend is received may be entitled to a deferral regime, and obtain a withholding tax
refund. The tax deferral ends in respect of the first financial year during which this U.S. Holder is in a profit making
position, as well as in the cases set out in Article 235 quater of the FTC. Finance Bill for 2022 extended the deadline
to claim the refund (December 31 of the second year following the year of payment instead of three months after the
end of the fiscal year following the payment of the income) and clarify the order in which the deferred taxes become
due (the forfeiture of the deferral applies in priority to the oldest withholding taxes). Also, pursuant to newly
introduced Article 235 quinquies of the FTC and under certain conditions, a corporate U.S. Holder may be entitled
to a refund of a fraction of the withholding tax, up to the difference between the withholding tax paid (on a gross
basis) and the withholding tax based on the dividend net of the expenses incurred for the acquisition and
conservation directly related to the income, provided (i) that these expenses would have been tax deductible had the
U.S. Holder been established in France, and (ii) that the tax rules in the United States do not allow the U.S. Holder
to offset the withholding tax.
Tax on Sale or Other Disposition
In general, under the Treaty, a U.S. Holder who is a U.S. resident for purposes of the Treaty will not be
subject to French tax on any capital gain from the redemption (other than redemption proceeds characterized as
dividends under French domestic tax law or administrative guidelines), sale or exchange of ADSs unless the ADSs
form part of the business property of a permanent establishment or fixed base that the U.S. Holder has in France.
Special rules apply to U.S. Holders who are residents of more than one country.
Material U.S. Federal Income Tax Considerations for U.S. Holders
The following is a description of the material U.S. federal income tax consequences to the U.S. Holders
described below of acquiring, owning and disposing of the ADSs. It is not a comprehensive description of all tax
considerations that may be relevant to a particular person’s decision to acquire securities. This discussion applies
only to a U.S. Holder that holds ADSs as “capital assets” (generally, property held for investment) under the U.S.
Internal Revenue Code of 1986, as amended (the “Code”). In addition, it does not describe all of the tax
considerations that may be relevant in light of a U.S. Holder’s particular circumstances, including U.S. federal estate
and gift taxes, the Medicare contribution tax on net investment income, the alternative minimum tax provisions of
the Code, the special tax accounting rules under Section 451(b) of the Code, any state, local, or non-U.S. tax
considerations, and tax considerations applicable to U.S. Holders subject to special rules, including, without
limitation:
•certain financial institutions;
•traders in securities who use a mark-to-market method of tax accounting;
•dealers in securities or currencies;
•persons holding ADSs as part of a hedging transaction, “straddle,” wash sale, conversion transaction or
integrated transaction or persons entering into a constructive sale with respect to the ADSs;
•regulated investment companies;
153
•insurance companies;
•real estate investment trusts, grantor trusts or other trusts;
•persons whose “functional currency” for U.S. federal income tax purposes is not the U.S. dollar;
•expatriates of the United States;
•tax exempt entities, including “individual retirement accounts” and “Roth IRAs”;
•entities or arrangements classified as partnerships or other pass-through entities for U.S. federal
income tax purposes (and investors therein);
•persons that received ADSs as compensation for the performance of services;
•persons that own or are deemed to own ten percent or more of our shares (by vote or value); and
•persons holding ADSs in connection with a trade or business, permanent establishment, or fixed base
outside the United States.
If an entity or arrangement that is classified as a partnership for U.S. federal income tax purposes holds the
ADSs, the U.S. federal income tax treatment of a partner in that partnership will generally depend on the status of
the partner and the activities of the partnership. Partnerships holding the ADSs and partners in such partnerships are
encouraged to consult their own tax advisers as to the particular U.S. federal income tax consequences of acquiring,
owning, and disposing of the ADSs.
This description is based on the Code, existing, proposed and temporary U.S. Treasury Regulations
promulgated thereunder and administrative and judicial interpretations thereof, in each case as in effect and available
on the date hereof. All of the foregoing is subject to change, which change could apply retroactively, and to differing
interpretations, all of which could affect the tax considerations described below. No rulings have been sought from
the U.S. Internal Revenue Service (the “IRS”), regarding the matters discussed herein and there can be no assurance
that the IRS will not take a contrary position concerning the tax consequences of the acquisition, ownership and
disposition of the ADSs or that such a position would not be sustained. U.S. Holders should consult their own tax
advisers concerning the U.S. federal, state, local and non-U.S. tax consequences of acquiring, owning, and disposing
of the ADSs in their particular circumstances.
As used for purposes of this section “—Material U.S. Federal Income Tax Considerations for U.S. Holders”, a
“U.S. Holder” is a holder who, for U.S. federal income tax purposes, is a beneficial owner of the ADSs that is an
initial purchaser of the ADSs sold in our initial public offering of our ADSs in the United States and is:
•an individual who is a citizen or resident of the United States;
•a corporation, or other entity taxable as a corporation, created or organized in or under the laws of the
United States, any state therein or the District of Columbia;
•an estate whose income is eligible for inclusion in gross income for U.S. federal income tax purposes,
regardless of its source; or
•a trust, if (A) a U.S. court is able to exercise primary supervision over the trust’s administration and
one or more United States persons (as such term is defined under the Code) have authority to control
all substantial decisions of the trust, or (B) the trust has a valid election in place under applicable U.S.
Treasury regulations to treat the trust as a United States person (as such term is defined under the
Code).
The discussion below assumes that the representations contained in the depositary agreement are true and that
the obligations in the deposit agreement and any related agreement will be complied with in accordance with its
terms. For U.S. federal income tax purposes, it is generally expected that a U.S. Holder of ADSs will be treated as
the beneficial owner of the underlying ordinary shares represented by the ADSs. The remainder of this discussion
assumes that a U.S. Holder of our ADSs will be treated in this manner. Accordingly, deposits or withdrawals of
ADSs for ordinary shares will generally not be subject to U.S. federal income tax.
U.S. Holders are encouraged to consult their own tax advisers concerning the U.S. federal, state, local
and foreign tax consequences of acquiring, owning and disposing of the ADSs in their particular
circumstances.
154
Taxation of Distributions
Subject to the passive foreign investment company (“PFIC”) rules described below, distributions paid on the
ADSs, other than certain pro rata distributions of the ADSs, will generally be treated as dividends to the extent paid
out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). We
do not maintain calculations of our earnings and profits under U.S. federal income tax principles, and so we expect
that distributions generally will be reported to U.S. Holders as dividends. Subject to applicable limitations, dividends
paid by a “qualified foreign corporation” are eligible for taxation at a preferential capital gains rate rather than the
marginal tax rates generally applicable to ordinary income provided that certain requirements are met. However, if
we are a PFIC (or treated as a PFIC with respect to the U.S. Holder) for the taxable year in which the dividend is
paid or the preceding taxable year (see discussion below under “Passive Foreign Investment Company Rules”), we
will not be treated as a qualified foreign corporation, and therefore the preferential capital gains tax rate described
above will not apply. Each U.S. Holder is advised to consult its tax advisors regarding the availability of the
preferential tax rate on dividends with regard to its particular circumstances.
A non-U.S. corporation (other than a corporation classified as a PFIC for the taxable year in which the
dividend is paid or the preceding taxable year) generally will be considered to be a qualified foreign corporation if:
(i) it is eligible for the benefits of a comprehensive tax treaty with the United States, which the Secretary of Treasury
of the United States determines is satisfactory for purposes of this provision, and which includes an exchange of
information provision; or (ii) with respect to any dividend it pays on shares that are readily tradable on an
established securities market in the United States. We believe that we qualify as a resident of France for the purposes
of, and are eligible for the benefits of, the income tax treaty between France and the United States, which the IRS
has determined is satisfactory for purposes of the qualified dividend rules, and that it includes an exchange of
information provision, although there can be no assurance in this regard. Further, our ADSs will generally be
considered to be readily tradable on an established securities marked in the United States, including the Nasdaq
Global Market. Therefore, subject to the discussion below under “Passive Foreign Investment Company Rules”, if
the income tax treaty between France and the United States is applicable, or if the ADSs are readily tradable on an
established securities market in the United States, dividends paid on the ADSs will generally be “qualified dividend
income” in the hands of individual U.S. Holders, provided that certain conditions are met, including conditions
relating to the holding period and the absence of certain risk reduction transactions.
A U.S. Holder must include the gross amount of a dividend without reduction for amounts withheld by us in
respect of French income taxes (see “Material United States Federal Income and French Tax Considerations—
Certain French Considerations”), even though the U.S. Holder did not in fact receive the amount associated with the
withheld French tax. The amount of the dividend will be treated as foreign-source dividend income to U.S. Holders
and will not be eligible for the dividends-received deduction generally available to U.S. corporations under the
Code. Dividends generally will be included in a U.S. Holder’s income on the date of the U.S. Holder’s receipt (or
deemed receipt) of the dividend. The amount of any distribution of property other than cash (excluding certain pro
rata distributions of ordinary shares or ADSs or rights to acquire ordinary shares or ADSs) will be the fair market
value of such property on the date of the distribution. The amount of any dividend income paid in euros will be the
U.S. dollar amount calculated by reference to the exchange rate in effect on the date of actual or constructive receipt,
regardless of whether the payment is in fact converted into U.S. dollars. If the dividend is converted into U.S. dollars
on the date of receipt, a U.S. Holder should not be required to recognize foreign currency gain or loss in respect of
the dividend income. A U.S. Holder may have foreign currency gain or loss if the dividend is converted into U.S.
dollars after the date of receipt.
Subject to applicable limitations, some of which vary depending upon the U.S. Holder’s particular
circumstances, French income taxes withheld from dividends on the ADSs at a rate not exceeding the rate provided
by the income tax treaty between France and the United States generally will be creditable against the U.S. Holder’s
U.S. federal income tax liability. Dividend distributions with respect to the ADSs generally will be treated as
‘‘passive category’’ income from sources outside the United States for purposes of determining a U.S. Holder’s U.S.
foreign tax credit limitation. The rules governing foreign tax credits are complex and U.S. Holders should consult
their tax advisers regarding the creditability of foreign taxes in their particular circumstances. In lieu of claiming a
foreign tax credit, U.S. Holders may, at their election, deduct foreign taxes, including any French income tax, in
computing their taxable income, subject to generally applicable limitations under U.S. law. An election to deduct
foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the taxable year.
Sale or Other Taxable Disposition of the ADSs
A U.S. Holder generally will recognize gain or loss for U.S. federal income tax purposes upon the sale,
exchange or other taxable disposition of the ADSs in an amount equal to the difference between the U.S. dollar
value of the amount realized from such sale or exchange and the U.S. Holder’s tax basis for those ADSs. Subject to
the PFIC rules described below, this gain or loss generally will be a capital gain or loss. The adjusted tax basis in an
ADS generally will be equal to the cost of such ADS. Capital gain from the sale, exchange or other taxable
155
disposition of ADSs of a non-corporate U.S. Holder is generally eligible for a preferential rate of taxation applicable
to capital gains, if the non-corporate U.S. Holder’s holding period determined at the time of such sale, exchange or
other taxable disposition for such ADSs exceeds one year (i.e., such gain is long-term taxable gain). The
deductibility of capital losses for U.S. federal income tax purposes is subject to limitations under the Code. Any
such gain or loss that a U.S. Holder recognizes generally will be treated as U.S. source income or loss for foreign tax
credit limitation purposes.
For a cash basis taxpayer, units of foreign currency paid or received are translated into U.S. dollars at the spot
rate on the settlement date of the purchase or sale. In that case, no foreign currency exchange gain or loss will result
from currency fluctuations between the trade date and the settlement date of such a purchase or sale. An accrual
basis taxpayer, however, may elect the same treatment required of cash basis taxpayers with respect to purchases
and sales of the ADSs that are traded on an established securities market, provided the election is applied
consistently from year to year. Such election may not be changed without the consent of the IRS. For an accrual
basis taxpayer who does not make such an election, units of foreign currency paid or received are translated into
U.S. dollars at the spot rate on the trade date of the purchase or sale. Such an accrual basis taxpayer may recognize
exchange gain or loss based on currency fluctuations between the trade date and the settlement date. Any foreign
currency gain or loss a U.S. Holder realizes will be U.S. source ordinary income or loss.
Passive Foreign Investment Company Rules
Under the Code, we will be a PFIC for any taxable year in which, after the application of certain “look-
through” rules with respect to subsidiaries, either (i) 75% or more of our gross income consists of “passive
income,” (“income test”) or (ii) 50% or more of the average quarterly value of our assets (generally determined on
the basis of a weighted quarterly average) consist of assets that produce, or are held for the production of, “passive
income.” Passive income generally includes dividends, interest, and gains from the sale or exchange of investment
property and rents or royalties other than rents or royalties which are received from unrelated parties in connection
with the active conduct of a trade or business. Passive assets include, among others, cash and assets readily
convertible into cash, while our goodwill and other unbooked intangibles associated with active business activities
may generally be treated as non-passive assets. In addition, for purposes of the above calculations, a non-U.S.
corporation that owns, directly or indirectly, at least 25% by value of the equity interests of another corporation is
treated as if it held its proportionate share of the assets of the other corporation, and received directly its
proportionate share of the income of the other corporation. If a corporation is treated as a PFIC with respect to a U.S.
Holder for any taxable year, the corporation will continue to be treated as a PFIC with respect to that U.S. Holder in
all succeeding taxable years, regardless of whether the corporation continues to meet the PFIC requirements in such
years, unless certain elections are made.
Based on our analysis of our financial statements, activities and relevant market and shareholder data, we do
not believe that we were a PFIC for the taxable year ended December 31, 2023. The determination of whether we
are a PFIC is a fact-intensive determination made on an annual basis and the applicable law is subject to varying
interpretation. Whether we are a PFIC for any taxable year will depend on the composition of our income and the
composition, nature and value of our assets from time to time (including the value or our goodwill, which may be
determined by reference to the value of our ADSs, which could fluctuate considerably). We currently do not
generate product revenues and therefore we may be a PFIC for any taxable year in which we do not generate
sufficient amounts of non-passive income to offset our passive income. As a result, there can be no assurance that
we will not be treated as a PFIC for the current or any future taxable year and our U.S. counsel expresses no opinion
with respect to our PFIC status for any prior, current or future taxable year. Even if we determine that we are not a
PFIC for a taxable year, there can be no assurance that the IRS, will agree with our conclusion and that the IRS
would not successfully challenge our position. If we are a PFIC for any year during which a U.S. Holder holds the
ADSs, unless certain elections have been made by the U.S. Holder, we generally will continue to be treated as a
PFIC with respect to such U.S. Holder for all succeeding years during which the U.S. Holder holds the ADSs, even
if we cease to meet the threshold requirements for PFIC status.
If we are a PFIC for any taxable year during which a U.S. Holder holds the ADSs, the U.S. Holder may be
subject to adverse tax consequences, regardless of whether we remain a PFIC. Generally, gain recognized upon a
disposition (including, under certain circumstances, a pledge) of the ADSs by the U.S. Holder would be allocated
ratably over the U.S. Holder’s holding period for such ADSs. The amounts allocated to the taxable year of
disposition and to years before we became a PFIC (“pre-PFIC Years”) would be taxed as ordinary income. The
amount allocated to each other taxable years would be subject to tax at the highest rate in effect for that taxable year
for individuals or corporations, as appropriate, and would be subject to an interest charge on the resulting tax
deemed deferred with respect to each such other taxable year. Further, to the extent that any distribution received by
a U.S. Holder on its ADSs exceeds 125% of the average of the annual distributions on such ADSs received by the
U.S. Holder during the (i) preceding three years or (ii) the U.S. Holder’s holding period, whichever is shorter, that
156
distribution would be subject to taxation in the same manner described immediately above with respect to gain on
disposition.
Alternatively, if we are a PFIC and if the ADSs are “regularly traded” on a “qualified exchange,” a U.S.
Holder could make a mark-to-market election that would result in tax treatment different from the general tax
treatment described in the preceding paragraph. The ADSs would be treated as “regularly traded” in any calendar
year in which more than a de minimis quantity of the ADSs are traded on a qualified exchange, including the Nasdaq
Global Market, on at least 15 days during each calendar quarter. The ADSs are listed on the Nasdaq Global Market,
and we expect, although no assurance can be given, that they will be regularly traded on the Nasdaq Global Market.
U.S. Holders should consult with their own tax advisors regarding potential availability of the mark-to-market
election.
If a U.S. Holder makes the mark-to-market election, the U.S. Holder generally will recognize as ordinary
income any excess of the fair market value of the ADSs at the end of each taxable year over their adjusted tax basis,
and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the ADSs over their fair
market value at the end of the taxable year (but only to the extent of the net amount of income previously included
as a result of the mark-to-market election). If a U.S. Holder makes the election, the U.S. Holder’s tax basis in the
ADSs will be adjusted to reflect these income or loss amounts. Any gain recognized on the sale or other disposition
of ADSs in a year when we are a PFIC will be treated as ordinary income and any loss will be treated as an ordinary
loss (but only to the extent of the net amount of income previously included as a result of the mark-to-market
election). If a U.S. Holder makes a mark-to-market election in respect of a corporation classified as a PFIC and such
corporation ceases to be classified as a PFIC, the holder will not be required to take into account the gain or loss
described above during any period that such corporation is not classified as a PFIC.
A timely election to treat a PFIC as a qualified electing fund under Section 1295 of the Code (“QEF Election”)
would result in alternative treatment. If a U.S. Holder makes a QEF Election for the first tax year of such U.S.
Holder’s holding period in which we are classified as a PFIC, then such U.S. Holder generally would not be subject
to the PFIC rules described above. Instead, a U.S. Holder that makes a timely and effective QEF Election will
currently include in gross income such U.S. Holder’s (a) pro rata share of our ordinary earnings as ordinary income
and (b) pro rata share of our net capital gain as long-term capital gain, regardless of whether we have made any
distributions of such earnings or gain. The U.S. Holder’s basis in its ADSs would be increased to reflect the amount
of such income inclusions. Generally, for this purpose, “ordinary earnings” are the excess of our (a) “earnings and
profits” over (b) net capital gain, and “net capital gain” is the excess of our (a) net long-term capital gain over (b) net
short-term capital loss.
A U.S. Holder that has made such a timely and effective QEF Election generally may receive a distribution
tax-free as a return of capital to the extent that such distribution represents “earnings and profits” that were
previously included in income by the U.S. Holder because of such QEF Election and such distribution will reduce
such U.S. holder’s adjusted tax basis in our ADSs to reflect the amount allowed as a tax free distribution because of
such QEF Election. A U.S. Holder that makes a QEF Election would generally recognize capital gain or loss on the
sale, exchange or other taxable disposition of its ADSs.
However, a U.S. Holder will only be able to make a QEF Election if we provide such U.S. Holder with certain
tax information annually, and we may determine not to provide such information. Furthermore, if the IRS
determines that we were a PFIC for a year with respect to which we had determined that we were not (or believed
we were not) a PFIC, it might be too late for a U.S. Holder to make a timely QEF Election, unless the U.S. Holder
qualifies under the applicable Treasury Regulations to make a retroactive (late) election. U.S. Holders should consult
their own tax advisors regarding the making of any such QEF Election.
In addition, if we are a PFIC or, with respect to particular U.S. Holders, are treated as a PFIC for the taxable
year in which we paid a dividend or for the prior taxable year, the preferential rates discussed above with respect to
dividends paid to certain non-corporate U.S. Holders would not apply.
If a U.S. Holder owns ADSs during any year in which we are a PFIC, the holder generally must file an IRS
Form 8621, or such other form as is required by the U.S. Treasury Department, generally with the holder’s federal
income tax return for that year.
U.S. Holders should consult their tax advisers regarding whether we are or may become a PFIC and the
potential application of the PFIC rules.
157
Information Reporting and Backup Withholding
Payments of distributions and sales proceeds that are made within the United States or through certain U.S.-
related financial intermediaries generally are subject to information reporting, and may be subject to backup
withholding, unless (i) the U.S. Holder is a corporation or other exempt recipient or (ii) in the case of backup
withholding, the U.S. Holder provides a correct taxpayer identification number and certifies that it is not subject to
backup withholding.
Backup withholding is not an additional tax. The amount of any backup withholding from a payment to a U.S.
Holder will be allowed as a credit against the holder’s U.S. federal income tax liability and may entitle it to a refund,
provided that the required information is timely furnished to the IRS.
Information With Respect to Foreign Financial Assets
Certain U.S. Holders who are individuals may be required to report information relating to their ownership of
an interest in certain foreign financial assets, including stock of a non-U.S. person, generally on Form 8938, subject
to exceptions (including an exception for stock held through a U.S. financial institution). In addition, certain U.S.
Holders may be required to file a FinCEN Form 114 (Report of Foreign Bank and Financial Accounts) with the U.S.
Treasury Department each year to report their interest in the ADSs. U.S. Holders should consult their tax advisers
regarding their reporting obligations with respect to the ADSs.
The above description is not intended to constitute a complete analysis of all tax consequences relating
to acquisition, ownership and disposition of the ADSs. You should consult your tax advisor concerning the tax
consequences of your particular situation.
F.Dividends and Paying Agent
Not applicable.
G.Statement by Experts
Not applicable.
H.Documents on Display
We are subject to the information reporting requirements of the Exchange Act applicable to foreign private
issuers and under those requirements we file reports with the SEC. Those reports may be inspected without charge at
the locations described below. As a foreign private issuer, we are exempt from the rules under the Exchange Act
related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders are
exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act.
In addition, we are not required under the Exchange Act to file periodic reports and financial statements with the
SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act.
Nevertheless, we file with the SEC an Annual Report on Form 20-F containing financial statements that have been
examined and reported on, with and opinion expressed by an independent registered public accounting firm.
We maintain a corporate website at www.abivax.com. We intend to post our annual report on our website
promptly following it being filed with the SEC. Information contained on, or that can be accessed through, our
website does not constitute a part of this Annual Report. We have included our website address in this Annual
Report solely as an inactive textual reference.
The Securities and Exchange Commission maintains a website (www.sec.gov) that contains reports, proxy and
information statements and other information regarding registrants, such as us, that file electronically with the SEC.
With respect to references made in this Annual Report to any contract or other document of our company,
such references are not necessarily complete and you should refer to the exhibits attached or incorporated by
reference to this Annual Report for copies of the actual contract or document.
I.Subsidiary Information
Not required.
158
J.Annual Report to Security Holders
To the extent we furnish an annual report to security holders, we will furnish any such report under the cover
of Form 6-K.
159
Item 11.Quantitative and Qualitative Disclosures About Market Risk
A description of quantitative and qualitative disclosures about market risk is disclosed in Note 27 to our
financial statements as of and for the year ended December 31, 2023 appearing elsewhere in this Annual Report on
Form 20-F.
The principal financial instruments we hold are cash and cash equivalents. The purpose of holding these
instruments is to finance our ongoing business activities. It is not our policy to invest in financial instruments for
speculative purposes. We do not use derivative financial instruments for hedging purposes.
The principal risks to which we are exposed are liquidity risk, interest rate risk, foreign currency exchange risk
and credit risk.
Liquidity Risk
Liquidity risk management aims to ensure that we dispose of sufficient liquidity and financial resources to be
able to meet our present and future obligations. We prepare short-term cash forecasts and annual operating cash flow
forecasts as part of our budget procedures. Prudent liquidity risk management involves maintaining sufficient
liquidity, having access to financial resources through appropriate credit facilities and being able to unwind market
positions.
Our operations have required substantial amounts of cash since inception. Developing pharmaceutical drug
candidates, including conducting clinical trials, is expensive, lengthy, and risky, and we expect our research and
development expenses to increase substantially in connection with our ongoing activities. Accordingly, we will
continue to require substantial additional capital to continue our clinical development activities and potentially
engage in commercialization activities. See "Item 5.B—Liquidity and Capital Resources.”
In order to meet any additional financing needs, we may seek to obtain one or more dilutive or non-dilutive
financings depending on market conditions.
Interest Rate Risk
We are exposed to market risks in connection with our medium- and long-term borrowings that are subject to
variable interest rates. We have not adopted any other recurring mechanism of hedging to protect against interest
rate fluctuations. We may consider in the future using a suitable policy to hedge interest rate risks in a more
significant manner, if needed.
Due to fluctuations in market interest rates and the refinancing of most of our indebtedness over the year
ended December 31, 2023, we have performed a reassessment of our exposure to interest rate risk. As of
December 31, 2023, following the full repayment of the First KC Notes, all of our financial liabilities accounted for
at amortized cost bear fixed interest rates and we therefore have limited exposure. We may reassess our exposure
after the potential future draw-downs of the second and third tranches of the Kreos / Claret Financing, which bear
variable interest rates.
Foreign Currency Exchange Risk
We are exposed to a risk of exchange rate fluctuations on commercial transactions performed in currencies
different from our functional currency in which we record the transactions. We have not adopted any other recurring
mechanism of hedging to protect against currency fluctuations. From time to time, we may nevertheless subscribe
for currency term accounts in order to cover a commitment in currency. We may consider in the future using a
suitable policy to hedge exchange risks in a more significant manner, if needed.
160
The following tables set forth the operating expenses we incurred in foreign currencies in the years ended
December 31, 2021, 2022 and 2023. Some figures have been rounded. Accordingly, the totals in the tables may not
be the exact sums of component items.
Year ended December 31, 2021 | Year ended December 31, 2022 | Year ended December 31, 2023 | ||||
Currency (thousands) | Foreign currency | Euros | Foreign currency | Euros | Foreign currency | Euros |
Australian dollar .......................................................... | — | — | 19 | 13 | — | — |
Brazilian real ............................................................... | — | — | — | — | — | — |
Chinese yuan renminbi ................................................ | — | — | — | — | 61 | 8 |
Danish kroner .............................................................. | — | — | — | — | 120 | 16 |
Hungarian forints ......................................................... | 1,454 | 4 | — | — | 3,517 | 9 |
Israeli shekel ................................................................ | — | — | 21 | 6 | — | — |
Japanese yen ................................................................ | 728 | 5 | 1,128 | 8 | — | — |
Pound sterling .............................................................. | 1,518 | 1,762 | 600 | 708 | 359 | 410 |
Swedish krona ............................................................. | 115 | 11 | 115 | 11 | 350 | 30 |
Swiss franc .................................................................. | 4 | 4 | 27 | 28 | 49 | 50 |
United States dollar ..................................................... | 1,494 | 1,262 | 1,426 | 1,390 | 10,861 | 10,112 |
Total | 5,313 | 3,048 | 3,336 | 2,164 | 15,317 | 10,636 |
For the year ended December 31, 2023, the total amount of operating expenses we incurred in foreign
currencies was €10.6 million, or 8.1% of our total operating expenses of €132.0 million in that year.
For the year ended December 31, 2022, the total amount of operating expenses we incurred in foreign
currencies was €2.2 million, or 4.4% of our total operating expenses of €69.4 million in that year.
For the year ended December 31, 2021, the total amount of operating expenses we incurred in foreign
currencies was €3.0 million, or 5.7% of our total operating expenses of €53.4 million in that year.
For the years ended December 31, 2023, December 31, 2022 and December 31, 2021, expenses in U.S. dollars
totaled €10.1 million, €1.4 million and €1.3 million respectively, based on the average annual exchange rate in effect
as of December 31, 2023, December 31, 2022 and December 31, 2021. As a result, an adverse 10% change in the
exchange rate for the U.S. dollar against the euro would have resulted in a foreign exchange rate loss of
approximately €0.4 million for 2023 and non material for the others periods.
Credit Risk
The credit risk related to our cash and cash equivalents is not significant in light of the quality of our co-
contracting financial institutions. As of December 31, 2023, substantially all our cash and cash equivalents were
maintained with two financial institutions in France and in the United States. While our deposit accounts are insured
up to the legal limit, substantially all of our bank deposit balances exceed this insured limit. As of December 31,
2023 we maintained €252 million in bank deposit accounts that are in excess of the legally insured limits in two
legally insured financial institutions. We have not experienced any losses in such accounts and we do not believe
that we are exposed to any significant credit risk related to these instruments.
The credit risk related to our other receivables and related account is minimal. In particular, the credit risk
related to advances made to CROs is deemed insignificant due to their credit ratings.
161
Item 12.Description of Securities Other than Equity Securities
A.Debt Securities
Not applicable.
B.Warrants and Rights
Not applicable.
C.Other Securities
Not applicable.
D.American Depositary Shares
Citibank, as depositary, registers and delivers our ADSs. Each ADS represents one ordinary share deposited
with Citibank Europe plc, located at 1 North Wall Quay, Dublin 1 Ireland, or any successor, as custodian for the
depositary. Each ADS will also represent any other securities, cash or other property that may be held by the
depositary. The depositary’s corporate trust offices at which the ADSs will be administered are located at 388
Greenwich Street, New York, New York 10013.
A deposit agreement among us, the depositary and the ADS holders sets out the ADS holder rights as well as
the rights and obligations of the depositary. New York law governs the deposit agreement and the ADSs. A copy of
the deposit agreement is incorporated by reference as an exhibit to this Annual Report on Form 20-F.
Fees and Charges
As an ADS holder, you will be required to pay the following fees under the terms of the deposit agreement:
Service | Fees |
Issuance of ADSs (e.g., an issuance of ADS upon a deposit of ordinary shares, upon a change in the ADS(s)- to-ordinary share ratio, or for any other reason), excluding ADS issuances as a result of distributions of ordinary shares) | Up to U.S. 5¢ per ADS issued |
Cancellation of ADSs (e.g., a cancellation of ADSs for delivery of deposited property, upon a change in the ADS(s)-to-ordinary share ratio, or for any other reason) | Up to U.S. 5¢ per ADS cancelled |
Distribution of cash dividends or other cash distributions (e.g., upon a sale of rights and other entitlements) | Up to U.S. 5¢ per ADS held |
Distribution of ADSs pursuant to (i) share dividends or other free share distributions, or (ii) exercise of rights to purchase additional ADSs | Up to U.S. 5¢ per ADS held |
Distribution of securities other than ADSs or rights to purchase additional ADSs (e.g., upon a spin-off) | Up to U.S. 5¢ per ADS held |
ADS Services | Up to U.S. 5¢ per ADS held on the applicable record date(s) established by the depositary bank |
162
Registration of ADS transfers (e.g., upon a registration of the transfer of registered ownership of ADSs, upon a transfer of ADSs into DTC and vice versa, or for any other reason) | Up to U.S. 5¢ per ADS (or fraction thereof) transferred |
Conversion of ADSs of one series for ADSs of another series (e.g., upon conversion of Partial Entitlement ADSs for Full Entitlement ADSs, or upon conversion of Restricted ADSs (each as defined in the Deposit Agreement) into freely transferable ADSs, and vice versa). | Up to U.S. 5¢ per ADS (or fraction thereof) converted |
As an ADS holder, you will also be responsible to pay certain charges such as:
•taxes (including applicable interest and penalties) and other governmental charges;
•the registration fees as may from time to time be in effect for the registration of ordinary shares on the share
register and applicable to transfers of ordinary shares to or from the name of the custodian, the depositary
bank or any nominees upon the making of deposits and withdrawals, respectively;
•certain cable, telex and facsimile transmission and delivery expenses;
•the fees, expenses, spreads, taxes and other charges of the depositary bank and/or service providers (which
may be a division, branch or affiliate of the depositary bank) in the conversion of foreign currency;
•the reasonable and customary out-of-pocket expenses incurred by the depositary bank in connection with
compliance with exchange control regulations and other regulatory requirements applicable to ordinary
shares, ADSs and ADRs; and
•the fees, charges, costs and expenses incurred by the depositary bank, the custodian, or any nominee in
connection with the ADR program.
ADS fees and charges for (i) the issuance of ADSs, and (ii) the cancellation of ADSs are charged to the person
for whom the ADSs are issued (in the case of ADS issuances) and to the person for whom ADSs are cancelled (in
the case of ADS cancellations). In the case of ADSs issued by the depositary bank into DTC, the ADS issuance and
cancellation fees and charges may be deducted from distributions made through DTC, and may be charged to the
DTC participant(s) receiving the ADSs being issued or the DTC participant(s) holding the ADSs being cancelled, as
the case may be, on behalf of the beneficial owner(s) and will be charged by the DTC participant(s) to the account of
the applicable beneficial owner(s) in accordance with the procedures and practices of the DTC participants as in
effect at the time. ADS fees and charges in respect of distributions and the ADS service fee are charged to the
holders as of the applicable ADS record date. In the case of distributions of cash, the amount of the applicable ADS
fees and charges is deducted from the funds being distributed. In the case of (i) distributions other than cash and (ii)
the ADS service fee, holders as of the ADS record date will be invoiced for the amount of the ADS fees and charges
and such ADS fees and charges may be deducted from distributions made to holders of ADSs. For ADSs held
through DTC, the ADS fees and charges for distributions other than cash and the ADS service fee may be deducted
from distributions made through DTC, and may be charged to the DTC participants in accordance with the
procedures and practices prescribed by DTC and the DTC participants in turn charge the amount of such ADS fees
and charges to the beneficial owners for whom they hold ADSs. In the case of (i) registration of ADS transfers, the
ADS transfer fee will be payable by the ADS Holder whose ADSs are being transferred or by the person to whom
the ADSs are transferred, and (ii) conversion of ADSs of one series for ADSs of another series, the ADS conversion
fee will be payable by the Holder whose ADSs are converted or by the person to whom the converted ADSs are
delivered.
In the event of refusal to pay the depositary bank fees, the depositary bank may, under the terms of the deposit
agreement, refuse the requested service until payment is received or may set off the amount of the depositary bank
fees from any distribution to be made to the ADS holder. Certain depositary fees and charges (such as the ADS
services fee) may become payable shortly after the closing of the ADS offering. Note that the fees and charges you
may be required to pay may vary over time and may be changed by us and by the depositary bank. You will receive
prior notice of such changes. The depositary bank may reimburse us for certain expenses incurred by us in respect of
the ADR program, by making available a portion of the ADS fees charged in respect of the ADR program or
otherwise, upon such terms and conditions as we and the depositary bank agree from time to time.
Taxes
As an ADS holder, you will be responsible for the taxes and other governmental charges payable on the ADSs
and the securities represented by the ADSs. We, the depositary bank and the custodian may deduct from any
163
distribution the taxes and governmental charges payable by holders and may sell any and all property on deposit to
pay the taxes and governmental charges payable by holders. You will be liable for any deficiency if the sale
proceeds do not cover the taxes that are due.
The depositary bank may refuse to issue ADSs, to deliver, transfer, split and combine ADRs or to release
securities on deposit until all taxes and charges are paid by the applicable holder. The depositary bank and the
custodian may take reasonable administrative actions to obtain tax refunds and reduced tax withholding for any
distributions on your behalf. However, you may be required to provide to the depositary bank and to the custodian
proof of taxpayer status and residence and such other information as the depositary bank and the custodian may
require to fulfill legal obligations. You are required to indemnify us, the depositary bank and the custodian for any
claims with respect to taxes based on any tax benefit obtained for you.
164
PART II
Item 13.Defaults, Dividend Arrearages and Delinquencies
Not applicable.
165
Item 14.Material Modifications to the Rights of Security Holders and Use of Proceeds
Initial Public Offering
On October 24, 2023, we sold 20,325,500 new ordinary shares (the "New Shares"), consisting of a public
offering of 18,699,460 ordinary shares in the form of ADSs, each representing the right to receive one ordinary
share, in the United States (the "U.S. Offering") and a concurrent offering of 1,626,040 ordinary shares in certain
jurisdictions outside of the United States to certain investors (the "European Private Placement" and together with
the U.S. Offering, the "Global Offering"). The offering price was set at $11.60 per ADS in the U.S. Offering and a
corresponding offering price of €10.9864 per ordinary share in the European Private Placement. The aggregate gross
proceeds amounted to approximately $235.8 million, equivalent to approximately €223.3 million (based on the
exchange rate then in effect), before deduction of underwriting commissions and estimated expenses payable by us.
All of the ADSs and ordinary shares in the Global Offering were offered by Abivax.
We incurred aggregate underwriting discounts of approximately $16.5 million and expenses of approximately
$7.0 million, resulting in net proceeds to us of approximately $212.2 million. No payments were made directly or
indirectly to any executive or supervisory board member of ours or to their associates, persons owning 10% or more
of any class of our equity securities, or to any of our affiliates. The offering commenced on October 18, 2023 and
did not terminate before all of the securities registered in the registration statement were sold. The effective date of
the registration statement, File No. 333-274780, for our initial public offering was October 19, 2023. Morgan
Stanley & Co. LLC and Leerink Partners LLC acted as joint global coordinators for the Global Offering and joint
bookrunners for the U.S. Offering. LifeSci Capital LLC acted as lead manager for the U.S. Offering. Bryan Garnier
Securities SAS acted as European lead manager for the European Private Placement.
There has been no material change in the planned use of proceeds from the Global Offering from that
described in the final prospectus related to the offering, which we filed with the SEC on October 23, 2023.
166
Item 15.Controls and Procedures
A.Disclosure Controls and Procedures
Our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial
officer), after evaluating the effectiveness of our “disclosure controls and procedures,” as such term is defined in
Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of December 31, 2023, have concluded that, as of such
date, our disclosure controls and procedures were not effective as a result of the material weaknesses described
below. We are undertaking the remedial steps to address the material weaknesses in our disclosure controls and
procedures as discussed below.
In conjunction with preparing our financial statements as of and for the years ended December 31, 2022 and
2021 and as of and for the six-month period ended June 30, 2023, material weaknesses in our internal controls over
financial reporting were identified. The material weaknesses related to a lack of risk assessment as well as formal,
documented and implemented processes, controls and review procedures, specifically due to a lack of a sufficient
number of professionals with an appropriate level of internal control knowledge, training and experience.
In response to the identified material weaknesses, management took a number of actions to improve the
internal control over financial reporting during the year ended December 31, 2023. These actions include, but are not
limited to, the following:
•Reinforcing the finance & accounting resources by hiring an SVP Finance based in the US and familiar
with US public listed companies; and
•Initiating a risk assessment and SOX documentation project with the support of external advisors.
As of December 31, 2023, management has concluded that the previously disclosed material weaknesses have
not been remediated. With the oversight of senior management and our audit committee, we continue to evaluate our
internal control over financial reporting and are taking several remedial actions to address the material weaknesses
that have been identified.
B.Management’s Annual Report on Internal Control Over Financial Reporting
This Annual Report does not include a report of management’s assessment regarding internal control over
financial reporting due to a transition period established by rules of the Securities and Exchange Commission for
newly public companies.
C.Attestation Report of the Registered Public Accounting Firm
This Annual Report does not include an attestation report of our registered public accounting firm due to a
transition period established by rules of the Securities and Exchange Commission for newly public companies.
D.Changes in Control over Financial Reporting
There has been no change in our internal control over financial reporting during the year ended December 31,
2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial
reporting.
167
Item 16.[Reserved]
Item 16A.Audit Committee Financial Expert
Our Board has determined that each of the members of our audit committee is independent within the meaning
of the applicable listing rules and the independence requirements contemplated by Rule 10A-3 under the Exchange
Act. Committee members must be competent in financial or accounting matters and at least one member must be
independent in accordance with the provisions of the Middlenext Code. Our Board has further determined that Mr.
Ignelzi is an “audit committee financial expert” as defined by SEC rules and regulations and that Mr. Ignelzi
qualifies as financially sophisticated under the applicable exchange listing rules.
Item 16B.Code of Ethics
We have adopted a Code of Business Conduct and Ethics, applicable to all of our employees, senior
management and directors, which is available on our website at www.abivax.com.
Item 16C.Principal Accountant Fees and Services
Audit Fees
The aggregate fees billed for the audit of our annual financial statements for the fiscal years ended December
31, 2023 and 2022 were €2.2 million and €0.8 million, respectively, and related to audit services provided by our
independent registered public accounting firm, PricewaterhouseCoopers Audit in connection with our annual audit,
half-year review, and review and maintenance of registration statements.
PricewaterhouseCoopers has served as our independent registered public accounting firm for 2022 and 2023.
Our accountants billed the following fees to us for professional services in each of those fiscal year:
(amounts in thousands of euros) | YEAR ENDED DECEMBER 31, 2022 | YEAR ENDED DECEMBER 31, 2023 |
Audit fees | 100 | 1,714 |
Audit-related fees | — | — |
Tax fees | — | — |
All other fees | 740 | 492 |
Total | 840 | 2,206 |
Audit-Related Fees
None
Tax Fees
None
All Other Fees
The aggregate fees billed for all other services for the fiscal year ended December 31, 2023 and 2022 were
€0.5 million and €0.7 million respectively. Other fees are the aggregate fees billed for other procedures required by
law related to services provided to our registration statements for capital increase and initial public offering on the
Nasdaq Global Market.
168
Audit Committee’s Pre-Approval Policies and Procedures
The Audit Committee is responsible for the appointment, replacement, compensation, evaluation and
oversight of the work of the independent auditors. As part of this responsibility, the Audit Committee pre-approves
all audit and non-audit services performed by the independent auditors in order to assure that they do not impair the
auditor’s independence from the Company in accordance with the Audit Committee’s pre-approval policy. All fees
in 2023 and 2022 described in this Item 16C above were pre-approved by the Audit Committee.
Item 16D.Exemptions from the Listing Standards for Audit Committees
Not applicable.
Item 16E.Purchases of Equity Securities by the Issuer and Affiliated Purchasers
None.
Item 16F.Change in Registrant’s Certifying Accountant
Not applicable.
Item 16G.Corporate Governance
As a French société anonyme (limited liability company) listed on Euronext Paris, we are subject to various
corporate governance requirements under French law. In particular, we refer to the Code of Corporate Governance
for small and medium-sized firms as published in September 2021 by Middlenext, as amended from time to time. In
addition, as a foreign private issuer listed on the Nasdaq Global Market, we are subject to Nasdaq’s corporate
governance listing standards. Nasdaq’s listing standards provide that foreign private issuers are permitted to follow
home country governance practices in lieu of Nasdaq rules, with certain exceptions. We currently rely on certain
exemptions for foreign private issuers and follow French corporate governance practices in lieu of Nasdaq corporate
governance rules, which would require that (i) a majority of our Board consists of independent directors and (ii) the
quorum for any meeting of the holders of ordinary shares be at least 331/3 % of the company's outstanding ordinary
shares.
Nasdaq rules require that a listed company specify that the quorum for any meeting of the holders of ordinary
shares be at least 331/3 % of the company's outstanding ordinary shares. Consistent with French Law, our by-laws
provide that, for ordinary shareholders’ meetings to be quorate, one-fifth of the holders of shares entitled to voting
rights must be present in person or vote by mail or by proxy or by authorized intermediary or by any means of
telecommunication permitting their identification. An extraordinary shareholders’ meeting is quorate if one-fourth of
the holders of shares entitled to voting rights are present or vote by mail or by proxy or by authorized intermediary
or by any means of telecommunication. As an exception, an extraordinary shareholders’ meeting deciding upon a
share capital increase by capitalization of reserves, profits or share premium as the same quorum requirement as an
ordinary shareholders’ meeting. If the requirements for a quorum are not satisfied, the meeting is adjourned. When
an adjourned ordinary shareholders’ meeting is resumed, there is no quorum requirement. When an adjourned
extraordinary shareholders’ meeting is resumed, there is a quorum of one-fifth of the holders of shares entitled to
voting rights. If a quorum is not present, the reconvened extraordinary shareholders’ meeting may be adjourned for a
maximum of two months. No deliberation by the shareholders may take place without a quorum. For special
meetings of holders of a certain class of shares, the quorum requirement is one-third of the certain class of shares
entitled to voting rights for the meeting convened on the first call, notice and one-fifth of the holders of shares
entitled to voting rights, should the meeting be reconvened.
In addition, we choose to take advantage of the following limited exemptions:
•Exemption from filing quarterly reports on Form 10-Q containing unaudited financial and other specified
information or current reports on Form 8-K upon the occurrence of specified significant events;
•Exemption from Section 16 rules requiring insiders to file public reports of their securities ownership and
trading activities and providing for liability for insiders who profit from trades in a short period of time; and
•Exemption from the requirement to obtain shareholder approval for certain issuances of securities,
including shareholder approval of share option plans.
169
We may choose to take advantage of additional exemptions and follow home country practices in lieu of
Nasdaq rules in the future.
Item 16H.Mine Safety Disclosure
Not applicable.
Item 16I.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Not applicable.
Item 16J.Insider Trading Policies
Pursuant to applicable SEC transition guidance, the disclosure required by Item 16J will be applicable to us
starting the fiscal year ending December 31, 2024.
Item 16K.Cybersecurity
Risk Management and Strategy
We have implemented and maintain various information security processes designed to identify, assess and
manage material risks from cybersecurity threats to our critical information systems, third party hosted services,
communications systems, hardware and software, and our critical data (including intellectual property, confidential
information that is proprietary, strategic or competitive in nature, and data related to our clinical trials and products)
(collectively, “Information Systems and Data”).
Our Chief Financial Officer as well as our external Data Protection Officer (“DPO”) and Information
Technology Director (“IT Director”), and other independent service providers help identify, assess and manage the
our cybersecurity threats and risks. Individuals in these roles identify and assess risks from cybersecurity threats by
monitoring and evaluating our threat environment using various methods including, for example, maintaining
manual and automated tools, conducting scans of our threat environment, and conducting vulnerability assessments.
Depending on the environment, we implement and maintain various technical, physical, and organizational
measures, processes, standards and policies designed to manage and mitigate material risks from cybersecurity
threats to our Information Systems and Data. These measures, processes, standards, and policies include, for
example: incident response plans and policies, personnel training, phishing test campaigns, penetration testing,
system backups, cybersecurity insurance, network security controls, segmentation for certain systems and data
access controls and physical security controls.
Our assessment and management of material risks from cybersecurity threats are integrated into our overall
risk management processes. For example, our external DPO and IT Director work with management in an effort to
prioritize our risk management processes and mitigate cybersecurity threats that are more likely to lead to a material
impact to our business.
We use independent service providers to assist us from time to time to identify, assess, and manage material
risks from cybersecurity threats, including for example: professional service firms, including legal counsel,
penetration testing firms, dark web monitoring services, cybersecurity consultants, and cybersecurity software
providers.
Further, we use independent service providers to perform a variety of functions throughout our business, such
as hosting companies and contract research organizations. We undertake efforts designed to manage cybersecurity
risks associated with our use of these providers. For certain vendors, these efforts include security questionnaires,
reviews of vendors’ written security programs, reviews of security assessments, audits, and vulnerability scans
related to the vendors. Depending on the nature of the services provided, the sensitivity of the Information Systems
and Data at issue, and the identity of the provider, our vendor management process may involve different levels of
assessment designed to help identify cybersecurity risks associated with a provider and impose contractual
obligations related to cybersecurity on the provider.
170
For a description of the risks from cybersecurity threats that may materially affect the Company and how they
may do so, see our risk factors under "Part I—Item 3D.—Risk Factors" in this Annual Report on Form 20-F,
including “If our information technology systems or those of the third parties upon which we rely, or our data are or
were compromised, we could experience adverse consequences resulting from such compromise, including but not
limited to: regulatory investigations or actions; litigation; fines and penalties; disruptions of our business
operations; reputational harm; loss of revenue and profits; and other adverse consequences.”
Governance
Our Board addresses our cybersecurity risk management as part of its general oversight function. The Board is
responsible for overseeing our cybersecurity risk management processes, including oversight and mitigation of risks
from cybersecurity threats. Our Committee of Executives (“COMEX”), in addition to those identified below,
provides input to the Board on cybersecurity threats. Our Committee of Executives consists of all our company's
officers along with our heads of manufacturing and quality.
Our cybersecurity risk assessment and management processes are implemented and maintained by certain
management team members, including our Chief Financial Officer (“CFO”) who oversees our external IT Director
and DPO. Our CFO has prior significant experience in strategic business operations.
Our CFO as well as our external IT Director and DPO are responsible for helping to integrate cybersecurity
risk considerations into our overall risk management strategy, and communicating key priorities to relevant
personnel. Our CFO is responsible for approving cybersecurity-related budgets, approving cybersecurity processes,
and reviewing security assessments and other security-related reports.
Our cybersecurity incident response procedures are designed to escalate certain cybersecurity incidents to
members of management depending on circumstances, including our CFO. Our CFO works with our incident
responders (such as the external IT Director and DPO) to help us mitigate and remediate cybersecurity incidents of
which they are notified. In addition, our incident response process includes reporting to the Board for certain
cybersecurity incidents.
The Board receives periodic communications from the CFO and others (such as the IT Director and DPO)
concerning our significant cybersecurity threats, risk and the processes we have implemented in an effort to address
them.
171
PART III
Item 17.Financial Statements
See response to Item 18.
172
Item 18.Financial Statements
See pages F-1 through F-74 of this Annual Report on Form 20-F.
173
Item 19.Exhibits
The following exhibits are filed herewith or incorporated herein by reference:
Exhibit Number | Description of Exhibit |
1.1 | By-laws (statuts) of the registrant (English translation) (incorporated by reference to Exhibit 3.1 of the Company’s Registration Statement on Form F-1 (File No. 333-274780) filed with the Commission on September 29, 2023) |
2.1* | |
2.2 | Form of Deposit Agreement (incorporated by reference to Exhibit (a) to the Form F-6 Registration Statement (File No. 333-274845), filed with the Commission on October 3, 2023) |
2.3 | Form of American Depositary Receipt (included in Exhibit 2.2) |
4.1 ^ | OCABSA Issue Agreement between Abivax SA and Kreos Capital VII (UK) Limited and Claret European Growth Capital Fund III SCSp dated August 20, 2023 (incorporated by reference to Exhibit 10.1 of the Company’s Registration Statement on Form F-1 (File No. 333-274780) filed with the Commission on September 29, 2023) |
4.2 ^ | Subscription Agreement between Abivax SA and Kreos Capital VII (UK) Limited, Kreos Capital VII Aggregator SCSp, Claret European Specialty Lending Company III, S.à r.l., Claret European Growth Capital Fund III SCSp dated August 20, 2023 (incorporated by reference to Exhibit 10.2 of the Company’s Registration Statement on Form F-1 (File No. 333-274780) filed with the Commission on September 29, 2023) |
4.3 ^ | Tranche A-B Warrants Issue Agreement between Abivax SA and Kreos Capital VII Aggregator SCSp and Claret European Growth Capital Fund III SCSp dated August 20, 2023 (incorporated by reference to Exhibit 10.3 of the Company’s Registration Statement on Form F-1 (File No. 333-274780) filed with the Commission on September 29, 2023) |
4.4 | Claret European Growth Capital Fund III SCSp dated August 20, 2023 (incorporated by reference to Exhibit 10.4 of the Company’s Registration Statement on Form F-1 (File No. 333-274780) filed with the Commission on September 29, 2023) |
4.5 ^ | (incorporated by reference to Exhibit 10.5 of the Company’s Registration Statement on Form F-1 (File No. 333-274780) filed with the Commission on September 29, 2023) |
4.6 ^ | August 20, 2023 (incorporated by reference to Exhibit 10.6 of the Company’s Registration Statement on Form F-1 (File No. 333-274780) filed with the Commission on September 29, 2023) |
4.7 ^ | (incorporated by reference to Exhibit 10.7 of the Company’s Registration Statement on Form F-1 (File No. 333-274780) filed with the Commission on September 29, 2023) |
4.8 ^ | September 1, 2017 (incorporated by reference to Exhibit 10.8 of the Company’s Registration Statement on Form F-1 (File No. 333-274780) filed with the Commission on September 29, 2023) |
4.9 ^ | GmbH dated January 1, 2022 (incorporated by reference to Exhibit 10.9 of the Company’s Registration Statement on Form F-1 (File No. 333-274780) filed with the Commission on September 29, 2023) |
4.10 ^ | (incorporated by reference to Exhibit 10.10 of the Company’s Registration Statement on Form F-1 (File No. 333-274780) filed with the Commission on September 29, 2023) |
4.11 ^ | Auxiliaires et de Synthèse dated March 11, 2016 (incorporated by reference to Exhibit 10.11 of the Company’s Registration Statement on Form F-1 (File No. 333-274780) filed with the Commission on September 29, 2023) |
174
4.12 ^ | Produits Chimiques Auxiliaires et de Synthèse dated March 2, 2021 (incorporated by reference to Exhibit 10.12 of the Company’s Registration Statement on Form F-1 (File No. 333-274780) filed with the Commission on September 29, 2023) |
4.13 ^ | (incorporated by reference to Exhibit 10.13 of the Company’s Registration Statement on Form F-1 (File No. 333-274780) filed with the Commission on September 29, 2023) |
4.14 ^ | (incorporated by reference to Exhibit 10.14 of the Company’s Registration Statement on Form F-1 (File No. 333-274780) filed with the Commission on September 29, 2023) |
4.15 ^ | Montpellier, and the Institut Curie dated December 18, 2008 (incorporated by reference to Exhibit 10.15 of the Company’s Registration Statement on Form F-1 (File No. 333-274780) filed with the Commission on September 29, 2023) |
4.16* | |
4.17* | |
4.18* | |
8.1 | List of subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 of the Company’s Registration Statement on Form F-1 (File No. 333-274780) filed with the Commission on September 29, 2023) |
12.1* | |
12.2* | |
13.1** | |
13.2** | |
97.1* | |
101.INS | Inline XBRL Instance Document |
101.SCH | Inline XBRL Taxonomy Extension Schema Document |
101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document |
101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document |
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |
* Filed herewith.
** Furnished herewith.
# Indicates a management contract or compensatory plan, contract or arrangement
^ Certain information has been excluded from this exhibit (indicated by “[***]”) because it is both not
material and is the type that the registrant treats as private or confidential.
175
SIGNATURES
The registrant hereby certifies that it meets all of the requirements for filing this Annual Report on Form 20-F
and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.
ABIVAX SA
By: /s/ Marc de Garidel
Marc de Garidel
Chief Executive Officer
Date: April 5, 2024
176
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Report of Independent Registered Public Accounting Firm (PCAOB ID No. | F-2 |
Consolidated Statements of Financial Position .................................................................................. | F-3 |
Consolidated Statements of Income (Loss) ....................................................................................... | F-4 |
Consolidated Statements of Comprehensive Income (Loss) ............................................................. | F-5 |
Consolidated Statements of Changes in Shareholders’ Equity .......................................................... | F-6 |
Consolidated Statements of Cash Flows ............................................................................................ | F-7 |
Notes to the Consolidated Financial Statements ................................................................................ | F-8 |
F-1
Report of Independent Registered Public Accounting Firm
To the Board of Directors and Shareholders of Abivax SA
Opinion on the Financial Statements
We have audited the accompanying consolidated statements of financial position of Abivax SA and its subsidiary
(the “Company”) as of December 31, 2023, 2022 and 2021, and the related consolidated statements of income (loss),
comprehensive income (loss), changes in shareholders’ equity and cash flows for each of the three years in the
period ended December 31, 2023, including the related notes (collectively referred to as the “consolidated financial
statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the
financial position of the Company as of December 31, 2023, 2022 and 2021, and the results of its operations and its
cash flows for each of the three years in the period ended December 31, 2023 in conformity with International
Financial Reporting Standards as issued by the International Accounting Standards Board and International
Financial Reporting Standards as adopted by the European Union.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is
to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public
accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are
required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the
applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB.
Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the
consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is
not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As
part of our audits we are required to obtain an understanding of internal control over financial reporting but not for
the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting.
Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial
statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial
statements. Our audits also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that
our audits provide a reasonable basis for our opinion.
/s/ PricewaterhouseCoopers Audit
April 5, 2024
We have served as the Company's auditor since 2013.
F-2
ABIVAX SA CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(Amounts in thousands of euros) | Notes | AS OF DECEMBER 31, 2021 | AS OF DECEMBER 31, 2022 | AS OF DECEMBER 31, 2023 | |||
ASSETS | |||||||
Non-current assets | |||||||
Goodwill | 6 | ||||||
Intangible assets | 7 | ||||||
Property, plant and equipment | 8 | ||||||
Other financial assets | 9 | ||||||
Other assets | 10 | ||||||
Total non-current assets | |||||||
Current assets | |||||||
Other financial assets | 9 | ||||||
Other receivables and assets | 10 | ||||||
Cash and cash equivalents | 11 | ||||||
Total current assets | |||||||
TOTAL ASSETS | |||||||
LIABILITIES AND SHAREHOLDERS' EQUITY | |||||||
Shareholders’ equity | |||||||
Share capital | |||||||
Premiums related to share capital | |||||||
Reserves | |||||||
Retained earnings | ( | ( | ( | ||||
Net loss for the period | ( | ( | ( | ||||
Total shareholders’ equity | 13 | ||||||
Non-current liabilities | |||||||
Retirement benefit obligations | 16 | ||||||
Provisions | |||||||
Borrowings | 15 | ||||||
Convertible loan notes | 15 | ||||||
Derivative instruments | 15 | ||||||
Royalty certificates | 15 | ||||||
Other financial liabilities | 15 | ||||||
Total non-current liabilities | |||||||
Current liabilities | |||||||
Borrowings | 15 | ||||||
Convertible loan notes | 15 | ||||||
Derivative instruments | 15 | ||||||
Other financial liabilities | 15 | ||||||
Trade payables and other current liabilities | 17.1 | ||||||
Tax and employee-related payables | 17.2 | ||||||
Deferred income | |||||||
Total current liabilities | |||||||
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY |
F-3
ABIVAX SA CONSOLIDATED STATEMENTS OF INCOME (LOSS)
(Amounts in thousands of euros, except per share amounts) | Notes | YEAR ENDED DECEMBER 31, 2021 | YEAR ENDED DECEMBER 31, 2022 | YEAR ENDED DECEMBER 31, 2023 | |||
Other operating income | 18 | ||||||
Total operating income | |||||||
Sales and marketing | 19.1 | ( | |||||
Research and development | 19.2 | ( | ( | ( | |||
General and administrative | 19.3 | ( | ( | ( | |||
Goodwill impairment loss | 6 | ( | |||||
Total operating expenses | ( | ( | ( | ||||
Operating loss | ( | ( | ( | ||||
Financial expenses | ( | ( | ( | ||||
Financial income | |||||||
Financial gain (loss) | 21 | ( | ( | ||||
Net loss before tax | ( | ( | ( | ||||
Income tax | 22 | ||||||
Net loss for the period | ( | ( | ( | ||||
Loss per share (€/share) | |||||||
Weighted average number of outstanding shares used for computing basic/diluted loss per share | |||||||
Basic / diluted loss per share (€/share) | 23 | ( | ( | ( |
F-4
ABIVAX SA CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(Amounts in thousands of euros) | Notes | YEAR ENDED DECEMBER 31, 2021 | YEAR ENDED DECEMBER 31, 2022 | YEAR ENDED DECEMBER 31, 2023 | |||
Net loss for the period | ( | ( | ( | ||||
Items that will not be reclassified to profit or loss | |||||||
Actuarial gains and losses on retirement benefit obligations | 16 | ||||||
Items that are or may be reclassified subsequently to profit or loss | |||||||
Foreign currency translation differences | |||||||
Other comprehensive income (loss) | |||||||
Total comprehensive income (loss) for the period | ( | ( | ( |
F-5
ABIVAX SA CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
(Amounts in thousands of euros) | Notes | NUMBER OF SHARES ISSUED | SHARE CAPITAL | PREMIUMS RELATED TO SHARE CAPITAL | TRANSLATION RESERVE | RETAINED EARNINGS | NET LOSS FOR THE YEAR | TOTAL SHAREHOLDER 'S EQUITY | ||||||
AS OF JANUARY 1, 2021 | - | - | ||||||||||||
Net loss for the period | 0 | — | — | — | — | - | - | |||||||
Other comprehensive income (loss) | 16 | 0 | — | — | — | — | ||||||||
Total comprehensive loss for the period | 0 | — | — | — | - | - | ||||||||
Appropriation of prior period net loss | 0 | — | — | — | - | |||||||||
Capital increase from issuance of ordinary shares | 13.3 | — | — | — | ||||||||||
Transaction costs related to capital increase | 13.3 | 0 | — | - | — | — | — | - | ||||||
Exercises of share warrants under the Equity line agreement | 13.2, 13.3 | — | — | — | ||||||||||
Exercises of share warrants | 13.3, 14 | — | — | — | ||||||||||
Shares based compensation expense | 14 | 0 | — | — | — | — | ||||||||
Transaction on treasury shares | 13.1 | 0 | — | — | — | — | ||||||||
AS OF DECEMBER 31, 2021 | - | - | ||||||||||||
AS OF DECEMBER 31, 2021 | - | - | ||||||||||||
Net loss for the period | 0 | — | — | — | — | - | - | |||||||
Other comprehensive income (loss) | 16 | 0 | — | — | — | — | ||||||||
Total comprehensive loss for the period | — | — | — | - | - | |||||||||
Appropriation of prior period net loss | 0 | — | — | — | - | |||||||||
Capital increase from issuance of ordinary shares | 13.3 | — | — | — | ||||||||||
Transaction costs related to capital increase | 13.3 | 0 | — | - | — | — | — | - | ||||||
Exercises of share warrants | 13.3, 14 | — | — | — | — | |||||||||
Shares based compensation expense | 14 | 0 | — | — | — | - | — | - | ||||||
Transactions on treasury shares | 13.1 | 0 | — | — | — | - | — | - | ||||||
AS OF DECEMBER 31, 2022 | - | - | ||||||||||||
AS OF DECEMBER 31, 2022 | - | - | ||||||||||||
Net loss for the period | 0 | — | — | — | — | - | - | |||||||
Other comprehensive income (loss) | 16 | 0 | — | — | — | |||||||||
Total comprehensive loss for the period | 0 | — | — | - | - | |||||||||
Appropriation of prior period net loss | 0 | — | — | — | - | |||||||||
Capital increase from issuance of ordinary shares | 13.3 | — | — | — | ||||||||||
Transaction costs related to capital increase | 13.3 | 0 | — | - | — | — | — | - | ||||||
Issue of convertible notes | 15.1. | 0 | — | — | — | — | ||||||||
Exercises of the Kreos share warrants | 13.3, 15.3 | — | — | — | ||||||||||
Exercises of other share warrants | 13.3, 14 | — | — | — | — | |||||||||
Shares based compensation expense | 14 | 0 | — | — | — | — | ||||||||
Transaction on treasury shares | 13.1 | 0 | — | — | — | — | ||||||||
AS OF DECEMBER 31, 2023 | - | - |
F-6
ABIVAX SA CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands of euros) | Notes | YEAR ENDED DECEMBER 31, 2021 | YEAR ENDED DECEMBER 31, 2022 | YEAR ENDED DECEMBER 31, 2023 | |||
Cash flows used in operating activities | |||||||
Net loss for the period | ( | ( | ( | ||||
Ajustments for: | |||||||
Elimination of amortization of intangibles and depreciation of property, plant and equipment | |||||||
Elimination of Impairment loss of goodwill | 6 | ||||||
Elimination of retirement benefit obligations | 16 | ||||||
Elimination of share-based compensation expenses | 14 | ( | |||||
(-) Net gain on sale of treasury shares | ( | ( | |||||
Interest expenses and other financial expenses | 21 | ||||||
Financial income | 21 | ( | ( | ||||
Effect of unwinding the discount related to advances | ( | ( | |||||
Increase/(decrease) in derivatives and liabilities fair value | 15 | ( | ( | ( | |||
Forgiveness of Covid 19 conditional advances | 17 | ( | |||||
Other | ( | ||||||
Cash flows used in operating activities before change in working capital requirements | ( | ( | ( | ||||
Decrease / (increase) in other receivables and other assets | ( | ( | |||||
Increase / (decrease) in trade payables | ( | ||||||
Increase / (decrease) in tax and social security liabilities | |||||||
Increase / (decrease) in deferred income and other liabilities | ( | ( | ( | ||||
Changes in working capital requirements | ( | ( | |||||
Cash flows used in operating activities | ( | ( | ( | ||||
Cash flows used in investing activities | |||||||
Acquisitions of intangible assets | ( | ||||||
Acquisitions of property, plant and equipment | ( | ( | ( | ||||
Advance made to CROs | 10 | ( | ( | ||||
Payments for the acquisition of Prosynergia, incl. related costs, net of cash acquired (1) | 4.15 & 10 | ( | ( | ||||
Increase in Deposits and other financial assets | 9 | ( | ( | ( | |||
Decrease in Deposits | 9 | ||||||
Repayment / (disbursement) of the advance made to the Nice CHU | 10 | ( | |||||
Interest received | |||||||
Cash flows used in investing activities | ( | ( | ( | ||||
Cash flows provided by (used in) financing activities | |||||||
Capital increases | 13 | ||||||
Transaction costs related to capital increase | 13 | ( | ( | ( | |||
Warrants subscription | |||||||
Repayments of KREOS (2) 1&2 bond loans | 15 | ( | ( | ( | |||
Repayments of convertible loan notes | 15 | ( | |||||
Net proceeds from convertible loan notes | 15 | ||||||
Repayment of PGE | 15 | ( | |||||
Net proceeds from sale of royalty certificate | 15 | ||||||
Net proceeds from sale of treasury shares | 15 | ||||||
Repayments of conditional advances | 15 | ( | ( | ( | |||
Payments of the lease liabilities | 15 | ( | ( | ( | |||
Interest paid | 15 | ( | ( | ( | |||
Other | |||||||
Cash flows provided by (used in) financing activities | |||||||
Effect of movements in exchange rates on cash held | 11 | ( | |||||
Increase (decrease) in cash and cash equivalents | ( | ||||||
Cash and cash equivalents at the beginning of the year | 11 | ||||||
Cash and cash equivalents at the end of the year | 11 | ||||||
Increase (decrease) in cash and cash equivalents | ( |
(1)Prosynergia SARL (or "Prosynergia")
(2)Kreos Capital V UK Ltd (or "Kreos")
F-7
ABIVAX SA NOTES TO THE FINANCIAL STATEMENTS
Note 1. The Group
ABIVAX SA (the “Company”) is a société anonyme incorporated under the laws of France on December 4, 2013. Its registered office
is located at 7-11 Boulevard Haussmann—75009 Paris, France. The Company is developing therapeutics that harness the body’s
natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
These consolidated financial statements as of and for the year ended December 31, 2023 comprise the Company and ABIVAX LLC
(the “Subsidiary”), the United States subsidiary of ABIVAX SA, created on March 20, 2023 under the laws of the State of Delaware
(together referred to as the “Group”).
The Group has incurred losses since its inception and had shareholders’ equity of €196,010 thousand as of December 31, 2023. The
Group anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its drug candidates
which are currently under development. Substantial additional financing will be needed by the Group to fund its operations and to
commercially develop its drug candidates.
The Group's future operations are highly dependent on a combination of factors, including: (i) the success of its research and
development activities; (ii) regulatory approval and market acceptance of its proposed future products; (iii) the timely and successful
completion of additional financing and (iv) the development of competitive therapies by other biotechnology and pharmaceutical
companies. As a result, the Group is, and expects to continue to be, in the short to mid-term, financed through the issuance of new
equity or debt instruments.
The Group is focusing its efforts on the following points:
•Continuation of the clinical development program for obefazimod in moderately to severely active ulcerative colitis (“UC”)
and Crohn’s disease (“CD”).
•Conducting a formal process evaluating oral and injectable combination therapy candidates with obefazimod in UC.
•Selecting a follow-on candidate for obefazimod.
The consolidated financial statements and related notes (the “financial statements”) have been prepared under the responsibility of
Note 2. Basis of preparation
Except for share data and per share amounts, the financial statements are presented in thousands of euros. Amounts are rounded up or
down the nearest whole number for the calculation of certain financial data and other information contained in these accounts.
Accordingly, the total amounts presented in certain tables may not be the exact sum of the preceding figures.
F-8
The consolidated financial statements of the Group as of and for the years ended December 31, 2021, 2022 and 2023 have been
prepared in accordance with both International Financial Reporting Standards (“IFRS”) as issued by the International Accounting
Standard Board (“IASB”) and IFRS as adopted by the European Union (“EU”) regulation n°1606/2002 of July 19, 2002. The term
“IFRS” refers collectively to International Accounting Standards (“IAS”) and IFRS as well as the interpretations issued by the
Standing Interpretations Committee (“SIC”) and the International Financial Reporting Interpretations Standards Committee (“IFRS
Preparation of the financial statements
The consolidated financial statements of the Group were prepared on a historical cost basis, with the exception of certain asset and
liability categories and in accordance with the provisions set out in IFRS such as employee benefits measured using the projected unit
credit method, the Heights notes (classified under "Convertible loan notes") measured at fair value and derivative financial instruments
measured at fair value.
The Group has incurred substantial operating losses since inception and expects to continue to incur significant operating losses for the
foreseeable future and may never become profitable. For the year ended December 31, 2023, the Group had a net loss of €147.7
million.
Since inception, the Group has financed its operations through the issuance of ordinary shares with gross aggregate proceeds of
€557.2 million, of which €130 million of gross proceeds were from offerings of its ordinary shares on Euronext Paris in February 2023
and €223.3 million of gross proceeds were from its offering of ordinary shares in the form of American Depository Shares ("ADS") on
the Nasdaq Global Market as well as ordinary shares in Europe (including France) and countries outside of the United States in a
private placement in October 2023, bank borrowings and structured loans for €125.0 million, reimbursements of Research Tax Credits
(Crédit d’Impôt Recherche (“CIR”)) in an aggregate amount of €31.1 million, subsidies received from Banque Publique
d’Investissement (“Bpifrance”) (including €13.5 million of subsidies and €6.6 million of conditional advances) and royalty certificates
in an amount of €2.9 million.
As a result of (a) the Group’s existing cash and cash equivalents of €251.9 million and other short term investments of €9.0 million as
of December 31, 2023 and (b) the drawdown of the second tranche of the Kreos / Claret Financing amounting to €25 million in gross
proceeds and announced on March 28, 2024, and (c) the expected reimbursement of the CIR from 2023 in the second half of 2024
amounting to €4.5 million, the Group expects, as of the date of issuance of these financial statements, to be able to fund its forecasted
cash flow requirements into the fourth quarter of 2025. This takes into account management's assumption that R&D expenditure will
be substantially increased in 2024 driven by the progression of the Phase 3 clinical trials of obefazimod in UC and the initiation of the
Phase 2b clinical trials for CD. Under these assumptions and based on the Group's current clinical plan, the Group would have
sufficient funds to finance its operations through the announcement of its top-line data from the Phase 3 ABTECT-1 and ABTECT-2
induction trials for UC.
Based on the above, these financial statements have been prepared on a going concern basis.
In February 2022, Russia invaded Ukraine. The conflict has already had major implications for the global economy and the rate of
inflation, particularly in relation to the supply of energy, raw materials and food products. It has also caused intense volatility on the
financial markets, something that is still ongoing at the reporting date and has pushed down stock market prices around the world.
Given these developments, the Group has decided not to include Russia and Belarus in its global Phase 3 program for obefazimod in
UC. However, the global scale of this conflict cannot be predicted at this stage. The Group, therefore, cannot rule out an adverse
impact of this conflict on its business, including in terms of access to raw materials, logistics, the performance of clinical studies and
in relation to any future financing the Group may seek.
F-9
The long-term safety and efficacy extension of the Phase 2b maintenance trial of obefazimod in moderately to severely active UC is
the Group’s only clinical trial with patients currently enrolled in Ukraine. The Phase 2b 12-month assessment was carried out in all
the Ukrainian patients before the war broke out and these patients are therefore included in the one-year maintenance results that were
reported on April 6, 2022. Ukrainian patients who completed the two-year Phase 2b maintenance trial have been transitioned to the
long-term safety and efficacy trial that is still on-going. None of these sites are located in the Crimea Region of Ukraine, the so-called
Donetsk People’s Republic, or the so-called Luhansk People’s Republic. The Group is also evaluating the possibility to include a few
Ukrainian sites in the western part of Ukraine in the ABTECT Phase 3 clinical trials.
Together with its CROs, the Group is making considerable efforts to ensure the follow-up of patients who are unable to come to the
study centers. Monitoring takes place through a remote monitoring system that was established and used successfully during the
The Group applied the following amendments to IFRS that are effective as of December 31, 2023:
•Amendments to IAS 1 Presentation of Financial Statements and IFRS Practice Statement 2 – Disclosure of Accounting
Policies;
•Amendments to IAS 8 – Definition of Accounting Estimates;
•Amendments to IAS 12 – Deferred Tax related to Assets and Liabilities arising from a Single Transaction;
•Amendments to IAS 12 – International Tax Reform—Pillar Two Model Rules;
•IFRS 17 – Insurance Contracts and related amendments.
The Group assessed the impacts resulting from the application of these issued accounting pronouncements and concluded that impacts
2023
The Group did not elect for early application of the following new standards, amendments and interpretations, which were issued but
not mandatory as of December 31, 2023:
•Amendments to IAS 1 Presentation of Financial Statements – Classification of Liabilities as Current or Non-current, and
Non-current Liabilities with Covenants, whose application is for annual reporting periods beginning on or after January
1, 2024; and
•Amendments to IAS 7 Statement of Cash Flows and IFRS 7 Financial Instruments: Disclosures – Supplier Finance
Agreements, whose application is for annual reporting periods beginning on or after January 1, 2024 (not yet approved
by the EU); and
•Amendments to IFRS 16 Leases: Lease Liability in a Sale and Leaseback, whose application is for annual reporting
periods beginning on or after January 1, 2024; and
F-10
•Amendments to IAS 21 The Effects of Changes in Foreign Exchange Rates – Lack of Exchangeability whose application
is for annual reporting periods beginning on or after January 1, 2025 (not yet approved by the UE).
The Group assessed the impacts resulting from the application of these issued accounting pronouncements and concluded that impacts
are not material, with the exception of the amendments to IAS 1, issued in 2020 and 2022, which aim at clarifying the requirements on
determining whether a liability is current or non-current, and require new disclosures for non-current liabilities that are subject to
future covenants. In accordance with these amendments, an entity shall classify a liability as current when it does not have the right at
the end of the reporting period to defer settlement of the liability for at least twelve months after the reporting period.
These amendments can impact liabilities with covenants which breach can render the related liabilities repayable within 12 months.
However, the Group has no such liabilities.
Under the amendments, a settlement of a liability includes transferring an entity's own equity instruments to the counterparty.
Therefore, if a liability has any conversion options that involve a transfer of the entity's own equity instruments, then these generally
affect its classification as current or non-current. As an exception, if these conversion options are recognized as equity under IAS 32,
then they do not affect the current or non-current classification of the liability.
As disclosed in Notes 15.1 and 15.2, the Group has convertible notes (the OCEANE as of December 31, 2021 and 2022 and the
Kreos / Claret OCABSA and the Heights convertible notes as of December 31, 2023, as defined below) that are convertible in
ordinary shares of the Group at any time at the option of the noteholders. In application of the amendments, the Group will no longer
be considered to have an unconditional right to defer the settlements of the OCEANE and the Heights convertible notes due to their
conversion options that are embedded derivatives not recognized as equity components. Consequently, the amendments will lead to
the reclassification of these convertible notes as current liabilities on a retrospective basis. The classification of the Kreos / Claret
OCABSA will not be impacted since they are compound instruments with conversion option and attached OCABSA warrants
recognized as an equity component.
Note 3. Significant events for the years ended December 31, 2021, 2022 and 2023 and subsequent events
Share capital issuance and unsecured senior convertible bonds exchangeable for new or existing shares (or “OCEANE”) issuance—
July 2021
The Company received a gross proceed of €85.0 million on July 30, 2021 through (i) the issuance of 1,964,031 ordinary shares with a
subscription price of €30.55 per share, and (ii) the issuance of €25,000 thousand in OCEANE, maturing on July 30, 2026. The
proceeds of the transaction mainly serve to finance the progress of ABX464 clinical trials in chronic inflammatory. See Note 15.5,
“OCEANE”.
COVID-19 BPI subsidies – March 2021
On March 5, 2021, the Company announced the interruption of the phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of
efficacy. As the Company terminated its financing agreement with Bpifrance in March 2021, Bpifrance made an additional payment of
€3.3 million in October 2021 to reimburse additional expenses incurred by the Company and agreed to waive the conditional advance
of €6.3 million. See Note 15.7, “Conditional Advances”.
Acquisition of Prosynergia SARL – April 2022
On April 1, 2022, the Company acquired 100 % of the share capital of Prosynergia SARL (or “Prosynergia”), a Luxembourg biotech
company, in order to strengthen its portfolio. The terms of the share purchase acquisition (or the “Prosynergia SPA”) entered on
November 15, 2021 included an early payment of €325 thousand made on November 25, 2021 (see Note 10), an additional payment of
€2,925 thousand made on April 1, 2022, and possible earn-out payments for a maximum additional amount of €4,000 thousand based
on the potential evolution of the Company’s market capitalization, a listing of the Company’s shares on Nasdaq or a M&A transaction
incurred before March 31, 2023. In addition, the Company granted a loan of €1,400 thousand to Prosynergia on December 1, 2021,
which term was at least on December 31, 2025 or at an earlier date in the event of a breach in the Prosynergia SPA (see Note 10,
“Other receivables and assets”). Such prepayment was repayable in cash only in the event the transaction is not completed.
Considering that Prosynergia only owned patent rights but did not enter into any employee contract, research agreement, collaboration
agreement or out-licensed agreement, it does not meet the definition of a business under IFRS 3. Consequently, the acquisition cost of
this group of assets was allocated between the identifiable assets and liabilities acquired, pro rata to their respective fair values as of
F-11
April 1, 2022, without recognition of goodwill. Also, the €1,400 thousand loan granted to Prosynergia in December 2021 was included
in the acquisition cost to be allocated, as it is considered a prepayment for the acquisition of the group of assets.
Merger with Prosynergia – December 2022
On December 12, 2022, the Company completed the merger with Prosynergia under the French legal procedure called “Transmission
Universelle de Patrimoine” (universal transfer of assets and liabilities). All of Prosynergia’s assets and liabilities were transferred to
the Company and Prosynergia was dissolved.
F-12
Impairment of ABX196 cash-generating unit
In the first half of 2022, management took into account significant external changes in the hepatocellular carcinoma (HC) treatment
landscape. These changes are expected to require a new, lengthy, heavy and risky internal development process (use of a combination
of compounds). In this context, entering into a licensing partnership to fund the completion of the clinical development of ABX196 is
the option being considered.
However, due to the lack of progress made in the negotiation of a development partnership, the Company made the decision to freeze
the development program for ABX196 in the treatment of hepatocellular cancer. This decision led to the full impairment of the
ABX196 goodwill, i.e. an impairment loss of €13,586 thousand related to Wittycell’s goodwill and €45 thousand related to licenses.
As of December 31, 2022, the value in use and the fair value less costs to sell of the ABX196 cash-generating unit (“CGU”) are nil .
Forfeiture of AGA plans
AGAs granted in September 2021 were subject to vesting conditions including the completion of a M&A transaction on or prior to
July 31, 2022. As the non-market performance vesting conditions were not satisfied, the Company recognized a reversal of related
compensation expense of €1,026 thousand and accrual for social taxes of €205 thousand in the financial statements for the period
ended December 31, 2022.
Repayment of the advance made to Nice CHU – August 2022
The €4,000 thousand advance made to Nice CHU was reimbursed in August 2022 for an amount of €3,302 thousand. The remaining
amount of €698 thousand was settled by way of compensation with a payable due to the Nice CHU related to the recharge of third-
party services expenses that had been invoiced to the Nice CHU as part of the miR-AGE project (see Note 10, “Other receivables and
assets”).
Change in governance – August 2022
On August 16, 2022, the Company announced a transition in the chairmanship of its Board of Directors. Philippe Pouletty, the
Company’s founder and Chairman of the Board of Directors since the Company was created in 2013, informed the Board of Directors
of his decision to resign as Chairman with immediate effect. However, after many years of successfully leading the Board of
Directors, Mr. Pouletty will continue to support the Company’s development as a member of the Board of Directors.
Pending the appointment of a new, permanent independent Chair, Ms. Corinna zur Bonsen-Thomas, an independent member of the
Board of Directors of the Company, carried out the role of interim Chair.
The Company completed €49.2 million cross-over financing with top-tier US and European investors – September 2022
On September 2, 2022, the Company announced oversubscribed financing of around €49.2 million, led by TCGX with the
participation of Venrock Healthcare Capital Partners, Deep Track Capital, Sofinnova Partners, Invus and Truffle Capital, top-tier
investors specializing in the biotechnology sector.
The financing consists of two transactions:
•a reserved capital increase of a gross amount of approximately €46.2 million through the issuance of 5,530,000 new
shares with a nominal value of €0.01 per share, representing 33 % of its current share capital, at a subscription price of
€8.36 per share; and
•an issue of royalty certificates with a subscription price amounting to €2.9 million. The royalty certificates give right to
their holders to royalties equal to 2 % of the future net sales of obefazimod.
F-13
(worldwide and for all indications) as from the commercialization of such product. The amount of royalties that may be
paid under the royalty certificates is capped at €172 million.
The proceeds of the financing will primarily be used to fund the advancement of Phase 3 clinical trials for obefazimod in ulcerative
colitis, expanding the Company’s cash runway to the end of Q1 2023.
Related transaction costs amounted to €3.3 million and were deducted from the share premiums.
Royalty certificates are recorded as financial liabilities at amortized cost (see Note 15.10).
The Company announces first US patient enrollment in global Phase 3 program with obefazimod in UC – October 2022
On October 11, 2022, the Company announced that the first patient was enrolled in the US into its global Phase 3 clinical program
with product candidate obefazimod for the treatment of moderately to severely active UC. IQVIA, a global premier contract research
organization, is responsible for coordinating the Company’s Phase 3 clinical trial for obefazimod in UC. As of December 31, 2022, the
undiscounted amount of the advance payments made by the Company in relation to the IQVIA agreement is €12,187 thousand. They
were recorded at inception at their fair value (discounted amount) and subsequently measured at amortized cost calculated using the
effective interest rate method. As of December 31, 2022, their carrying amount is €10,471 thousand. The repayment dates of these
advances are scheduled between April 2025 and July 2026 (see Note 9).
The Company announces successful oversubscribed €130.0 million cross-over financing at market price with top-tier US and
European Biotech investors – February 2023
On February 22, 2023, the Company announced the successful pricing of an oversubscribed €130.0 million financing with high-
quality US and European biotech specialist investors, led by TCGX, with participation from existing investors Invus, Deep Track
Capital, Sofinnova Partners, Venrock Healthcare Capital Partners, as well as from new investors Great Point Partners, LLC, Deerfield
Management Company, Commodore Capital, Samsara BioCapital, Boxer Capital and others, by way of a reserved capital increase of
€130 million through the issuance of 20,000,000 newly-issued ordinary shares with a nominal value of €0.01 per share, representing
Related transaction costs amounted to €6.7 million and were deducted from the share premiums.
Change in governance and management – February-August 2023
On April 5, 2023, the Company announced the appointment of Marc de Garidel as Chief Executive Officer (“CEO”) and Interim
Board Chair, effective May 5, 2023. Corinna zur Bonsen-Thomas stepped down as acting Chair, a position she held since August
2022, and remains a Board Member. Prof. Hartmut J. Ehrlich, M.D., retired from the CEO position, which he held since the
Company’s founding in 2013, and will stay on as a strategic advisor until the transition is complete. The Company expects to appoint
a long-term Board Chair in 2024.
On February 17, 2023, and April 18, 2023, the Company respectively announced the appointments of Dr. Sheldon Sloan, M.D., M.
Bioethics as new Chief Medical Officer and Michael Ferguson as new Chief Commercial Officer.
On July 11, 2023, the Group announced the appointments of June Lee, M.D. and Troy Ignelzi as new independent members of the
Group’s Board of Directors, replacing Joy Amundson and Jean-Jacques Bertrand.
On August 23, 2023, the Group announced the appointment of Patrick Malloy as new Senior Vice President Investor Relations.
F-14
Creation of Abivax LLC – March 2023
On March 20, 2023, Abivax LLC (or “the Subsidiary”), was incorporated as a Limited Liability Company under the laws of Delaware.
As of the issuance of the financial statements, the Company has full ownership over the Subsidiary. The Subsidiary will host the
Group’s operations in the United States.
Cash less exercise of the Kreos A&B BSA – May 2023
On May 24, 2023, Kreos Capital V UK Ltd (or “Kreos”) opted for the cash less exercise option of the share warrants they held (as
defined in Note 15.3), implemented through the repurchase by the Group of 43,070 tranche A share warrants (“Kreos A BSA”) and
the exercise by Kreos of the outstanding Kreos A & B BSA. The accounting treatment of the operation is set forth in Note 15.3.
Free shares compensation plans – July-December 2023
In July, September and December 2023, the Group issued five free shares compensation plans (attributions gratuites d’actions, or
“AGAs”) to certain of its officers and employees, representing a maximum of 2,601,296 shares in the aggregate. The detailed terms
and conditions and the accounting treatment of these plans are presented in Note 14.
The Group secures financing up to €150 million from two structured debt financing transactions – August 2023
On August 20, 2023, the Group concurrently signed two structured debt financing transactions for a total amount of up to €150 million
consisting of (i) up to €75 million from Kreos Capital and Claret European Growth Capital (the “Kreos / Claret Financing”) together
with the issuance of warrants (“the Kreos / Claret BSA”) exercisable to receive ordinary shares of the Company, for an aggregate
exercise price of up to €8 million and (ii) up to €75 million from a fund advised by Heights Capital Management, Inc. (the “Heights
Financing” and together with the Kreos / Claret Financing, the “Transaction”). The detailed structure and characteristics of the
Transaction are set forth in Notes 15.1 and 15.2.
The first tranches of the Kreos / Claret Financing and the Heights Financing, for €25 million and €35 million, respectively, were
drawn on August 22, 2023, and August 24, 2023, respectively. In addition, the Group concurrently granted to Kreos and Claret, for no
additional consideration, warrants exercisable to receive ordinary shares of the Company for an aggregate exercise price of up to
€4 million.
As part of the Transaction, the Group is also repaying in full a total outstanding amount of €33 million under (i) the pre-existing debt
agreements with Kreos for a total amount of €8 million and (ii) the pre-existing OCEANE bonds for a total amount of €25 million by
way of set-off with the Heights Financing, thereby fully repaying such pre-existing indebtedness.
The net proceeds of the drawdown of the first tranche of the Kreos / Claret Financing and of the Heights Financing which, net of the
refinancing of the existing indebtedness, amount to €27 million in the aggregate, are expected to be allocated mainly to the
development of obefazimod for the treatment of adults with moderately to severely active UC and other potential chronic
inflammatory indications, as well for working capital and general corporate purposes of the Group.
On November 2, 2023, the Group granted additional warrants to Kreos and Claret, for an aggregate exercise price of up to €4 million,
in order to secure the future drawdown of the third tranche of the Kreos / Claret debt financing. The detailed characteristics of the
issuance is set forth in Note 15.1.
The Group announces closing of its Initial Public Offering on the Nasdaq Global Market – October 2023
On October 24, 2023, the Group announced the closing of its previously announced initial public offering on the Nasdaq Global
Market by way of a capital increase of 20,325,500 new ordinary shares, consisting of a public offering of 18,699,460 ordinary shares
in the form of American Depositary Shares (“ADSs”), each representing the right to receive one ordinary share, in the United States
(the “US Offering”), and a concurrent offering of 1,626,040 ordinary shares in certain jurisdictions outside of the United States to
certain investors (the “European Private Placement”, and together with the U.S. offering, the “Global Offering”). The offering price
was set at $11.60 per ADS in the U.S. Offering and a corresponding offering price of €10.9864 per ordinary share in the European
Private Placement. All of the ADSs and ordinary shares in the Global Offering were offered by the Group. The ADSs began trading on
the Nasdaq Global Market on October 20, 2023. The aggregate gross proceeds amount to approximately $235.8 million, equivalent to
approximately €223.3 million based on the exchange rate then in effect, before deduction of underwriting commissions and estimated
expenses payable by the Group.
The net proceeds of the Global Offering amount to $212.2 million (€202.0 million), after deducting $23.6 million (€21.3 million) in
transaction costs. These costs were deducted from the share premiums.
F-15
The Group expects to use the net proceeds from the Global Offering as follows:
•approximately €160.0 million ($168.9 million) to fund the development of obefazimod for UC;
•approximately €14.0 million ($14.8 million) to fund the development of obefazimod for CD; and
•the remainder for working capital and for other general corporate purposes, including in the continued research to identify
new compounds and the payment of maturities of existing debt agreements as they become due (mostly allocated to payments
under the Kreos / Claret Financing, and assuming that the Group will repay the Heights Financing through the issuance of
new shares instead of making cash payments).
Changes in management – February-April 2024
On February 7, 2024, the Group announced the appointments of Ana Sharma as Vice President, Global Head of Quality.
On April 2, 2024, the Group announced the appointment of Camilla Soenderby as Independent Board Member and also a member of
the Nomination and Compensation Committee. Ms. Soenderby replaces Santé Holdings S.R.L., represented by Mr. Paolo Rampulla,
who will continue to contribute to the work of the Board of Directors as an observer alongside Mr. Maurizio PetitBon from Kreos
Capital/Blackrock.
Share-based compensation plans – February-March 2024
In February 2024, the Group issued a free-share compensation plan to certain of its officers and employees, representing a maximum
of 1,549,125 shares in the aggregate, the vesting of which is subject to the following service condition: 50 % of the AGAs vest at the
end of a two-year period from the allocation date, 25 % at the end of a three-year period from the allocation date and 25 % at the end of
a four-year period from the allocation date.
In March 2024, the Group granted its independent Board members the right to subscribe up to 77,820 share warrants (BSA) in the
aggregate, the vesting of which (if subscribed) is subject to a service condition of four years , by tranches of 25 % each, vested on each
anniversary date.
Drawdown of Tranche B of the Kreos / Claret Financing – March 2024
On March 28, 2024, the Group drew down €25 million related to Tranche B of senior secured non-convertible bonds from the Kreos /
Claret Financing. This second tranche consists in 25,000,000 senior secured non-convertible bonds with a par value of EUR 1.00
each, that will not be listed on any market.
A variable interest rate of 7.5 % + European Central Bank Base Rate (MRO) (with a floor at 2.5 % and a cap at 4 %) applies to such
tranche. These non-convertible bonds will be repaid monthly through March 31, 2027, after a deferred repayment of the principal until
February 1, 2025.
Note 4. Accounting principles
Following initial recognition, goodwill is stated at cost less any accumulated impairment losses (see Note 4.4).
In respect of business combinations prior to January 1, 2020, in accordance with IFRS 1 exemption, goodwill is included on the basis
F-16
Pursuant to IAS 38—Intangible Assets, intangible assets acquired are recognized as assets on the statements of financial position at
their acquisition cost.
Licenses
Payments for separately acquired research and development are capitalized within “Other intangible assets” provided that they meet
the definition of an intangible asset: a resource that is (i) controlled by the Group, (ii) expected to provide future economic benefits for
the Group and (iii) identifiable (i.e., it is either separable or arises from contractual or legal rights). In accordance with paragraph 25 of
IAS 38—Intangible Assets, the recognition criterion relating to the likelihood of future economic benefits generated by the intangible
asset, is presumed to be achieved for research and development activities when they are acquired separately. In this context, amounts
paid to third parties in the form of initial payments or milestone payments relating to pharmaceutical specialties that have not yet
obtained a marketing authorization are recognized as intangible assets. These rights will be amortized on a straight-line basis, after
obtaining the marketing authorization, over their useful life. Unamortized rights (before marketing authorization) are subject to
impairment tests in accordance with the method defined in Note 4.4.
Research and development costs
Pursuant to IAS 38 – Intangible Assets, research costs are expensed in the period during which they are incurred. Development costs
are only recognized as intangible assets if the following criteria are met:
•it is technically feasible to complete the development of the project;
•it is the Group’s intention to complete the project and to utilize it;
•it has capacity to utilize the intangible asset;
•there is proof of the probability of future economic benefits associated with the asset
•there is availability of the technical, financial and other resources for completing the project; and
•there is a reliable evaluation of the development expenses.
The initial measurement of the asset is the sum of expenses incurred starting on the date on which the development project meets the
above criteria. Because of the risks and uncertainties related to regulatory authorizations and to the research and development process,
the Group believes that the six criteria stipulated by IAS 38 have not been fulfilled to date and the application of this principle has
resulted in all development costs being expensed as incurred in all periods presented.
Other intangible assets
Other intangible assets mainly consist of acquired software. Costs related to the acquisition of software licenses are recognized as
assets based on the costs incurred to acquire and set up the related software. Other intangible assets are amortized using the straight-
Pursuant to IAS 16 – Property, Plant and Equipment, property, plant and equipment are recognized at their acquisition cost (purchase
price and directly attributable costs) or at their production cost by the Group, as applicable.
F-17
useful lives applied are as follows:
DEPRECIATION PERIOD | ||
Buildings | ||
Office fixtures and fittings | ||
Equipment | ||
Industrial materials and equipment | ||
Technical facilities | ||
Furniture and computer equipment: | ||
Office equipment | ||
IT equipment | ||
Furniture | ||
(1)Office fixtures and fittings estimated useful lives correspond to the Headquarters residual estimated lease term.
The useful lives of property, plant and equipment as well as any residual values are reviewed at each year-end and, in the event of a
Goodwill and intangible assets not yet available for use are not amortized and are tested for impairment annually.
In addition, the Group assesses at the end of each reporting period whether there is an indication that intangible assets and property,
plant and equipment may be impaired. Pursuant to IAS 36—Impairment of Assets, criteria for assessing indication of loss in value may
notably include performance levels lower than forecast, a significant change in market data or the regulatory environment, or
obsolescence or physical damage of the asset not included in the amortization/depreciation schedule.
For the purpose of impairment testing, goodwill and intangible assets not yet available for use are allocated to each of the Group’s
CGUs expected to benefit from synergies arising from the business combination or from the use of the intangible assets.
An impairment loss is recognized when the carrying amount of a CGU, including the goodwill, exceeds the recoverable amount of the
CGU. The recoverable amount of a CGU is the higher of the CGU’s fair value less cost to sell and value-in-use. The total impairment
loss of a CGU is allocated first to reduce the carrying amount of goodwill allocated to the CGU and then to the other assets of the
CGU pro-rata on the basis of the carrying amount of each asset in the CGU.
An impairment loss on goodwill is not reversed in a subsequent period. Impairment losses on intangible assets and property, plant and
Other financial assets (advances, loans and deposits granted to third parties and other short-term investments) and other receivables are
non-derivative financial assets with fixed or determinable payments that are not listed on an active market. They are initially
recognized at fair value plus transaction costs that are directly attributable to the acquisition or issue of the financial asset.
IFRS 9 – Financial Instruments requires an entity to recognize a loss allowance for expected credit losses on a financial asset at
amortized cost at each statement of financial position date. The amount of the loss allowance for expected credit losses equal to: (i) the
12—month expected credit losses or (ii) the full lifetime expected credit losses. The latter applies if credit risk has increased
F-18
The Group classifies investments as cash equivalents in the statements of financial position and statements of cash flows when they
meet the conditions of IAS 7—Statement of Cash Flows, i.e., when they are:
•held in order to face short-term cash commitments; and
•short term and highly liquid assets at acquisition date, readily convertible into known amount of cash and not exposed to
Ordinary shares are classified in shareholders’ equity. Costs associated with the issuance of new shares are directly accounted for in
shareholders’ equity in diminution of issuance premium.
The Group’s own shares bought in the context of a brokering/liquidity agreement entered with an independent broker are presented as
F-19
Since its inception, the Group has established several plans for compensation settled in equity instruments in the form of founders’
share subscription warrants (“bons de souscription de parts de créateur d’entreprise” or “BCE”), share subscription warrants (“Bons de
souscription d’actions,” or “BSA”) and free shares (“Attributions gratuites d’actions,” or “AGA”), granted to its employees, corporate
officers and scientific consultants.
Pursuant to IFRS 2—Share-based Payment, these awards are measured at their fair value on the date of grant. The values of the equity
instruments are determined using the option pricing model (in particular, a Black and Scholes model for the BCE and BSA plans and a
Monte-Carlo simulation for the AGA plans which include market performance vesting conditions) based on the value of the
underlying equity instrument at grant date, the volatility observed in a sample of comparable listed companies and the estimated life of
the related equity instruments.
The Group recognizes the fair value of these awards as a share-based compensation expense over the period in which the related
services are received, i.e. over the vesting period, with a corresponding increase in shareholders’ equity. Share-based compensation is
recognized by installments in consistency with their graded vesting schedule, when applicable.
The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and non-market
performance conditions are expected to be met, such that the amount ultimately recognized is based on the number of awards that meet
the related service and non-market performance conditions at the vesting date.
For share-based payment awards with market vesting conditions and non-vesting conditions, the grant-date fair value of the share-
based payment is measured to reflect such conditions and there is no true-up for differences between expected and actual outcome.
The measurement of the fair value of BSA, BCE and AGA incorporates the market-based vesting conditions and non-vesting
Note 4.8.1. Financial liabilities at amortized cost
Pursuant to IFRS 9 – Financial Instruments, the borrowings, the debt component of the Kreos / Claret OCABSA (classified as
convertible loan notes – see Compound instruments Compound instruments below) and Other financial liabilities (conditional
advances and royalty certificates) other than financial derivative liabilities are measured at amortized cost. They are initially
recognized at fair value and subsequently measured at amortized cost calculated using the effective interest rate (“EIR”) method. The
transaction costs that are directly attributable to the issue of the financial liability reduce that financial liability. These expenses are
then amortized over the lifetime of the liability, on the basis of the EIR. The EIR is the rate that exactly discounts estimated future
cash payments through the expected life of the financial liability to the amortized cost of a financial liability. Financial liabilities that
are due within one year are presented as current financial liabilities in the statements of financial position.
Royalty certificates
Royalty certificates meet the definition of financial liabilities. The Group concluded that they do not include embedded derivatives
related to the variability of royalties that are based on future net sales. In addition, the Group concluded that the prepayment options
were separate derivative instruments as their redemption price did not reimburse holders for an amount up to the approximate present
value of lost interest for the remaining term of the host contracts. However, their value at inception and subsequent dates is nil and has
no impact on the financial statements.
F-20
Royalty certificates are initially measured at fair value (refer to note 15.10 for valuation model applied). They are subsequently
measured at amortized cost calculated using the EIR method. The EIR is calculated based on future cash flows, which are estimated on
the basis of development and commercialization plans and budgets approved by the Board of Directors of the Group, and probability-
weighted to reflect the probability of success of clinical studies and any other uncertainty affecting them. If there is a change in the
timing or amount of estimated cash flows, then the gross carrying amount of the amortized cost of the financial liability is adjusted in
the period of change to reflect the revised actual and estimated cash flows, with a corresponding income or expense being recognized
in profit or loss. The revised gross carrying amount of the amortized cost of the financial liability is calculated by discounting the
future revised estimated cash flows at the original EIR.
Conditional advances and State guaranteed loan – “PGE”
Accounting treatment for conditional advances and the State-guaranteed loan (Prêt garanti par l'Etat, "PGE") is set forth in Note 4.9.
Leases
Accounting treatment for lease liabilities is set forth in Note 4.12.
Note 4.8.2. Financial liabilities measured at fair value through profit or loss
Derivative instruments
BSA attached to Kreos 1 bonds, the conversion option of OCEANE, certain prepayment options of bonds and the Kreos / Claret
warrants are derivatives instruments. Derivatives are recognized initially at fair value at the date the derivative contract is entered into
and are subsequently remeasured to their fair value at each reporting date. The resulting gain or loss from change in the fair value is
recognized in profit or loss immediately, as financial expenses or income.
Hybrid instruments
OCEANE bonds and Heights convertible notes (whose characteristics are described in Note 15.2 and Note 15.5) are hybrid
instruments. A “hybrid contract” is a contract that includes both a non-derivative host contract and one or more embedded derivatives.
Embedded derivatives are required to be separated from the host contract (bifurcated) if: the economic characteristics and risks of the
embedded derivative are not closely related to those of the host, a separate instrument with the same terms as the embedded derivative
would meet the definition of a derivative, and the hybrid contract is not measured at fair value through profit or loss.
Separable embedded derivatives are required to be measured at fair value at each reporting date, with changes in fair value recognized
in profit or loss. The initial bifurcation of a separable embedded derivative does not result in any gain or loss being recognized.
Because the embedded derivative component is measured at fair value on initial recognition, the carrying amount of the host contract
on initial recognition is the difference between the carrying amount of the hybrid instrument and the fair value of the embedded
derivative. If the fair values of the hybrid instrument and host contract are more reliably measurable than that of the derivative
component - e.g. because of the availability of quoted market prices - then it may be acceptable to use those values to determine the
fair value of the derivative on initial recognition indirectly - i.e. as a residual amount.
The Heights convertible notes issued on August 24, 2023 included embedded derivatives as detailed in Note 15. The Group concluded
that these features were embedded derivatives that would modify the cash flows required under the contract and require to be
bifurcated from their host contract. The Group being unable to reliably value each embedded derivative at issuance date and on
subsequent reporting dates, it measured the whole hybrid instrument at fair value through profit or loss (“FVTPL”) as permitted by
IFRS 9. Instruments measured at FVTPL under these conditions are measured at their fair value on issuance and on subsequent
reporting dates, with changes in fair value recognized in profit or loss.
Compound instruments
The Kreos / Claret OCABSA are compound instruments (whose characteristics are described in Note 15.1). A “compound contract” is
a contract that includes both a debt component and an equity component. The debt component (excluding the conversion option and
the attached OCABSA warrants) is initially recognized at fair value and subsequently measured at amortized cost calculated using the
EIR method. The equity component corresponding to the conversion option and the attached OCABSA warrants is recorded in equity,
for the difference between the whole instrument’s fair value (its nominal value) and the standalone fair value of the debt component.
F-21
Fair value measurement
When measuring the fair value of an asset or a liability, the Company uses market observable data as far as possible. Fair values are
categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:
•level 1: fair value calculated using quoted prices in an active market for identical assets and liabilities;
•level 2: fair value calculated using valuation techniques based on observable market data such as prices for assets and
liabilities or similar parameters quoted in an active market;
•level 3: fair value calculated using valuation techniques based in whole or in part on unobservable inputs such as prices
in an inactive market or a valuation based on multiples of unlisted securities.
The Group benefits from the provisions of Articles 244c of the French General Tax Code relating to the French research tax credit
(“Crédit d’Impôt Recherche” or “CIR”). The CIR is granted to companies in order to encourage them to conduct technical and
scientific research. Companies that prove that they have expenditures which meet the required criteria (research expenditures located
in France or, since January 1, 2005, within the European Union or in another state that is a party to the Agreement on the European
Economic Area and has concluded a tax treaty with France that contains an administrative assistance clause) receive a tax credit that
can be used for the payment of the corporate tax due for the fiscal year in which the expenditures were made and the next three fiscal
years, or as applicable, companies may receive cash reimbursement for any excess portion at the three-year period following the fiscal
year of the expenditures. Only those companies meeting the EU definition of a small or medium-sized entity (“SME”) are eligible for
payment in cash of their research tax credit (to the extent not used to offset corporate tax payables) in the year following the request
for reimbursement. The expenditures taken into account for the calculation of the CIR involve only research expenses.
The CIR is presented under “Other operating income” in the statements of income (loss) as it is accounted for as a government grant
as defined in IAS 20 – Accounting for Government Grants and Disclosure of Government Assistance, and as “Other receivables and
assets” in the statement of financial position until its payment is received.
Subsidies
Subsidies are non-repayable grants received by the Group and recognized in the financial statements when there exists reasonable
assurance that the Group will comply with the conditions attached to the subsidies and the subsidies will be received.
Subsidies that are upfront payments are presented as deferred income and recognized through “Other operating income” for the
amount of the expenses incurred as part of the research program to which the subsidy relates.
A subsidy that is to be received either as compensation for expenses or for losses already incurred, or for immediate financial support
of the Group without associated future costs, is recognized in the Statements of income (loss) as “Other operating income” when there
The Group receives conditional advances to finance at below market interest rate research and development projects. Due to the
innovative nature of its drug candidate development programs, the Group has benefited from certain sources of financial assistance
from Bpifrance. Bpifrance provides financial assistance and support to emerging French enterprises to facilitate the development and
commercialization of innovative technologies.
Funds received from Bpifrance in the form of conditional advances are recognized as financial liabilities, as the Group has a
contractual obligation to reimburse Bpifrance for such conditional advances in cash based on a repayment schedule. Each award of an
advance is made to help fund a specific development milestone. More tails on conditional advances are provided in Note 15.7.
Receipts or reimbursements of conditional advances are reflected as financing transactions in the statements of cash flows.
The difference between the present value of the advance at market rate (i.e., present value of contractual cash flows including principal
and interests, discounted using a market rate as effective interest rate in accordance with IFRS 9) and the amount received as cash
from the Bpifrance constitutes a subsidy within the meaning of IAS 20. Considering that these advances do not finance fixed assets,
these subsidies are presented as “Deferred income” in the statement of financial position and recognized in the statement of net income
(loss) as “Other operating income“ on a systematic basis over the periods in which the Group recognizes as expenses the related costs
for which the grants are intended to compensate.
F-22
The incremental interest expense resulting from the difference between (a) the market interest rate and the (b) below-market rate is
spread over the contractual period until the last repayment and recognized in the statement of income (loss) accordingly, using the EIR
method. In the event of a change in estimate of contractual cash flows due under the conditional advances, the Group recalculates the
book value of the debt resulting from the discounting of the anticipated new future cash flows at the initial EIR. The adjustment is
recognized in the statements of income (loss) for the period during which the modification is recognized.
In the statements of financial position, these conditional advances are recorded in “Other financial liabilities” as current or non-current
portion depending on their maturity. In the event Bpifrance waived the repayment of the advance, the corresponding liability is
derecognized and treated as a subsidy in the statements of income (loss).
The benefit resulting from the low interest of PGE loans is also recognized as a subsidy corresponding to the difference between the
present value of the PGE at market rate and the amount received as cash. The accounting treatment is therefore similar to the above-
mentioned accounting treatment for conditional advances. PGE are recorded in “Borrowings” as current or non-current portion
The Group’s employees in France benefit from retirement benefits provided under French law, which consist in the following:
•compensation paid by the Group to employees upon their retirement (a defined benefit plan); and
•payments of retirement pensions by the social security agencies, which are financed by the contributions made by the
Group and employees. As they meet the definition of a defined contribution plan, the liabilities are presented as Tax and
employee-related payables in the statement of financial position.
In accordance with IAS 19 – Employee Benefits, the liability with respect to defined benefit plans is estimated by using the projected
credit unit method. According to this method, the cost of the retirement benefit is recognized in the statements of income (loss). The
retirement benefit commitments are valued at the current value of the estimated future payments, discounted using the market rate for
high quality corporate bonds with a term and currency that correspond to that estimated for the payment of the benefits. The Group
applied the decision of the IFRS IC, published on May 24, 2021, that concluded that, in the case that no rights were acquired in the
event of departure before retirement age and that the rights were capped after a certain number of years of seniority (“30 years”), the
commitment would only be recognized for the last 30 years of the employee’s career within the Group.
The difference between the amount of the provision at the beginning of a period and at the close of that period is recognized through
operating expenses for the portion representing the costs of services rendered and financial expenses for the net interest costs, and
through other comprehensive income (loss) for the portion representing the actuarial gains and losses due to changes in assumptions
F-23
Provisions correspond to commitments resulting from litigation and various risks to which the Group may face in the context of its
operations. In accordance with IAS 37 – Provisions, Contingent Liabilities and Contingent Assets, a provision is recorded when the
Group has an obligation to a third party resulting from a past event that will likely result in an outflow of resources to the third party,
and for which future cash outflows may be estimated reliably. The amount recorded as a provision is an estimate of the expenditure
As lessee, the Group assesses whether a contract contains a lease at inception of a contract and upon the modification of a contract.
The Group elected to allocate the consideration in the contract to the lease and non-lease components on the basis of the relative
standalone price. The Group recognizes a right-of-use asset and a corresponding lease liability for all arrangements in which it is a
lessee, except for leases with a term of 12 months or less (short-term leases) and low-value leases (value of the underlying asset below
€5.0 thousand). For these short-term and low-value leases, the Group recognizes the lease payments as an operating expense on a
straight-line basis over the term of the lease.
The lease liability is initially measured at the present value of the future lease payments as from the commencement date of the lease
to the end of the lease term. The lease terms used by the Group reflect the non-cancellable terms of each contract, plus any extension
or termination options that the Group is reasonably certain to exercise or not exercise for all of the leases periods covered by the
extension options. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, the
Group incremental borrowing rate for the asset subject to the lease in the respective markets.
The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever there is a
change to the lease terms or expected payments under the lease, or a modification that is not accounted for as a separate lease. The
portion of the lease payments attributable to the repayment of lease liabilities and the portion attributable to payment of interests are
recognized in cash flows used in financing activities.
Right-of-use assets are initially recognized on the balance sheet at cost, which comprises the amount of the initial measurement of the
corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease
incentives received and any initial direct costs incurred by the Group, and expected costs for obligations to dismantle and remove
right-of-use assets when they are no longer used.
Right-of-use assets are depreciated on a straight-line basis from the commencement date of the lease over the shorter of the useful life
of the right-of-use asset or the end of the lease term.
Right-of-use assets are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be
Pursuant to IAS 21 – The Effects of Changes in Foreign Exchange Rates, transactions performed by the Group in currencies other than
their functional currency, which is the Euro, are translated at the prevailing exchange rate on the transaction date.
Trade receivables and payables and liabilities denominated in a currency other than the functional currency are translated at the
F-24
French tax authorities, using tax rates and tax laws enacted or substantively enacted at the end of the reporting period in accordance
with IAS 12 – Income Tax.
The income tax charge for the period comprises current tax due and the deferred tax charge. The tax expense is recognized in the
statement of income (loss) unless it relates to items recorded in other comprehensive income (loss) or directly in equity, in which case
the tax is also recorded in other comprehensive income (loss) or directly in equity.
Current taxes
The current tax expense is calculated based on taxable profit for the period, using tax rates enacted or substantively enacted at the
Deferred taxes are recognized when there are temporary differences between the carrying amount of assets and liabilities in the
Group’s financial statements and the corresponding tax basis used to calculate taxable profit. Deferred taxes are not recognized if they
arise from the initial recognition of an asset or liability in a transaction other than a business combination which, at the time of the
transaction, does not affect either the accounting or the taxable profit (tax loss).
The Group applies the Amendments to IAS 12 – Deferred Tax related to Assets and Liabilities arising from a Single Transaction,
issued on May 7, 2021, and presents the deferred tax assets and liabilities arising from such transactions separately within Note 22 -
Income tax, rather than on a net basis. The Amendments have no impact on the Statements of financial position and the Statement of
comprehensive income (loss) for the periods presented.
Deferred tax assets
Deferred tax assets are recognized for all deductible temporary differences, unused tax losses and unused tax credits to the extent that
it is probable that the temporary difference will reverse in the foreseeable future and that taxable profit will be available against which
the deductible temporary difference, unused tax losses or unused tax credits can be utilized. See Note 4.16. Use of judgments and
From April 1, 2022 up until the merger completed on December 12, 2022, the Company owned a 100 % ownership interest of
Prosynergia and as such, controlled Prosynergia. The Company had power over Prosynergia, was exposed or had rights to variable
returns from its involvement with the entity and had the ability to affect those returns through its power over the entity.
The financial statements of Prosynergia were therefore included in the consolidated financial statements of the Company from the date
control was obtained, i.e. April 1, 2022. Prosynergia was merged into the Company in December 12, 2022.
Considering that Prosynergia only owned patent rights but did not enter into any employee contract, research agreement, collaboration
agreement or out-licensed agreement, it did not meet the definition of a business under IFRS 3. Consequently, the acquisition cost of
this group of assets was allocated between the identifiable assets and liabilities acquired, pro rata to their respective fair values as of
April 1, 2022, without recognition of goodwill. For this purpose, the following approach was applied: first measurement of any
identifiable asset or liability initially measured at an amount other than cost in accordance with the applicable standards, deduction
from the cost of the group of assets of the amounts allocated to these assets and liabilities, and then allocation of the residual cost of
acquisition to the remaining identifiable assets and liabilities based on their relative fair values at the date of acquisition.
F-25
Also, the €1,400 thousand loan granted to Prosynergia in December 2021 was included in the acquisition cost to be allocated, since, in
substance, it was considered as a prepayment for the acquisition of the group of assets, which is repayable in cash in the event of non-
completion of the transaction.
The potential earn-out payment to be paid in the first half of 2023 was measured at fair value on April 1, 2022, for an amount of
€1,446 thousand, and included in the acquisition cost. This earn out could be triggered in the event the Group’s market capitalization
was in excess of €300 million (valued at certain specified record dates), a listing of the Group’s shares on Nasdaq or a merger and
acquisition transaction prior to March 31, 2023. The amount of the earn-out was equal to 1 % of the difference between the Group’s
market capitalization and €300 million, subject to a maximum amount of €4.0 million. It was payable in the first half of 2023 if
conditions were met. No amount was payable in the event the Group’s market capitalization was lower than €300 million. The related
financial liability was subsequently remeasured to its fair value as of December 31, 2022 estimated to nil (see Note 15.9). The
remeasurement resulted in a financial income of €1,446 thousand over the year ended December 31, 2022.
As a consequence of the earn-out condition not being met on March 31, 2023, the related financial liability was derecognized.
(Amounts in thousands of euros) | Amount allocated as of April 1, 2022 |
Cash prepayment made in 2021 ........ | |
Loan granted to Prosynergia in 2021 | |
Cash payment made in 2022 ............. | |
Acquisition fees (1) ........................... | |
Earn-out measured at fair value ........ | |
Total acquisition cost allocated ...... | |
Patents ............................................... | |
Cash and cash equivalents ................ | |
Total assets ...................................... | |
Total liabilities ................................. | ( |
Total net assets ................................ |
The acquisition cost was mainly allocated to Prosynergia’s patents US 10,464,903 (filed on March 20, 2017 and granted on November
5, 2019), EP3 429 998 (filed on March 20, 2017 and granted on September 1, 2021) and continuation US 10,745,357 (filed on
November 1, 2019 and granted on August 18, 2020). All patents will expire in 2037.
These patents cover alternative synthesis process for obefazimod and a family of close chemical analogues. They also cover
alternative forms of obefazimod (salts thereof and crystalline forms of said salts), the pharmaceutical composition comprising them,
In order to prepare financial statements in accordance with IFRS, estimates, judgments and assumptions were made by the Group’s
management which could affect the reported amounts of assets, liabilities, contingent liabilities, income and expenses.
These estimates are based on the assumption of going concern and are prepared in accordance with information available at the date
the financial statements were prepared. They are reviewed on an ongoing basis using past experience and various other factors
considered to be reasonable as the basis to measure the carrying amount of assets and liabilities. Estimates may be revised due to
F-26
changes in the underlying circumstances or subsequent to new information. Actual results may differ significantly from these
estimates in line with assumptions or different conditions.
This note provides an overview of the areas that involved a higher degree of judgement or complexity, and of items which are more
likely to be materially adjusted due to changes in estimates and assumptions. Detailed information about each of these estimates and
judgements is included in other notes together with information about the basis of calculation for each affected line item in the
financial statements.
•Recognition and measurement of impairment of CGUs. The main assumptions used for the impairment test include
(a) the amount of cash flows that are set on the basis of the development and commercialization plans and budgets
approved by Board of Directors, (b) assumptions related to the achievement of the clinical trials and the launch of the
commercialization, (c) the discount rate, (d) assumptions on risk related to the development and (e) for the
commercialization, selling price and volume of sales. The sensitivity analysis in respect of the recoverable amount of the
CGUs is presented in Note 6.
•Measurement of share-based payments granted to employees, corporate officers and scientific consultants, such as BCE,
BSA and AGA, which is based on actuarial models; these models require the use by the Group of certain calculation
assumptions such as the estimated vesting, the occurrence dates of a change of control or a M&A transaction dates, the
percentage of success (“POS”) of obefazimod, the expected volatility and maturity of the underlying equity instrument
(see Note 4.7 and Note 14),
•Fair value measurement at inception and after of derivative financial instruments resulting from (i) the warrants issued
concomitantly with the issuance of the straight and convertible bonds to Kreos on July 24, 2018 (or “Kreos 1”), (ii) the
prepayment option attached to the straight and convertible bonds issued to Kreos on October 2, 2020 (or “Kreos 2”), and
(iii) the prepayment option attached to the issuance of bond convertible into new or existing shares in July 30, 2021 (or
“OCEANE”) (see Notes 15), (iv) the Kreos / Claret BSA issued on August 21, 2023 and November 2, 2023, related to
tranches A-B and tranche C, respectively.
•Fair value measurement of financial liabilities at inception (see Note 15), and after (for the Heights convertible notes
issued on August 24, 2023) measured at fair value at each reporting period, with fair value changed recognized in profit
or loss,
•Amortized cost measurement of royalty certificates, based on the following assumptions: (a) future cash flows, estimated
on the basis of development and commercialization plans and budgets approved by the Board of Directors and (b) the
effective interest rate. The sensitivity analysis in respect of the measurement of royalty certificates is presented in Note
15,
•Fair value measurement of the call option resulting from the equity line contracts entered into on September 30, 2019 (or
“Equity lines”) (see Note 13.2),
•Estimation of CIR, based on internal and external expenses, which meet the required criteria, incurred by the Company
each year (see Note 4.9),
•Recognition of deferred tax assets: availability of future taxable profit against which deductible temporary differences
and tax losses carried forward can be utilized and whether sufficient evidence exists (see Note 22).
•Recognition of deferred tax assets: tax deductibility of future royalty payments related to the royalty certificates issued in
September 2022 (see Notes 15 and 22).
The main critical judgments made by the Group’s management impact the following items:
•Accounting treatment of specific conditions of share-based compensation plans (see Notes 4.7 and 14).
•Accounting treatment of the 2018 & 2020 Kreos 1 & 2 bonds, the 2021 OCEANE bonds, and the August 2023 Kreos /
Note 5. Segment information
The assessment of the Group’s performance and the decisions about resources to be allocated are made by the chief operating decision
maker, based on the management reporting system of the Group. The Group identified the Chief Executive Officer of the Group as
F-27
“Chief operating decision maker”. The Chief operating decision maker reviews on an aggregated basis the incurred expenses for
allocating and evaluating performance of the Group.
The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future.
Substantially all operations, assets, liabilities, and losses of the Group are located in France. As of December 31, 2023, the US
Subsidiary’s contributions to the Group’s assets, liabilities and net losses were less than 5
Note 6. Goodwill and impairment test
Goodwill relates to the acquisition of Splicos SAS and Wittycel SAS that occurred in 2014 (i.e., prior the transition date to IFRS),
which were merged into the Group in the same year.
Goodwill from Splicos SAS and Wittycel SAS acquisition corresponds to the “Modulation of RNA biogenesis / splicing”
technological platform and the “iNKT agonists” technological platform, respectively, from which derived the lead drug candidates of
the Group: ABX464 and ABX196, respectively.
IFRS 3 was not applied to acquisitions of subsidiaries deemed to be a business within the meaning of IFRS, carried out before the
IFRS transition date, i.e., January 1 2020. Due to the application of this exemption, the previous accounting for business combinations
in accordance with French GAAP remains unchanged (no identified Intellectual Property, Research & Development (“IPR&D”) assets
are recognized in the statement of financial position).
The carrying amounts of the goodwill resulting from Splicos SAS and Wittycel SAS acquisitions were, as of December 31, 2021,
€18,419 thousand and €13,586 thousand, respectively.
In accordance with IAS 36, goodwill is allocated to CGUs at a level corresponding to the lead drug candidates. Thus, goodwill from
Splicos SAS and Wittycel SAS are allocated to ABX464 CGU and ABX196 CGU, respectively.
Goodwill impairment tests are undertaken annually or more frequently if events or changes in circumstances indicate a potential
impairment, in accordance with IAS 36. The carrying amount of goodwill is compared to the recoverable amount, which is the higher
value in use and the fair value less costs to disposal.
As of December 31, 2021, 2022 and 2023 the recoverable amount used for the impairment test of each CGU was the value in use. This
value in use was based on a net present value calculation, using the following assumptions as of December 31, 2021, 2022 and 2023:
•Cash flows are set on the basis of the development and commercialization plans and budgets approved by Board of
Directors;
•A discount rate (or “WACC”) of 15 % as of December 31, 2023, 14 % as of December 31, 2022 and 13.5 % as of
December 31, 2021;
•A risk of development is taken into consideration by applying probabilities of success (or “POS”) of reaching future
phases of development to cash flows related to the commercialization phase. Those average probabilities of success of
R&D projects are based on public sources (INFORMA databases).
•For the commercialization phase, selling price and sales volume are estimated on the basis of the potential market and
the observed performances of comparable drugs currently on the market.
The impairment tests resulted in no
During the year ended December 31, 2022, management took into account significant external changes in the hepatocellular
carcinoma (HC) treatment landscape. These changes were expected to require a new, lengthy, heavy and risky internal development
process (use of a combination of compounds). For this purpose, entering into a licensing partnership to fund the completion of the
clinical development of ABX196 was being considered. As of December 31, 2022, due to the lack of progress made in the negotiation
of a development partnership, the Group made the decision to freeze the development program for ABX196 in the treatment of
hepatocellular cancer. In this context, the impairment test carried out as of December 31, 2022 resulted in the full impairment of the
goodwill resulting from the acquisition of Wittycell SAS and other assets included in the ABX196 CGU, i.e. an impairment loss of
€13,632 thousand as of December 31, 2022 (€13,586 thousand related to goodwill and €45 thousand related to other assets – see Note
7).
F-28
Sensitivity testing as of December 31, 2021, 2022 and 2023:
The Group has conducted an analysis of the sensitivity of the impairment tests to changes in the key assumptions used to determine the
recoverable amount of the CGUs to which goodwill is allocated.
Regarding ABX464, as the product is currently under development, a clinical trial failure or a failure to obtain a marketing approval
could result in an impairment. The results of the impairment test indicate a headroom level that is high enough so that any reasonably
possible change in any of the key assumptions (except clinical failure) would not lead to any impairment.
Regarding ABX196:
•as of December 31, 2022, as above-mentioned, the net book value of the CGU was brought to zero after recording an
impairment of €13,632 thousand.
•as of December 31, 2021, an increase in WACC of 3.7 percentage points, or a reduction in sales of 22 %, or a reduction
Note 7. Intangible assets
Intangible assets are mainly comprised of the intellectual property underlying:
(i)The exclusive license agreement with the Scripps Research Institute, University of Chicago and Brigham Young
University for which the Group paid a milestone of €45 thousand in September 2019 as a result of an IND filling of
ABX196. The value in use and the fair value less costs to disposal of the ABX196 CGU being nil as of December 31,
2022, a €45 thousand impairment loss was recorded during the year ended December 31, 2022 (see Note 6).
(ii)The collaboration and license agreement with the CNRS, Montpellier 2 university and the Curie for which the Group
paid a milestone of €40 thousand in September 2019 as a result of the entry in phase 2 of ABX464.
(iii)Patents acquired through the acquisition of Prosynergia of €6,529 thousand (cf. Note 4). The patents are not yet
amortized, similarly to licenses, and are included in the ABX464 CGU for impairment test purposes.
F-29
Licenses and patents recognized as Intangible assets are not amortized since they are not operating in a manner intended by the
management. As a consequence, and in accordance with IAS 36, those assets were subject to an annual impairment test as of
December 31, 2021, 2022 and 2023, which did not
€45 thousand impairment loss recorded during the year ended December 31, 2022.
(amounts in thousands of euros) | LICENCES | SOFTWARES | PATENTS | OTHER INTANGIBLE ASSETS | TOTAL | ||||
GROSS VALUES | |||||||||
AS OF JANUARY 1, 2021 | |||||||||
Acquisition | |||||||||
Disposal | |||||||||
Transfer | |||||||||
AS OF DECEMBER 31, 2021 | |||||||||
Acquisition | |||||||||
Disposal | |||||||||
Transfer | |||||||||
AS OF DECEMBER 31, 2022 | |||||||||
Acquisition | |||||||||
Disposal | |||||||||
Transfer | |||||||||
AS OF DECEMBER 31, 2023 |
(amounts in thousands of euros) | LICENCES | SOFTWARES | PATENTS | OTHER INTANGIBLE ASSETS | TOTAL | ||||
AMORTIZATION | |||||||||
AS OF JANUARY 1, 2021 | - | - | |||||||
Increase | - | - | |||||||
Decrease | |||||||||
AS OF DECEMBER 31, 2021 | - | - | |||||||
Increase | - | - | - | ||||||
Decrease | |||||||||
AS OF DECEMBER 31, 2022 | - | - | - | ||||||
Increase | - | - | |||||||
Decrease | |||||||||
AS OF DECEMBER 31, 2023 | - | - | - |
F-30
(amounts in thousands of euros) | LICENCES | SOFTWARES | PATENTS | OTHER INTANGIBLE ASSETS | TOTAL | ||||
NET BOOK VALUES | |||||||||
AS OF JANUARY 1, 2021 | |||||||||
AS OF DECEMBER 31, 2021 | |||||||||
AS OF DECEMBER 31, 2022 | |||||||||
AS OF DECEMBER 31, 2023 |
Note 8. Property, plant and equipment
December 31, 2021, 2022 and 2023:
(amounts in thousands of euros) | BUILDINGS | EQUIPMENT | FURNITURE AND COMPUTER EQUIPMENT | TOTAL | OF WHICH ROU | ||||
GROSS VALUES | |||||||||
AS OF JANUARY 1, 2021 | |||||||||
Acquisition | |||||||||
Disposal | ( | ( | ( | ( | |||||
Transfer | |||||||||
AS OF DECEMBER 31, 2021 | |||||||||
Acquisition | |||||||||
Disposal | ( | ( | ( | ( | ( | ||||
Transfer | |||||||||
AS OF DECEMBER 31, 2022 | |||||||||
Acquisition | |||||||||
Disposal | ( | ( | ( | ( | |||||
Transfer | |||||||||
AS OF DECEMBER 31, 2023 |
F-31
(amounts in thousands of euros) | BUILDINGS | EQUIPMENT | FURNITURE AND COMPUTER EQUIPMENT | TOTAL | OF WHICH ROU | ||||
DEPRECIATION | |||||||||
AS OF JANUARY 1, 2021 | ( | ( | ( | ( | ( | ||||
Increase | ( | ( | ( | ( | ( | ||||
Decrease | |||||||||
AS OF DECEMBER 31, 2021 | ( | ( | ( | ( | ( | ||||
Increase | ( | ( | ( | ( | ( | ||||
Decrease | |||||||||
AS OF DECEMBER 31, 2022 | ( | ( | ( | ( | ( | ||||
Increase | ( | ( | ( | ( | ( | ||||
Decrease | |||||||||
AS OF DECEMBER 31, 2023 | ( | ( | ( | ( | ( |
(amounts in thousands of euros) | BUILDINGS | EQUIPMENT | FURNITURE AND COMPUTER EQUIPMENT | TOTAL | OF WHICH ROU | ||||
NET BOOK VALUES | |||||||||
AS OF JANUARY 1, 2021 | |||||||||
AS OF DECEMBER 31, 2021 | |||||||||
AS OF DECEMBER 31, 2022 | |||||||||
AS OF DECEMBER 31, 2023 |
Right of use assets relate to buildings, vehicles and furniture. The net book value of right of use assets related to buildings amounted to
€147 thousand, €1,224 thousand and €453 thousand as of December 31, 2021, 2022 and 2023 respectively.
Acquisitions over the year ended December 31, 2022 mainly include the right of use asset related to the new Headquarters entered into
in July 2022 (see Note 15.8), as well as office fittings and IT equipment. Disposals over the period mainly include the right of use
assets related to the former headquarters.
Acquisitions over the year ended December 31, 2023 mainly include the right of use asset related to the new Boston offices entered
into in November 2023. Decreases mainly include the remeasurement of the right of use asset related to the reassessment of the Paris
Note 9. Other financial assets
F-32
(amounts in thousands of euros) | AS OF DECEMBER 31, 2021 | AS OF DECEMBER 31, 2022 | AS OF DECEMBER 31, 2023 | ||
OTHER FINANCIAL ASSETS | |||||
Advances related to CRO contracts | |||||
Deposits | |||||
Other | |||||
Total other non-current financial assets | |||||
Other investments | |||||
Deposits | |||||
Total other current financial assets | |||||
Other financial assets |
Advances related to CRO contracts
These advances granted in 2022 for clinical studies are to be recovered at the end of the studies after final reconciliation with pass-
through costs, which are being invoiced and paid as studies are carried out. These long-term advances were measured at fair value on
initial recognition, using discount rates ranging from 0.19 % to 7.16 %, and are subsequently measured at amortized cost.
During the first half of 2023, additional advances related to CRO contracts amounting to €1,620 thousand were made (undiscounted
amount). These long-term advances were measured at fair value on initial recognition, using discount rates ranging from 7.09 % to
At inception, a prepaid expenses asset was recognized for the difference between the advances’ nominal value and fair value, and
spread over the term of the advances, at the rate of recognition of the related R&D expenses (see Note 10).
Other investments
Other investments consist of 6-month term deposits that do not qualify for a classification under cash and cash equivalents.
Deposits
Deposits include the deposits paid under the Kreos 1 & 2 bond loans (reimbursed in August 2023), the deposits paid under the
liquidity agreement, the security deposits under the Paris and Boston offices lease contracts and other security deposits.
Note 10. Other receivables and other assets
(amounts in thousands of euros) | AS OF DECEMBER 31, 2021 | AS OF DECEMBER 31, 2022 | AS OF DECEMBER 31, 2023 | ||
OTHER RECEIVABLES AND OTHER ASSETS | |||||
Prepaid expenses - non current | |||||
Total non-current other assets | |||||
Research tax credit ("CIR") | |||||
VAT receivables | |||||
Advance made to the Nice CHU | |||||
Advance payments for the acquisition of Prosynergia | |||||
Prepaid expenses | |||||
Credit notes | |||||
Total current other receivables and assets | |||||
Other receivables and other assets |
F-33
Research tax credit (“CIR”)
The CIR is recognized as Other Operating Income (see note 4.9) in the year to which the eligible research expense relates. The Group
received the payments of the CIR for 2021 and 2022 tax years in the amount of respectively €4,204 thousand and €4,476 thousand
and expects to receive the CIR for 2023 tax year of €4,493 thousand in 2024.
VAT Receivables
Value-added tax (“VAT”) receivables relate primarily to the deductible VAT and VAT refunds claimed.
Their increase as of December 31, 2023 compared to December 31, 2022 is due to the increase in trade payables and accrued invoices
over the period (see Note 17.1).
Advance made to the Nice CHU
On January 20, 2021, the Group amended the research agreement entered with the University Hospital Center of Nice (or “Nice
CHU”) on September 25, 2020, which consisted in the conduct of a study to test whether ABX464 could prevent the development of
severe Covid-19 disease in the participants. The Group agreed to advance amount of €4,000 thousand to Nice CHU corresponding to
the expenses recharged by its third parties for the year ended December 31, 2021. An amount of €3,302 thousand was reimbursed in
August 2022. The remaining €698 thousand amount was settled by way of compensation with a payable due to the Nice CHU related
to the recharge of third-party services expenses.
Advance payment for the acquisition of Prosynergia
In the context of the acquisition of Prosynergia, the Group made an initial payment of the acquisition price of €325 thousand on
November 25, 2021.
On December 1, 2021, the Group signed a loan agreement with Prosynergia for €1,400 thousand. Prosynergia committed to reimburse
the loan at the end of the contract, on December 31, 2025. The purpose of the loan was to allow early repayment by Prosynergia of all
its existing indebtedness and was a suspensive condition for the acquisition of Prosynergia shares provided by the Share purchase
agreement entered with the shareholder of Prosynergia on November 15, 2021. For accounting purposes, this loan was considered as a
prepayment for the acquisition of the group of assets, which was repayable in cash only in the event the acquisition is not completed.
As of December 31, 2022, there was no more loan recognized following the merger of the Company and Prosynergia on December 12,
2022.
F-34
Prepaid expenses
Prepaid expenses as of December 31, 2021 include costs related to the acquisition of Prosynergia for €451 thousand. During the year
ended December 31, 2022, these costs were then included in the acquisition price of Prosynergia which was allocated to acquired
patents (see Notes 3.2 and 4.15).
Prepaid expenses as of December 31, 2022 include prepaid expenses related to CRO contracts for amount of €1,714 thousand (see
Note 9).
Prepaid expenses as of December 31, 2023 include prepaid expenses related to CRO contracts for an amount of €1,347 thousand (see
Note 9) and deferred transactions costs related to tranches B and C of the Kreos / Claret financings for an amount of €3,152 thousand
(most of which represents the issuance date fair value of the tranche A-B and C Kreos / Claret BSA, representing origination fees for
the future drawdowns of the tranches B and C of the Kreos / Claret Financing, See Note 15.1) and other expenses from various
Note 11. Cash and cash equivalents
(amounts in thousands of euros) | AS OF DECEMBER 31, 2021 | AS OF DECEMBER 31, 2022 | AS OF DECEMBER 31, 2023 | ||
CASH AND CASH EQUIVALENTS | |||||
Cash equivalents | |||||
Cash | |||||
Cash and cash equivalents |
Cash equivalents mainly include term deposits with short-term maturities.
As of December 31, 2023, in addition to the Group’s bank accounts, cash includes notice accounts amounting to €231,562 thousand.
These funds are available on demand within 24 hours and without penalty.
The increase in cash and cash equivalents over the year ended December 31, 2023 is mainly explained by the proceeds from (i) the
Kreos / Claret and Heights Financings from August 2023 and (ii) the Group’s Global Offering conducted in October 2023 (see Note
3.3).
As of December 31, 2023, the impact of the revaluation of cash and cash equivalents held in U.S. dollars into the Group's presentation
Note 12. Financial assets and liabilities
levels in the fair value hierarchy.
Tax and employee-related payables are non-financial liabilities and are therefore excluded from the tables below. They are
presented in Note 17.2.
F-35
AS OF DECEMBER 31, 2021 | |||||||||
(amounts in thousands of euros) | AMOUNT RECOGNIZED IN THE STATEMENT OF FINANCIAL POSITION | FAIR VALUE | ASSETS/ LIABILITIES AT FAIR VALUE THROUGH PROFIT AND LOSS | ASSETS AT AMORTIZED COST | LIABILITIES AT AMORTIZED COST | ||||
Other financial assets (2) | — | ||||||||
Other receivables and assets (2) | — | ||||||||
Cash and cash equivalents (1) | — | ||||||||
Total financial assets | — | ||||||||
Financial liabilities—non-current portion (4, Note 15) | — | ||||||||
Financial liabilities—current portion (3, Note 15) | — | ||||||||
Trade payables and other current liabilities (3) | — | ||||||||
Total financial liabilities | — | ||||||||
AS OF DECEMBER 31, 2022 | |||||||||
(amounts in thousands of euros) | AMOUNT RECOGNIZED IN THE STATEMENT OF FINANCIAL POSITION | FAIR VALUE | ASSETS/ LIABILITIES AT FAIR VALUE THROUGH PROFIT AND LOSS | ASSETS AT AMORTIZED COST | LIABILITIES AT AMORTIZED COST | ||||
Other financial assets (2) | — | ||||||||
Other receivables and assets (2) | — | ||||||||
Cash and cash equivalents (1) | — | ||||||||
Total financial assets | — | ||||||||
Financial liabilities—non-current portion (4, Note 15) | — | ||||||||
Financial liabilities—current portion (3, Note 15) | — | ||||||||
Trade payables and other current liabilities (3) | — | ||||||||
Total financial liabilities | — | ||||||||
AS OF DECEMBER 31, 2023 | |||||||||
(amounts in thousands of euros) | AMOUNT RECOGNIZED IN THE STATEMENT OF FINANCIAL POSITION | FAIR VALUE | ASSETS/ LIABILITIES AT FAIR VALUE THROUGH PROFIT AND LOSS | ASSETS AT AMORTIZED COST | LIABILITIES AT AMORTIZED COST | ||||
Other financial assets (2) | — | ||||||||
Other receivables and assets (2) | — | ||||||||
Cash and cash equivalents (1) | — | ||||||||
Total financial assets | — | ||||||||
Financial liabilities—non-current portion (4, Note 15) | — | ||||||||
Financial liabilities—current portion (3, Note 15) | — | ||||||||
Trade payables and other current liabilities (3) | — | ||||||||
Total financial liabilities | — | ||||||||
(1) The fair value of cash and cash equivalents is determined based on Level 1 fair value measurement and corresponds to the
market value of the assets.
F-36
(2) The carrying amount of financial assets measured at amortized cost is deemed to be a reasonable estimate of fair value, except
for the long-term advances made to CROs, whose fair value is determined based on Level 3 fair value measurement and is estimated
based on future cash-flows discounted at market rates, using credit spreads ranging from 16 bp to 476 bp as of December 31, 2022 and
+100 bp would result in a decrease in the advances fair value by €240 thousand and €23 thousand respectively.
(3) The carrying amount of short-term financial liabilities measured at amortized cost was deemed to be a reasonable estimate of
fair value.
(4) The fair value of Kreos BSA A&B, OCEANE conversion option, royalty certificates, Heights convertible notes and Kreos /
Claret BSA is based on Level 3 fair value measurement and is estimated based on models and assumptions detailed in Note 15. The
fair value of other long-term financial liabilities is determined based on Level 3 fair value measurement and is estimated based on
future cash-flows discounted at market rates, using the following assumptions:
• For the debt components of Kreos 1&2 bonds, a credit spread of 1,058 bp as of December 31, 2021 and 1,475 bp as of
December 31, 2022.
As of December 31, 2021 and 2022, an increase in the credit spread by +100 bp would result in a decrease in the Kreos 1&2
bonds fair value by €209 thousand and €68 thousand, respectively.
•For the debt component of OCEANE bonds, a credit spread similar to that detailed in Note 15.
As of December 31, 2021, and 2022, an increase in the credit spread by +100 bp would result in a decrease in the OCEANE
debt component fair value by €648 thousand and €476 thousand, respectively.
•For the debt component of Kreos / Claret OCABSA debt component, a credit spread of 960 bp as of August 22, 2023 and 900
bp as of December 31, 2023.
As of August 22, 2023 and December 31, 2023, an increase in the credit spread by +100 bp would result in a decrease in the
Kreos / Claret OCABSA debt component fair value by respectively €624 thousand and €538 thousand.
•For the conditional advances and the PGE loan, a credit spread of 850 bp as of December 31, 2021, 1,475 bp as of December
31, 2022 and 900 bp as of December 31, 2023.
•An increase in the credit spread by +100 bp would result in the following:
•As of December 31, 2021, 2022 and 2023, a decrease in the PGE loan fair value by €102 thousand, €55 thousand, and
€39 thousand respectively.
•As of December 31, 2021, 2022 and 2023, a decrease in the RNP-VIR conditional advance fair value by €61 thousand,
€31 thousand and €15 thousand respectively.
•As of December 31, 2021, 2022 and 2023, a decrease in the CARENA conditional advance fair value by €58 thousand,
€37 thousand and €37 thousand respectively.
•As of December 31, 2021 and 2022, a decrease in the Ebola conditional advance fair value by €3 thousand, €1 thousand
and €1 thousand, respectively.
Note 13. Shareholders’ equity
The Group manages its capital to ensure that the Group will be able to continue as a going concern while maximizing the return to
shareholders through the optimization of the debt and equity balance.
As of December 31, 2021, the Group’s share capital amounted to €168 thousand divided into 16,764,051 ordinary shares issued with a
par value of €0.01 each, fully paid up, after taking into account the various capital increases that took place since the inception (see
Note 13.3).
As of December 31, 2022, the Group’s share capital amounted to €223 thousand divided into 22,313,185 ordinary shares issued with
a par value of €0.01 each, fully paid up, after taking into account the various capital increases that took place since the inception (see
Note 13.2).
F-37
As of December 31, 2023, the Group’s share capital amounted to €629 thousand divided into 62,928,818 ordinary shares issued with
a par value of €0.01 each, fully paid up, after taking into account the various capital increases that took place since the inception (see
Note 13.3).
Share capital does not include founders’ share subscription warrants (“bons de souscription de parts de créateur d’entreprise” or
“BCE”), share subscription warrants (“Bons de souscription d’actions,” or “BSA”) and free shares (“Attributions gratuites
d’actions,” or “AGA”) that have been granted to certain investors or natural persons, both employees and non-employees of the
Group, but not yet exercised.
Treasury shares
The Group held 8,600 , 12,000 and 11,339 of its own shares as of December 31, 2021, 2022 and 2023, respectively.
The number of outstanding ordinary shares (excluding treasury shares held by the Group) was 16,755,451 , 22,301,185 and 62,917,479
as of December 31, 2021, 2022 and 2023, respectively.
Equity line agreement with Kepler Cheuvreux
The Group entered into an equity line agreement with Kepler Cheuvreux in September 2019. In accordance with the terms of this
agreement, Kepler Cheuvreux, acting as financial intermediary and guarantor of the transaction, committed to subscribe for 730,000
shares, at its own initiative, following a schedule lasting no longer than 24 months, at an issuance price based on an average market
price weighted according to the volumes traded over the two trading days preceding each issue, less a maximum discount of 7.0 %. On
September 24, 2021, the Group extended the agreement for an additional period of 12 months for the unsubscribed shares at that date.
On October 1, 2022, the agreement ended and the 300,000 outstanding BSAs lapsed.
NUMBER OF BSAs OUTSTANDING | MAXIMUM NUMBER OF SHARES TO BE ISSUED | NUMBER OF BSAs EXERCISED | NUMBER OF BSAs LAPSED | NUMBER OF BSAs OUTSTANDING | MAXIMUM NUMBER OF SHARES TO BE ISSUED | |
FOR THE YEAR ENDED | ||||||
AS OF DECEMBER 31, 2021 | DECEMBER 31, 2022 | AS OF DECEMBER 31, 2022 | ||||
BSAs granted under the Equity line agrement ...................................... | ( | |||||
Considering that the Group could terminate or suspend the Equity line agreement by buying back the BSAs or increasing the
minimum exercise price and that Kepler Cheuvreux was committed to subscribe the shares if the conditions were met, the BSAs
granted to Kepler Cheuvreux under the Equity line agreements were off-balance sheet commitments rather than derivative
instruments.
The increases in the share capital for the year ended December 31, 2021 relate to:
•The completion of a capital increase of €59,982 thousand on July 27, 2021 by issuing 1,964,031 ordinary shares with a par
value of €0.01 per share and a subscription price of €30.55 per share;
•The exercises of 167,749 share warrants for the year ended December 31, 2021 (see Note 14), resulting in a capital increase
of €1,522 thousand by issuing 167,749 ordinary shares with a par value of €0.01 per share and an average subscription price
of €8.49 per share;
F-38
•The exercises of 312,000 share warrants under the Equity line agreement for the year ended December 31, 2021 (see Note
13.2), resulting in a capital increase of €8,094 thousand, net of commissions, by issuing 312,000 ordinary shares with a par
value of €0.01 per share and an average subscription price of €27.13 per share;
Incremental costs directly attributable to the issue of new shares were classified as a deduction of shareholders’ equity and amounted
to €4,090 thousand for the year the year ended December 31, 2021.
The increases in the share capital for the year ended December 31, 2022 relate to:
•The completion of a capital increase of €46,231 thousand on September 7, 2022 by issuing 5,530,000 ordinary shares with a
par value of €0.01 per share and a subscription price of €8.36 per share;
•The exercises of 522 share warrants for the year ended December 31, 2022 (see Note 14), resulting in a capital increase of
€3 thousand by issuing 19,134 ordinary shares with a par value of €0.01 per share and an average subscription price of €0.14
per share;
Incremental costs directly attributable to the issue of new shares were classified as a deduction of shareholders’ equity and amounted
to €3,280 thousand for the period ended December 31, 2022.
The increases in the share capital for the year ended December 31, 2023 relate to:
•The completion of a capital increase of €130,000 thousand on February 22, 2023 by issuing 20,000,000 new ordinary shares
with a par value of €0.01 per share and a subscription price of €6.50 per share;
•The cash-less exercise of 67,887 Kreos A BSA and 31,696 Kreos B BSA on May 24, 2023, resulting in a capital increase of
€1,850 thousand by issuing 99,583 ordinary shares with a par value of €0.01 per share and an average subscription price of
€18.57 per share, which includes the impact of the derecognition of the BSA derivative financial liability; and
•The completion of the Group’s Global Offering on the Nasdaq Global Market on October 24, 2023, by way of a capital
increase of 20,325,500 new ordinary shares, consisting of the U.S. Offering of 18,699,460 ordinary shares in the form of
ADSs, and the European Private Placement of 1,626,040 ordinary shares, with a par value of €0.01 per share and an offering
price set at $11.60 per ADS in the U.S. Offering and a corresponding offering price of €10.9864 per ordinary share in the
European Private Placement.
•The exercise of 1,906 other share warrants, by issuing 190,550 ordinary shares with a par value of €0.01 per share and an
average subscription price of €0.01 per share (see Note 14).
Incremental costs directly attributable to the issue of new shares, including underwriting commissions and offering expenses related to
the Global Offering, were classified as a deduction of shareholders’ equity and amounted to €28,111 thousand for the period ended
December 31, 2023.
Distribution of dividends
The Group did not distribute any dividends for any of the periods presented, does not have any present plan to pay any cash dividends
on its equity securities in the foreseeable future and currently intends to retain all available funds and any future earnings to operate
Note 14. Share-based payments
The Group has granted BCEs, BSAs and free shares (attributions gratuities d’actions, or “AGAs”). These plans qualify as “equity
settled” under IFRS 2. The Group does not have any obligation to purchase these instruments in the event of departure or if a specific
event does not occur.
Valuation methods of BCEs, BSAs and AGAs
The fair value of share-based awards was determined at grant date using the Black Scholes model for the BCEs and BSAs and the
Monte-Carlo simulation for AGAs plans with market performance conditions.
The assumptions used to estimate the fair value of the instruments are presented below and include:
•Expected maturity of the options;
F-39
•Expected volatility based on the historical market share price available;
•Expected dividends based on management best estimate;
•Risk-free interest rate based on French OAT rates measured at grant dates;
•Share price, including offered in case of change of control (only for the market conditions applicable to the free-share plans
AGA 2021 and AGA 2023-1) is based on Monte-Carlo simulations and taking into account a change of control premium
based on the management best estimate.
BCEs
with IFRS 2 – Share-based Payment:
GRANT DAT E | TYPE | NUMBER OF BCEs ISSUED | NUMBER OF BCE OUTSTANDI NG AS OF JANUARY 1, 2023 | NUMBER OF LAPSED BCEs | NUMBER OF EXERCISED BCEs | NUMBER OF BCEs OUTSTANDI NG | NUMBER OF BCEs EXERCISAB LE | MAXIMUM NUMBER OF SHARES TO BE ISSUED IF ALL CONDITION S ARE MET | ||||||||
YEAR ENDED DECEMBER 31, 2023 | AS OF DECEMBER 31, 2023 | |||||||||||||||
2014-03-11 | BCE-2014-2 | ( | ||||||||||||||
2014-03-11 | BCE-2014-4 | ( | ||||||||||||||
2016-11-07 | BCE-2016-1 | |||||||||||||||
2017-01-23 | BCE-2017-1 | |||||||||||||||
2017-11-20 | BCE-2017-2 | ( | ||||||||||||||
2017-11-20 | BCE-2017-4 | |||||||||||||||
2017-11-20 | BCE-2017-5 | |||||||||||||||
2018-03-15 | BCE-2018-1 | |||||||||||||||
2018-05-14 | BCE 2018-3 | |||||||||||||||
2018-05-14 | BCE-2018-4 | |||||||||||||||
2018-05-14 | BCE-2018-5 | |||||||||||||||
Total BCEs | ( | ( | ||||||||||||||
The BCEs include a service condition under which the beneficiary must still be an employee, a corporate officer or a scientific
consultant of the Group at the time of vesting.
The exercise rights for most of the BCEs are vested annually and have the following vesting terms:
•25 % of the award vests on the first anniversary of the date of grant for all currently issued BCEs; and
•For the remaining 75 % of the award, the BCEs vest 1/48th per month over four years from the anniversary date of the grant.
Most of the BCEs plans (all BCEs plans except BCE 2014-2 fully vested as of January 1, 2020) include or partially include non-
market performance conditions (obtaining financing of €100 million, positive results on clinic studies, signature of informed consent
in a clinical phase, signing a license agreement, FDA authorization). The level of achievement of the non-market performance
conditions are taken into account in determining the number of BCEs allocated initially and reassessed at each closing date.
In the event of a change of control or a M&A transaction, all the BCEs will become immediately exercisable. A change of control is
defined as a new investor/company holding directly or indirectly more than 50 % of the share capital or voting rights. As such the
probable vesting date of each plan corresponds to the weighted average of probable change of control dates.
F-40
BSAs
accordance with IFRS 2—Share-based Payment:
GRANT DATE | TYPE | NUMBER OF BSAs ISSUED | NUMBER OF BCAs OUTSTANDI NG AS OF JANUARY 1, 2023 | NUMBER OF LAPSED BSAs | NUMBER OF EXERCISED BSAs | NUMBER OF BSAs OUTSTANDI NG | NUMBER OF BSAs EXERCISAB LE | MAXIMUM NUMBER OF SHARES TO BE ISSUED IF ALL CONDITIONS ARE MET | ||||||||
YEAR ENDED DECEMBER 31, 2023 | AS OF DECEMBER 31, 2023 | |||||||||||||||
2014-03-11 | BSA-2014-3 | ( | ||||||||||||||
2015-12-04 | BSA-2015-11 | |||||||||||||||
2015-12-04 | BSA-2015-12 | |||||||||||||||
2017-09-18 | BSA-2017-1 | |||||||||||||||
2018-01-22 | BSA-2018-1 | |||||||||||||||
2014-03-11 | BSA-2014-4 | |||||||||||||||
2014-03-11 | BSA-2014-5 | ( | ||||||||||||||
Total BSAs | ( | |||||||||||||||
The BSAs include a service condition under which the beneficiary must still be an employee, a corporate officer or a scientific
consultant of the Group at the time of vesting.
The exercise rights for most of the BSAs are vested annually and have the following vesting terms:
•25 % of the award vests on the first anniversary of the date of grant for all currently issued BSAs; and
•For the remaining 75 % of the award, the BSAs vest 1/48th per month over four years from the anniversary date of the grant.
All of the BSAs plans include or partially include non-market performance conditions (positive results on clinic studies, signature of
informed consent in a clinical phase, signing a license agreement, FDA authorization). The level of achievement of the non-market
performance conditions are taken into account in determining the number of BSAs allocated initially and reassessed at each closing
date.
In the event of a change of control or a M&A transaction, all the BSAs will become immediately exercisable. A change of control is
defined as a new investor/company holding directly or indirectly more than 50 % of the share capital or voting rights. As such the
probable vesting date of each plan corresponds to the weighted average of probable change of control dates.
AGAs
accordance with IFRS 2—Share-based Payment:
F-41
GRANT DATE | TYPE | NUMBER OF AGAs ISSUED | NUMBER OF AGAs OUTSTANGING AS OF JANUARY 1, 2023 | NUMBER OF LAPSED AGAs | NUMBER OF EXERCISED AGAs | NUMBER OF AGAs OUTSTANDING | ||||||
AS OF DECEMBER 31, 2023 | ||||||||||||
2023-07-11 | AGA-2023-1 | |||||||||||
2023-07-11 | AGA-2023-2 | |||||||||||
2023-09-28 | AGA-2023-3 | |||||||||||
2023-09-28 | AGA-2023-4 | |||||||||||
2023-12-01 | AGA-2023-5 | |||||||||||
Total AGAs |
TYPE | FAIR VALUE OF THE UNDERLYING SHARE | FAIR VALUE OF THE AGA | AGA PRICE | MATURITY | VOLATILITY | RISK FREE RATE | ||||||
AGA 2021 | € | € | 2022-07-31 | - | ||||||||
AGA 2023-1 (Tranches 1-4) | € | € | N/A | N/A | N/A | |||||||
AGA 2023-1 (Tranche 5) | € | € | 2024-12-31 | |||||||||
AGA 2023-1 (Tranche 6) | € | € | 2024-07-11 | |||||||||
AGA 2023-2 (Tranche 1) | € | € | N/A | N/A | N/A | |||||||
AGA 2023-2 (Tranche 2) | € | € | N/A | N/A | N/A | |||||||
AGA 2023-3 | € | € | N/A | N/A | N/A | |||||||
AGA 2023-4 | € | € | N/A | N/A | N/A | |||||||
AGA 2023-5 | € | € | N/A | N/A | N/A |
•AGAs granted in September 2021
AGAs granted in September 2021 are subject to a vesting service condition of one year following the grant date. The number of shares
that will be finally vested under this plan will depend on the following conditions: if a M&A transaction is completed on or prior to
July 31, 2022 and the price per ordinary share of the Group retained in the framework of the M&A transaction is at least equal to €100
per share (or lower than €100 per share) then 100 % (or 75 %) of the shares initially granted will be vested. The AGAs are forfeited if a
M&A transaction is not completed on or prior to July 31, 2022.
These conditions qualify as both a non-market performance condition (occurrence or not of a M&A transaction before July 31, 2022)
and a market condition (number of shares depending on the share price offered in case of a M&A transaction before July 31, 2022)
under IFRS 2 principles.
The level of achievement of the market condition is directly included in the unit fair value of the free shares and the probability of a
M&A transaction before July 31, 2022 is included in the estimation of the number of shares that will be finally vested by the
beneficiaries.
As of December 31, 2021, considering that it was probable that an M&A transaction would occur before July 31, 2022, 100 % of the
shares originally granted were included in the calculation of share based payment expenses. In addition, the Group recognized an
accrual for social taxes related to the AGA 2021 plan of €205 thousand as of December 31, 2021.The total share-based compensation
expense amounted to €828 thousand (€389 thousand in research and development and €440 thousand in general and administrative,
respectively).
F-42
During the period ended December 31, 2022, the AGAs were all forfeited since no M&A transaction was completed on or prior to
July 31, 2022. This resulted in a reversal of the related compensation expense of €1,026 thousand and the reversal of the accrual for
social taxes of €205 thousand that was recorded as of December 31, 2021.
AGAs granted in July 2023
(a) Pursuant to a Board decision on July 11, 2023, the Group allocated a total number of 1,382,796 AGAs to Mr Marc de Garidel, as
the Group’s Chief Executive Officer, to which performance conditions and service conditions apply (AGA plan 2023-1):
•For 212,738 AGAs 2023-1 (tranche 1): the acquisition period shall end on the first anniversary of the allocation date;
•For 638,214 AGAs 2023-1 (tranche 2): the AGAs 2023-1 shall progressively be definitively acquired on a monthly basis over
a period of three years starting after the first anniversary of the allocation date;
•For 212,738 AGAs 2023-1 (tranche 3): the acquisition period shall end on the latest date between (i) the first anniversary of
the allocation date, and (ii) the date on which a specific performance condition related to regulatory approval is fulfilled;
•For 106,369 AGAs 2023-1 (tranche 4): the acquisition period shall end on the latest date between (i) the first anniversary of
the allocation date, and (ii) the date on which the Group successfully completes a public offering raising at least $100 million
in gross proceeds (the condition was met on October 24, 2023);
•For 106,369 AGAs 2023-1 (tranche 5): the acquisition period shall end on the latest date between (i) the first anniversary of
the allocation date, and (ii) the date on which a specific performance condition related to the Group’s market capitalization is
fulfilled;
•For 106,368 AGAs 2023-1 (tranche 6): the acquisition period shall end on the first anniversary of the allocation date subject
to the completion, prior to such date, of a tender offer on the securities issued by the Group, at a predetermined minimum
price, and resulting in a change of control of the Group;
•Additionally, AGAs related to tranches 1 to 5 are subject to a vesting acceleration condition in case of a tender offer on the
securities issued by the Group and resulting in a change of control of the Group.
The Group qualified those conditions under IFRS 2 principles as follows:
•Conditions related to tranches 1 and 2 qualify as service conditions under IFRS 2 principles.
•Conditions related to tranches 3 and 4 qualify as service and non-market performance conditions. Their levels of achievement
are reflected in the number of instruments that are expected to vest and were estimated by management based on observable
industry-specific data.
•Conditions related to tranches 5 and 6 qualify as service and market performance conditions. The levels of achievement of
market conditions are reflected in the unit fair value of the free shares and were estimated by management using the valuation
methods and assumptions set out above. The valuation of tranche 6 also incorporates management’s estimate of the
probability of a M&A transaction prior to the limit date.
•The vesting acceleration condition in case of a tender offer on the securities issued by the Group and resulting in a change of
control of the Group qualifies as a non-market performance condition.
(b) Pursuant to a Board decision on July 11, 2023, the Group allocated a total number of 100,000 AGAs to Mr. Hartmut Ehrlich, as the
Group’s former Chief Executive Officer to which the following conditions apply (AGA plan 2023-2):
•For 25,000 AGAs 2023-2 (tranche 1): the acquisition period shall end on the first anniversary of the allocation date, and is
not subject to a future service condition;
•For 75,000 AGAs 2023-2 (tranche 2): the acquisition period shall end on the latest date between (i) the first anniversary of
the allocation date, and (ii) the date on which a specific condition, related to positive results on clinical studies, is fulfilled.
The acquisition is not subject to a future service condition. Additionally, the tranche is subject to a vesting acceleration
condition in case of a tender offer on the securities issued by the Group and resulting in a change of control of the Group.
This tranche qualifies as a non-vesting condition. Its level of achievement is reflected in the unit fair value of the free shares,
and was estimated by management based on observable industry-specific data.
AGAs granted in September and December 2023
F-43
On September 28, 2023 and December 1, 2023, certain of the Group’s officers and employees were allocated respectively 985,750
AGAs (AGA plans 2023-3 and 2023-4) and 132,750 AGAs (AGA plan 2023-5) in the aggregate, the vesting of which is subject to
certain conditions:
•Subject to remaining employed with the Group, each such officer or employee’s AGAs will be vested as follows: (i) 50 % at
the end of a two-year period from the allocation date, (ii) 25 % at the end of a three-year period from the allocation date and
(iii) 25 % at the end of a four-year period from the allocation date (service condition).
•Of the 1,118,500 AGAs, 254,250 AGAs are subject to an additional non-market performance condition of the successful
completion of a public offering raising at least $200 million in gross proceeds. This condition was met on October 24, 2023.
Additionally, all the 2023-3, 2023-4 and 2023-5 AGAs are subject to a vesting acceleration condition in case of a tender offer on the
securities issued by the Group and resulting in a change of control of the Group.
TYPE (in thousands of euros) | YEAR ENDED DECEMBER 31, 2021 | YEAR ENDED DECEMBER 31, 2022 | YEAR ENDED DECEMBER 31, 2023 | |||
BCEs | ( | ( | ( | |||
BSAs | ||||||
AGAs | ( | ( | ||||
Social taxes related to AGAs | ( | ( | ||||
Total | ( | ( |
F-44
Note 15. Financial liabilities
(amounts in thousands of euros) | |||||
FINANCIAL LIABILITIES | AS OF DECEMBER 31, 2021 | AS OF DECEMBER 31, 2022 | AS OF DECEMBER 31, 2023 | ||
Kreos 1 & 2 bond loans | |||||
Lease liabilities | |||||
PGE | |||||
Borrowings | |||||
Oceane | |||||
Heights convertible notes | |||||
Kreos / Claret convertible notes (OCABSA) | |||||
Convertible loan notes | |||||
Kreos A & B BSA | |||||
Oceane conversion option | |||||
Derivative instruments | |||||
Conditional advances Bpifrance | |||||
Royalty certificates | |||||
Other financial liabilities | |||||
Total non-current financial liabilities | |||||
Kreos 1 & 2 bond loans | |||||
Lease liabilities | |||||
PGE | |||||
Borrowings | |||||
OCEANE | |||||
Heights convertible notes | |||||
Convertible loan notes | |||||
Conditional advances Bpifrance | |||||
Prosynergia earn-out liability | |||||
Other financial liabilities | |||||
Kreos / Claret BSA | |||||
Derivative instruments | |||||
Total current financial liabilities | |||||
Total financial liabilities |
On August 20, 2023, the Group entered into a structured debt financing agreement with Kreos and Claret (the Kreos / Claret
Financing), for up to €75,000 thousand.
The Kreos / Claret Financing consists of three tranches of €25,000 thousand each in aggregate principal amount (of which only the
first tranche has been drawn as of December 31, 2023):
•The first tranche (“tranche A”) in aggregate principal amount of €25,000 thousand takes the form of senior secured
convertible bonds with warrants attached (the “Kreos / Claret OCABSA”) and was drawn on August 22, 2023. The Kreos /
Claret OCABSA are convertible into ordinary shares at any time from their issuance at the request of their holders at a fixed
conversion price of €21.2209 , subject to standard adjustments, including anti-dilution and dividend protections.
F-45
Interest on the Kreos / Claret OCABSA accrues at a 9.00 % annual fixed interest rate, payable in quarterly installments. The
Kreos / Claret OCBSA’s maturity date is March 31, 2027, it being specified that the scheduled date of final repayment is
January 1, 2027.
The Group is allowed to prepay the amounts due under the Kreos / Claret OCABSA at any time. In such case, the Group will
be required to pay a sum equal to (i) the principal outstanding at the time of the prepayment (plus accrued interests), plus (ii)
an aggregate of all remaining interest payments that would have been paid throughout the remainder of the term of the
tranche, discounted to present value by applying a discount rate of 4 %, plus (iii) an end-of-loan exit fee equal to 8.0 % of the
amounts drawn thereunder. In case of prepayment, the holders of the Kreos / Claret OCABSA will have the option to request
a conversion of their Kreos / Claret OCABSA instead of a cash repayment, in which case, the end-of-loan exit fee is not
payable by the Group.
The warrants included in the Kreos / Claret OCABSA will only become exercisable in case of prepayment in cash of the
Kreos / Claret convertible bonds by the Group. Upon exercise of the warrants, their holders will be able to subscribe to the
same number of ordinary shares (and at the same price conditions) as they would have been able to subscribe had they
converted the Kreos / Claret OCABSA which have been prepaid in cash. Any warrants not exercised on or prior to January 1,
2027 will become automatically null and void. For the avoidance of doubt, if the Group does not prepay any Kreos / Claret
OCABSA in cash prior to their scheduled repayment dates, none of the warrants will be exercisable.
•The second tranche (“tranche B”) in aggregate principal amount of €25,000 thousand takes the form of senior secured non-
convertible bonds and was drawn on March 28, 2024. The drawdown of the second tranche was subject to a maximum 10 %
Debt-To-Market Capitalization Ratio at the time of drawdown. The “Debt-To-Market Capitalization Ratio” is calculated on
any relevant date, by dividing (i) the indebtedness of the Group (including amounts due under the Kreos / Claret Financing
but excluding amounts due under the Heights Financing), by (ii) the market capitalization of the Group calculated by
multiplying the number of outstanding ordinary shares by the closing price of the ordinary shares on such relevant date.
•The third tranche (“tranche C”) in aggregate principal amount of €25,000 thousand takes the form of senior secured non-
convertible bonds and may be drawn before July 31, 2024, subject to satisfaction of customary closing conditions. The
drawdown of the third tranche is subject to a maximum 10 % Debt-To-Market Capitalization Ratio at the time of drawdown
(excluding the Heights Financing) and is conditional on the Group raising a minimum of $125,000 thousand in gross
proceeds through a listing on Nasdaq before June 30, 2024. This condition was met on October 24, 2023 (see Note 3.3).
A variable interest rate of 7.5 % + European Central Bank Base Rate (MRO) (with a floor at 2.5 % and a cap at 4 %) applies to
the second and third tranche. These two tranches will be repaid monthly through March 31, 2027, after a deferred repayment
of the principal (i) until October 1, 2024, for the second tranche, or February 1, 2025, if the conditions to draw the third
tranche are met, and (ii) until February 1, 2025, for the third tranche.
The Group is allowed to prepay the amounts due under the second and third tranches of the Kreos / Claret Financing at any
time. In such case, The Group will be required to pay a sum equal to (i) the principal outstanding at the time of the
prepayment (plus accrued interests), plus (ii) an aggregate of all remaining interest payments that would have been paid
throughout the remainder of the term of the applicable tranche, discounted to present value by applying a discount rate of 4 %,
plus (iii) an end-of-loan exit fee equal to 6.0 % of the amounts drawn under the applicable tranche.
The Kreos / Claret Financing provides for certain restrictive covenants (subject to customary exceptions) which include, among other
things, restrictions on the incurrence of indebtedness, cross-default, the distribution of dividends and the grant of security interests. As
security for the Kreos / Claret Financing, the lenders benefit from the grant of first-ranking collateral on The Group’s principal
tangible and intangible assets, including pledges over The Group’s business (fonds de commerce) as a going concern and intellectual
property rights in The Group's lead drug candidate, as well as pledges over The Group’s bank accounts and receivables. Such
securities apply to all tranches of the Kreos / Claret Financing.
In addition to the Kreos / Claret OCABSA, the Group has issued warrants (the “tranche A-B BSA”) for a global subscription price of
€1.00 , giving Kreos and Claret the right to subscribe to up to 214,198 new ordinary shares at an exercise price of €18.6744
(corresponding to a 10 % premium over the 15-day VWAP prior to the date on which their issuance was decided). On November 2,
2023, a second tranche of 405,832 Kreos / Claret warrants (the “tranche C BSA”) was issued. The exercise price of the additional
warrants is equal to approximately €9.86 (corresponding to 110 % of the 15-day VWAP prior to the date on which their issuance was
decided). The number of warrants issued corresponds to €4,000,000 divided by the aforementioned exercise price (i.e. 405,832
warrants). Of these additional warrants, 50 % are exercisable immediately and the remaining 50 % (“the conditional warrants”) shall
F-46
only be exercisable if the third tranche of the Kreos / Claret Financing is drawn by the Group. The Kreos / Claret warrants can be
exercised over a period of 7 years from their issuance date or up until the date of the successful closing of a tender offer for the
ordinary shares, whichever is earlier. At the time of exercise of the Kreos / Claret warrants, the holders of the warrants are eligible to
sell part of their warrants to the Group in accordance with a put option agreement to allow for a cashless exercise.
On August 22, 2023, the Group repaid in full the pre-existing debt agreements with Kreos for a total amount of €7,661 thousand. The
accounting treatment of this transaction is explained in Note 15.3.
Accounting treatment
The Kreos / Claret OCABSA are issued at market conditions: the net issuance proceeds reflect the fair value of the instruments at
inception.
The OCABSA are compound instruments, split between (i) a debt component (then measured at amortized cost) and (ii) an equity
component corresponding to the conversion option and the attached OCABSA warrants.
As the adjustment provisions of the OCABSA conversion ratio are aimed at preserving the rights of the bondholders and are anti-
dilutive in nature rather than a down-round protection, the Group determined that the conversion option of the OCABSA is considered
to result in the delivery of a fixed number of shares, and is therefore an equity instrument (the equity component of the bonds).
The OCABSA warrants were attached to each bond issued in the Tranche A closing and are not transferrable until after a prepayment.
The OCABSA warrants become exercisable (i) upon the Group electing to prepay the bonds and (ii) in the event of the absence of the
conversion notice from the bondholders for the full amount of the prepayment. As such, the warrants are not freely transferable until
the prepayment is made. Thus, the OCABSA warrants are considered as an embedded component of the bonds rather than a separate
stand-alone financial instrument. In all scenarios under which the exercisability conditions are satisfied, and whereby the bondholder’s
option to elect to convert the bonds was considered, the number of total ordinary shares issuable upon warrant exercise as a result of
prepayment and/or conversion option exercise remains fixed. Thus, the warrants represent an equity-classified component of the
bonds.
The issuer prepayment option was deemed closely related to the host debt instrument and therefore does not meet the definition of a
derivative instrument to be bifurcated.
The right granted to the Group to issue the amortized bonds under tranches B and C in the future, upon meeting certain conditions,
does not meet the definition of a liability and is considered an off-balance sheet loan commitment received from the issuer.
As the A-B and C warrants (the Kreos / Claret BSA) are contractually transferable separately from the bonds and are redeemable in a
variable number of ordinary shares of the Group, they are classified as standalone derivative financial liabilities.
As the A-B and C warrants (the Kreos / Claret BSA) represent compensation for the realized and future bond issuances of respectively
tranches A-B and C and are an integral part of generating such bond issuances, the Group determined that they are in nature
origination fees.
As the A-B warrants are associated with both the OCABSA issued under tranche A and the amortized bonds issued under tranche B,
the Group allocated the initial fair value of the A-B warrants based on the pro-rata value of the proceeds to be received under each
tranche. The initial fair value of the A-B warrants allocated to tranche A will be deferred and accounted for as an adjustment to the
EIR of tranche A debt component. Subsequent changes in the fair value will be recognized through profit or loss. The initial value of
the A-B warrant allocated to tranche B accounted for as a derivative financial liability is deferred as prepaid expenses and will not be
recognized in profit or loss until the occurrence of the drawdowns of tranche B, which is deemed probable by management.
On November 2, 2023 (issuance date of the Kreos / Claret tranche C BSA), a derivative financial liability was recognized for their
initial fair value with a counterparty in prepaid expenses. On that date, the Group, based on management’s latest projections, did not
consider the drawdown of the tranche C bonds to be probable. Therefore, the amount of prepaid expenses allocated to the tranche C
BSA is amortized on a straight-line basis over the period between November 2, 2023 and July 31, 2024 (the limit date for the
drawdown of the tranche C bonds).
Measurement of the debt and equity components of the OCABSA
F-47
At inception, the fair value of the debt component of the OCABSA amounts to €23,995 thousand, using a market rate assumption of
€25,000 thousand) and the standalone fair value of the debt component. Therefore, the equity component amounts to €1,005 thousand.
It is not subsequently remeasured.
On the same date, using the same assumptions and an increase in market rate by 100 bp would result in a decrease in the fair value of
the debt component and an increase in the value of the equity component by €624 thousand.
Measurement of the Kreos / Claret tranche A-B-C BSA
The Kreos / Claret tranche A-B and tranche C BSA are measured at fair value using a Black-Scholes valuation model. The model
considers two probability-weighted scenarios, i.e. (i) the 7-year expiry of the BSA and (ii) an earlier exercise upon a tender offer. The
main data and assumptions are the following:
Kreos/Claret Tranche A-B BSA - August 2023 | AS OF AUGUST 22, 2023 (Tranche A-B) | AS OF DECEMBER 31, 2023 | |
Number of outstanding BSA | |||
Exercise price per share | € | € | |
Ordinary share price | € | € | |
Exercise date | 19/08/2030 (expiry) 18/02/2027 (tender offer) | 19/08/2030 (expiry) 18/02/2027 (tender offer) | |
7-year expiry scenario probability | |||
Volatility | |||
Dividend | |||
Risk-free rate | |||
Fair value of issued Kreos/Claret Tranche A-B BSA |
Kreos/Claret Tranche C BSA - November 2023 | AS OF NOVEMBER 2, 2023 | AS OF DECEMBER 31, 2023 | |
Number of outstanding BSA | |||
of which, number of conditional BSA | |||
Exercise price per share | € | € | |
Ordinary share price | € | € | |
Exercise date | 01/11/2030 (expiry) 18/02/2027 (tender offer) | 01/11/2030 (expiry) 18/02/2027 (tender offer) | |
7-year expiry scenario probability | |||
Probability of Drawdown of Tranche C credit facility | |||
Volatility | |||
Dividend | |||
Risk-free rate | |||
Fair value of issued Kreos/Claret Tranche C BSA |
F-48
As of August 20, 2023 (date of issuance of the tranche A-B BSA), using the same assumption with an increase of +1 % volatility, €
+1 share price, +1 % risk-free rate or +5 % in the probability of achieving the 7-year expiry scenario would result in an increase of the
tranche A-B BSA fair value by respectively €48 thousand, €197 thousand, €64 thousand and €64 thousand.
As of November 2, 2023 (date of issuance of the tranche C BSA), using the same assumption with an increase of +1 % volatility, €
+1 share price, +1 % risk-free rate or +5 % in the probability of achieving the 7-year expiry scenario would result in an increase of
tranche A-B BSA fair value by respectively €28 thousand, €232 thousand, €42 thousand and €36 thousand.
As of December 31, 2023, using the same assumption with an increase of +1 % volatility, €+1 share price, +1 % risk-free rate and +5 %
in the probability of achieving the 7-year expiry scenario would result in an increase of Kreos / Claret A-B and C BSA fair value by
respectively €96 thousand, €401 thousand, €95 thousand and €76 thousand.
On August 20, 2023, the Group entered into a convertible notes subscription agreement with Heights, which provided for up to
€75,000 thousand in financing, consisting in two tranches:
•The first tranche (“tranche A”) of €35,000 thousand in aggregate principal amount was drawn on August 24, 2023 and is
composed of 350 amortizing senior convertible notes with a nominal value of €100,000 each and a fixed conversion price of
€23.7674 (corresponding to a 40 % premium over the 15-day VWAP prior to the date on which their issuance is decided, and
subject to standard adjustments, including anti-dilution and dividend protections).
•The second tranche (“tranche B”) of €40,000 thousand in aggregate principal amount is composed of 400 amortizing senior
convertible notes with a nominal value of €100,000 each, and a conversion price (if any) that will be equal to 130 % of the 15-
day VWAP immediately preceding the date on which their issuance will be decided.
It may be drawn during the period from the date immediately following the three-month anniversary of the issuance of the
first tranche to the first-year anniversary of the issuance of the first tranche (i.e. August 24, 2024), in up to two separate
closings to provide the Group with additional flexibility to request a partial drawdown.
and the average daily valued traded of ordinary shares (“ADVT”) over the three-month period preceding the drawdown, as
follows:
Average market capitalization | ADVT | Maximum cumulated amount outstanding under both first and second tranches of the Heights Financing: |
At least € | At least € | € |
At least € | At least € | € |
At least € | At least € | € |
Interest on the Heights convertible notes accrues at a 6.00 % annual fixed interest rate payable in quarterly installments in cash or, at
the option of the Group, in ordinary shares.
The Heights convertible notes will be repaid through sixteen quarterly installment payments, beginning three months after their
issuance date (corresponding, for the first tranche, to a final repayment date on August 24, 2027). Installments are payable in cash or,
at the option of the Group, in ordinary shares.
Any interest or installment payments in shares will be made on the basis of a share price equal to 90 % of the Market Price of the
ordinary shares at the time of payment, where “Market Price” refers to the arithmetic average of the daily volume weighted average
price (“VWAP”) for the ordinary shares on the two (2 ) days with the lowest daily VWAPs out of the five (5 ) trading days immediately
preceding the applicable date, but in no event greater than the VWAP of the ordinary shares on the applicable date. The Market Price
may not be higher than the applicable conversion price. Issuances of ordinary shares may not be made at a price lower than a 15 %
discount to the 15-day VWAP at the time of the decision to issue the Heights convertible notes (i.e., €14.4303 per ordinary share.).
F-49
The Heights convertible notes include the following conversion and settlement options:
•Conversion at the option of the noteholders: the notes are convertible into the Group’s ordinary shares at the option of the
noteholders at any time during the period beginning on the tranche A notes closing until the fifth business day prior to the
maturity date. The ordinary shares issued would be equal to the product of (i) the conversion ratio in effect on the exercise
date, (ii) a fraction, the numerator of which is the outstanding principal amount per note and the denominator of which is the
initial principal amount of €100,000 per note, and (iii) the number of notes for which the conversion right has been exercised.
•Settlement in shares at the option of the Group: the Group has the option to settle any interest or principal due with its own
ordinary shares (with respect to all but not some of the notes outstanding), subject to a price limit. The ordinary shares
issuable will be the lower of the conversion ratio or 90 % of the fair market value of the Group’s ordinary shares.
•Settlement in shares at the option of the noteholders (“SSO Investor Price Limit Option”): the noteholders may require a
principal payment to be settled in shares in the event the share settlement price on any principal payment date is below the
price limit in effect (initially €14.4303 , subject to adjustments as described in the key terms below) and the Cash Carve-Out
(i.e. €13.125 million – the amount of cash permitted to be paid to Heights for principal payments) has been utilized such that
it does not allow payment in full of the principal payment. The majority noteholder may agree to waive the cash payment
(which would otherwise be deferred until the original maturity date) and require the Group to exercise the share settlement
option for the principal payment required. A number of the ordinary shares issuable is based on the price limit in effect.
•Repayment of the notes upon an Event of Default (as defined below): the noteholder may notify the Group of their decision
to cause the notes to become payable at a price equal to the Early Redemption Amount (as defined below) upon an Event of
Default. The Early Redemption Amount means an amount equal to the greater of (a) 120 % of the outstanding principal of the
note and (b) the market price of a number of shares issuable per note had the conversion right been exercised. Events of
Default include the following: default in any payment due on the notes, failure to deliver shares upon exercise of conversion
right or share settlement option, default of the Group on any obligation under the agreement, and other events.
•Repayment or purchase of the notes upon change of control, a delisting, or free float event (each, a “Put Event”): Upon a Put
Event, the noteholder has an option to require the Group to redeem or, at the Group’s option, to purchase all of the notes at
the total aggregate amount equal to the outstanding principal and interest accrued through the date of a Put Event.
The Heights Financing is a senior, unsecured financing. The terms and conditions of the Heights convertible notes include a standard
negative pledge providing that any security granted in favor of other borrowed debt or debt instruments should also be granted in favor
of the Heights convertible notes on an equal basis (with the exception of the securities issued pursuant to the Kreos / Claret Financing,
as detailed above).
On August 24, 2023, the Group repaid in full an outstanding amount of €25,102 thousand, corresponding to the outstanding
OCEANE bonds, by way of set-off with the Heights Financing. The accounting treatment for this transaction is explained in Note
15.5.
Accounting treatment and measurement
The Group concluded that, except for the repayment or purchase option of the notes upon a Put Event, the above-mentioned
conversion and settlement options represented embedded derivatives that required to be bifurcated from their host contract. The Group
being unable to reliably value each embedded derivative at issuance date and on subsequent reporting dates, it measured the whole
instrument at fair value through profit or loss (“FVTPL”) as permitted by IFRS 9. Instruments measured at FVTPL under these
conditions are measured at their fair value on issuance and on subsequent reporting dates, and the amount of change in the fair value of
the financial liability is presented in profit or loss.
At inception, the Heights convertible notes were measured at fair value, which differs from the issuance proceeds by €2,359 thousand.
Since the fair value measurement of the instrument is evidenced by a valuation technique that does not only use data from observable
markets, the carrying amount was adjusted to defer the difference between the fair value measurement and the transaction price, and
the day one gain is therefore recognized in financial income on a straight-line basis over the term of the instrument.
F-50
As of December 31, 2023, the amount by which the carrying value of the notes is adjusted to take into account the unrecognized day
one gain is €2,147 thousand.
The fair value of the Heights convertible notes (including the embedded features) has been measured with a Monte Carlo model,
considering two probability-weighted scenarios: (i) a Put Event or Default/Dissolution scenario and (ii) a voluntary conversion at
maturity scenario. The main data and assumptions are the following:
Heights convertible notes - August 2023 | AS OF AUGUST 24, 2023 | AS OF DECEMBER 31, 2023 | |
Number of outstanding notes | |||
Original principal amount (in thousands of €) | |||
Interest rate | |||
Conversion price per share | € | € | |
Ordinary share price | € | € | |
Maturity date | 24/08/2025 (put event) 24/08/2027 (HTM/voluntary conversion) | 24/08/2025 (put event) 24/08/2027 (HTM/voluntary conversion) | |
Held to maturity / voluntary conversion scenario probability | |||
Initial price limit | € | € | |
Early redemption amount (put event) | |||
Volatility | |||
Credit spread | |||
Risk-free rate | |||
Fair value of Heights convertible notes (in thousands of €) |
As of August 24, 2023, using the same assumptions with an increase of +1 % volatility, €+1 share price, +1 % risk-free rate and +1 %
probability of achieving the held to maturity scenario would result in a change in the Heights convertible notes fair value by
respectively €+239 thousand, €+1,069 thousand, €-239 thousand and €-80 thousand.
As of December 31, 2023, using the same assumptions with an increase of +1 % volatility, €+1 share price, +1 % risk-free rate and
+1 % probability of achieving the held to maturity scenario would result in a change in the Heights convertible notes fair value by
respectively €+18 thousand, €+352 thousand, €-366 thousand and €-364 thousand.
On July 24, 2018, the Group entered into a Venture Loan Agreement, a Straight Bonds Issue Agreement and a Convertible Bonds
Issue Agreement with Kreos Capital V (UK) Ltd., (or “Kreos”), which provided for up to €20,000 thousand in financing.
Pursuant to the terms of the agreements, Kreos agreed to subscribe for €16,000 thousand in non-convertible bonds and
€4,000 thousand in convertible bonds, to be issued by the Group in two tranches of €10,000 thousand each. The tranches were issued
in July 2018 and May 2019, respectively.
The convertible bonds were convertible into new ordinary shares of the Group at any time from their issuance and at the discretion of
their holders. In October 2020, Kreos required the conversion of all the convertible bonds they held (2,000,000 for Tranche A and
F-51
Each tranche bears an 8 % annual interest rate, plus 3-month Euribor, including a floor at 8 % and a cap at 9 %, and must be repaid in 54
monthly installments, after a deferred repayment of the nominal value to 12 months for the first tranche (“Tranche A”) and 6 months
for the second tranche (“Tranche B”). In addition, each tranche bears exit fees of 9 % of the total drawdown amount (i.e.
€900 thousand per tranche), payable upon the last monthly installment (exit fees remain payable in full in case of early redemption).
Pursuant to the terms of the agreements, the Group has the right, at any time but with no less than 30 days prior notice to Kreos, to
prepay or purchase the non-convertible and convertible bonds, exclusively in full. The prepayment will be equal to (i) the principal
amount outstanding, plus (ii) exit fees of 9 % of the total draw down amount and (iii) the sum of all interest repayments which would
have been paid throughout the remainder of the term of the relevant tranche discounted by 4 % per annum.
The agreements do not contain any financial covenants.
In connection with each tranche, the Group issued 110,957 tranche A share warrants (or “Kreos A BSA”) and 74,766 tranche B share
warrants (or “Kreos B BSA”), each, for a global subscription price of €1 . Each Kreos A BSA and Kreos B BSA gives rights to one
new ordinary share at an exercise price of €7.21 less a discount and €10.70 less a discount, respectively. Both Kreos A BSA and Kreos
B BSA are freely transferrable among financial institutions and are exercisable over a 10-year period from the issue date. In addition,
the Group granted to the holders of the Kreos A BSA and the Kreos B BSA the option to sell to the Group, upon each exercise of all or
parts of the Kreos A BSA, at the put price defined in the agreement, a proportion of the number of the warrants, for the sole purpose of
implementing a cash less exercise of the Kreos A BSA and Kreos B BSA.
The variation in the Kreos 1 & 2 bond loans during the periods ended December 31, 2021 and 2022 is primarily related to
reimbursements of capital and interests. As of December 31, 2022, the A tranche of the Kreos 1 bond loan has come to maturity and
was repaid in full.
On August, 21, 2023, the B tranche of the Kreos 1 bond loan as well as the A & B tranches of the Kreos 2 bond loan were repaid in
full, for an amount of €7,661 thousand, using the proceeds from the new Kreos / Claret Financing (see Note 3.3).
The Group granted to the holders of the Kreos A BSA and the Kreos B BSA the option to sell to the Group, upon each exercise of all
or parts of the Kreos A BSA, at the put price defined in the agreement, a proportion of the number of the warrants, for the sole purpose
of implementing a cashless exercise of the Kreos A BSA and Kreos B BSA.
On May 24, 2023, the holders opted for the cashless exercise option of the share warrants they held, implemented through the
repurchase by the Group of 43,070 Kreos A BSA and 43,070 Kreos B BSA and the issuance by the Group of respectively 67,887 and
Accounting treatment
The Kreos 1 financing package is issued at market conditions: the net issuance proceeds reflect the fair value of the instruments at
inception.
The straight bond tranches are split between i) a debt component (then measured at amortized cost), and ii) a premium corresponding
to the initial fair value of attached BSA (then remeasured at fair value through profit and loss).
The BSA attached to all tranches (both straight and convertible) do not meet the “fixed for fixed” criteria (non cash settlement option
which may result in exchanging a variable number of shares, for a variable price), and are accounted for as standalone derivative
instruments.
The issuer prepayment options meet the definition of a separate derivative. However, their value at inception and subsequent dates is
As the differences identified between the terms of the Kreos 1 & 2 bond loans and the new Kreos / Claret Financing were considered
substantial, the repayment transaction on August 21, 2023 was accounted for as a debt extinguishment. The repayment of the Kreos
1&2 bond loans led to the recognition of a loss on extinguishment amounting to €170 thousand, primarily due to (i) the payment of
future interests as per the terms of the prepayment option and (ii) unamortized exit and issuance fees, reducing the carrying value of
the liabilities.
Measurement of Kreos A BSA & Kreos B BSA
F-52
assumptions are the following:
Kreos A BSA - June 1, 2018 | As of and for the year ended December 31, 2021 | As of and for the year ended December 31, 2022 | As of May 24, 2023 (exercise date) | ||
Number of outstanding Kreos A BSA | |||||
Exercise price per share | € | € | € | ||
Ordinary share price | € | € | € | ||
Residual maturity | |||||
Volatility | N/A | ||||
Dividend | N/A | ||||
Risk-free rate | N/A | ||||
Fair value of issued Kreos A BSA (in thousands of €) |
Kreos B BSA - June 1, 2019 | As of and for the year ended December 31, 2021 | As of and for the year ended December 31, 2022 | As of May 24, 2023 (exercise date) | ||
Number of outstanding Kreos B BSA | |||||
Exercise price per share | € | € | € | ||
Ordinary share price | € | € | € | ||
Residual maturity | |||||
Volatility | N/A | ||||
Dividend | N/A | ||||
Risk-free rate | N/A | ||||
Fair value of issued Kreos B BSA (in thousands of €) |
As of December 31, 2021, using the same assumption with an increase of +1 % volatility, €+1 share price and +1 % risk-free rate would
result in an increase of Kreos A&B BSA fair value of €16 thousand, €176 thousand, and €69 thousand respectively.
As of December 31, 2022, using the same assumption with an increase of +1 % volatility, €+1 share price and +1 % risk-free rate would
result in an increase of Kreos A&B BSA fair value of €6 thousand, €78 thousand, and €12 thousand, respectively.
On May 24, 2023, the holders opted for the cashless exercise option of the share warrants they held. At this date, the fair value of
exercised warrants of €1,850 thousand was reclassified from derivative financial liabilities to equity. As of this date, due to the put
option being exercised by the holders, the fair value of the BSAs is deemed equal to their intrinsic value, which is equal to the
difference between the share price on May 24, 2023 and their exercise price.
On October 13, 2020, the Group obtained a straight bond loan of €15,000 thousand from Kreos corresponding to two tranches of
€10,000 thousand (“Tranche A”) and €5,000 thousand (“Tranche B”), with an option for an additional €5,000 thousand.
Tranches A and B were paid in October and November 2020, respectively, with the following conditions. Each tranche bears an 8 %
annual interest rate, plus 3-month Euribor, for the first 12 monthly installments, after which the annual interest rate is increased to a
fixed rate of 9.75 % for the following 36 monthly installments. Each tranche is to be repaid in 36 monthly installments starting from
October 2021 and November 2021, for the tranche A and B, respectively. The agreements do not contain any financial covenants.
In addition, each tranche bears exit fees of 4 % of the total drawdown amount (i.e. €400 thousand €200 thousand for Tranche A & B,
respectively), payable upon the last monthly installment (exit fees remain payable, in full or partially, in case of early redemption).
Pursuant to the terms of the agreements, the Group has the right, at any time but with no less than 30 days prior notice to Kreos, to
prepay or purchase the non-convertible exclusively in whole. The prepayment will be equal to (i) the principal amount outstanding,
F-53
plus (ii) exit fees of 2 % of the outstanding amount in the event of prepayment occurring between the 18th and the 30th installment or
exit fees of 4 % of the outstanding amount in the event of prepayment occurring after the 30th installment and (iii) the sum of all
interest repayments which would have been paid throughout the remainder of the term of the relevant tranche discounted by 4 % per
annum.
On August, 21, 2023, the B tranche of the Kreos 1 bond loan as well as the A & B tranches of the Kreos 2 bond loan were repaid in
full, for an amount of €7,661 thousand, using the proceeds from the new Kreos / Claret Financing (see Note 3.3). The accounting
treatment of the extinguishment of these liabilities is set forth in Note 15.3.
Accounting treatment
The Kreos 2 straight bonds were initially measured at fair value, which corresponds to the net cash proceeds, and subsequently
measured at amortized cost.
In addition, the prepayment option is a separate derivative instrument as the redemption price does not reimburse Kreos for an amount
up to the approximate present value of lost interest for the remaining term of the host contract. However, its fair value at inception and
subsequent dates is nil as per Schoenbucher model, and has no impact on the financial statements.
The Group received a gross proceed of €85,000 thousand on July 30, 2021 through (i) the issuance of 1,964,031 shares with a
subscription price of €30.55 per share (see Note 13.3 (changes in share capital)) for gross amount of €60,000 thousand, and (ii) the
issuance of €25,000 thousand in OCEANE, maturing on July 30, 2026. The proceeds of the transaction mainly serve to finance the
progress of ABX464 clinical trials in chronic inflammatory diseases.
The OCEANE bears a 6 % interest rate per year, payable semi-annually January 30, and July, 31 from January 31, 2022.
The OCEANE shall be convertible into new ordinary shares and/or exchanged for existing ordinary shares of the group at any time
from their issuance and at the discretion of their holders. The conversion ratio is one ordinary share of the Group per OCEANE,
representing a conversion price set to €38.19 per ordinary share. This conversion price is updated (decrease only) 18 months, 24
months, 36 months after OCEANE issuance date to match the volume weighted average price of the thirty trading days that precedes
the update subjected to the following floor threshold. The floor threshold for the 18-month update matches 85 % initial conversion
price (€32.462 per ordinary share). The floor threshold for the 24-month update matches 70 % initial conversion price (€26.733 per
ordinary share). The floor threshold for the 36-month update matches 68 % initial conversion price (€25.969 per ordinary share).
OCEANE terms and conditions anticipate a conversion ratio adjustment in order to preserve the rights of OCEANE holders with the
following achievements made by the group: issuance of new shares with the preemptive subscription right, attribution of free shares or
securities for the benefit of all the shareholders, number of share multiplication, shares consolidation, increase of the nominal value by
incorporation of reserves, profits or bonuses, distribution of dividends, premiums or reserves, mergers, scission, repurchase of shares
above market value, capital reduction, creation of preferred shares.
On August 24, 2023, the outstanding OCEANE including accrued interests were repaid in full, for an amount of €25,102 thousand,
using the proceeds from the new Heights Financings (see Note 3.3).
Accounting treatment and measurement
As the conversion ratio is adjusted 18 months, 24 months, and 36 months after the issuance date of the OCEANE bond with the
weighted average price of the shares and is subject to a floor and a cap, the conversion does not result in the delivery of a fixed
number of shares. Consequently, the OCEANE bond is recorded as an hybrid instrument which includes i) a debt host contract
accounted for at amortized cost, and ii) a conversion option which is a embedded derivative accounted for at fair value through profit
and loss.
measured with a Monte Carlo model using a Longstaff Schwartz algorithm, with a 53 % share price volatility, a 1,400 bp credit spread
assumption and a €31.50 share price.
F-54
OCEANE | AS OF DECEMBER 31, 2021 | AS OF DECEMBER 31, 2022 | AS OF AUGUST 24, 2023 | ||
Risk free rate | - | ||||
Credit spread | |||||
Ordinary share price | € | € | € | ||
Expected term | July 21, 2026 | July 21, 2026 | July 21, 2026 | ||
Volatility | |||||
Dividend | |||||
Fair value of issued OCEANE (in thousands of €) |
As of July 30, 2021, the issuance price of €25,000 thousand has been split between i) a financial liability for €17,839 thousand, and ii)
a financial derivative for €7,161 thousand.
As of December 31, 2021, the fair value of the conversion option amounts to €5,929 thousand, based on the same valuation model, a
credit spread assumption of 1,159 bp, a share price of €28.55 , and a price volatility of 47 %. As of December 31, 2021, using the same
assumptions, an increase of +1 % volatility, €+1 share price and +1 % risk free rate would result in an increase of the OCEANE
conversion option fair value of €114 thousand, €337 thousand, and €243 thousand, respectively.
As of December 31, 2022, the fair value of conversion option amounts to €142 thousand, based on the same valuation model, a credit
spread assumption of 1,475 bp, a share price of €6.18 , and a price volatility of 44 %. As of December 31, 2022, using the same
assumptions, an increase of +1 % volatility, €+1 share price and +1 % risk free rate would result in an increase of the OCEANE
conversion option fair value of €17 thousand, €97 thousand, and €15 thousand respectively.
As of August 24, 2023, the date at which the OCEANE were repaid, the fair value of conversion option amounts to €1,762 thousand,
based on the same valuation model, a credit spread assumption of 1,398 bp, a share price of €16.74 , and a price volatility of 37 %. As
of August 24, 2023, using the same assumptions, an increase of +1 % volatility, €+1 share price and +1 % risk free rate would result in
an increase of the OCEANE conversion option fair value of €80 thousand, €364 thousand, and €121 thousand respectively.
As the differences identified between the terms of the OCEANE and the new Heights convertible notes were considered substantial,
the transaction was accounted for as a debt extinguishment. The repayment of the OCEANE led to the recognition of a loss on
extinguishment amounting to €3,069 thousand.
In June 2020, the Group subscribed to a PGE from Société Générale with an initial maturity of 12 months at 0.25 % and a five-year
extension option. In March 2021, the Group exercised the five-year extension option with a one-year deferral of the principal
repayment, with the following conditions:
•Rate: 0.58 % per annum excluding insurance and state guaranteed premium,
•State guaranteed premium of €138 thousand to be paid by installments over the contract period starting in June 2021,
and
•Reimbursement by yearly installments from June 2021 to June 2026.
The benefit resulting from the low interest nature of the award as a subsidy was recognized as other income during the period ended
December 31, 2020 for an amount of €377 thousand.
The variation in the PGE loan over the periods ended December 31, 2021, 2022 and 2023 is primarily related to the reimbursement of
capital and interests.
F-55
(amounts in thousands of euros) | |||||
CONDITIONAL ADVANCES | AS OF DECEMBER 31, 2021 | AS OF DECEMBER 31, 2022 | AS OF DECEMBER 31, 2023 | ||
RNP VIR – Bpifrance | |||||
CARENA – Bpifrance | |||||
EBOLA – Bpifrance | |||||
COVID-19 – Bpifrance | |||||
Total conditional advances |
RNP-VIR – Bpifrance
Under the RNP-VIR contract, the Group was eligible to receive up to €6.3 million in conditional advances to further develop methods
for the discovery of new molecules for the treatment of viral infectious diseases through the development of the “Modulation of RNA
biogenesis” platform. As of December 31, 2022, the Group had received €4,032 thousand, of which €1,756 thousand was received in
September 2017, €346 thousand in August 2018 and €1,930 thousand in November 2019. The repayment of these funds is spread from
the date on which the repayments are called by BPI.
See Note 25.2. Commitments under BPI conditional advances.
CARENA – Bpifrance
Under the CARENA agreement, the Group was eligible to receive up to €3,840 thousand to develop a therapeutic HIV treatment
program with ABX464. As of December 31, 2022, the Group received €2,187 thousand, of which €1,150 thousand was received in
December 2013, €1,008 thousand in September 2014 and €29 thousand received in June 2016.
The repayment of the advance is spread from the date on which the repayments are called by BPI. An additional repayment is
provided for based on the income the Group generates through this research and development program.
See Note 25.2. Commitments under BPI conditional advances.
EBOLA – Bpifrance
Under the Bpifrance and Occitanie region joint aid agreement, the Group received a total of €390 thousand (€300 thousand as of
December 31, 2017 and €90 thousand as of December 31, 2019). The reimbursement is spread from 2019 to June 2024.
COVID-19 – Bpifrance
In May 2020, Bpifrance granted the Group with a conditional advance of up to a total of €15,869 thousand under the COVID-19
agreement to complete the miR-AGE study to demonstrate the efficacy and safety of ABX464 for the treatment of COVID-19 patients
at risk of developing severe forms of the disease thanks to an anti- inflammatory and antiviral effect.
Unless the project failed, the repayment of these funds were to be spread over five years from March 31, 2023.
As of December 31, 2020, the Group had received a grant of €1,587 thousand and a repayable advance of €6,348 thousand.
In view of the study results and the recommendations of the Data and Safety Monitoring Board, the Group terminated the study on
March 5, 2021. As Bpifrance had recorded the project as a failure, the repayable advance of €6,348 thousand paid in 2020 was
recognized as a grant. As of December 31, 2021, the Group had also received the remainder of the grant, amounting to
€3,279 thousand.
F-56
(amounts in thousands of euros) | LEASE LIABILITY |
AS OF JANUARY 1, 2021 | |
(+) Increase | |
(-) Decrease | ( |
AS OF DECEMBER 31, 2021 | |
AS OF DECEMBER 31, 2021 | |
(+) Increase | |
(-) Decrease | ( |
AS OF DECEMBER 31, 2022 | |
AS OF DECEMBER 31, 2022 | |
(+) Increase | |
(-) Decrease | ( |
AS OF DECEMBER 31, 2023 |
Lease liabilities mainly relate the Group’s headquarters in Paris, the Boston office entered into in November 2023 and to a lesser
extent to vehicles, parking lots and printers (Note 8).
The lease for the Group’s corporate headquarters in Paris, France at 5 Rue de la Baume, 75008 Paris ended in August 2022. A new
lease for premises at 7-11 Boulevard Haussmann, 75009 Paris started in July 2022. It has a three-year duration, with a tacit renewal
option for approximately two years and the possibility to break the contract one year before the end. As of December 31, 2022, per
Management, renewal and termination options were not reasonably certain due to the forecasted development of the Group, which
could lead the Group to relocate at the end of the initial term. In September 2023, the Group was notified by the lessor of its intention
to exercise its option to terminate the contract on June 30, 2024. Consequently, the Group reassessed the lease term and recorded a
decrease in the related lease liability by €622 thousand and a corresponding decrease in the right of use asset for the same amount.
In November 2023, the Subsidiary entered a lease contract for its new Boston offices. It has a two-year duration, with an option to
renew the contract for an additional period of two years . Per Management, the renewal option is not reasonably certain due to the
forecasted development of the Subsidiary, which may lead it to relocate at the end of the initial term.
As of December 31, 2021, 2022 and 2023, the lease liabilities of the Paris headquarters and Boston offices represented 92 %, 97 % and
Lease expenses related to contracts for which a lease liability and right of use asset is recognized under IFRS 16 were €250 thousand,
€424 thousand and €548 thousand for the years ended December 31, 2021, 2022 and 2023, respectively. They were recognized for (i)
€244 thousand, €414 thousand and €498 thousand as Depreciation expenses and (ii) €5 thousand, €10 thousand and €13 thousand as
Interest expenses, for the years ended December 31, 2021, 2022 and 2023, respectively.
Lease expenses related to short-term lease contracts and low value assets that are not included in the valuation of the lease liability
amount to €25 thousand, €331 thousand and €334 thousand for the years ended December 31, 2021, 2022 and 2023, respectively.
The terms of the share purchase acquisition of Prosynergia include a possible earn out triggered in the event the Company’s
market capitalization is in excess of €300 million (evaluated at certain specified record dates), a listing of the Company’s shares
on Nasdaq or a merger and acquisition transaction prior to March 31, 2023. The amount of the earn-out is equal to 1 % of the
difference between the Company’s market capitalization and €300 million, subject to a maximum amount of €4.0 million.
F-57
This potential earn-out payment was measured at fair value on April 1, 2022 (acquisition date), for an amount of
€1,446 thousand, and included in the acquisition cost.
As of December 31, 2022, the fair value of the earn-out liability was insignificant. Since its payment was not triggered by March
31, 2023, the liability was extinguished and thus reversed.
The Prosynergia earn-out liability is measured at fair value using a Black-Scholes valuation model. The main data and
assumptions are the following:
Prosynergia earn-out | As of April 1, 2022 | As of and for the period ended December 31, 2022 |
Risk free rate | ( | |
Market capitalization (in thousands of €) | ||
Ordinary share price (€) | ||
Time to maturity | ||
Volatility | ||
Dividend | ||
Fair value of the earn-out liability (in thousands of €) | ( |
As of April 1, 2022, using the same assumption with an increase of +1 % volatility, €+1 share price and +1 % risk free rate would
result in an increase of the earn-out liability fair value by €12 thousand, €132 thousand and €17 thousand, respectively.
As of December 31, 2022, the fair value of the earn-out liability is approximately €0 . Using the same assumption with an increase of
+1 % volatility, €+1 share price and +1 % risk free rate would result in an increase of the earn-out liability fair value by an amount
less than €1
On September 2, 2022, the Group completed a financing of €49,162 thousand, consisting of two transactions:
•a reserved capital increase of a gross amount of €46,231 thousand through the issuance of 5,530,000 new shares with a
nominal value of €0.01 per share at a subscription price of €8.36 per share; and
•an issue of royalty certificates with a subscription price amounting to €2,931 thousand. The royalty certificates give right to
their holders to royalties equal to 2 % of the future net sales of obefazimod (worldwide and for all indications) as from the
commercialization of such product. The amount of royalties that may be paid under the royalty certificates is capped at
€172,000 thousand.
Related transaction costs amounted to €3,280 thousand and are recorded in equity, since entirely related to the reserved capital
increase.
As of December 31, 2022, following a change in the estimate of future royalty cash flows, the certificates’ amortized cost was
remeasured at €3,287 thousand, using the original EIR calculated at the date of issuance. The change in estimate resulted in a decrease
in the related interest expense by €100 thousand over the period ended December 31, 2022.
In April 2023, the Group reassessed its estimate of the probability of future royalty cash flows related to the royalty certificates. This
change reflected the higher probability to reach the objectives of the development and commercialization plans following the recent
changes in management and governance, as well as results from its Phase 2b open-label maintenance trial in UC, as released in April
2023. Subsequently, in June 2023 and December 2023, the Group revised the development and commercialization plans of
F-58
obefazimod and reassessed its estimate of future royalty cash flows accordingly. These changes in estimates resulted in a
remeasurement of the certificates’ amortized costs, using the original EIR of 34 % calculated at the date of issuance, which led to an
increase by €6,421 thousand of the royalty certificates liability. The expense was recorded within the interest expenses in the
Statements of Income (Loss).
Consequently, the total interest expense (including the unwinding of discount) related to royalty certificates amounts to
€8,942 thousand for the year ended December 31, 2023.
Fair value
The fair value of the royalty certificates, calculated using the same model as their initial measurement, amounts to €3,307 thousand as
of December 31, 2022 and €12,395 thousand as of December 31, 2023.
The fair value of the royalty certificates is based on the net present value of royalties, which depends on assumptions made by the
Group with regards to the probability of success of its studies (“POS”), the commercialization budget of obefazimod (“peak
penetration”) and the Group's WACC. In addition, royalty projections have been adjusted to reflect any difference between the
Group’s value derived from management projections and the Group’s market capitalization.
As of December 31, 2022, using the same assumptions with an increase of +5 points of POS, +5 % of peak penetration (best case
scenario) and +1 % WACC would result in a change in the royalty certificates fair value by respectively €+299 thousand, €
+221 thousand and €-191 thousand. Using the same assumptions with a decrease of -5 points of POS, -5 % of peak penetration (worst
case scenario) and -1 % WACC would result in a change in the royalty certificates fair value by respectively €-294 thousand,
€-347 thousand and €+205 thousand.
As of December 31, 2023, using the same assumptions with an increase of +5 points of POS, +5 % of peak penetration (best case
scenario), +1 % WACC and €+1 share price would result in a change in the royalty certificates fair value by respectively €
+1104 thousand, €+1757 thousand, €-577 thousand and €+1325 thousand. Using the same assumptions with a decrease of -5 points of
POS, -5 % of peak penetration (worst case scenario) and -1 % WACC and €-1 share price would result in a change in the royalty
certificates fair value by respectively €-1104 thousand, €-2311 thousand, €+612 thousand and €-1325 thousand.
(Amounts in thousands of euros) | |||||||||||||||||||
FINANCIAL LIABILITIES (excluding derivatives instruments) | Kreos 1 & 2 bond loans | Oceane | Kreos & Claret convertible notes (OCABSA ) | Heights convertible notes | PGE | Conditional advances BPI | Lease liabilities | Prosynergia earn-out liability | Royalty certificates | Total | |||||||||
AS OF JANUARY 1, 2021 | |||||||||||||||||||
Proceeds | |||||||||||||||||||
Repayments | ( | ( | ( | ( | |||||||||||||||
Interest paid | |||||||||||||||||||
Non-cash changes: interest expense and other | |||||||||||||||||||
Non-cash changes: classification of the conversion option as a derivative instrument | ( | ( | |||||||||||||||||
Non-cash changes: subsidies | ( | ( | |||||||||||||||||
Non cash changes: additional leases |
F-59
AS OF DECEMBER 31, 2021 | |||||||||||||||||||
Proceeds | |||||||||||||||||||
Repayments | ( | ( | ( | ( | |||||||||||||||
Interest paid | ( | ( | ( | ( | |||||||||||||||
Non-cash changes: interest expense and other | |||||||||||||||||||
Non-cash changes: classification of the conversion option as a derivative instrument | |||||||||||||||||||
Non-cash changes: subsidies | ( | ( | |||||||||||||||||
Non cash changes: additional leases | |||||||||||||||||||
AS OF DECEMBER 31, 2022 | |||||||||||||||||||
(Amounts in thousands of euros) | |||||||||||||||||||
FINANCIAL LIABILITIES (excluding derivatives instruments) | Kreos 1 & 2 bond loans | Oceane | Kreos & Claret convertible notes (OCABSA ) | Heights convertible notes | PGE | Conditional advances BPI | Lease liabilities | Prosynergia earn-out liability | Royalty certificates | Total | |||||||||
AS OF DECEMBER 31, 2022 | |||||||||||||||||||
Proceeds | |||||||||||||||||||
Repayments | ( | ( | ( | ( | ( | ( | ( | ||||||||||||
Interest paid | ( | ( | ( | ( | ( | ( | ( | ||||||||||||
Non-cash changes: classification of the warrants as a derivative instrument | ( | ( | |||||||||||||||||
Non-cash changes: classification of the conversion option in equity | ( | ( | |||||||||||||||||
Non-cash changes: (gain)/loss on recognition or derecognition | ( | ||||||||||||||||||
Non-cash changes: interest expense and other | |||||||||||||||||||
Non-cash changes: amortized cost remeasurement | ( | ||||||||||||||||||
Non-cash changes: other fair value remeasurement | ( | ( | |||||||||||||||||
Non cash changes: additional leases | |||||||||||||||||||
AS OF DECEMBER 31, 2023 |
For the year ended December 31, 2023, proceeds from the issuance of the Kreos / Claret OCABSA are presented net of transaction
costs, amounting to €1,881 thousand. Net proceeds from convertible loan notes of €55,841 disclosed in the Consolidated Statements of
Cash Flows also include transaction fees of (i) €750 thousands related to the Kreos / Claret B and C tranches and recorded in prepaid
expenses (see Note 10) and (ii) €1,528 thousand related to the Heights convertible notes.
F-60
For the year ended December 31, 2023, repayments of the OCEANE are presented net of the repurchase of the conversion option,
valued at €1,762 thousand on the date of repayment, which is presented in Note 15.12. The aggregate repayment amounts to
€25,000 thousand.
(amounts in thousands of euros) | Kreos A BSA | Kreos B BSA | OCEANE conversion option | Kreos/Claret BSA | Total | ||||
DERIVATIVE FINANCIAL INSTRUMENTS | |||||||||
AS OF JANUARY 1, 2021 | |||||||||
(+) Issuance | |||||||||
(+) Increase in fair value | |||||||||
(-) Decrease in fair value | ( | ( | ( | ( | |||||
AS OF DECEMBER 31, 2021 | |||||||||
AS OF DECEMBER 31, 2021 | |||||||||
(+) Increase in fair value | |||||||||
(-) Decrease in fair value | ( | ( | ( | ( | |||||
AS OF DECEMBER 31, 2022 | |||||||||
AS OF DECEMBER 31, 2022 | |||||||||
(+) Issuance | |||||||||
(+) Increase in fair value | |||||||||
(-) Decrease in fair value | ( | ( | |||||||
(-) Repurchases | ( | ( | ( | ( | |||||
(-) Exercises | ( | ( | ( | ||||||
AS OF DECEMBER 31, 2023 |
On May 24, 2023, the holders opted for the cashless exercise option of the share warrants they held. At this date, the fair value of
exercised warrants of €1,850 thousand was reclassified from derivative financial liabilities to equity. As of this date, due to the put
option being exercised by the holders, the fair value of the BSAs is deemed equal to their intrinsic value, which is equal to the
difference between the share price on May 24, 2023 and their exercise price.
are gross and undiscounted, and include contractual interest payments.
F-61
AS OF DECEMBER 31, 2021 | |||||||||||
CURRENT AND NON-CURRENT FINANCIAL LIABILITIES | GROSS AMOUNT | CONTRACTUAL CASH FLOWS | LESS THAN 1 YEAR | FROM 1 TO 2 YEARS | FROM 2 TO 5 YEARS | LONGER THAN 5 YEARS | |||||
(amounts in thousands of euros) | |||||||||||
Kreos 1 & 2 bond loans | |||||||||||
Oceane | |||||||||||
PGE | |||||||||||
Conditional advances BPI | |||||||||||
Lease liabilities | |||||||||||
Derivative instruments | |||||||||||
Total financial liabilities | |||||||||||
AS OF DECEMBER 31, 2022 | |||||||||||
CURRENT AND NON-CURRENT FINANCIAL LIABILITIES | GROSS AMOUNT | CONTRACTUAL CASH FLOWS | LESS THAN 1 YEAR | FROM 1 TO 2 YEARS | FROM 2 TO 5 YEARS | LONGER THAN 5 YEARS | |||||
(amounts in thousands of euros) | |||||||||||
Kreos 1 & 2 bond loans | |||||||||||
Oceane | |||||||||||
PGE | |||||||||||
Conditional advances BPI | |||||||||||
Royalty certificates | |||||||||||
Lease liabilities | |||||||||||
Derivative instruments | |||||||||||
Total financial liabilities | |||||||||||
AS OF DECEMBER 31, 2023 | |||||||||||
CURRENT AND NON-CURRENT FINANCIAL LIABILITIES | GROSS AMOUNT | CONTRACTUAL CASH FLOWS | LESS THAN 1 YEAR | FROM 1 TO 2 YEARS | FROM 2 TO 5 YEARS | LONGER THAN 5 YEARS | |||||
(amounts in thousands of euros) | |||||||||||
Heights convertible notes | |||||||||||
Kreos/Claret convertible notes (OCABSA) | |||||||||||
PGE | |||||||||||
Conditional advances BPI | |||||||||||
Royalty certificates | |||||||||||
Lease liabilities | |||||||||||
Derivative instruments | |||||||||||
Total financial liabilities | |||||||||||
The contractual cash flows above do not include potential future royalty payments related to the royalty certificates, amounting to 2 %
of the future net sales of obefazimod (worldwide and for all indications). The amount of royalties that may be paid under the royalty
certificates is capped at €172.0 million in the aggregate. Royalty payments are expected to take place before the expiry date of the
certificates, which is 15 years after their issuance date (September 2, 2037), and would be included in the "from 2 to 5 years" and
"longer than 5 years" maturity categories according to management's projections.
Note 16. Retirement benefit obligations
Retirement benefit obligations include the liability for the defined benefit plan, measured based on the provisions stipulated
under the applicable collective agreements, i.e. the French pharmaceutical industry’s collective agreement. This commitment
only applies to employees subject to French law. The main actuarial assumptions used to measure the retirement benefit
obligations are as follows:
F-62
ACTUARIAL ASSUMPTIONS | YEAR ENDED DECEMBER 31, 2021 | YEAR ENDED DECEMBER 31, 2022 | YEAR ENDED DECEMBER 31, 2023 | ||
Retirement age | |||||
Collective agreement | Pharmaceutical industry | Pharmaceutical industry | Pharmaceutical industry | ||
Discount Rate (IBoxx Corporates AA) | |||||
Mortality rate table | INSEE 2016-2018 | INSEE 2016-2018 | INSEE 2016-2018 | ||
Salary increase rate | |||||
Turnover rate | Decreasing from years-old to years-old | Decreasing from years-old to years-old | Decreasing from years-old to years-old | ||
Employee contribution rate |
(amounts in thousands of euros) | RETIREMENT BENEFIT OBLIGATIONS |
AS OF JANUARY 1, 2021 | |
Service cost | |
Interest cost | |
Benefits paid | ( |
Actuarial gains and losses | ( |
AS OF DECEMBER 31, 2021 | |
Service cost | |
Interest cost | |
Benefits paid | |
Actuarial gains and losses | ( |
AS OF DECEMBER 31, 2022 | |
Service cost | |
Interest cost | |
Benefits paid | |
Actuarial gains and losses | ( |
AS OF DECEMBER 31, 2023 |
Employees in the U.S. benefit from defined contribution plans (401(k)).
Note 17. Payables and other current liabilities
F-63
(amounts in thousands of euros) | |||||
TRADE PAYABLES AND OTHER CURRENT LIABILITIES | AS OF DECEMBER 31, 2021 | AS OF DECEMBER 31, 2022 | AS OF DECEMBER 31, 2023 | ||
Trade payables | |||||
Accrued invoices | |||||
Other | ( | ||||
Trade payables and other current liabilities |
No discount was applied to payables and related accounts for which maturity does not exceed one year. As a result, their fair value
approximates their carrying amount.
The increase in trade payable and other current liabilities over the year ended December 31, 2023 is mainly due to the increase in
operating expenses over the period.
(amounts in thousands of euros) | |||||
TAX AND EMPLOYEE-RELATED PAYABLES | AS OF DECEMBER 31, 2021 | AS OF DECEMBER 31, 2022 | AS OF DECEMBER 31, 2023 | ||
Employee-related payables | |||||
Social security and other | |||||
Other tax and related payments | |||||
Tax and employee-related payables |
The increase in employee-related, social security and other payables over the year ended December 31, 2023 is mainly related to the
changes in the management team and recruitment of additional experienced employees, including C-levels, over the period (see Note
Note 18. Operating income
(amounts in thousands of euros) | |||||
OPERATING INCOME | YEAR ENDED DECEMBER 31, 2021 | YEAR ENDED DECEMBER 31, 2022 | YEAR ENDED DECEMBER 31, 2023 | ||
Research tax credit ("CIR") | |||||
Subsidies | |||||
Other | |||||
Total operating income |
Operating income is composed as follows:
Research tax credit (“CIR”)
The Group carries out research and development projects. As such, it has benefited from a research tax credit for the years ended
December 31, 2021, 2022 and 2023 for an amount of €4,204 thousand, €4,476 thousand and €4,493 thousand, respectively (see Note
4.9).
Subsidies
F-64
Subsidy income primarily relates to Bpifrance agreement to finance the “COVID-19” project. This financing was granted under the
French Future Investments Project. This study was conducted with the participation of the University Hospital of Nice, which directly
manages part of the financing of the COVID-19 clinical trial.
For the year ended December 31, 2021, the Group recognized as a subsidy: (i) €4,459 thousand corresponding to the conditional
advance received in June 2020 (discounted amount) which had been waived by Bpifrance in April 2021 (See Note 15.7, “Conditional
advances”), and (ii) an additional payment of €3,279 thousand received in October 2021 to reimburse additional expenses incurred
Note 19. Operating expenses
(amounts in thousands of euros) | |||||
SALES AND MARKETING | YEAR ENDED DECEMBER 31, 2021 | YEAR ENDED DECEMBER 31, 2022 | YEAR ENDED DECEMBER 31, 2023 | ||
Personnel costs | |||||
Consulting and professional fees | |||||
Other sales and marketing expenses | |||||
Sales & Marketing |
For the year ended December 31, 2023, sales and marketing expenses amount to €6,431 thousand. No
were incurred in prior periods. These expenses consist primarily in consulting costs associated with market research and re-branding
of the Group in preparation of the Global Offering, as well as an early team build out in preparation for our future sales and
commercialization efforts in the U.S..
(amounts in thousands of euros) | |||||
RESEARCH AND DEVELOPMENT EXPENSES | YEAR ENDED DECEMBER 31, 2021 | YEAR ENDED DECEMBER 31, 2022 | YEAR ENDED DECEMBER 31, 2023 | ||
Sub-contracting, studies and research | |||||
Personnel costs | |||||
Consulting and professional fees | |||||
Intellectual property fees | |||||
Other research and development expenses | |||||
Research and development expenses |
Research and development expenses consist primarily of the following items:
•Personnel expenses, including salaries, benefits, and share-based compensation expenses, for employees engaged in
research and development activities;
•Sub-contracting, collaboration and consultant expenses that primarily include the cost of third-party contractors such as
CROs who conduct our non-clinical studies and clinical trials, and research related to proprietary platforms, as well as
investigative sites and consultants that conduct our preclinical studies and clinical trials;
F-65
•Expenses incurred under agreements with contract manufacturing organizations (“CMOs”), including manufacturing
scale-up expenses and the cost of acquiring and manufacturing preclinical study and clinical trial materials;
•Expenses relating to preclinical studies and clinical trials;
•Expenses relating to regulatory affairs;
•Allocated expenses for facility costs, including rent, utilities and maintenance; and
•Expenses relating to the implementation of the quality assurance system.
For the year ended December 31, 2022, research and development expenses were €48,295 thousand, as compared to €47,781 thousand
for the year ended December 31, 2021. This increase was primarily due to the €20,841 thousand increase in UC expenses, following
the strong progress of obefazimod in this indication since 2021, as the Group completed the Phase 2b clinical trial in early 2022 and
initiated Phase 3 clinical trial in the first half of 2022 (see Note 3.2 The Group announces first US patient enrollment in global Phase
3 program with obefazimod in UC – October 2022). This increase is offset by a decrease by €13,943 thousand in transversal activities,
as the Group completed existing studies, a decrease by €2,021 thousand in Crohn’s Disease research expenses and a decrease by
€2,834 thousand in Rheumatoid Arthritis expenses.
For the year ended December 31, 2023, research and development expenses were €103,176 thousand, as compared to
€48,295 thousand for the year ended December 31, 2022. This increase was primarily due to the €45,233 thousand increase in UC
expenses, due to the progress of Phase 3 clinical trials for obefazimod in UC (Phase 3 costs are significantly more expensive than
Phase 2), the €2,735 thousand increase in CD expenses, due to the planning costs incurred for the CD trial, and the €4,477 million
increase in transversal activities related the (i) the overall expansion of the R&D headcount to support the growing organization and
(ii) the issuance of new equity awards to officers and employees.
(amounts in thousands of euros) | |||||
GENERAL AND ADMINISTRATIVE EXPENSES | YEAR ENDED DECEMBER 31, 2021 | YEAR ENDED DECEMBER 31, 2022 | YEAR ENDED DECEMBER 31, 2023 | ||
Personnel costs | |||||
Consulting and professional fees | |||||
Other general and administrative expenses | |||||
General and administrative expenses |
General and administrative expenses consist primarily of personnel-related expenses, including salaries, benefits and share-based
compensation expenses, for personnel other than employees engaged in research and development activities. General and
administrative expenses also include fees for professional services, mainly related to audit and legal services, consulting costs,
communications and travel costs, allocated expenses for facility costs, including rent, utilities and maintenance, directors’ attendance
fees, and insurance costs.
For the year ended December 31, 2022, general and administrative expenses were €7,492 thousand, as compared to €5,580 thousand
for the year ended December 31, 2021. This increase was primarily driven by other general and administrative expenses, as well as an
increase in consulting and professional fees. The €2,233 thousand increase in other general and administrative expenses in 2022 was
primarily related to financial and legal consulting fees. These increases are partially offset by a decrease in personnel costs, mainly due
to a reversal of share-based compensation expenses.
For the year ended December 31, 2023, general and administrative expenses were €22,390 thousand, as compared to €7,492 thousand
for the year ended December 31, 2022. This increase was primarily due to increase in personnel costs by €11,702 thousand, resulting
from the issuance of new equity awards to officers and employees, management changes that occurred during the period (see Note 3.3
Change in governance and management – February-August 2023 ) and the increased G&A headcount to support the expansion of the
overall organization, as well as increased legal and professional fees and other costs associated with operating as a dual-listed public
company.
F-66
(amounts in thousands of euros) | YEAR ENDED DECEMBER 31, 2021 | YEAR ENDED DECEMBER 31, 2022 | YEAR ENDED DECEMBER 31, 2023 | ||
Statutory Auditor, certification of individual and consolidated financial statements | |||||
Issuer | |||||
Other procedures required by law | |||||
Issuer | |||||
Total |
Note 20. Employees
HEADCOUNTS | YEAR ENDED DECEMBER 31, 2021 | YEAR ENDED DECEMBER 31, 2022 | YEAR ENDED DECEMBER 31, 2023 | ||
France | |||||
United States | |||||
Total |
Note 21. Financial gain (loss)
(amounts in thousands of euros) | |||||
FINANCIAL GAIN (LOSS) | YEAR ENDED DECEMBER 31, 2021 | YEAR ENDED DECEMBER 31, 2022 | YEAR ENDED DECEMBER 31, 2023 | ||
Interest on Kreos 1 & 2 straight bond loans | ( | ( | ( | ||
Interest on convertible loan notes | ( | ( | ( | ||
Interest on conditional advances | ( | ( | ( | ||
Interest on royalty certificates | ( | ( | |||
Interest on lease liabilities | ( | ( | ( | ||
Increase in derivatives fair value | ( | ||||
Loss on derecognition of financial liabilities | ( | ||||
Transaction costs | ( | ||||
Foreign exchange losses | ( | ||||
Other | ( | ( | ( | ||
Financial expenses | ( | ( | ( | ||
Interest income | |||||
Decrease/(increase) in derivatives fair value | |||||
Decrease/(increase) in other liabilities at fair value through profit and loss | |||||
Effect of unwinding the discount related to advances made to CROs | |||||
Day-one gain on recognition of financial liabilities | |||||
Gain on derecognition of financial liabilities | |||||
Other financial income | |||||
Financial income | |||||
Financial gain (loss) | ( | ( |
F-67
Increases and decreases in the fair value of derivatives are detailed in Notes 15.1, 15.3 and 15.12.
Increases and decreases in other liabilities at FVTPL relate to the Prosynergia earn-out liability for the year ended December 31, 2022
(see Note 15.9) and the Heights notes for the year ended December 31, 2023 (see Note 15.2).
Transaction costs for the year ended December 31, 2023 mainly relate to Heights notes.
Gains and losses on the recognition and derecognition of financial liabilities are set forth in Notes 15.2. to 15.5.
Foreign exchange losses for the year ended December 31, 2023 mainly relate to the translation of cash and cash equivalents held in
U.S. dollars into the Group's presentation currency as of December 31, 2023 (see Note 11), resulting in a loss of €3,196 thousand, and
to a €1,488 thousand loss resulting from foreign exchange operations.
Note 22. Income tax
The income tax rate applicable to the Company is the French corporate income tax rate, i.e. 26.5%, 25% and 25% for the years ended
December 31, 2021, 2022 and 2023, respectively.
The income tax rates applicable to the Subsidiary are the federal income tax rate of 21% and the State income tax rate of 4.35%, i.e. a
total of 25.35% for the year ended December 31, 2023.
(In thousands of euros, except percentage) | YEAR ENDED DECEMBER 31, 2021 | YEAR ENDED DECEMBER 31, 2022 | YEAR ENDED DECEMBER 31, 2023 | ||
Loss before tax | ( | ( | ( | ||
Statutory French tax rates | 26.50% | 25.00% | 25.00% | ||
Nominal income tax using statutory French tax rate | |||||
Tax effect of: | |||||
Tax rates in foreign jurisdictions | |||||
Share-based payment | ( | ( | |||
CIR | |||||
Transaction costs related to capital increase | |||||
Decrease / (increase) in derivatives fair value and other | |||||
Non-recognition of deferred tax assets related to tax losses and temporary differences | ( | ( | ( | ||
Other | ( | ( | ( | ||
Effective income tax (loss) |
F-68
(In thousands of euros) | |||||
DEFERRED TAX ASSETS AND LIABILITIES BY NATURE | AS OF DECEMBER 31, 2021 | AS OF DECEMBER 31, 2022 | AS OF DECEMBER 31, 2023 | ||
Retirement benefit obligation | |||||
Leases | |||||
Other financial liabilities | |||||
Tax losses carryforward | |||||
Other items | |||||
Deferred tax assets | |||||
Subsidies | |||||
Leases | |||||
Other financial liabilities | |||||
Other items | |||||
Deferred tax liabilities | |||||
Deferred tax assets, net | |||||
Unrecognized deferred tax assets | ( | ( | ( | ||
Total deferred taxes, net recognized in the statement of financial position |
The Group incurred tax losses in the reporting periods ended December 31, 2021, 2022 and 2023. As the recoverability of these tax
losses is not considered probable in subsequent periods due to the uncertainties inherent in the Group’s business, the Group has not
recognized deferred tax assets beyond deferred tax liabilities arising within the same taxable entity under the same taxable regime and
with consistent timing of reversal, after considering, if applicable, limitations in the use of deductible tax losses carried forward from
prior periods applicable under tax laws in France and in the U.S..
The accumulated tax loss carry forwards for the Company amount to €232,167 thousand, €308,829 thousand and €459,752 thousand
as of December 31, 2021, 2022 and 2023, respectively, and do not have any expiration date.
The accumulated tax loss carry forwards for the U.S. Subsidiary consist of federal Net Operating Loss ("NOL") carry forwards and
amount to €38 thousand as of December 31, 2023. They do not have any expiration date.
Note 23. Income (loss) per share
Basic losses per share is calculated by dividing income (loss) attributable to equity holders of the Group by the weighted-
average number of outstanding ordinary shares for the year.
Diluted losses per share are calculated by adjusting the weighted average number of ordinary outstanding shares to assume
conversion of all dilutive potential ordinary shares.
(amounts in thousands of euros, except share data) | |||||
BASIC AND DILUTED LOSS PER SHARE | YEAR ENDED DECEMBER 31, 2021 | YEAR ENDED DECEMBER 31, 2022 | YEAR ENDED DECEMBER 31, 2023 | ||
Weighted average number of outstanding shares | |||||
Net loss for the period | ( | ( | ( | ||
Basic and diluted loss per share (€/share) | ( | ( | ( |
Potential dilutive instruments (BCEs, BSAs, AGAs, Equity lines, BSA Kreos 1, OCEANE, Kreos/Claret BSA, Kreos/Claret
OCABSA and Height notes) have been excluded from the computation of diluted weighted-average shares outstanding, because
such instruments had an antidilutive impact due to the losses reported. As of December 31, 2021, 2022 and 2023, the number of
potential dilutive instruments were 1,873,216 , 1,707,037 and 28,754,280 respectively, giving rights to a maximum number of shares
F-69
Note 24. Related parties
following:
(In thousands of euros) | |||||
COMPENSATION | YEAR ENDED DECEMBER 31, 2021 | YEAR ENDED DECEMBER 31, 2022 | YEAR ENDED DECEMBER 31, 2023 | ||
Fixed compensation owed | |||||
Variable compensation owed | |||||
Contributions in-kind | |||||
Employer contributions | |||||
Attendance fees—Board of Directors | |||||
Share-based payments | ( | ||||
Departure indemnities | |||||
Total | |||||
As of December 31, 2021 and 2022, the liability related to post-employment defined benefit obligations (corresponding to the legal
retirement benefits obligations) for members of the Group’s Board of Directors and Chief Executive Officer amounts to €141 thousand
and €149 thousand.
As of December 31, 2023 there was no liability related to post-employment defined benefit obligations for members of the Group’s
Board of Directors and Chief Executive Officer. No other post-employment benefits are granted.
Other arrangements with our Directors and Executive Officers
The Group entered into an intellectual property assignment agreement with CEO Hartmut Ehrlich on July 7, 2021. The purpose of this
agreement is to transfer to the Group all the intellectual property rights held by Hartmut Ehrlich on certain patents of which he is a co-
inventor. No compensation has been paid in respect of this transfer.
In connection with Dr. Hartmut Ehrlich’s retirement as CEO, the Group entered into a transition protocol with Dr. Ehrlich in April
2023. Pursuant to the transition protocol, Dr. Ehrlich remained the Group employee on a part-time basis until December 31, 2023 in a
capacity as advisor to the new Chief Executive Officer against payment of a total compensation of €100,000 , and a departure
indemnity equal to €1,209,825 was stated.
The Group entered into a management contract with CEO Marc de Garidel on April 18, 2023.
Note 25. Off-balance sheet commitments given
Collaboration, research and development, and licensing agreements, and licensing options related to the “Modulation of RNA
biogenesis” platform.
•Exclusive licensing agreement with the CNRS, the University of Montpellier and the Institut Curie
On December 4, 2008, the French National Centre for Scientific Research (CNRS), the University of Montpellier and
the Institut Curie granted the Group four exclusive licenses. These licenses cover the use of their technology and
products by the Group in the field of human and veterinary health relating to the use of synthetic products modifying
mRNA splicing, for research, diagnosis, prevention and treatment of any possible indication. The licensing agreement
includes low single-digit royalties based on future net sales to be paid by the Group.
•Framework agreement for research collaboration to create a cooperative laboratory (ended December 31, 2021)
On December 11, 2008, the Group, the CNRS (French National Centre for Scientific Research) and the University of
Montpellier entered into a research collaboration agreement for a duration of two years in order to conduct a common
research program in the fields of screening and development of anti-HIV and antiviral compounds, anti-cancer and anti-
metastasis compounds and compounds targeting certain genetic diseases. The term and content of research programs
have been changed by successive amendments in force until December 31, 2021. Each party retains ownership of its
previously acquired intellectual property rights. The parties are co-owners of the research results. Since this agreement
ended on December 31, 2021, a hosting agreement was signed with CNRS in 2022, it was successively renewed up until
F-70
December 31, 2023 and December 31, 2024 so that the Group can continue its research program at the CNRS center for
the years 2023 and 2024.
•Collaboration agreement with the CNRS, the University of Montpellier, the Group and Evotec
In support of the development of the cooperative laboratory, the CNRS, the University of Montpellier, the Group and
Evotec International GmbH have entered into a collaboration agreement on the development of the “Modulation of RNA
biogenesis” platform, effective October 19, 2018. The molecules generated in the framework of this collaboration are the
property of the Group, the University of Montpellier and the CNRS under the same terms and conditions as the research
collaboration agreement on the creation of the cooperative laboratory. The agreement ended on December 31, 2021.
•Research collaboration contract with the CNRS, the University of Montpellier and the Institut Curie
Concomitantly with the research collaboration framework contract relating to the creation of a cooperative laboratory the
parties have signed a financial agreement defining the financial terms for the exploitation of patents. This contract was
signed on 15 April 2009 for a duration of one year and was subsequently renewed up until March 31, 2022. In December
2022, Abivax and the Institut Curie concluded a new contract for a duration of one year , renewable by amendment,
granting Abivax access to some of the Institute’s equipment and consumables. In December 2023, the contract was
renewed for another year, under similar conditions.
•Research and development contract with license option with the CNRS, the University of Montpellier and Theradiag
The CNRS, the University of Montpellier, the Group and Theradiag have set up a collaborative project called CARENA,
which has been in operation since February 8, 2013. Its purpose is to conduct joint research and development programs
in the fields of obesity, HIV and HTLV-1, in connection with the funding obtained through the Bpifrance CARENA
project. On February 18, 2015, Bpifrance accepted the reorganization of the “CARENA” project proposed by the Group,
following the abandonment of the obesity project. At this time, Theradiag is no longer involved in the collaborative
project.
Under the terms of the collaborative project, the Group will have the exclusive and global exploitation rights to the
proprietary results of the CNRS and to those of the University of Montpellier as well as a share of the common results of
which the CNRS and the University of Montpellier are co-owners. Furthermore, Theradiag granted the Group an
exclusive and global license option for exploitation of its own results as well as a share of the common results of which
it will be a co-owner. This option may be exercised by the Group throughout the duration of the contract and within a
period of two years after its expiration or cancellation.
Exclusive licensing contract with “The Scripps Research Institute, University of Chicago and Brigham Young University” with the
“Immune Stimulation” platform (ABX196 product)
On 11 November 2006, The Scripps Research Institute (La Jolla, California, USA), in agreement with the University of Chicago
(Chicago, Illinois, USA) and Brigham Young University (Provo, Utah, USA), granted the Group an exclusive license in the field of
human and veterinary health on its technology and products relating to the use of iNKT agonists for research, diagnosis, prevention
and treatment of all possible indications. In consideration for the licensing rights granted to it under the agreement, the Group must:
•pay The Scripps Research Institute milestones at different stages of clinical and regulatory development of the first
product (the milestones amount to $50 thousand at IND filing, paid in September 2019 and capitalized, $300 thousand at
Phase 3 and $500 thousand at IND approval) and low single-digit royalties for vaccines, diagnostic tests and therapeutic
products, according to the amount of net sales, and
•give The Scripps Research Institute, University of Chicago and Brigham Young University an equitable interest in the
Group (as of the date of these financial statements, these three academic institutions hold 0.41 % of the Group’s
undiluted capital).
The contract shall be terminated at the expiry of the last licensed patent in force in the last country and/or ten years after the last
marketing of the product, service or process derived from the know-how or the licensed equipment.
Bpifrance CARENA contract
As part of the development of therapeutic and diagnostic solutions targeting alternative splicing and RNA interference in the fields of
virology (HIV-AIDS, HTLV-1) and metabolism (obesity), SPLICOS (absorbed by the Group on 31 October 2014) has entered into a
Master Support Agreement with Bpifrance as well as a conditional advance contract in the name of the “CARENA” Strategic
Industrial Innovation Project dated December 16, 2013. The Group, acting as project leader for the CARENA project, is associated as
part of a consortium contract with Theradiag, a Group specializing in in vitro diagnostics and the development of theranostic tests for
monitoring biotherapies, as well as at the CNRS and the University of Montpellier.
F-71
The CARENA project aims to develop the anti-HIV-AIDS therapeutic program with the compound ABX464 up to the Phase 2b study,
as well as a companion test set up by Theradiag simultaneously with the clinical development. Beyond the anti-HIV-AIDS program,
the CARENA project should extend its pharmacological investigations to another retrovirus that could be combated by the same
approach: HTLV-1.
The Group is committed to reimbursing the received conditional advances up to €3,840 thousand. The Group will also have to pay an
annuity of 50 % of the proceeds from the sale of the intellectual property rights resulting from the project, as well as the sale of the
prototypes, preproduction and models produced under the project; The sum due to BPI under this provision will be deducted from the
repayment of the conditional advances. In addition, if the advance is repaid under the conditions outlined above, the Group will pay to
Bpifrance, over a period of five consecutive years after the date on which the repayment schedule ends and provided that the Group
has reached cumulative pre-tax revenue greater than or equal to €50 million, an amount equal to 1.20 % of the annual revenue
generated from the sale of the products developed as part of the project. This supplementary payment amount is capped at
€6,800 thousand. The total period, including fixed payments and incentive payments, is limited to 15 years.
Bpifrance RNP-VIR contract
In pursuit of the CARENA project, focused on the clinical development of a drug molecule and demonstrating the validity of an
innovative therapeutic approach targeting viral RNPs, the Group has entered into a Master Support Agreement with Bpifrance as well
as a beneficiary agreement with conditional advance for the “RNP-VIR” structuring research and development project for
competitiveness dated December 16, 2016.
The RNP-VIR project will further the discovery of new molecules aimed at the treatment of multiple infectious diseases by the
development of the antiviral technology platform. The Group, acting as project leader of the RNP-VIR project, is associated in a
consortium contract with the CNRS and the University of Montpellier.
The Group is committed to reimburse the received conditional advances up to €6,576 thousand. If applicable, the Group will also have
to pay an annuity of 50 % of the proceeds from the sale of the intellectual property rights resulting from the project, as well as the sale
of the prototypes, preproduction and models produced under the project. The sum due to Bpifrance under this provision will be
deducted from the last payment (and if needed from the previous payments).
If the advance is repaid under the conditions outlined above, the Group will pay to Bpifrance, over a period of five consecutive years
following the date on which the repayment schedule ends and provided that the Group has reached cumulative pre-tax revenue greater
than or equal to €25 million, an amount equal to 3 % of the annual revenue generated from the sale of products developed as part of the
project. The supplementary payments amount is capped at €5,500 thousand. The total period, including fixed payments and incentive
payments, is limited to 15 years.
Bpifrance Ebola
The Bpifrance and Occitanie Region joint support agreement granted on June 2, 2017 consists of conditional advances to the Group
for a total amount of up to €390 thousand, based on the success of the program (respectively €130 thousand from the Languedoc
Roussillon Midi Pyrénées Region and €260 thousand from Bpifrance). In September 2019, the Group decided to terminate this
program, due to the existence of a vaccine in the process of being licensed for this indication as well as changes in the macroeconomic
climate for public funding.
The reimbursement of the conditional advance is spread until June 2024.
As part of the KREOS 1 & 2 bonds, Kreos benefits from first-rate collateral on the Group’s principal tangible and intangible assets,
including its commercial fund, intellectual property rights in its principal drug candidates, as well as a pledge of the Group’s bank
accounts and claims.
On August 21, 2023, the outstanding Kreos 1 & 2 bond loans were repaid in full, using the proceeds from the new Kreos / Claret
Financing (see Note 3.3).
The Kreos / Claret Financing provides for certain restrictive covenants (subject to customary exceptions) which include, among other
things, restrictions on the incurrence of indebtedness, cross-default, the distribution of dividends and the grant of security interests. As
security for the Kreos / Claret Financing, the lenders benefit from the grant of first-ranking collateral on The Group’s principal
tangible and intangible assets, including pledges over The Group’s business (fonds de commerce) as a going concern and intellectual
property rights in The Group's lead drug candidate, as well as pledges over The Group’s bank accounts and receivables. Such
securities apply to all tranches of the Kreos / Claret Financing.
F-72
The Heights Financing is a senior, unsecured financing. The terms and conditions of the Heights convertible notes include a standard
negative pledge providing that any security granted in favor of other borrowed debt or debt instruments should also be granted in favor
of the Heights convertible notes on an equal basis (with the exception of the securities issued pursuant to the Kreos / Claret Financing,
as detailed above).
In the ordinary course of business, the Group regularly uses the services of subcontractors and enters into research and partnership
arrangements with various contract research organizations, or CROs, and with public- sector partners or subcontractors, who conduct
clinical trials and studies in relation to the drug candidates.
At December 31, 2022, the Group’s commitments amounted to €194,731 thousand. The cost of services performed by CROs is
recognized as an operating expense as incurred.
At December 31, 2023, the Group’s commitments amounted to €201,777 thousand. The cost of services performed by CROs is
recognized as an operating expense as incurred.
The lease for the Group’s corporate headquarters in Paris, France at 5 Rue de la Baume, 75008 Paris ended in August 2022. A new
lease for premises at 7-11 Boulevard Haussmann, 75009 Paris started in July 2022 and will end on June 30, 2024.
In November 2023, the Subsidiary entered a lease contract for its new Boston offices. It has a two-year duration, with an option to
renew the contract for an additional period of two years . Per Management, the renewal option is not reasonably certain due to the
Note 26. Off-balance sheet commitments received and contingent assets
The maximum amounts receivable by the Group after December 31, 2023 under the “RNP-VIR” and “CARENA” and innovation
agreements entered into with Bpifrance, subject to the provision of evidence to support the forecast expenses and the achievement of
scientific milestones, are €3,255 thousand and €1,853 thousand, respectively.
As part of the Kreos / Claret Financing agreement, the Group has received loan commitments from Kreos and Claret for the tranches B
and C, of €25,000 thousand in aggregate principal amount each (subject to the conditions set forth in Note 15.1.). The limit dates for
the drawdowns are March 31, 2024 and July 31, 2024 respectively.
As part of the Heights Financing agreement, the Group has received a loan commitment from Heights for the tranche B, of up to
€40,000 thousand in aggregate principal amount (subject to the conditions set forth in Note 15.2.). The limit date for the complete
drawdown is August 24, 2024.
Note 27. Management and assessment of financial risks
The principal financial instruments held by the Group are cash and cash equivalents. The purpose of holding these instruments is to
finance the ongoing business activities of the Group. It is not the Group’s policy to invest in financial instruments for speculative
purposes. The Group does not use derivative financial instruments for hedging purposes.
The principal risks to which the Group is exposed to are liquidity risk, interest rate risk, foreign currency exchange risk, credit risk and
fair value risk.
F-73
Liquidity risk
Liquidity risk management aims to ensure that the Group disposes of sufficient liquidity and financial resources to be able to meet
present and future obligations.
The Group prepares short-term cash forecasts and annual operating cash flow forecasts as part of its budget procedures.
Prudent liquidity risk management involves maintaining sufficient liquidity, having access to financial resources through appropriate
credit facilities and being able to unwind market positions.
The Group’s operations have consumed substantial amounts of cash since inception. Developing pharmaceutical drug candidates,
including conducting clinical trials, is expensive, lengthy and risky, and the Group expects its research and development expenses to
increase substantially in connection with its ongoing activities. Accordingly, the Group will continue to require substantial additional
capital to continue its clinical development activities and potentially engage in commercialization activities.
The Group's estimate of its cash runway as of the date of approval of these financial statements is set forth in Note 2 - Going concern.
Interest rate risk
The Group is exposed to market risks in connection with its medium and long-term borrowings subject to variable interest rates.
Due to fluctuations in market interest rates and the refinancing of most of its indebtedness over the year ended December 31, 2023, the
Group has performed a reassessment of its exposure to interest rate risk. As of December 31, 2023, following the full repayment of the
Kreos 1 bonds, all the Group’s non-derivative financial liabilities accounted for at amortized cost bear fixed interest rates. Therefore,
the Group has limited exposure.
The Group may reassess its exposure after the potential future drawdowns of the tranches B and C and the Kreos/Claret Financing,
which bear variable interest rates.
Foreign currency risk
The Group is exposed to a risk of exchange rates fluctuations on commercial transactions performed in currencies different from the
functional currency of the Group entity recording the transactions.
For the years ended December 31, 2023, 2022 and 2021, expenses in U.S. dollars totaled €10,112 thousands, €1,390 thousands and
€1,262 thousands respectively, based on the average annual exchange rate in effect as of December 31, 2023, December 31, 2022 and
December 31, 2021. As a result, an adverse 10 % change in the exchange rate for the U.S. dollar against the euro would have resulted
in a foreign exchange rate loss of approximately €386 thousand for 2023 and non material amounts for the others periods.
At this stage, the Group has not adopted any other recurring mechanism of hedging to protect its activity against currency fluctuations.
From time to time, the Group may nevertheless subscribe currency term accounts in order to cover a commitment in currency as
described above. The Group may consider in the future using a suitable policy to hedge exchange risks in a more significant manner if
needed.
Credit risk
The credit risk related to the Group’s cash and cash equivalents is not significant in light of the quality of the co-contracting financial
institutions. As of December 31, 2023, substantially all of the Group’s cash and cash equivalents were maintained with two financial
institutions in France and in the United States. While the Group’s deposit accounts are insured up to the legal limit, the maintained
balances may, at times, exceed this insured limit. As of December 31, 2023, the Group maintained €251,616 thousand in bank deposit
accounts that are in excess of the legally insured limit in two legally insured financial institutions. The Group has not experienced any
losses in such accounts and does not believe that it is exposed to any significant credit risk related to these instruments.
The credit risk related to the Group’s other receivables and related account is minimal. In particular, the credit risk related to advances
made to CROs (see Note 9) is deemed insignificant due to their credit ratings.
F-74